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Summary 
Discoveries related to the peculiar disease of African trypanosomiasis have occurred 
throughout the centuries. ‘Sleeping Sickness’, the short name for human African 
trypanosomiasis (HAT), is derived from changes in the sleep-wake pattern seen in HAT 
patients as the presence of the trypanosoma parasite in the brain causes a slow neurological 
breakdown. Although major epidemics have been recorded over the past centuries, the 
number of cases have declined rapidly over the last decade placing HAT in the position of 
reaching elimination. In 2011, the World Health Organization (WHO) set a range of targets for 
eradication, elimination, or control of 17 neglected tropical diseases, but it still remains unclear 
how achievable many of these goals are, and what are the best ways forward. The Swiss 
Tropical and Public Health Institute (Swiss TPH) was supported to develop EICs for 
onchocerciasis, lymphatic filariasis (LF), and human African trypanosomiasis (HAT).  Unlike 
filarial parasites that respond well to preventative chemotherapy oral treatments, 
trypanosoma parasites involve a more complex diagnostic and treatment paradigm. For this 
reason, a unique approach was taken to developing an EIC for HAT T.b. gambiense. 
Evidence was collected systematically to address the initial questions posed by the Ernst 
Strüggmann Forum “Eradication Investment Case” (EIC) framework.  From this information, 
potential strategies using current available tools and potential technologies were hypothesized 
that could be simulated through prospective modelling exercises to evaluate various 
outcomes. A  dynamical model was also developed to simulate HAT T.b. gambiense 
transmission, and to forecast the impact of current and emerging innovations on the key 
concerns of the EIC: elimination, costs, health impact, cost-effectiveness, and number of cases. 
Modelling was also done to simulate household surveys to evaluate the impact of elimination 
on poverty. In addition a discrete event simulation model evaluated the possibility of 
integration comparing old and new strategies, while a social justice assessment was 
undertaken to ascertain which strategies would lead to ethical compromises within potential 
elimination programs. 
The EIC results provide various options for stakeholders moving towards HAT elimination, 
but substantial funds will be required. In addition, trade-offs between cost-effectiveness, social 
justice and elimination targets in the next few decades will need to be made. Integration is 
feasible with new technologies and will provide more flexibility to capacity in high risk foci 
areas, but further exploration of this methods use within an EIC still needs to be explored. The 
multiple components of the EIC appear suitable for MCDA and this is also a methodological 
option to consider for future decision making within EICs. 
Overall, the EIC has proven to be a useful approach that is both technically feasible and 
informative for deliberations within a disease under review for elimination. It is now 
recommended that funders use the results to move forward with elimination campaigns. 
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1. Introduction 
1.1 A historical overview of African trypanosomiasis 
African trypanosomiasis is a disease caused by the transmission of the Trypanosoma parasite 
by the tsetse fly from host to host. The first written account of African trypanosomiasis began 
during Antiquity where the Egyptians noticed their cattle manifesting a disease with similar 
symptoms of what is described as African animal trypanosomiasis (‘nagana’) today.(Headrick 
2014) Subsequently, an Arabian geographer and historian mentioned cases approximately 
during the 10th and 12th centuries.(Steverding 2008) The transatlantic slave trade during the 
16th century presented an opportunity for the western world to witness the disease, as medical 
personnel responsible for the health of individuals purchased into slavery noticed they had 
peculiar symptoms. The first signs of neurological problems were seen at the end of the 18th  
century while the link to the disease to swollen lymph glands was discovered by Thomas 
Winterbottom(1766-1859) in the early 19th century.(Steverding 2008)  In 1889-1896, post-
industrial technologies in combination with colonial expansion into Africa displaced 
communities and allowed for movement into areas infested with flies that were previously 
uninhabitable making inhabitants susceptible to a new killer – ‘sleeping sickness’. (Steverding 
2008; de Raadt 2015) This incited a disease outbreak from 1896 thru 1906 with such significance 
that colonies decided to intentionally fund scientific investigation into the disease 
transmission and possible treatments.(Headrick 2014) The results were a series of key 
discoveries in the early 1900s from European Scientists regarding the parasite and role of the 
tsetse fly in transmission of the disease from host to host. At this time, the parasite was 
differentiated from those transmitted to animals (i.e. Trypanosoma congolense, Trypanosoma 
vivax) and those primarily affecting human reservoirs (Trypanosoma brucei (T.b.) rhodesiense and 
T.b. gambiense) A few drugs to treat the disease were identified at the beginning of the 20th 
century along with ideas for ‘bush clearing’ to prevent transmission in areas densely 
populated by the tsetse fly. Post-world war I (1914-1918)(Steverding 2008), a second major 
HAT epidemic began but since there was now a treatment available;  surveillance teams were 
able to be deployed, under the direction of Eugene Jamot (1879-1937), to systematically 
identify and treat individuals for the disease.(Steverding 2008) In addition, insecticides and 
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DDT aerial spraying were discovered for fly eradication along with two additional drug 
treatments during the 1930s and 1940s. The plethora of activity near this era for sleeping 
sickness was so vast that it gained international attention and was often a topic of European 
media. (Refer to Figure 1) 
Although the drug treatments and insecticides are now known to be highly toxic (Robays et 
al. 2007) and the military approach to forcing individuals to participate in village screening 
activities would now be seen as unethical – this combination of activities led to the rapid 
decline of disease by the 1960s. At this time in history, many African nations were able to 
develop independence from colonial rule and in turn abandoning to previous efforts to 
maintain disease suppression. Furthermore in the 1970s a global ban on DDT aerial spraying 
prevented vector control endeavours leading to the return of tsetse infestation and parasite 
transmission to resurge.(Steverding 2008) Although the card agglutination trypanosomiasis 
test (CATT) was developed during 1978 to assist with disease staging and drug treatments 
were identified as potentials in 1980 and 1990, HAT control fell to the background. It was not 
until 1997, as case numbers began to rise again, active surveillance teams of the colonial era 
were re-established through Medecin sans Frontieres (MSF). Successful eradication of tsetse 
flies in Zanzibar in 1997, also gave hope to the possibility that fly eradication was possible 
while groups dedicated to new diagnostics and treatments (Foundation for Innovative New 
Diagnostics n.d.; Drugs for Neglected Diseases initiative (DNDi) 2014b) were launched in 2006 
demonstrating a new interest for the disease that had not been seen since the earlier 20th 
century.   
Figure 1. Colonial pictures related to treatment and diagnosis of HAT 
 
 
 
ф 
 
 
 
ф 
фImages in Figure 5 may be available in the printed version upon request to the University of Basel (diss-ub@unibas.ch) 
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Figure 2. Historical overview of African trypanosomiasis (historical points summarized from Steverding 
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1.2 A current synopsis of human African trypanosomiasis 
Trypanosoma brucei gambiense  
Today African trypanosomiasis is colloquially referred to as ‘sleeping sickness’. African 
animal trypanosomiasis (AAT) which is at times referred to as ‘nagana’ is caused by the 
parasite Trypanosoma brucei (T.b.) rhodesiense, T.b. vivax, and T.b. evansi.(Molyneux & Ashford 
1983)   Trypanosoma brucei rhodesiense can also be transmitted to humans and is an acute illness 
lasting 6 months before inevitable death in the absence of treatment, while the main reservoir 
host for T.b. gambiense are humans. The main focus of the thesis presented here will be on 
Trypanosoma brucei (T.b.) gambiense hence onward since it is of primary health concern for 
human hosts.1  T.b. gambiense is often referred to as Gambiense HAT or g-HAT.   
Figure 3. Cases of human African trypanosomiasis across the Democratic Republic of the Congo - T.b. gambiense 
 
(Simarro et al. 2010) 
 
Geographically, T.b. gambiense has been restricted to Sub-Saharan African with no overlap of 
rhodesiense HAT except in Uganda where both parasitic strains are found. Geographic areas 
                                                     
1 The expert task advisory  group (TAG) that was created for the EIC grant # OPP1037660 by the BMGF decided in September 
2013 that the focus for HAT elimination should be on T.b. gambiense as it proportionately affects a greater amount of humans, than 
T.b. rhodesiense and the current interventions are targeted to T.b. gambiense specifically 
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with the potential for transmission are referred to as a ‘focus’, and have been categorized into 
areas of low, moderate  and high transmission .(Jose R Franco et al. 2014; World Health 
Organization (WHO) 2013c) Currently there are over 57 million living in areas at risk of g-
HAT with 63% of the at risk population coming from the Democratic Republic of the Congo 
as shown in Figure 3. (Jose R Franco et al. 2014) 
Much of what is known about HAT still arises from the early discoveries at the beginning of 
the 20th century previously described. The family of Trypanosoma that affects homosapiens was 
found by the Scottish pathologist, David Brucei and hence the ‘subgenus’ name of brucei is 
attached to such Trypanosoma. The trypanosomes come from the family of unicellular parasites 
with single flagella. The parasite has one large mitochondria and is surrounded with an outer 
coat of variant surface glycoproteins (VSG) that can change repeatedly to evade attacks of 
human antibodies the human body.(Brun et al. 2010) Although the body responds with 
specific antigens to fight of Trypanosoma infection, researchers still struggle to understand 
which antigens are most important with the continually morphology of the VSG coat. This has 
led to delays in technologies for diagnostics as the sensitivity for detecting the correct antigen 
are difficult.(Sutherland 2016) Potential treatments that counteract the parasite usually act on 
‘paralyzing’ the trypanosomes and arrest the proliferation of cells which is a similar property 
of cancer cells – hence chemotherapy approaches have proven to be successful treatments for 
Gambiense HAT.(Swiss TPH 2015)  
It is known that the tsetse fly of the genus Glossina is the primary vector living near streams in 
foci of woodland savannah and riverine forests, with G. palpalis palpalis, G.p. gambiensis and G. 
fuscipes being the three main vectors for Gambiense HAT transmission. (Jose R Franco et al. 
2014) Their life cycle unlike other insects is more similar to mammals as female flies only mate 
once and has one larva in her lifetime. For this reason, fly eradication is seen as feasible as 
vector control methods interrupt the life cycle with ease.(Swiss TPH 2015) Prevention for 
disease transmission can be taken against the vectors through targets, sterile insect technique 
(SIT), aerial spraying; insecticides poured over cattle however for the most part have been 
restricted to uses of AAT.(Keating et al. 2015) 
As outlined in Figure 4, the tsetse fly is not simply a mechanical vector of transmission but 
plays a role in the cyclical transmission of the parasite. The fly ingests the parasite from an 
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infected individual from its salivary glands which undergo transformation in its midgut and 
are then return to the salivary glands to transmit to another host. Within host, the 
trypanosomes enter the blood stream and over time progress to the blood lymph and cerebral 
spinal fluid (CSF). Although traditionally the main routes of transmission are confirmed 
through the fly and host interactions, recent reviews postulate there may be alternative routes 
of transmission. These include congenital transmission from mother to child, infection via 
blood transfusions or organ transplants, and one historically documented incidence through 
sexual transmission. (Lindner & Priotto 2010; Jose R Franco et al. 2014) There are also cases 
throughout history of asymptomatic carriers with case reports of individuals presenting with 
disease more than 10 years after infection.(De Silva & Sumarto 2014; Sudarshi & Brown 2015; 
Bucheton et al. 2011) Human hosts for Gambiense HAT are indisputably the main reservoir, 
but evidence of trypanosomes in pigs and dogs show that there could be potential animal hosts 
that serve as reservoirs.(Bucheton et al. 2011)  
Figure 4. Life cycle of human African trypanosomiasis 
 
Lifecycle of the African trypanosome, (Kennedy 2013) 
The presence of the trypanosome in the blood represents only the first stage of disease which 
presents itself with mild symptoms of fever, headache, pruritus, lymphadenopathy and at 
times hepatosplenomegaly (Brun et al. 2010). Stage 2 of the disease occurs once the parasite 
has passed the blood-brain barrier and occurs in approximately 18 months without 
intervention. The symptoms here are sleep disturbances (hence the colloquial name ‘sleeping 
sickness’) and psychiatric manifestations which may be misdiagnosed as mental illness. (Brun 
et al. 2010)   
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As previously described, active case detection by Eugen Jamot began in 1926 (Refer to Figure 
5A) and the mechanism to identify patients in their villages then is still used today (Refer to 
Figure 5B) “Passive surveillance” refers to the healthcare system where patients self-report to 
local facilities (refer to Figure 5C) however this is usually once symptoms have progressed to 
stage 2 as the mildness of earlier symptoms from stage 1 are often misdiagnosed as other 
febrile related illness. Risk factors in rural areas generally are related to interactions by rivers, 
in combination with farming or work related activities in tsetse infested areas. (Jose R Franco 
et al. 2014)  There are also risk factors in areas with water supply in peri-urban 
settings.(Bilonda Mpiana et al. 2015; Jose R Franco et al. 2014)  
 
Figure 5. Surveillance mechanisms for human African trypanosomiasis 
ф ф 
A. Active screening in colonial era HAT 
patient 
B. Active screening in the 21st century 
(courtesy of Dr. Christian Burri) 
ф 
C. Health care centre (passive surveillance) in rural health care system (courtesy of Dr. Christian 
Burri) 
фImages in Figure 5 may be available in the printed version upon request to the University of Basel (diss-ub@unibas.ch) 
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1.3 The Elimination Investment Case (EIC) for human African 
trypanosomiasis Trypanosoma brucei gambiense 
It is at this point in history where global funders interested in seeing the elimination of HAT 
across the planet find themselves. Based on the historical evidence, HAT has now repositioned 
itself near elimination that was once observed in the 1960s. Efforts to eradicate infectious 
diseases have occurred numerous times over the past century. The most commonly 
remembered eradication campaigns include the malaria spraying programs in Latin America 
from the 1930s to 1970 (Centers for Disease Control and Prevention (CDC) 2012) as well as the 
successful March of Dimes campaign for poliomyelitis in the United States of America.(Global 
Polio Eradication Initiative n.d.; March of Dimes n.d.)  Although global eradication efforts for 
malaria and polio continue to take economic and disease burden assessments into account to 
allow for strategic planning (Duintjer Tebbens et al. 2010; Penny et al. 2016), clear analysis for 
many of the world’s neglected diseases remain to be done. The number of cases for HAT 
reported in 2015 is expected to be less than 3000 which is the lowest number of HAT cases 
documented to date.2 (Sutherland 2016) But in order to move towards successful elimination 
without coming face with disease resurgence needs to be strategic.  While historically the 
response to HAT interventions has been reactive, we are provided with the unique position of 
evaluating how to move forward with the current and potential tools in the pipeline for 
elimination and beyond.  
In 1998, Dowdle first proposed specific descriptions of what control, elimination, eradication 
and extinction were. (Refer to Table 1) Then WHO brought to light many abandoned diseases 
(NTDs) in 2011 and provided a roadmap to elimination (WHO 2012) as a guide to catalyse 
nations towards elimination measures. This initiated a global response to focus on the 
suggested 17 disease areas identified, that were later endorsed by the London 
Declaration.(London Declaration 2013) With global funders and national leaders interested in 
elimination, there was a need to provide comprehensive information regarding what such 
                                                     
2 The reader should note that the cases surveyed annual are only a proportion of all potential areas. The true number of HAT cases is unknown 
and is estimated to be 3x the number of cases found (Stone et al. 2016)  
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campaigns would entail and more importantly the monetary requirements that would be 
needed. As elimination campaigns ensue, it is thought the costs begin to rise which often leaves 
funders with angst regarding how to prepare, ensure or secure funds for eradication and 
elimination campaigns.(Sutherland 2016) Hence there is a need to formally assess and 
anticipate approaches to eradication/elimination in order to sustain successful campaigns of 
this sort. 
Table 1. Definitions of control, elimination, eradication and extinction 
 Definition 
Control The reduction of disease incidence. prevalence ,morbidity or mortality to a 
Locally acceptable level as a result of deliberate efforts; continued intervention measures are 
required to maintain the reduction. Example: diarrhoeal diseases. 
Elimination  
Disease Reduction to zero of the incidence of a specified disease in a defined geographical area as a 
result of deliberate efforts. Continued intervention measures are required. Example: neonatal 
tetanus. 
Infection Reduction to zero of the incidence of infection caused by a specific agent in 
a defined geographical area as a result of deliberate efforts: continued measures to prevent 
re-establishment of transmission are required. Example: measles, Poliomyelitis. 
Eradication Permanent reduction to zero of the worldwide incidence of infection caused by a specific 
agent as a result of deliberate efforts: intervention measures are no longer needed. Example: 
smallpox. 
Extinction The specific infectious agent no longer exists in nature or in the laboratory Example: none. 
(Dowdle 1998) 
 
In 2010 the Ernst Strüngmann Forum provided a guide to developing an elimination or 
eradication investment case (EIC) (Tediosi et al. 2013) with a comprehensive list of open 
questions (refer to appendix A) that should be addressed if such an endeavour was to be 
undertaken. However, the document provided a more generic approach and did not specify 
which methodologies would be necessary to assess such investments or how it could be 
amended depending on the disease being evaluated. In 2012 a grant from the Bill and Melinda 
Gates Foundation (BMGF)3 was provided to the Swiss Tropical and Public Health Institute 
(Swiss TPH) under the direction of Dr. Fabrizio Tediosi to complete an EIC for three neglected 
tropical diseases (NTDs): onchocerciasis (river blindness), lymphatic filariasis (LF) 
(elephantiasis) and human African trypanosomiasis (sleeping sickness). Both river blindness 
and elephantiasis have well established mass drug administration (MDA) campaigns already 
                                                     
3BMGF Grant # OPP1037660 
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underway to elimination that would have to scale up in order to reach disease eradication, but 
the case for HAT was not so clear. As the project progressed, the approach to assessing 
eradication goals was deemed unfeasible hence the term ‘elimination’ investment case is taken 
for HAT (Sutherland 2016).   
Many nations that provide national health services (NHSs) (World Health Organization 
(WHO) 2015) use a health technology assessment approach to decide whether or not a new 
drug or intervention is worth investing in for their national budgets.  Hence, at the onset of 
the project HTA techniques of using secondary evidence for clinical epidemiology and 
economic evaluation were readily adopted. It was proposed at that time that the main analyses 
would use modelling to conduct a cost-effectiveness analysis, and also explore health systems 
modelling. However, even with these two analyses, additional questions regarding socio-
economic outcomes, health systems strengthening, equity and governance would need to be 
resolved.  
 Thesis objective 
The main objective was to address questions proposed in Ernst Strüngmann Forum for an EIC 
taking in considerations elements of strategies for control and elimination in relation to: 
budget, cost-effectiveness, financial protection, equity, health systems and governance. 
 Thesis outline  
The 1st chapter of the thesis by Steinmann et al.(Steinmann et al. 2015) describes an overview 
of HAT treatments, diagnostics, surveillance approaches and possible vector control tools.  The 
2nd chapter is a review of economic evaluations for HAT (Sutherland et al. 2015) that was 
undertaken to determine if there was a need to pursue a formal economic evaluation for HAT 
or if cost-effectiveness analysis of the current and future treatments had already been assessed. 
Once it was established that previous economic evaluations had not been done in regards to 
control and elimination using current and future interventions, a systematic review of costs 
was completed in the 3rd chapter (Keating et al. 2015) to gather the necessary financial 
parameters that would be needed to complete such an analysis. The 4th chapter then describes 
a full economic evaluation of the control and elimination strategies by foci area based on the 
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dynamical transmission model developed by at the Swiss TPH for the EIC project. (Chris M. 
Stone & Chitnis 2015)  Financial costs and out-of-pocket payments will be forecasted at a global 
level within the 5th chapter while the 6th chapter focuses on the potential integration of the new 
technologies in the healthcare systems. The 7th chapter addresses ethical concerns using a 
normative approach developed in collaboration with Dr. Maria Merrit.  The overall results of 
the assessments conducted as part of the EIC in regards to their benefits, limitations, 
applications and potential for further research in relation to investments for elimination are 
then reviewed in the final discussion.   
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2.1 Abstract 
Objectives  
The World Health Organization (WHO) has identified Human African Trypanosomiasis 
(HAT) as a candidate disease for elimination by 2020. We review current and emerging tools 
for Gambiense HAT control and elimination, and propose strategies that integrate these tools 
with epidemiological evidence.  
Methods  
We reviewed the scientific literature to identify contemporary and emerging tools and 
strategies for controlling and eliminating Gambiense HAT. Through an iterative process 
involving key stakeholders, we then developed comprehensive scenarios leading to 
elimination, considering both established and new tools for diagnosis, case treatment and 
vector control.  
Results  
Core components of all scenarios include detecting and treating cases with established or 
emerging techniques. Relatively more intensive scenarios incorporate vector control. New 
tools considered include tiny targets for tsetse fly control, use of rapid diagnostic tests and oral 
treatment with fexinidazole or oxaboroles. Scenarios consider the time when critical new tools 
are expected to become ready for deployment by national control programmes. Based on a 
review of the latest epidemiological data, we estimate the various interventions to cover 
1,380,600 km2 and 56,986,000 people. 
Conclusions 
A number of new tools will fill critical gaps in the current armamentarium for diagnosing and 
treating Gambiense HAT. Deploying these tools in endemic areas will facilitate the 
comprehensive and sustainable control of the disease considerably, and contribute to the 
ultimate goal of elimination.   
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2.2 Introduction 
Human African trypanosomiasis (HAT) or sleeping sickness is a neglected tropical disease 
(NTDs) that has been earmarked by the World Health Organization (WHO) for elimination by 
2020 (WHO 2012). In 2014, WHO approved a declaration on Gambiense HAT elimination 
(http://www.who.int/trypanosomiasis_african/meeting_declaration_2014/en/) (Holmes 2014) 
and one on Rhodesiense HAT 
(http://www.who.int/trypanosomiasis_african/meeting_declaration_rhodesiense_2014/en/). 
The two disease forms are caused by Trypanosoma brucei gambiense and T. b. rhodesiense, 
respectively. They occur in separate geographical regions, are transmitted in different 
ecological settings and by different Glossina (tsetse fly) species, and have different hosts and 
degrees of virulence(Brun et al. 2010; Malvy & Chappuis 2011). T. b. gambiense is endemic in 
west and central Africa where it occurs in riverine savannah, forests and mangroves. It is an 
anthroponotic parasite found in a range of animals, most notably pigs, but the role of the 
zoonotic reservoir in human epidemiology is still not fully understood for the different 
endemic settings. T. b. rhodesiense occurs mainly in savannah areas in eastern and southern 
Africa. It is a typical zoonotic parasite that infects mostly wild mammals and cattle, and only 
occasionally crosses over to humans (Welburn et al. 2009; Funk et al. 2013). Infections progress 
in two stages: haemo-lymphatic and meningo-encephalitic. T. b. gambiense is a chronic disease 
characterised by fever, chills, headache, pruritus, lymphadenopathy and, less commonly, 
hepatosplenomegaly during the first phase; and by sleep disturbances, neurologic and 
psychiatric disorders in the second stage. Rhodesiense HAT has a more acute course. 
Untreated, HAT is usually fatal. Considering the profound differences between the biology 
and epidemiology of Gambiense and Rhodesiense HAT, distinct strategies for their control 
and elimination are required (Simarro et al. 2013). Our focus here is on Gambiense HAT, as 
the animal reservoir of T. b. rhodesiense includes wild animals and would require their 
treatment or removal of tsetse flies from all endemic areas to permanently prevent human 
infections. 
Gambiense HAT occurs in 24 countries (Anonymous 2006). However, cases are currently only 
reported from 13 countries. The total endemic area is estimated to be 1.3808 million km2, with 
a population of 56.983 million people (Pere P Simarro et al. 2012). A total of 7,106 cases were 
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reported in 2012 (http://apps.who.int/gho/data/node.main.A1635?lang=en). In 2001, 26,117 
Gambiense HAT cases were reported(Simarro et al. 2013). The estimated number of cases per 
year is currently about three times higher than the diagnosed number, down from a factor of 
12 in 1995 (Simarro et al. 2013; Anonymous 2006; Fevre, Wissmann, et al. 2008). In 2010, the 
estimated burden of HAT was 560,000 DALYs (Murray et al. 2012), including 9,100 deaths 
(Lozano et al. 2012). A comparison of total DALYs in 1990 and in 2010 suggests a reduction of 
72.5% (Murray et al. 2012).  
For historical, epidemiological and ecological reasons, elimination of Gambiense HAT has 
been deemed a feasible pursuit. Following epidemic outbreaks in the early 1900s, extensive 
and strictly enforced parasitological screening and treatment of populations came close to 
reducing the number of yearly reported cases to zero (Simarro et al. 2008), although many 
cases may have gone undiagnosed. Following a resurgence in the 1990's, cases are again on 
the decline and control is aided by a renewed focus on the disease and by a number of 
improvements in diagnostics and treatments (reviewed below) that have helped to reduce the 
rate of underreporting. Gambiense HAT appears to be an anthroponotic disease, so treating 
the human population alone should reduce Rc, the reproduction number of the disease in the 
presence of control, to less than one. However, epidemiological and ecological questions 
remain. Consequently, there is uncertainty about how best to maximise the effectiveness of 
available tools and about the best way forward as new diagnostics, treatments and vector 
control options become available. In resource-constrained settings, optimising approaches 
while accounting for the various sources of uncertainty is an important but challenging task. 
Here, we synthesise our findings from a literature review and from consultations with experts 
on currently available and emerging tools. Based on these findings, we propose different 
scenarios for combining and deploying them, and discuss how these tools may change the 
landscape of HAT control. These scenarios will be used to develop models examining the 
financial, operational and technical feasibility of HAT elimination and eradication. Results will 
be communicated in a subsequent report.  
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2.3 Methods 
This work is part of an Eradication Investment Case (EIC) for HAT. An integral part of 
developing EICs is developing scenarios that can then be compared. We followed the general 
principles for scenario development outlined by Tediosi et al (Tediosi et al. 2013). The process 
started with a survey of peer-reviewed scientific literature and relevant grey literature, 
including official WHO statistics about the epidemiology of Gambiense HAT over the last 
century, with a focus on the contemporary situation and fluctuations in response to targeted 
interventions. The same sources were consulted to review current activities for controlling the 
disease. The review was complemented by a survey of national HAT control programme 
managers to identify commonly used tools and strategies along with their coverage and 
effectiveness. In a next step, information was collected on Gambiense HAT control tools under 
development, their predicted effectiveness and the proposed strategies for their deployment. 
Lastly, data from the literature review was corroborated and complemented by key informant 
interviews with representatives from academia and from relevant institutions such as the 
WHO, the Drugs for Neglected Diseases initiative (DNDi), the Foundation for Innovative New 
Diagnostics (FIND), and the Pan African Tsetse and Trypanosomiasis Eradication Campaign 
(PATTEC). The information was used to develop preliminary scenarios describing possible 
control and elimination strategies. In an iterative process, these draft scenarios were circulated 
widely among the constituents mentioned above and improved based on their feedback.  
Three periods were defined based on the time during which important tools currently under 
development are expected to be available for deployment by national Gambiense HAT control 
programmes: 2013 – 2015, 2016 – 2018 and 2019 onwards. A baseline scenario (2013 – 2015) 
was identified, considering the current standard tools for diagnosing and treating Gambiense 
HAT and contemporary strategies for deploying them in endemic countries. An elimination 
scenario I (2013 – 2015) was also developed to include vector control with standard methods. 
Alternative scenarios were prepared considering the key diagnostics, drugs and vector control 
tools currently being brought to market or in the later stages of development, and their 
respective target dates for mass deployment. The less ambitious scenarios (elimination III for 
2016 – 2018 and elimination V and VII for 2019 onwards) served as counterfactual conditions 
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against which to compare one or more other scenarios for the respective period, in terms of 
cost and benefits.  
To construct standardised scenarios that consider key differences between the epidemiology 
and ecology of endemic areas, foci were stratified by intensity of transmission as suggested by 
the WHO (Simarro et al. 2013). The following WHO goals and definitions were incorporated: 
elimination in 80% of all endemic foci by 2015 and global elimination by 2020 (WHO 2012), 
with the latter goal defined as (i) <1 case/10,000 people/year in at least 90% of all endemic foci; 
and (ii) <2000 new cases annually (Maurice 2013; World Health Organization (WHO) 2013b). 
After 2020, efforts should be made to ultimately reduce incidence to 0 by 2030 (World Health 
Organization (WHO) 2013b).  
2.4 Results: Tools for HAT control 
 Evolution of HAT control principles  
Historically, sleeping sickness went through several cycles of epidemic, intensive control in 
response to high numbers of fatalities, tapering off of the epidemic, and neglect (Courtin, 
Jamonneau, Duvallet, Garcia, et al. 2008; Hide 1999; Nimmo 2010; Steverding 2008). Early 
efforts focused on vector control through bush clearing (predominant in English colonies) 
(Solano et al. 2013), chemoprophylaxis (predominant in French colonies) and mobile teams for 
active case finding and treatment. The latter still constitutes the mainstay of efforts to control 
T. b. gambiense (Brun et al. 2010). History suggests that any new attempt to eliminate the disease 
will only succeed if commitment is sustained through appropriate investments, efficacious 
tools and approaches, effective deployment, and programme adaptations to local conditions 
(Welburn et al. 2009).  
Theoretically, the incidence of Gambiense HAT can be reduced in two ways: (i) by reducing 
the parasite reservoir in humans through diagnosis and treatment of those infected, thereby 
minimising the chances of a feeding tsetse fly becoming infected, and (ii) by curbing 
transmission from the flies to humans via vector control efforts that reduce the tsetse 
population and/or reduced tsetse life expectancy (Simarro et al. 2013). The optimal balance 
between treating humans and vector control has only been explored theoretically and without 
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considering costs (Artzrouni & Gouteux 2007). At realistic rates of disease progression, the 
decision to add vector control to case detection and treatment should depend on the “intrinsic 
contamination rate” (a term proportional to vectorial capacity) in a focus. The intensity of 
transmission should inform the design of locally-adapted and effective interventions (Simarro 
et al. 2013). The focus should be on diagnosing and treating human cases to reduce the parasite 
reservoir, supplemented by vector control to reduce transmission. While active and passive 
case detection yield excellent public health benefits, the strategy usually does not result in the 
cessation of local HAT transmission as often the ones who are the most exposed (farmers, 
fishermen, hunters, plantation workers) (Laveissière et al. 2005) do not get screened. It has 
been estimated that when 75% of the population is screened for HAT, only 50% of the actual 
cases are detected. Furthermore, there is increasing evidence that traditional screening 
approaches miss some T. b. gambiense infections among people that are either asymptomatic 
carriers or sero-positives; these individuals are not confirmed as infected by parasitological 
techniques but will ultimately develop HAT (World Health Organization (WHO) 
2013c)(Jamonneau et al. 2012; Bucheton et al. 2011). In the presence of the vector, these 
untreated carriers contribute to parasite dissemination. Under such conditions, transmission 
of T. b. gambiense will not be interrupted without vector control (Solano et al. 2013). Vector 
control is recommended by the WHO in areas where case findings do not result in satisfactory 
incidence reductions (Simarro et al. 2013). If vector control results in a reduction of animal 
trypanosomiasis, economic benefits often ensue, providing a powerful argument in favour of 
promoting — and adopting — tsetse control measures (Swallow et al. 1995). However, the 
number of cattle is low in many Gambiense HAT foci. 
Low parasite concentrations in blood make HAT diagnosis complex (World Health 
Organization (WHO) 2013a). The card agglutination test for trypanosomiasis (CATT) was 
developed in the 1970s and remains the standard screening test to detect T. b. gambiense 
infections (Patrick Mitashi et al. 2012). Parasitological confirmation is mandatory for treating 
a patient, and stage differentiation is needed to determine the treatment strategy. CATT 
performance is generally good, with 87 – 98% sensitivity and 93 –95% specificity (Malvy & 
Chappuis 2011). However, the positive predictive value (PPV) is low as the disease prevalence 
is usually very low. The following drugs and regimens are commonly used to treat Gambiense 
HAT: pentamidine (intramuscular; first stage); nifurtimox-eflornithine combination therapy 
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(NECT; nifurtimox oral, eflornithine intravenous infusion; second stage) and melarsoprol 
(intravenous; second line drug for second stage disease). Prompt treatment offers good 
prospects for curing first stage cases and second stage cases (treated with NECT). Melarsoprol 
is highly toxic, causing an encephalopathic syndrome that can be fatal. In addition, high rates 
of treatment failure have been reported from some locations (Brun et al. 2010; Malvy & 
Chappuis 2011).  
 Case detection, diagnostics and treatment 
There are two strategies for identifying Gambiense HAT cases, with the choice of strategy 
depending on endemicity levels (Simarro et al. 2013): (i) passive case detection through routine 
health care activities, and (ii) active case detection via screen and treat campaigns by 
specialised mobile teams. As Gambiense HAT is a chronic disease, passive case detection is an 
important strategy for identifying cases, accounting for half of all identified cases. However, 
health care facilities are either absent or insufficiently equipped and staffed throughout many 
HAT endemic areas (Simarro et al. 2014). In screen and treat campaigns, residents of T. b. 
gambiense-endemic areas are systematically tested with the CATT (Patrick Mitashi et al. 2012). 
Positive results are confirmed parasitologically, followed by disease staging and initiation of 
appropriate treatment in appropriately equipped health facilities. Screening campaigns are 
vertical interventions that can be deployed in the absence of local health care infrastructure. 
Campaigns typically focus on high-incidence areas for 1-2 years, until case numbers drop to a 
level that no longer justifies the massive effort. Thus, passive case detection needs to be 
maintained simultaneously in areas covered by screen and treat campaigns. The latter tend to 
identify mainly stage 1 cases while the majority of cases identified through passive case 
detection are stage 2. Patients suffering from stage 2 of the disease are more likely to seek 
health care and receive a correct diagnosis from the health care system than those in stage 1. 
Epidemiologically, stage 1 cases are more significant for transmission as they are more 
infectious and exposed to tsetse than stage 2 cases. While diagnostic capacity to identify 
suspect cases must be available down to the lowest and most peripheral level of the health 
care system, confirmation and treatment capacity can be concentrated at regional or, ideally, 
district level (Simarro et al. 2013; Palmer et al. 2013).  
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WHO suggests the following thresholds for the frequency of active case finding (Simarro et al. 
2013): (i) high-intensity transmission (≥1 case/1000 population and year; corresponding to very 
high and high risk areas (Pere P Simarro et al. 2012)): screening once/year; (ii) moderate-
intensity transmission (≥1 case/10,000 population and year but <1 case/1000 population and 
year; corresponding to moderate risk areas (Pere P Simarro et al. 2012)): screening once every 
two years; (iii) low-intensity transmission (<1 case/10,000 population and year; corresponding 
to low and very low risk areas (Pere P Simarro et al. 2012)): no active case finding. 
It is impossible to repeatedly screen the entire human population due to avoidance (resulting 
from fear of stigma) and costs (Robays et al. 2007; Hasker et al. 2011). Other problems include 
indifference to repeated testing and waning interest in the face of declining local incidence, 
population mobility, poor access (logistics, social and political fragility) and the high costs of 
vertical screen and treat campaigns. There are also sero-positive individuals who are 
parasitologically negative and therefore not treated (Jamonneau et al. 2012; Kagbadouno et al. 
2012), while some identified cases may refuse treatment. All of these factors pose challenges 
to eliminating the parasite from the human reservoir. 
 Vector control 
The fragile biological cycle of T. b. gambiense, including the low reproductive capacity of the 
tsetse fly and the low proportion of infected tsetse (Brun et al. 2010; Malvy & Chappuis 2011), 
indicates that transmission breaks down with reduced tsetse population density. In west 
African savannahs, transmission no longer exists despite the continuous presence of tsetse; yet 
transmission had been intense in the 1930s – 40s (Courtin, Jamonneau, Duvallet, Camara, et al. 
2008). Of note, the cessation of transmission in these areas cannot be linked to deliberate tsetse 
control activities. A variety of tools for tsetse control are available in Gambiense HAT endemic 
areas, most notably traps and insecticide-treated targets. Targets — essentially simplified traps 
— are assumed to be more efficient for vector control than traps. While large targets are 
optimal for savannah tsetse (Morsitans group), multiple smaller targets have been shown to 
be more effective than fewer, larger ones for riverine tsetse (Palpalis group) (Esterhuizen et al. 
2011). The exact colour of the targets is also important (Lindh et al. 2012). Targets are well 
accepted by local people but questions regarding the sustainability of deployment remain. The 
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environmental impact of vector control using traps and targets is considered to be acceptable, 
even within national parks (Esterhuizen et al. 2011).  
Pyrethroids (e.g. deltamethrin) are used to spray tsetse resting and breeding sites. Aerial 
spraying of tsetse habitats is less relevant for T. b. gambiense, which is primarily found in 
forested areas nowadays. To be successful, the scale of control operations focusing on T. b. 
gambiense depends on the size of the focus (generally <500 km2) and must aim to reduce tsetse 
populations by 70% – >95% (Ian Hastings, personal communication) for 5 – 6 years (e.g. by 
implementing fly control at a level that results in a daily death rate of 2 – 4% (Artzrouni & 
Gouteux 2007)), after which time local T. b. gambiense transmission is assumed to have ceased, 
particularly if initial screen and treat efforts have reduced the parasite reservoir in the human 
population.  
The sterile insect technique (SIT; the release of sterile males) is not well suited to eliminate 
Gambiense HAT from its typically small-scale foci where tsetse constantly immigrate from 
surrounding, non-HAT-endemic areas. Technical, financial and operational issues also limit 
mass deployment of SIT (Torr et al. 2005).  
 Tools currently under development  
A number of new tools are currently being developed to diagnose and treat HAT and to 
control tsetse. Novel diagnostic tools and drugs promise to make diagnosis easier and more 
sensitive and to make treatment safer. Tiny targets for tsetse promise monetary savings and 
easier deployment compared to current standard traps and targets (Box 1). Figure 6 
summarises the current development status of a number of diagnostic tools and drugs that are 
potentially relevant for HAT control and elimination. The year in which new technologies 
become available is uncertain. In general, the development and release of diagnostic tests is 
faster than that of novel drugs. The delay between the availability of a new tool and its 
adoption and use in national Gambiense HAT control programmes is similarly uncertain but 
experience with NECT suggests that transition times can be fairly short(P P Simarro et al. 
2012). However, it must be noted that the introduction of a new molecule might need more 
time than the switch to other known molecules, as was the case for NECT.  
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Box 1.  
The first generation RDTs using native antigens, now produced by Standard Diagnostics (SD) and Coris, are an alternative to 
CATT. Owing to their product specifications, they can be used both for individual screening in health centres and for mass 
screening of the population. They require minimal infrastructure and medical training. As in the case of positive CATT results, 
parasitological confirmation of positive cases is required prior to the start of treatment due to their insufficient specificity 
(resulting in a low positive predictive value, given the low prevalence of infections) and due to the cost and complexity of 
current treatments. The second generation tests using recombinant antigens promise the following benefits: (i) easier and 
cheaper production compared to first generation tests; and (ii) detection of both T. b. gambiense and T. b. rhodesiense (CATT 
only works for T. b. gambiense).  
The mAECT, LED fluorescence microscopy and LAMP improve the sensitivity of parasitological diagnosis (confirmation of T. 
b. gambiense infection) in CSF (mAECT) and blood (LED fluorescence microscope and LAMP). LAMP facilitates DNA 
detection in both fresh and dry blood, making it possible to centrally test samples collected in locations without suitable 
laboratory infrastructure. Current development efforts for these tools focus on technology transfer, reducing costs and 
demonstrating the suitability of the methods for HAT endemic settings.  
The current approach for disease staging involves a lumbar puncture to obtain CSF, followed by its examination (with or 
without prior concentration) to determine the presence or absence of parasites and a white blood cell count. An RDT for HAT 
staging and monitoring treatment progress based on CSF biomarkers would improve the suitability of the test for resource-
constrained settings and likely its sensitivity. If such an RDT were based on blood biomarkers instead of CSF biomarkers, it 
would remove the need for lumbar puncture, again greatly improving its appeal to patients (pain) and health care 
professionals (ease of handling, need for specialised training).  
Two compounds are currently undergoing clinical tests: fexinidazole and an oxaborole. Fexinidazole is being developed as an 
alternative to NECT for the treatment of stage 2 T. b. gambiense HAT. The primary outcome of the current phase II/III trial is 
non-inferiority of fexinidazole to NECT. There are strong indications that fexinidazole could also be used to treat stage 1 T. b. 
gambiense and T. b. rhodesiense (both stages). Fexinidazole offers the following advantages: (i) superior safety profile compared 
to that of NECT and other drugs that it could potentially replace; (ii) easier administration than NECT (fexinidazole: one oral 
dose per day for 10 days; NECT: nifurtimox: three oral doses per day for 10 days plus eflornithine: 2x2 h intravenous infusions 
per day for seven days); (iii) long shelf life under tropical climate conditions; (iv) simplified logistics (NECT: four full 
treatments: 36 kg of 37.5 dm3); (v) reduced costs in terms of production (currently used drugs are donated rather than 
purchased by endemic countries), logistics, storage, administration, side effect management, etc.; (vi) better acceptance by 
patients. Together, these benefits would enable treatment provision at more peripheral levels of the health care system, 
facilitating access to treatment in rural settings. From the patient’s perspective, treatment with fexinidazole is more attractive 
due to easier administration and a favourable side effect profile, potentially reducing no-show rates after diagnosis and drop-
out rates during treatment.  
Using similar fexinidazole regimens to treat stage 1 and 2 T. b. gambiense HAT would eliminate the need for staging. Combined 
with a sensitive test for confirmatory parasitological diagnosis in blood, it would remove the need for lumbar puncture. This 
could also reduce drop-out/no-show rates of HAT suspects identified with rapid screening tests. 
The oxaborole SCYX-7158 has some advantages over fexinidazole, namely a single oral dose as opposed to 10 daily oral doses 
and protection against re-infection for a limited period due to the high level of active compound retained in the body over an 
extended period of time (at least two months). Some of the assumed advantages of both drugs still need to be confirmed in the 
on-going and upcoming clinical trials.  
The combination of a highly sensitive screening tool (i.e. RDT) and a safe (i.e. few and only trivial – moderate side effects), 
relatively cheap and easily administered (i.e. oral) drug (ideally single dose) for both stage 1 and 2 of both T. b. gambiense and 
T. b. rhodesiense could justify the unintentional treatment of a certain number of false-positive cases (note: a screening test needs 
to maximise sensitivity at the cost of specificity), altogether removing the need for confirmation of infections, staging and 
treatment progress monitoring. 
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Figure 6. Current developmental status of selected new tools for the diagnosis, treatment and surveillance of 
HAT that are relevant for its control and elimination (Source: DNDi and FIND) 
 
FIND has recently summarised advances in the development of rapid screening tests for T. b. 
gambiense, including tests to confirm the disease, to determine disease stage and to monitor 
treatment progress (FIND 2013). Other tests are also being developed (Büscher et al. 2014; 
Büscher et al. 2013), including syndromic algorithms (Palmer et al. 2013). The Institute of 
Tropical Medicine in Antwerp, Belgium has recently developed two rapid diagnostic test 
formats, a dipstick and a lateral flow device, the latter of which has been commercialised by 
Coris (Büscher et al. 2014; Büscher et al. 2013). A first generation lateral flow rapid diagnostic 
test (RDT) using native trypanosome antigens is commercially available (SD Bioline HAT) and 
used in Uganda and other countries. In our scenarios, we expect universal adoption of RDTs 
by 2016. The SD tests are individually packed and stable at 40°C for 25 months. The test 
substrate is whole blood from a finger prick and no additional infrastructure is required to run 
the test. The Coris test has comparable characteristics. A second generation RDT is under 
development and is based on recombinant antigens and designed to detect both T. b. gambiense 
and T. b. rhodesiense (for which currently no serological tests exist). We expect it to be available 
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in 2019. Considering the limited positive predictive value of serological tests in low-prevalence 
settings, parasitological tools remain important. The production of the mini-anion exchange 
centrifugation technique (mAECT), an established technique for parasitological confirmation 
of HAT infections in cerebrospinal fluid (CSF), has been successfully transferred to the 
Democratic Republic of Congo (DRC). Further parasitological confirmation tests to detect 
parasites in blood based on a light-emitting diode (LED) fluorescence microscope or loop-
mediated isothermal amplification of DNA (LAMP) are being evaluated. These methods 
promise cost savings and higher diagnostic sensitivity than conventional methods. An RDT 
for disease staging and for monitoring treatment progress based on molecules (namely, 
neopterin or CXCL13) in the CSF is being developed, though its use may be limited if new 
drugs come to market that can safely and efficiently treat both disease stages. The possibility 
of exploiting blood biomarkers is also being explored. 
With regard to drugs, the nitroimidazole compound fexinidazole (Torreele et al. 2010; Brun et 
al. 2011; Maser et al. 2012) is currently undergoing phase II/III trials for treating Gambiense 
HAT stage 2 disease and is scheduled to be submitted for registration in late 2015 (approval 
expected in 2016). Originally, fexinidazole was intended to first replace nifurtimox-
eflornithine combination therapy (NECT) for treating stage 2 T. b. gambiense HAT and later, in 
a second step in 2019, stage 1 T. b. gambiense and T. b. rhodesiense HAT. Efforts are now 
underway to amend the protocol of the current trial to allow simultaneous registration for 
treating stage 1 and stage 2 Gambiense HAT. Administration of the drug is oral, with one daily 
dose for 10 days. The benzoxaborole SCYX-7158 is another drug candidate currently under 
development. It is well absorbed upon oral administration and is designed as a single dose 
application to cure both stage 1 and stage 2 forms of T. b. gambiense and T. b. rhodesiense 
(Maser et al. 2012; Jacobs et al. 2011). The drug is only slowly metabolized and eliminated from 
the body, and is expected to confer protection against re-infection for at least two months post-
treatment. The drug is currently undergoing phase I clinical trials and we expect it to be 
commercially available by 2019.  
Mini targets of reduced size (Esterhuizen et al. 2011) and higher attractiveness to tsetse flies 
(Lindh et al. 2012; Rayaisse et al. 2010) compared to standard ones promise considerable cost 
effectiveness gains as they are more effective, require less material per killed tsetse, and are 
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easier and thus cheaper to deploy (Solano et al. 2013). They are already available for 
deployment.  
2.5 Results: Scenarios for HAT control 
Proposed scenarios for controlling and eliminating Gambiense HAT 
A total of nine scenarios were developed based on the overview of current and emerging tools 
for diagnosing and treating Gambiense HAT and for killing tsetse flies. Each scenario describes 
interventions for case identification, diagnostics, treatment and vector control to be 
implemented in the given period (Figure 7).  
Figure 7. Summary of scenarios for control and elimination of Gambiense HAT 
 
The baseline scenarios for each period rely on case detection for identifying infected 
individuals and for determining their treatment, i.e. a reduction of the parasite reservoir in 
humans. Diagnosis and treatment approaches evolve as new technologies become available. 
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Suggested intervals for active case finding (screening) campaigns depend on the current 
transmission intensity (once a year in high-intensity transmission areas, every two years in 
moderate-intensity transmission areas) while passive case detection must be available 
throughout the endemic area. Active screening is implemented until incidence reaches the 
low-transmission threshold (<1 case/10,000 population per year). In the period 2013 – 2015, 
diagnosis and treatment follow current standard approaches: truck-based mobile teams use 
CATT for screening, parasitological confirmation of infection is based on the visualization of 
parasites, lymph node aspirate or CSF is obtained by lumbar puncture, staging is based on 
CSF examination (criteria for stage 2: detection of parasites or >5 white blood cells/mm3), 
treatment is with pentamidine for stage 1 disease and NECT for stage 2, and treated patients 
are followed to detect relapses and to verify treatment success.  
Changes for the period 2016 – 2018 include the introduction of RDTs (first generation) for 
screening by mobile teams relying on motorbikes instead of trucks, and the introduction of 
fexinidazole to treat stage 2 patients. Parasitological confirmation and staging remain 
important and are performed either by truck-based teams or in health facilities. From 2019 
onwards, option 1 assumes that staging (and hence, obligatory lumbar puncture) is not 
required anymore as fexinidazole is used to treat both stage 1 and stage 2 of the disease. In 
option 2, a switch to second generation RDTs and the introduction of oxaboroles for treatment 
mean that neither confirmation nor staging of infections are required any longer, and that 
treated individuals are protected against re-infection for a certain period. 
To accelerate Gambiense HAT elimination, vector control is proposed for high-transmission 
foci or even across all areas with active transmission, along with screen and treat and passive 
case detection, as appropriate. The cheapest and most effective vector control tools available 
are proposed, i.e. baited and insecticide-treated targets, deployed at a density of 20/linear km 
or ~10/km2 for palpalis group tsetse in riverine foci. Depending on local conditions, 
modifications may ultimately be required along these lines: (i) foci with high cattle/livestock 
density: insecticide treatment of livestock; (ii) forest foci: targets at higher density; (iii) 
mangrove foci: ground/boat-based spraying (in addition to targets if the latter can be deployed 
at all). Elimination scenario I for 2013 – 2015 can be summarised as follows: standard targets 
are used for vector control in addition to the diagnostic and treatment algorithms established 
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for the Gambiense HAT control scenario for the same period. In elimination scenario II for 
2013 – 2015, tiny targets replace the standard targets for vector control. Elimination scenario 
IV for 2016 – 2018 and elimination scenarios VI and VIII for 2019 onwards resemble the control 
scenarios for the respective periods with the addition of tiny targets for vector control.  
 Target areas and target population for Gambiense HAT control and 
elimination 
The basic Gambiense HAT control and elimination scenarios III, V and VII cover all areas and 
populations at very high to moderate risk according to Simarro et al. (Pere P Simarro et al. 
2012), translating into a an area of 693,600 km2 inhabited by 19,596,000 people in 13 countries 
(Table 2). Among them, three countries (Cameroon, Côte d’Ivoire, Sierra Leone) had no 
functional national HAT programme at the time of the last comprehensive review 
(Anonymous 2006). Meanwhile, Cameroon and Côte d’Ivoire have been able to re-establish 
their respective programmes. The population at risk in Sierra Leone is 1,000 people on <100 
km2. 
A comprehensive Gambiense HAT elimination programme would need to cover all potential 
transmission areas. This translates into an area of 1,380,600 km2, inhabited by 56,986,000 
people in 14 countries (Table 2). The population at risk in countries without a functional 
control programme (Anonymous 2006) is 171,000 people on 1,800 km2 in Sierra Leone and 
2,182,000 people on 71,000 km2 in Nigeria.  
Compared to the base scenarios, interventions with the aim of accelerated Gambiense HAT 
elimination would need to cover twice the area at risk (an expansion from 693,600 km2 to 
1,380,600 km2) and 2.9 times more people (an expansion from 19,596,000 individuals to 
56,986,000 individuals).
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Table 2. Area and population at risk of Gambiense HAT, stratified by control and programme status and scenario (source: Simarro et al.) 
 Area (km2)    Population     
National programme status Number of 
countries 
Very high 
and high risk 
Moderate 
risk 
Low and 
very low risk 
Total Very high 
and high risk 
Moderate 
risk 
Low and 
very low risk 
Total 
Current control and 
elimination scenarios III, V 
and VII 
         
Active national HAT 
control programme 
104 234,500 454,600 N.A. 689,100 5,162,000 14,175,000 N.A. 19,337,000 
No active national HAT 
control programme 
35 0 4,500 N.A. 4,500 0 259,000 N.A. 259,000 
Total 13 234,500 459,100 N.A. 693,600 5,162,000 14,434,000 N.A. 19,596,000 
Elimination scenarios I, II, 
IV, VI and VIII 
         
Active national HAT 
control programme 
106 234,500 454,600 636,700 1,325,800 5,162,000 14,175,000 31,993,000 51,330,000 
No active national HAT 
control programme 
47 0 4,500 50,300 54,800 0 259,000 5,397,000 5,656,000 
Total 14 234,500 459,100 687,000 1,380,600 5,162,000 14,434,000 37,390,000 56,986,000 
                                                     
4 Angola, CAR, Chad, Congo, DRC, Equatorial Guinea, Gabon, Guinea, South Sudan, Uganda. 
5 Cameroon, Côte d’Ivoire and Sierra Leone (with 1,800 km2 at risk, inhabited by 171,000 people where transmission is believed to have ceased). 
6 Angola, CAR, Chad, Congo, DRC, Equatorial Guinea, Gabon, Guinea, South Sudan, Uganda. 
7 Cameroon, Côte d’Ivoire, Nigeria and Sierra Leone (the last with 1,800 km2 at risk, inhabited by 171,000 people where transmission is believed to have ceased). 
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2.6 Discussion 
Eliminating Gambiense HAT is a declared goal of WHO (WHO 2012). However, the most 
effective strategy for reaching this outcome is not yet clear. Elimination, defined as the 
sustained cessation of transmission of a pathogen in a defined geographic area as a result of 
human activities, can be achieved by ensuring that Rc, is below 1 for a sufficient amount of 
time. This can be achieved either by reducing the force of infection on humans through vector 
control or by reducing the force of infection on vectors by treating infective humans. As has 
been pointed out for malaria elimination (Moonen et al. 2010), sustaining the status of 
elimination requires either: i) eliminating the vector in addition to the pathogen; ii) preventing 
re-introduction from neighbouring areas that may not (effectively) be pursuing elimination 
through border screening; or iii) coordinating and implementing an effective elimination 
campaign in all endemic areas. Although elimination of tsetse may be easier to achieve than 
that of mosquito species (e.g. (Vreysen et al. 2000)), many areas, particularly riverine ones, may 
be prone to reinvasion due to the dispersal behaviour of tsetse (Rogers & Randolph 2002). 
Likewise, border screening for HAT is complicated by test system specifications, movements 
related to armed conflict and the occurrence of the disease in remote, often inaccessible or 
poorly served locations. Thus, in the absence of eradication, most HAT endemic countries will 
need to maintain post-elimination surveillance and response systems to prevent 
reestablishment via migrant cases. What is unknown is whether post-elimination surveillance 
can rely on the currently established passive case detection or whether more intense, active 
surveillance will be required and should the approach differ between areas with varying basic 
reproduction numbers (receptivity).  
Although Gambiense HAT elimination has been deemed achievable, several challenges and 
uncertainties remain, such as gaining access for sufficient periods of time to areas that are 
currently experiencing political upheaval or strife (Simarro et al. 2013) or are otherwise 
inaccessible, as well as uncertainty regarding the extent to which these areas serve as sources 
of reinfection to nearby foci. Similarly, although case underreporting has greatly decreased 
over the past two decades, the latest estimates still assume a factor of three (Simarro et al. 
2011). The spatial distribution of these unrecognised cases could affect elimination campaigns 
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if they represent previously unknown pockets of transmission. Other sources of reinfection 
relate to uncertainty regarding the true case fatality rate (Jamonneau et al. 2012; Checchi et al. 
2008), the frequency of non-fatal infections and the extent to which trypanotolerant individuals 
contribute to transmission, if at all. 
Similar uncertainty exists regarding the existence and importance of non-human animal 
reservoirs for T. b. gambiense. Based on investigations using mathematical models of pathogen 
transmission, several authors have posited that since the contribution of humans to the basic 
reproduction number of HAT is below one, a contribution from a non-human reservoir is 
probable (Funk et al. 2013; Rogers 1988). Others have argued that the contribution of animal 
reservoirs is likely negligible (Simarro et al. 2013). Resolving this debate is currently a priority 
as the existence of non-human reservoirs would necessitate a change in strategy or even affect 
the prospects of elimination. 
We present options for achieving Gambiense HAT elimination that include both established 
and novel tools and that are considered relevant by a large panel of experts. These scenarios 
are simplified representations of the true efforts needed to eliminate the disease and it is likely 
that a combination of strategies will be needed to account for local realities. The inclusion of 
tools currently under development increases the uncertainty that the scenarios can one day be 
applied as described but most agree that only the advent of critically needed drugs and 
diagnostic tools will allow for Gambiense HAT elimination (Brun et al. 2010). The location and 
extent of traditional Gambiense HAT foci has been mapped over recent years and is now well 
established in most countries (Pere P Simarro et al. 2012; Simarro et al. 2010). Thus, mapping 
requirements for planning Gambiense HAT elimination are minimal. Another critical issue for 
any elimination programme is the sustainability of efforts needed until the last case has been 
treated and recurrence of the infection can be ruled out with a high degree of confidence. 
Surveillance and active response systems will become increasingly important as case numbers 
decline and the focus shifts from standardised approaches to tailored solutions adapted to the 
realities of the remaining pockets of transmission. Gambiense HAT arguably is already close 
to such a situation, with transmission mostly restricted to remote and under-served 
communities.  
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Any effort to eliminate Gambiense HAT must ensure that capacity for passive case detection 
and appropriate treatment of identified cases can reach the required levels across the entire 
focus. Following the cessation of local Gambiense HAT transmission, robust and effective 
surveillance coupled with an active rapid response mechanism to any new cases is required 
until transmission also ceases in neighbouring foci. Surveillance thus needs to be established 
throughout the focus and maintained for several years after the last case has been detected 
(World Health Organization (WHO) 2013b). Projecting the effectiveness and costs of such an 
active surveillance-response system is challenging as little experience exists to guide such 
efforts, not only in the field of Gambiense HAT but also for other diseases (Kelly et al. 2013).  
Other important research questions are: What is the likelihood that the stated goal will be 
achieved when a given scenario is implemented over a certain time and how long would it 
take to achieve the intended outcome? What is the overall cost of implementing the scenarios 
and what are the public health and health service implications? For established methods, 
experience with control programmes can provide insights into these questions for specific 
localities. For instance, an intense period of twice-yearly population screening using the 
indirect immunofluorescent antibody test (IFAT) and treatment of serological cases resulted 
in a remarkable decline of prevalence from 1.42% to 0.03% over the course of six years in the 
Luba focus of Bioko Island. Less frequent screening of the population was maintained for the 
following 14 years until the focus was considered inactive (Simarro et al. 2006). Such insights 
clearly have value for policy makers but it is debatable whether these experiences can be 
extrapolated to other foci with different characteristics. For example, Luba is located on an 
island and would therefore be less prone to immigration of either infected flies or humans; it 
also had an excellent level of participation and acceptance of screening and treatment. Such 
extrapolation is necessary, however, and will also have to include predictions about the 
duration of interventions and the likelihood of reaching elimination. By considering (multiple) 
technologies that are currently under development, we increased the uncertainty of the 
expected outcomes; some tools may not ultimately become available or only become available 
later than anticipated. Additionally, new tools may lead to more than increased efficacy or 
decreased costs; they could also potentially allow for strategic changes.  
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Here, we have given an overview of nine distinct strategies that reflect not only the currently 
available tools at our disposal but also highlight novel strategies according to their projected 
release dates and speculate on their relevance for Gambiense HAT elimination. The multitude 
of options available and the low number of cases precludes conducting controlled trials for all 
of these scenarios. Finding the optimal scenario for a given endemic setting should therefore 
be informed by theoretical work. A possible framework for guiding such decisions is given by 
benefit-cost and cost-effectiveness analyses, based on appropriate costing and dynamic 
transmission models and on an understanding of the wider societal implications of HAT 
elimination. Our scenarios can form the basis for modelling feasibility and the health and 
economic impacts of Gambiense HAT elimination (Tediosi et al. 2013), providing valuable 
information to a wide range of actors working on HAT control, research and development. 
The advent of powerful tools to detect and treat HAT cases and control tsetse flies at a time of 
unprecedented political commitment and financial investments in NTD control offers a unique 
opportunity to eliminate the disease. The rigorous implementation of trials to test the efficacy 
of novel tools will already go some way towards contributing to the local Gambiense HAT 
elimination, since they require an appropriate number of patients, the provision of quality care 
and the establishment of infrastructure, all of which will have a lasting impact on the local 
epidemiology in the few remaining foci where an appropriate number of new cases occur.  
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3.1 Abstract 
Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite 
Trypanosoma brucei gambiense or T. b. rhodesiense. It is transmitted to humans via the tsetse fly.  
Approximately 70 million people worldwide were at risk of infection in 1995, and 
approximately 20,000 people across Africa are infected with HAT.  The objective of this review 
was to identify existing economic evaluations in order to summarise cost-effective 
interventions to reduce, control, or eliminate the burden of HAT. The studies included in the 
review were compared and critically appraised in order to determine if there were existing 
standardised methods that could be used for economic evaluation of HAT interventions or if 
innovative methodological approaches are warranted. A search strategy was developed using 
keywords and was implemented in January 2014 in several databases. The search returned a 
total of 2,283 articles. After two levels of screening, a total of seven economic evaluations were 
included and underwent critical appraisal using the Scottish Intercollegiate Guidelines 
Network (SIGN) Methodology Checklist 6: Economic Evaluations.   Results from the existing 
studies focused on the cost-effectiveness of interventions for the control and reduction of 
disease transmission. Modelling was a common method to forecast long-term results, and 
publications focused on interventions by category, such as case detection, diagnostics, drug 
treatments, and vector control. Most interventions were considered cost-effective based on the 
thresholds described; however, the current treatment, nifurtomix-eflornithine combination 
therapy (NECT), has not been evaluated for cost-effectiveness, and considerations for cost-
effective strategies for elimination have yet to be completed. Overall, the current evidence 
highlights the main components that play a role in control; however, economic evaluations of 
HAT elimination strategies are needed to assist national decision makers, stakeholders, and 
key funders. These analyses would be of use, as HAT is currently being prioritized as a 
neglected tropical disease (NTD) to reach elimination by 2020.   
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3.2 Background 
Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite 
Trypanosoma brucei gambiense or T. b. rhodesiense and is transmitted to humans via the tsetse fly.  
Approximately 70 million people worldwide were at risk of infection in 1995 (WHO n.d.), and 
although 7,216 cases were reported in 2012 (World Health Organization (WHO) 2013c), it is 
estimated that approximately 20,000 people across Africa are infected with HAT (World 
Health Organization (WHO) 2013c).  According to the Global Burden of Disease, recent 
estimates of years lived with disability (YLDs) for HAT annually range from 2,000 to 25,000 
(Vos et al. 2012). There are approximately 30 African countries affected by this disease, and it 
has been identified by the World Health Organization (WHO) as a neglected tropical disease 
(NTD) (WHO 2013).  
WHO describes the disease as a neurological breakdown that is caused by the trypanosome 
parasite in the brain, which eventually leads to a coma or death if a patient is not treated 
(World Health Organization (WHO) 2013a).  Patients are identified by self-reporting to health 
care centres (referred to as “passive case detection”), while active screening by trained 
professionals in mobile teams continues in high- and moderate-transmission areas. Active 
screening campaigns are carried out in remote villages, and a series of tests are used for the 
diagnosis of the disease. The current diagnostic algorithms for HAT include the card 
agglutination test for trypanosomiasis (CATT) followed by full blood assays to identify the 
parasite microscopically. Lumbar puncture with parasitological confirmation is then used for 
staging of the disease. Patients that are diagnosed with HAT are then referred to HAT 
treatment centres. Limited active screening is done for T. b. rhodesiense because there is no 
serological test available to facilitate easy identification. Hence, most T. b. rhodesiense cases are 
detected by clinical signs and symptoms. The subsequent diagnostic steps are similar to T. b. 
gambiense in that parasite detection is done using chancre aspirate or blood, and staging of the 
disease again uses cerebrospinal fluid obtained from lumbar puncture.  The treatments for T. 
b. gambiense and T. b. rhodesiense also differ. Treatment for T. b. gambiense includes a 7-day 
intramuscular injection treatment of pentamidine for patients in stage 1 of the disease that is 
generally well tolerated, with minor adverse events.  Nifurtimox-eflornithine combination 
therapy (NECT) is a 14-day in-hospital chemotherapy treatment that is required for patients 
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suffering from stage 2 of HAT. The adverse events commonly seen in patients treated with 
NECT are considered to be mild to moderate in severity. For HAT T. b. rhodesiense, the 
treatment for stage 1 includes weekly intravenous injections of suramin over the course of 5 
weeks (World Health Organization (WHO) 2013a). Negative reactions to suramin coincide 
with the patient’s health status, but overall, it is a well-tolerated treatment. Stage 2 treatment 
for T. b. rhodesiense is a 10-day treatment of melarsoprol. Melarsoprol is the most toxic of the 
HAT treatments, leading to encephalopathic syndrome in 5% to 18% of patients treated and 
often resulting in death. Vector control methods for prevention of HAT T. b. rhodesiense are 
commonly used, as the disease is well-known to have an animal reservoir that contributes to 
transmission in both human and animal populations (World Health Organization (WHO) 
2013a).   In regards to HAT T. b. gambiense, historically, vector control has not been suggested. 
However, evidence of an animal reservoir for T. b. gambiense has been discussed (Simo et al. 
2014; Funk et al. 2013), and vector control was recently encouraged by WHO as an integrated 
strategy for HAT (World Health Organization (WHO) 2013a).  
The year scheduled for HAT elimination is 2020 (WHO 2012), and as this deadline approaches, 
research groups are currently developing new drug treatments and diagnostic tools (Büscher 
et al. 2014; Drugs for Neglected Diseases initiative (DNDi) 2014b; Foundation for Innovative 
New Diagnostics n.d.) for HAT. Additionally, experts in vector control methods are also 
seeking interventions that would be more cost-effective and feasible for communities at risk 
for the disease. Even traditional teams that have gone out via trucks are now being 
reconsidered in combination with newer drug treatments using motorbike teams. Although 
some screening programs include a component of community sensitization, community 
involvement within control and elimination campaigns and knowledge of how this “disease 
awareness” is translated into behavioural changes and attitudes within affected populations 
need to be considered. There is now a need to evaluate not only the possibility of control and 
elimination for HAT but also how these new interventions and approaches may contribute to 
the grand scheme of such endeavours. 
WHO has provided recommendations to improve certain factors likely to achieve elimination 
(World Health Organization (WHO) 2013c), and decision makers have also committed to 
funding the elimination of the disease (London Declaration 2013);  yet, a clear path to the 
Page 64 of 321 
 
achievement of this goal is not available, nor is it clear what the most efficient pathway 
towards elimination would be. In addition, thus far there has been no synthesis of the current 
costs and effectiveness of all strategies that could intervene in the transmission of the disease. 
The objective of this review was to identify existing economic evaluations in order to 
summarise cost-effective interventions to reduce, control, or eliminate the burden of HAT. The 
studies included in the review were compared and critically appraised in order to determine 
if there were standardised methods that could be used for economic evaluations of HAT 
interventions or if innovative methodological approaches are warranted.  
3.3 Methods  
 Literature Search Strategy 
A literature search was conducted via the OvidSp interface on January 22, 2014 using 
keywords for HAT specific to the Medical Subject Headings (MeSH) terms required for 
Medical Literature Analysis and Retrieval System Online (MEDLINE) and Embase databases. 
An economic filter developed by Scottish Intercollegiate Guidelines Network (SIGN) was also 
applied. (Refer to Supporting Information S1.) The Journal Storage (JSTOR) database was also 
searched using the following key words: African trypanosomiasis OR trypanosom& OR 
"sleeping sickness" AND cost& AND economics.  In addition, the following keywords were 
also searched in the Database of Abstracts of Reviews of Effects (DARE), National Health 
Service Economic Evaluation Database Health Technology Assessment (NHSEED HTA), and 
Cochrane databases: “African” AND “Trypanosomiasis” OR “sleeping sickness”.  All citations 
were downloaded into Mendeley, where duplicates were identified and removed.  
 Literature Screening & Inclusion/Exclusion Criteria 
Screening of the articles was done in two stages. At the first level, all titles and abstracts were 
screened.  Articles that were considered potentially relevant were then assessed at the second 
level, in which the full text was read. After reading the full text, articles that still met the 
inclusion criteria were considered. A full description of the inclusion and exclusion criteria is 
available in appendix B. Data were screened on both levels according to the outline of 
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population-intervention-comparators-outcomes-setting (PICOS) criteria, in which the 
population pertained to humans. Evaluations regarding strains of both HAT T. b. gambiense 
and T. b. rhodesiense were reviewed, although outcomes only pertaining to humans impacted 
by the disease were taken into consideration (no animal implications). Interventions (I) and 
comparators (C) included any intervention that could lead to prevention or reduction of 
disease in human populations (including vector control). The outcomes (O) that were 
considered for review were costs, consequences (life-years saved [LYS], disability-adjusted life 
years [DALYs], etc.), and the incremental cost-effectiveness ratio (ICER), while the setting (S) 
included any African country. For the purpose of this analysis, an economic evaluation was 
defined by the Drummond et al. definition of a “full economic evaluation,” and therefore, both 
costs and consequences of two or more alternatives had to be present in the analyses evaluated 
(Drummond et al. 2005). In cases in which an incremental analysis was not performed, articles 
were not excluded. Instead, if there was sufficient information in the publication to calculate 
the ICER, it was calculated during the review process. If there was insufficient information to 
calculate the ICER, it was noted in the critical appraisal that an incremental analysis was not 
present. No time constraints were added to the search. 
 Quality Assessment and Critical Appraisal 
The quality of the included studies was assessed using the SIGN Methodology Checklist 6: 
Economic Evaluations Version 3.0 (Scottish Intercollegiate Guidelines Network (SIGN) n.d.), 
which was composed of two parts. The first portion contained questions regarding the internal 
and external validity of the publication. Items in the sections were assessed using answers of 
“Yes,” “No,” or “Can’t say.” The second portion of the checklist addressed the reviewers 
overall assessment of the study and also provided the reviewer with an area to judge if the 
article was “unacceptable,” “acceptable,” or of “high quality.” Studies that received a “Yes” 
on 65% or more of the questions in Section 1 were considered acceptable to the authors.  
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3.4 Results 
 Literature Search Results 
The NHSEED, JSTOR, MEDLINE, and Embase searches yielded a total of seven articles, 1,000 
articles, 595 articles, and 673 articles, respectively.  An additional eight articles from the grey 
literature, reference lists, and referrals from subject matter experts were also included. There 
were a total of 2,283 studies found, and after the removal of duplicates, 2,095 were chosen for 
primary screening (title and abstracts). A total of 41 publications were then selected for full-
text screening. Thirty-four studies were excluded after full-text review, and reasons for 
exclusion were recorded. (Refer to Table 3) Seven full texts (Shaw 1989; Politi et al. 1995; Shaw 
& Cattand 2001; Lutumba, Robays, Miaka, et al. 2005a; Lutumba, Meheus, et al. 2007; Lutumba, 
Makieya, et al. 2007b; Robays et al. 2008)  were included for full critical appraisal and data 
abstraction for analysis.  (Refer to Figure 8) 
Table 3. Characteristics of excluded studies at second-level screening 
Author Year Reason excluded 
Abila (Abila et al. 2007)  2007 Cost-effectiveness but interventions and 
outcomes related to fly population only 
Brandl  (F E Brandl 1988) 1988 Costs only, no effectiveness 
Brightwell (Brightwell et al. 1991)  1991 Cost per trap discussed, paper related to 
effectiveness of trap as opposed to cost-
effectiveness of relative comparators 
Checchi (Checchi et al. 2011) 2011 Screening algorithms (sensitivity/specificity 
outcomes only) 
Esterhuizen (Esterhuizen et al. 2011)  2011 No actual costs discussed, just effectiveness of 
fly traps 
Etchegorry (Etchegorry et al. 2001)  2001 Costs only, no effectiveness 
Fèvre (Fevre, Wissmann, et al. 2008) 2008 DALYs and burden of illness 
Fèvre (Fevre, Odiit, et al. 2008) 2008 DALYs and burden of illness 
Gouteux (Gouteux et al. 1987) 1987 Costs only, no effectiveness 
Jordan (JORDAN 1961) 1961 Discussion only of economic importance, not 
actual economic analysis 
Kamuanga (Mulumba Kamuanga et al. 2001) 2001 CBA using CV but outcomes  based on 
preference for animals and not HAT 
Laveissière (Laveissiere & Grebaut 1990) 1990 Costs only, no effectiveness 
Laveissière (Laveissiere et al. 1998) 1998 Costs only, no effectiveness 
Leygues (Leygues & Gouteux 1989) 1989 Socioeconomic outcomes, not cost-effectiveness 
Lutumba (Lutumba, Robays, Miaka mia Bilenge, et 
al. 2005) 
2005 Costs only, no effectiveness 
Lutumba (Lutumba et al. 2006)  2006 Costs only, no effectiveness 
Matemba (Matemba et al. 2010) 2010 Costs and DALYs for one area, not comparative 
analysis 
McDermott (McDermott & Coleman 2001)  2001 Modelling of vector control only, not actual 
economic analysis 
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Mitashi (P Mitashi et al. 2012) 2012 Screening algorithms (sensitivity/specificity 
outcomes only) 
Mugasa (Mugasa et al. 2012)  2012 Screening algorithms (sensitivity/ specificity 
outcomes only) 
Okoth (Okoth 1991)  1991 Costs only, no effectiveness 
Putt (Putt et al. 1988) 1988 Costs only, no effectiveness 
Ruiz-Postigo (Ruiz Postigo et al. 2001) 2001 Costs only, no effectiveness 
Shaw (Shaw 2004)  2004 Chapter 20 about the economics of 
trypanosomiasis; summary of research but no 
formal incremental CEA  
Shaw (Shaw et al. 2006) 2006 Prevention and outcomes focussed on livestock, 
not human outcomes 
Shaw (Shaw et al. 2007) 2007 Costs only, no effectiveness 
Shaw (Shaw 2009) 2009 Costs only, no effectiveness 
Shaw (Shaw et al. 2013) 2013 Costs only, no effectiveness 
Simarro (Simarro et al. 2011) 2011 Costs only, no effectiveness 
Simarro (P P Simarro et al. 2012)  2012 Costs only, no effectiveness 
Trowbridge (Trowbridge et al. 2000) 2000 Abstract only; did not mention any costs, just 
DALYs  
Vale (Vale & Torr 2005) 2005 Cost and benefits but related to vector control 
interventions related to fly populations only 
Vos (Vos et al. 2012) 2012 DALYs and burden of illness 
WHO Report (World Health Organization (WHO) 
1998) 
1998 Costs only, no effectiveness 
Abbreviations: CBA, cost-benefit analysis; CV, contingent valuation, CEA = cost-effectiveness analysis, DALYs=disability adjusted life years 
Figure 8. PRISMA diagram 
 
 Quality Assessment and Critical Appraisal 
The quality scores for the seven included studies (Shaw 1989; Politi et al. 1995; Shaw & Cattand 
2001; Lutumba, Robays, Miaka, et al. 2005a; Lutumba, Meheus, et al. 2007; Lutumba, Makieya, 
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et al. 2007b; Robays et al. 2008)  displayed in Table 4 (SIGN Methodology Checklist 6: Economic 
Evaluations) demonstrated that on average 81% (67%–89%) of the items stipulated by the 
SIGN checklist were addressed. Economic theory suggests that individuals have a time 
preference in regards to gains, and hence, costs and outcomes in the future are less valuable 
than those in the present (Morris et al. 2007). This concept is referred to as “discounting” and 
is standard methodology in economic evaluation; however, five out the seven studies in this 
review did not address it (Politi et al. 1995; Shaw & Cattand 2001; Lutumba, Robays, Miaka, et 
al. 2005a; Lutumba, Meheus, et al. 2007; Robays et al. 2008). Each publication considered the 
cost and consequence compared to more than one intervention for HAT; however, three of the 
publications (Shaw 1989; Shaw & Cattand 2001; Lutumba, Robays, Miaka, et al. 2005a) did not 
include an incremental analysis to examine the marginal benefit of adopting one intervention 
compared to the next best option. A single study (Lutumba, Meheus, et al. 2007) did not have 
a clear objective, and Shaw’s study did not justify the study design or clearly describe the cost 
sources (Shaw 1989). All but one study (Lutumba, Makieya, et al. 2007b) completed a 
sensitivity analysis in addition to the base results. All studies discussed the economic 
importance of the question and had outcomes that could be relevant for decision makers. 
Overall, all studies were judged to be “acceptable” for this review.   
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Table 4. Critical appraisal (Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist 6: Economic Evaluations) 
Author Question Shaw (Shaw 
1989)  
Politi (Politi et 
al. 1995)  
Shaw (Shaw & 
Cattand 2001)  
Lutumba(Lutu
mba, Robays, 
Miaka, et al. 
2005b)  
Lutumba  
(Lutumba, 
Makieya, et al. 
2007b)  
Lutumba 
(Lutumba, 
Meheus, et al. 
2007)  
Robays (Robays 
et al. 2008)  
Year   1989 1995 2001 2005 2007 2007 2008 
SECTION 1. Internal Validity               
1.1 The study addresses 
an appropriate and 
clearly focused 
question 
Yes Yes Yes Yes No Yes Yes 
1.2 The economic 
importance of the 
question is clear 
Yes Yes Yes Yes Yes Yes Yes 
1.3  The choice of study 
design is justified  
Can't say Yes Yes Yes Yes Yes Yes 
1.4 All costs that are 
relevant from the 
viewpoint of the study 
are included  and are 
measured and valued 
appropriately 
No Yes Yes Yes Yes Yes Yes 
1.5 The outcome 
measures used to 
answer the study 
question are relevant 
to that purpose and 
are measured and 
valued appropriately 
Yes Yes Yes Yes Yes Yes Yes 
1.6 If discounting of 
future costs and 
outcomes is necessary, 
it has been performed 
correctly 
Yes NA No NA Yes NA Can't say 
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1.7 Assumptions are 
made explicit and a 
sensitivity analysis 
performed 
Yes Yes Yes Yes No Yes Yes 
1.8 The decision rule is 
made explicit, and 
comparisons are made 
on the basis of 
incremental analysis 
No Yes No No*  Yes Yes Yes 
1.9 The results provide 
information of 
relevance to policy 
makers 
Yes Yes Yes Yes Yes Yes Yes 
Total 
fulfilment 
  6 8 7 7 7 8 8 
    67% 89% 78% 78% 78% 89% 89% 
SECTION 2. Overall Assessment of the Study  
  
2.1 How well was the 
study conducted? 
Acceptable Acceptable Acceptable Acceptable Acceptable Acceptable Acceptable 
2.2 Are the results of this 
study directly 
applicable to the 
patient group 
targeted by this 
guideline? 
Yes Yes Yes Yes Yes Yes Yes 
*Base case analysis was not incremental, but sensitivity analysis had an incremental analysis 
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 Characteristics of Included Economic Evaluations  
Each of the seven included publications had varying characteristics, as summarised in Table 
5. The first publication of a full economic evaluation for HAT identified was completed in 1989 
by Alexandra Shaw (Shaw 1989), with the next publication coming in 1995 (Politi et al. 1995).  
The remaining five publications were published from 2005 to 2008 (Lutumba, Robays, Miaka, 
et al. 2005b; Lutumba, Makieya, et al. 2007b; Lutumba, Meheus, et al. 2007; Shaw & Cattand 
2001; Robays et al. 2008). The evaluations covered four African countries: Democratic Republic 
of the Congo (DRC), Uganda, Côte d’Ivoire, and Angola. Most (3/7) evaluations (n=3) came 
from DRC (Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007; Lutumba, 
Makieya, et al. 2007b), with one study from Côte d’Ivoire (Shaw 1989), one study from Uganda 
(Politi et al. 1995), one study from Angola (Robays et al. 2008), and finally one study that 
included an analysis from both Uganda and Côte d’Ivoire (Shaw & Cattand 2001). Economic 
evaluations concerning HAT in human populations looked almost exclusively at the disease 
T. b. gambiense (71%), although in two instances the disease strain was not specified explicitly 
(Shaw 1989; Robays et al. 2008). A total of four economic evaluations (Shaw 1989; Lutumba, 
Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007; Robays et al. 2008) were considered 
cost-effectiveness analyses (CEA) in which the cost for a desired effect or consequence (e.g., 
lives saved, years of infection avoided, etc.) was measured. Two studies (Politi et al. 1995; 
Lutumba, Makieya, et al. 2007b)  included both a CEA and cost utility analysis (CUA) in which 
the utility was measured in DALYs. One study exclusively completed a CUA in which cost 
per DALY averted was measured as the main outcome (Shaw & Cattand 2001).  Overall, there 
was only one publication that was found in an “economic” journal, as the remaining articles 
were published in journals pertaining to tropical medicine and infectious diseases. Funding 
for the research was often not mentioned. However, WHO was referred to as a means of 
support in two publications (Politi et al. 1995; Lutumba, Robays, Miaka, et al. 2005b), and 
support from the Belgian Directorate General for Development Cooperation was also 
mentioned (Lutumba, Robays, Miaka, et al. 2005b).  
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Table 5. Characteristics of included economic evaluations 
Author Shaw (Shaw 
1989)  
Politi (Politi et al. 
1995)  
Shaw (Shaw & 
Cattand 2001)  
Lutumba(Lutumba, 
Robays, Miaka, et 
al. 2005b)  
Lutumba  
(Lutumba, 
Makieya, et al. 
2007b)  
Lutumba 
(Lutumba, 
Meheus, et al. 
2007)  
Robays (Robays 
et al. 2008)  
Year 1989 1995 2001 2005 2007 2007 2008 
Type of Intervention Case Detection 
and Diagnosis + 
Treatment,  
Vector Control  
Treatment  Case Detection 
and Diagnosis  
Diagnosis  Case Detection 
and Diagnosis  
Diagnosis  Treatment  
Country Côte D’Ivoire Uganda Uganda, Cote 
D’Ívoire 
DRC DRC DRC Angola 
Disease Strain Not mentioned T. b. gambiense T. b.  gambiense T. b.  gambiense T. b. gambiense T. b.  gambiense T. b.  gambiense* 
Type of Economic 
Evaluation 
CEA  CEA/CUA CUA CEA CEA/CUA CEA CEA 
Journal Annales de la 
Société belge de 
médecine 
tropicale 
Health Economics Médicine 
Tropicale 
Tropical Medicine 
and International 
Health 
Emerging 
Infectious 
Diseases 
Emerging 
Infectious 
Diseases 
Tropical Medicine 
and International 
Health 
Funding Not mentioned Internship at 
WHO 
Not mentioned WHO 
(Organisation 
mondiale de la 
Santé) and bourse 
de doctorat 
Direction Générale 
de la Coopération 
au Développement 
du Royaume de 
Belgique avec 
l'Institut de 
Médecine Tropicale 
Prince Leopold 
Financed partly 
by doctoral grant 
from the Belgian 
Directorate 
General for 
Development 
Cooperation by 
WHO 
None 
mentioned 
None 
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Additional 
Institutional 
Collaborators  
Members at  
WHO, member 
from Oxford 
University; 
VEERU 
Departments in 
WHO: Division of 
Intensified 
Cooperation with 
countries, 
Division of 
Control of 
Tropical Diseases 
and Special 
Programme in 
Tropical Disease 
Research; Batelle 
MEDTAP, 
London; 
anonymous 
referees 
TDR/WHO as 
Institutional 
collaborators 
None National Program 
in DRC 
HAT experts None 
Abbreviations: MEDTAP,  Medical Technology Assessment and Policy; TDR, Tropical Disease Research; VEERU, Veterinary Epidemiology and Economics Research Unit. *Inferred T. b. gambiense because of treatments being used. 
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 Interventions 
The majority (5/7) of the publications evaluated interventions that included case detection and 
diagnosis, while two of the articles evaluated treatment interventions of melarsoprol and 
eflornithine (difluoromethlyornithine [DFMO]) for stage 2, as the treatment for stage 1 was 
always considered to be pentamidine (Politi et al. 1995; Robays et al. 2008). Two publications 
by Lutumba (Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007) looked 
exclusively at sensitivity and specificity of diagnostic algorithms and staging algorithms, 
while one study also looked at the differences between treatment and vector control 
interventions in addition to case detection and diagnosis (Shaw 1989). The study by Shaw in 
1989 was the only publication that included a comparative economic analysis for vector control 
as an intervention to control HAT in a human population.   
 Economic Evaluation Description 
Key insights regarding the details of the included economic evaluations are described below 
and also summarised in Table 6.   
Methods and Software 
Six of the seven included studies used modelling to measure outcomes for the economic 
evaluation. Only one study completed an economic evaluation alongside a clinical trial. The 
most common form of modelling was decision tree modelling; the structure of the remaining 
models was not described in detail although they were all described as being implemented 
with spreadsheets. For decision tree models, TreeAge software (TreeAge Software, 
Williamstown, Massachusetts, United States) was used for three of four studies (Lutumba, 
Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007; Robays et al. 2008), and one 
publication did not mention which software was used. The two spreadsheet models that were 
reviewed (Shaw 1989; Shaw & Cattand 2001) used Super-Calc 4 (Sorcim, Silicon Valley, 
California, US) and Microsoft Excel (Microsoft Corp., Redmond, Washington, US) software, 
while the economic evaluation alongside clinical trial (EEACT) (Lutumba, Makieya, et al. 
2007b) relied on Microsoft  Access (Microsoft Corp., Redmond, Washington, US), Microsoft 
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Excel (Microsoft Corp., Redmond, Washington, US), and Epi Info 2002 (Centers for Disease 
Control and Prevention, Atlanta, Georgia, US).  
Model Structure, Assumptions & Validation 
A visual diagram of the model was provided for five of the six studies that included models 
(Politi et al. 1995; Shaw & Cattand 2001; Lutumba, Robays, Miaka, et al. 2005b; Lutumba, 
Meheus, et al. 2007; Robays et al. 2008).  Although descriptions of the six models were 
available, no details of the assumptions or justification for the inputs used in the modelling 
were addressed in any of the included literature. None of the articles reported completing an 
internal validation of the models, but the authors of one article (Lutumba, Meheus, et al. 2007)  
did compare their outcomes to other literature in similar areas for external validity.  
Population, Setting, and Perspective 
In one of the modelling studies, the number of patients modelled was not mentioned, while 
the remaining studies included 690 to 1,000,000 hypothetical patients. The clinical trial 
included a total of 57 patients from 47 households (Lutumba, Makieya, et al. 2007b). As 
mentioned previously, the populations were based on four countries (DRC, Côte D’Ivoire, 
Angola, and Uganda), with different settings including: rural communities, health centres, and 
a sleeping-sickness hospital ward.  
In one case (Shaw 1989), the perspective of the analysis was not mentioned, but two articles 
approached the economic evaluation from a societal perspective (Politi et al. 1995; Lutumba, 
Makieya, et al. 2007b), and the remaining four articles used the provider perspective (e.g., a 
donor or national health service) (Shaw & Cattand 2001; Robays et al. 2008; Lutumba, Robays, 
Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007).   
Additional Inputs, Outcomes, and Features of Included Economic Evaluations  
Data sources for the economic evaluations came from clinical trials, primary data collection 
from national programmes (e.g., Programme National de Lutte contre la Trypanosomiase 
Humaine Africaine [PNTHLA], Médecins Sans Frontières [MSF], and National Sleeping 
Sickness Programme Uganda), reports from WHO, available literature, and from speaking 
with experts in the arena of HAT. Prevalence values were not mentioned in two studies and 
ranged from 0.1% to 70% in the remaining literature.  
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All costs were evaluated in US dollars (USD} (Shaw 1989; Politi et al. 1995; Shaw & Cattand 
2001; Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Makieya, et al. 2007b; Robays et al. 2008) 
except for one study by Lutumba et al. (Lutumba, Meheus, et al. 2007) that estimated cost-
effectiveness in euros. Three studies reported only one outcome, while the remaining studies 
reported two outcomes in terms of cost per outcome. Cost per DALY averted was reported in 
three studies, while cost per LYS was reported in four studies. Cost per years of life lost (YLL), 
cost per patient/control case detected or patient cured, and cost per infection prevented were 
also examples of cost-effectiveness reported in the literature reviewed. Shaw (1989) and Shaw 
and Catt and reported time horizons of 20 years and one year, respectively (Shaw 1989; Shaw 
& Cattand 2001). Studies that used decision tree modelling did not report time horizons as 
decision trees have no time-related component (Politi et al. 1995; Lutumba, Robays, Miaka, et 
al. 2005b; Lutumba, Meheus, et al. 2007). The two remaining studies did not report a discrete 
time horizon for the analysis (Lutumba, Makieya, et al. 2007b; Robays et al. 2008). Two 
publications reported using discount rates of 10% (Shaw 1989; Robays et al. 2008), while one 
publication reported using a discount rate of 3% (Lutumba, Makieya, et al. 2007b).  The 
remaining publications did not mention any discounting (Politi et al. 1995; Shaw & Cattand 
2001; Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007), which was 
probably due to the fact that decision trees were used and therefore had no time horizon that 
or the time span modelled was one year or less. Two of the seven articles made explicit 
references to willingness-to-pay (WTP) thresholds for the cost-effectiveness of HAT as 
US$25/DALY (Politi et al. 1995; Shaw & Cattand 2001). One article mentioned that the WHO-
CHOICE (CHOosing Interventions that are Cost-Effective) considered the gross domestic 
product (GDP) per capita of a country to be used as the WTP threshold for choosing between 
competing interventions (Robays et al. 2008; Evans et al. 2005). The remaining publications 
(Shaw 1989; Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Makieya, et al. 2007b; Lutumba, 
Meheus, et al. 2007; Robays et al. 2008) made no reference to a WTP threshold for the economic 
analysis under evaluation.
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Table 6. Description of included economic evaluation 
Author Shaw (Shaw 
1989)  
Politi (Politi et al. 
1995)  
Shaw (Shaw & 
Cattand 2001)  
Lutumba(Lutumba, 
Robays, Miaka, et 
al. 2005b)  
Lutumba  
(Lutumba, 
Makieya, et al. 
2007b)  
Lutumba 
(Lutumba, 
Meheus, et al. 
2007)  
Robays (Robays 
et al. 2008)  
Year 1989 1995 2001 2005 2007 2007 2008 
Method/Structure Modelling Modelling Modelling Modelling Field Study 
(Economic 
Study) 
Modelling Modelling 
Model Description (if 
applicable) 
Spreadsheet 
model that 
simulates 
outcomes  
Decision Tree with 
inclusion of relapses  
Spreadsheet 
model that 
simulates 
outcomes based 
on the five 
strategies 
identified 
Decision Tree NA Decision 
Tree. 
Complex 
decision tree 
model with 
separate arms 
for each stage 
of detection 
in the 
treatment 
algorithm 
specified. End 
diagnosis for 
positive tests 
is first or 
second stage 
of HAT. 
HAT-positive 
and HAT-
negative 
populations 
examined to 
account Sens 
and Spe for 
Decision Tree.  
Melarsoprol and 
DMFO 
treatment arm 
options. Patients 
treated with 
melarsoprol 
have no 
complications or 
arsenic 
encephalopathy. 
Patients with no 
complications 
may relapse or 
be cured, while 
patients with an 
adverse event 
AE have a 
probability of 
survival prior to 
being cured or 
relapsing. 
Patients treated 
with DMFO 
have a 
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TN, TP, FP, 
and FN. 
probability of 
surviving 
treatment or 
dying. Survivors 
are cured or 
relapse.  All 
relapse patients 
(DMFO and 
melarsoprol) 
have the 
possibility of 
being cured or 
proceed to 
death.  
Software Super-Calc 4 Not mentioned Microsoft Excel TreeAge  Microsoft 
Access, 
Microsoft Excel, 
Epi Info 2002 
Data Pro 2004  
(TreeAge) 
TreeAge Pro 
2006 
Population Description  HAT 
population 
1,000 hypothetical 
patients with T. b. 
gambiense in stage 2 
100,000 
hypothetical 
people 
modelled, 
containing 10 
rural health 
centres and 20 
community 
health workers 
1,000,000 
hypothetical 
patients 
Economic study 
of 57 patients, 
47 households 
(21%); Median 
age was 26 
years (4–72 
years); 57% of 
patients were 
female; 63% of 
patients in stage 
1 
In model 50% 
of patients in 
stage 1 and 2 
equally 
690 stage 2 
patients 
Area Description Cote D’Ívoire 
(Vavoua 
focus), forest 
zone with 
scattered 
hamlets 
Uganda Daloa, Côte 
D’Ivoire/Moyo 
District Uganda 
DRC Single outbreak 
of HAT in 2000–
2002 Buma, a 
rural 
community of 
1,300 people 
(Buma centre + 
Probabilities, 
baseline data, 
costs and 
time 
developed 
from study in 
Kwamouth 
Sleeping 
sickness ward in 
Caixto, Angola 
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Kimpolo) 35 km 
south of 
Kinshasa in the 
DRC affected by 
outbreak of 
HAT 
between 
February and 
March 2004 
Prevalence 5% year one  
(incidence 
1%) 
Not mentioned Range 0.01%–
70% 
1.00% Buma: 5.92% (77 
Cases/1,300 
population).  
Based on local 
data:  Buma 
centre—2% 
(20/1,000)  
Kimpolo—19% 
(57/300) 
1.00% Not mentioned 
Data Sources/Inputs CATT test & 
mAECT—
Côte D’Ivoire 
Available literature, 
clinical trials; reports 
of National Sleeping 
Sickness Programme-
Uganda, personal 
communication from 
experts, 
WHO/CDT/TDR 
Costs and 
estimates from 
WHO Technical 
Report Series 
881, published 
in 1998  
HAT Programme in 
the DRC, PNTHLA, 
literature and 
reports from 
Trypanosomiasis 
Bureau 
Data from this 
study, 
information 
from PNTHLA 
in DRC;  costs 
included cost 
consultation 
fees, cost of 
travel, lab, 
household 
expenses 
(except 
diagnostictest), 
and cost of 
hospitalization 
(including food 
for patient and 
caregiver); 
treatment costs 
(drug cost 
included but 
Annual 
reports from 
PNTHLA; 
study in 
Kwamouth, 
previous 
literature 
regarding Sen 
and Spe; 
treatment 
efficacy rates 
included 
were for first 
generation 
treatment 
pentamidine 
(stage 1) and 
melarsoprol 
(stage 2). 
Costs include 
screening, 
MSF Program in 
Angola 
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specific 
treatments not 
mentioned, 
injections, small 
materials, 
syringes, and 
needles); value 
of each work 
day lost 
(estimated on a 
person basis).  
DALYs were 
calculated 
estimated based 
on HAT-related 
death based on 
family recall 
and possible 
HAT-related 
deaths. 
Calculated HAT 
disability 
before, during, 
and after 
treatment. 
DALYs 
calculated as 
per Murray et 
al.  
confirmation 
and treatment 
and costs 
generated by 
each 
algorithm. 
screening 
costs 
included 
vehicle, 
depreciation, 
operation 
costs, and 
CATT 
reagents. 
Perspective Not 
mentioned 
Societal Donors and 
National 
Healthcare 
System 
Healthcare system Societal Healthcare 
system 
Healthcare 
system 
Costs Valuation $ (USD UNK 
year) 
$ (USD 1992) $ (USD 1995) $ (USD 2002) $ (USD 2002) € (May 2003)  $ (USD 2005) 
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Consequence Units 1. Year of 
infection 
prevented 
per person. 
1. DALY. 2. Life 
saved. 
1. Patient 
detected. 2. 
DALY averted. 
1. Life saved. 1. DALY. 2. 
Control case 
detected/patient 
cure. 
1. Life saved. 1. Life saved. 2. 
YLL. 
Cost/Consequence 
valuation 
$/infection 
prevented 
1. $/DALY averted***.  
2. $/life saved. 
1. $/patient 
detected. 2. 
$/DALY 
averted. 
1. $/life saved. 1. $/DALY 
averted.  2. 
$/control case 
detected or 
patient cured. 
€/life saved 1. $/life saved.  2. 
$/YLL averted. 
Time Horizon 20 years 
(Vector 
Control and 
Screen & 
Treat) 
NA—DT One year 
(simulation 
repeated at 
different 
prevalence, but 
always same 
time horizon) 
NA—DT None NA—DT  20 Years.  
(Although, this 
seems a bit 
unclear since  a 
DT requires no 
discounting due 
to short time 
horizon) 
Discount rate 10% NA—DT NA—one year 
only 
NA—DT DALYs—3% NA—DT 10% on hospital 
building 
Validation No No No No Compared their 
results to other 
literature (e.g., 
Shaw and  
Cattand, etc.) 
They 
discussed the 
limitations of 
the study 
No 
CE Threshold Not 
mentioned 
$25/DALY (World 
Bank) 
$25/DALY 
(WHO) 
Not mentioned Not 
mentioned—
just mentioned 
that within 
range of Shaw 
and Cattand 
(2001) results 
Not 
mentioned, 
but 
competing 
strategies 
made a clear 
case for CE 
due to 
dominance 
and extended 
dominance 
WHO-CHOICE 
(World Health 
Organization 
(WHO) 2003)  
threshold;  
products less 
than GDP per 
capita (very cost-
effective);  
products less 
than three times 
the GDP per 
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capita (cost-
effective)   
Alternative 
Scenarios/Interventions 
1. 
Assumption 
A (constant 
incidence):     
find and treat   
vector 
control 
(traps/targets 
+ ground 
spraying).  2. 
Assumption 
B (variable 
incidence):    
find and treat    
vector 
control 
(traps/targets 
+ ground 
spraying). 
1. None.  2. 
Melarsoprol  
Melarsoprol. 3. 
Melarsoprol  
Eflornithine (DFMO). 
4. Eflornithine  
Eflornithine (DFMO). 
First Scenario: 
1a. Systematic 
fixed 
postsurveillance 
at rural health 
centres (N=1, 
screens 300 ppl) 
. 1b. Road 
blocks near 
centres, usually 
set up on 
market days. 2. 
Filter paper 
sample (rural 
health centres 
N=10, screens 
3,000 ppl) . 3. 
Filter paper 
sample 
(community 
health workers 
N=20, screens 
24,000 ppl) . 4. 
Polyvalent 
mobile teams (N 
= 1, screens 
20,000). 5. 
Monovalent 
mobile teams 
(N=1, screens 
36,000).  Second 
1. PG (LNP). 2. 
CATT. 3. PG (LNP) 
+ CATT. 
None versus 
active 
screening.         1. 
Treatment 
alone. 2. Active 
screening + 
treatment. 
1. LNP-FBE-
TBF. 2. LNP-
CTC. 3. LNP-
CATT 
titration-
CTC-
mAECT. 4. 
LNP-CTC-
mAECT. 5. 
LNP-TBF-
CTC-
mAECT. 6. 
LNP-CTC-
CATT 
titration. 7. 
LNP-TBF-
CTC-
mAECT-
CATT 
titration. 
1. Melarsoprol.  
2. Eflornithine 
(DFMO). 
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Scenario: same 
as above but 
using data from 
Moyo District of 
Uganda 
ICER Results Refer to Table 7. 
Subgroup Analyses No No No No No No No 
SA Yes Yes Yes Yes No Yes Yes 
Description of SA and 
Results 
1. Costs were 
double and 
halved.  2. 
Prevalence at 
the start of 
the model.  3. 
Incidence in 
the absence 
of control 
work.  4. 
Stability of 
prevalence in 
the absence 
of control 
activities.  5. 
Number of 
years control 
was 
1. Consequences of 
modified assumptions 
regarding treatment 
effectiveness.  2. 
Modified 
assumptions 
regarding the costs of 
treatments and 
working days lost by 
patients and/or 
relatives.  3. Other 
variables (under table 
payments, shadow 
price of working day, 
rates of 
noncompliance).  
Results:  If 
melarsoprol is less 
SA looked at 
multiplying the 
number of 
DALYs averted 
per patient 
(which was 
assumed to be 
15) by 1.5, 2, or 
2.5 at varying 
prevalence.   
Results:  Cost 
per DALY 
averted 
becomes more 
favourable as 
prevalence 
increases. None 
of these results 
1. The Spe of PG test 
was varied 
comparing CATT  
to PG + CATT.  2.  
Additional SA of 
the ($/LYS) varying 
the prevalence of 
HAT, costs of tests, 
and Sen/Spe of PG, 
CATT, and Sen of 
parasitology.  
Results:  When the 
Spe of PG was 52%, 
the ICER of CATT + 
PG compared to 
CATT was 
$5,000/LYS. When 
the Spe of PG was 
NA Looked at 
several 
parameters 
including  
prevalence of 
HAT, cost of 
mAECT, 
CATT whole 
blood Spe 
and Sens of 
CTC, 
mAECT, FBE, 
CATT whole 
blood, and 
LNP.  Results: 
Tornado 
diagram 
demonstrated 
Authors 
explored both 
situations with 
drug costs and 
excluding drug 
costs. Tornado 
diagram 
demonstrated 
that the 
following 
parameters were 
examined: death 
rate, relapse 
rates of 
treatments, 
death rates and 
death rates due 
to AEs,  drug 
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undertaken 
was varied. 6. 
Importance 
of animal 
reservoir by 
varying 
assumptions 
in A and B 
(this was a bit 
unclear).  
Results:  
When costs 
were halved 
or doubled, 
the cost per 
benefit unit 
was also 
halved or 
doubled. It 
was more 
cost-effective 
to carry out 
interventions 
in areas with 
higher 
prevalence. 
Increasing 
incidence 
made vector 
control more 
profitable 
under A and 
B, but not for 
finding and 
treating 
patients. 
effective than current 
evidence, then the 
relative cost-
effectiveness of 
eflornithine would 
improve making 
scenario/interventions 
‘2’, ‘3’ and ‘4’ 
potentially cost-
effective. If 
melarsoprol 
effectiveness 
improved, then 
scenario/intervention 
‘3’ would be 
dominated by 
scenario/intervention 
‘2’ making 
scenario/intervention 
‘2’ the most cost-
effective option. If the 
effectiveness of 
eflornithine in late 
stage patients is as 
high in refractory 
patients who take 
melarsoprol, then 
scenario/intervention 
‘3’ dominates 
scenario/intervention 
‘4’  leaving both 
scenario/intervention 
‘2’ and ‘3’ as 
potentially cost-
effective options. 
Working days lost by 
were 
incremental. 
70%, the ICER of 
CATT + PG 
compared CATT 
was $3,175/LYS. 
When the Spe of PG 
was 90%, the ICER 
of CATT + PG 
compared to CATT 
was $1,225/LYS. 
Results from 
varying prevalence 
showed that $/LYS 
decreased as 
prevalence 
increased; however; 
none of these 
results were 
incremental.  
that CATT 
whole blood 
Spe had the 
greatest 
impact on the 
ICER; also 
examined 
function as 
variation of 
prevalence 
and CE ratio 
(but this was 
not an 
incremental 
analysis) was 
more 
favourable as 
prevalence 
increased. 
They also 
varied the 
impact of 
discovering 
the FN (data 
was not 
shown) and 
stated that if 
FNs 
presented 
themselves 
for treatment 
the 
differences in 
CE were 
reduced.   
costs, building 
costs. Results: 
DMFO 
treatment 
becomes CE 
when 
melarsoprol 
death rate is 
greater than 16% 
and when death 
rate due to 
melarsoprol is 
greater than 70% 
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Prevalence 
had a 
positive 
correlation 
with 
profitability 
over time. 
Adding years 
to which 
control was 
undertaken 
reduced the 
cost per 
benefit for 
finding and 
treating  
patients, but 
not for vector 
control. 
Variance in 
the animal 
reservoir had 
a larger 
impact on the 
cost-
effectiveness 
of finding 
and treating 
patients than 
on vector 
control.  
None of these 
results were 
incremental. 
patients and/or 
relatives as well as 
other variables had 
little impact on cost-
effectiveness when 
varied.  
PSA No No No No No No No 
Page 86 of 321 
 
VOI No No No No No No No 
** calculated ICERs based on information presented in the paper. 
Abbreviations: CDT, community-directed treatment; CE,  cost-effectiveness; DT, decision tree; FN, false negative; FP, false positive; FBE, fresh blood examination; NA, not applicable; PG, palpation ganglionnaire; PNLTHA, Programme National de Lutte 
contre la Trypanosomiase Humaine Africaine; Sen, Sensitivity; Spe, Specificity; SA, sensitivity analysis; TDR, Tropical Disease Research; TN,  true negative; TP, true positive; USD, United States dollar; UNK, unknown; VOI,  value of information 
analysis.  . 
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Base Case and Sensitivity Analyses  
A full description of the economic outcomes for each study is outline in Table 7. The results 
from the sensitivity analyses conducted for the included publications are provided in Table 6. 
A total of 5 studies (Politi et al. 1995; Lutumba, Meheus, et al. 2007; Lutumba, Robays, Miaka, 
et al. 2005b; Lutumba, Makieya, et al. 2007b; Robays et al. 2008) discussed cost-effectiveness 
results by calculating incremental cost-effectiveness ratios (ICERs), which are summarised in 
Table 6.  Lutumba and colleagues published cost-effectiveness analyses of varying diagnostic 
algorithms for HAT (Lutumba, Robays, Miaka, et al. 2005b; Lutumba, Meheus, et al. 2007). 
Their results in 2005 demonstrated that lymph node puncture (LNP) in addition to CATT was 
more cost-effective ($20/LYS) relative to CATT alone or LNP alone (Lutumba, Robays, Miaka, 
et al. 2005b). In 2007, LNP followed by capillary tube centrifugation (CTC) and mini-anion 
exchange centrifugation technique (mAECT) (€76/LYS); LNP followed by thick blood film 
(TBF), CTC, and mAECT (€200/LYS);  and LNP followed by TBF, CTC, mAECT, and CATT 
titration (€2,618/LYS) were deemed cost-effective relative to four other diagnostic algorithms. 
Although the strengths of these cost-effective algorithms were noted, Lutumba and colleagues 
noted that some of these algorithms may not be feasible to carry out in the field (Lutumba, 
Meheus, et al. 2007). In regards to treatment regimens, Politi’s analysis (Politi et al. 1995) in 
1995 demonstrated that based on a WTP of US$25/DALY, melarsoprol alone (initial treatment 
and relapses) was cost-effective at US$8/DALY (US$209/LYS) compared to no treatment. 
Politi’s analysis also demonstrated that a treatment pathway of melarsoprol with treatment 
relapses on Eflornithine (difluoro-methylornithine [DMFO]) (US$41/DALY and 
US$1,033/LYS) or DMFO for both treatment and relapses (US$167/DALY and US$4,444/LYS) 
would not have been considered cost-effective based on the aforementioned cost-effectiveness 
threshold of US$25/DALY (Politi et al. 1995).   A more recent publication by Robays 
demonstrated that DFMO was more cost-effective than melarsoprol (US$1,596/LYS and 
US$58/control case detected) when donated drug costs were not included; the analysis of cost-
effectiveness was based on WHO-CHOICE’s suggestion that interventions at a cost of GDP 
per capita are very cost-effective and interventions at three times GDP per capita are cost-
effective (WHO n.d.). When donated drug costs were included, Robays found that DFMO was 
more cost-effective than melarsoprol at US$8,169/LYS and US$299/control case detected.  
Lutumba et al. (Lutumba, Makieya, et al. 2007b) found that active screening (case detection) in 
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addition to treatment was more cost-effective than treatment alone at $17/DALY averted and 
$301/control case detected or patient cured.  
Two studies (Shaw 1989; Shaw & Cattand 2001) did not report cost and effect results 
incrementally.  Although Shaw et al. (Shaw & Cattand 2001; Shaw 1989) conducted several 
analyses exploring combinations of case detection, diagnostics, treatment, and vector control, 
outcomes were not compared incrementally; consequently, ICERs were not attained. They did 
calculate $/patient detected with varying prevalence for five strategies and found that lower 
prevalence rates were associated with higher $/DALY and higher prevalence rates with lower 
$/DALY; these were based on average cost-effectiveness ratios, not ICERs.  
All but one study included some form of one-way sensitivity analysis (OWSA). No studies 
completed subgroup analyses or conducted probabilistic sensitivity analyses (PSA), and 
hence, results were not presented using cost-effectiveness acceptability curves (CEAC).  
Additional measures of uncertainty were not explored in the form of a value of information 
(VOI) analysis in any of the reviewed publications.  
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Table 7. ICER results from economic evaluations 
Author, Year Type of Intervention Name of Intervention ICER Results 
   Cost/DALY 
Averted 
Cost/LYS Cost/YLL 
Averted 
Cost/Control 
Case Detected 
Shaw, 2001 (Shaw & 
Cattand 2001)  
Case detection and 
diagnosis 
1. Systematic fixed post surveillance at 
rural health centres  
NA NA NA NA 
  2. Filter paper sample (rural health 
centres) 
    
  3. Filter paper sample (community 
health workers)  
    
  4. Polyvalent mobile teams      
  5. Monovalent mobile teams      
Lutumba, 2005 
(Lutumba, Robays, 
Miaka, et al. 2005b)  
Diagnosis 1. CATT - 1. - - - 
  2. LNP  2. dominated by 1   
  3. LNP + CATT  3. $20*    
Lutumba, 2007 
(Lutumba, Meheus, et al. 
2007)  
Diagnosis 1. LNP-FBE-TBF - 1. - - - 
  2. LNP-CTC  2. ED by 4   
  3. LNP-CATT titration-CTC-mAECT  3. ED by 4    
  4. LNP-CTC-mAECT  4. €76   
  5. LNP-TBF-CTC-mAECT  5. €200   
  6. LNP-CTC-CATT titration  6. dominated by 5    
  7. LNP-TBF-CTC-mAECT-CATT 
titration 
 7. €2,618   
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Politi, 1995 (Politi et al. 
1995)  
Treatment 1. None 1. - 1. - - - 
  2. Melarsoprol  Melarsoprol 2. $8 2. $209   
  3. Melarsoprol  DFMO 3. $41  3. $1,033   
  4. DFMO  DFMO 4. $167 4. $4,444   
Robays, 2008 (Robays et 
al. 2008)  
Treatment  - Donated drug costs not 
included: 
Donated 
drug costs 
not 
included: 
- 
  1. Melarsoprol  1. - 1. -  
  2. DFMO  2. $1596 2. $58  
    Donated drug  costs 
included: 
Donated 
drug costs 
included:  
 
    1. -  1. -  
    2.$8,169 2.$299  
Lutumba, 2007 
(Lutumba, Makieya, et al. 
2007b)  
Case detection and 
diagnosis, treatment 
1. Treatment alone 1. - - - 1. - 
  2. Active screening + treatment 2.$17   2. $301 
Shaw 1989 (Shaw 1989)  Case detection and 
diagnosis, treatment , 
vector control 
1. Find and Treat NA NA NA NA 
  2. Vector control (traps/targets + 
ground spraying) 
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3.5 Discussion 
A review of previous evidence has demonstrated that there have been only a few economic 
evaluations conducted to assess the cost-effectiveness of interventions to control HAT and 
reduce disease burden. From this evidence alone, it would prove difficult for decision makers 
to strategize on which interventions would be most cost-effective for elimination; however, 
the results do provide some insights into the key components of HAT disease control and how 
these components could be translated into HAT elimination strategies, which could then be 
assessed through economic evaluation. 
 
Overall the strengths of this review are that it highlights the components that play a role in 
disease control and reduction of transmission and emphasizes that these are the components 
that should be incorporated into elimination strategies. Case detection, diagnosis, treatment, 
and vector control are the four categories of interventions that have been considered thus far 
in the literature. Strategies towards elimination should continue to consider the impact of these 
components but also aim to highlight their individual and collective use within a formal 
strategy for reaching elimination. This was highlighted in the study by Lutumba et al. 
(Lutumba, Makieya, et al. 2007b) in which case-detection with treatment was compared to 
treatment alone and also in the work by Shaw and colleagues in 1989 in which essentially all 
four categories were evaluated with varying incidence. Within diagnostics, algorithms for 
CATT showed that the addition of tests led to more efficient outcomes (Lutumba, Meheus, et 
al. 2007). However, there is still a gap in cost-effectiveness knowledge of the current treatment 
for HAT, NECT. Global investors, partners, and academic groups (World Health Organization 
(WHO) n.d.; Bill & Melinda Gates Foundation n.d.; Department for International Development 
n.d.; Swiss TPH 2014; Liverpool School of Tropical Medicine n.d.; Foundation for Innovative 
New Diagnostics n.d.; Drugs for Neglected Diseases initiative (DNDi) 2014b) are now working 
together not only to control and treat this disease but also to develop novel diagnostic tools 
(Foundation for Innovative New Diagnostics n.d.; Büscher et al. 2014) and drug treatments 
(Drugs for Neglected Diseases initiative (DNDi) 2014b). It would be useful to compare NECT 
to interventions that have recently come or are near entry to the market (e.g., fexinidazole 
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(Drugs for Neglected Diseases initiative (DNDi) 2014b) and rapid diagnostic tests (Foundation 
for Innovative New Diagnostics n.d.; Büscher et al. 2014)).  Shaw et al (Shaw 1989; Shaw & 
Cattand 2001) and Lutumba (Lutumba, Makieya, et al. 2007b)  both made reference to the 
benefits of combining interventions for treatment, and it would be wise for stakeholders to 
move beyond this and develop more complicated and time-sensitive strategies with 
interventions not only on their own but in combination to identify the most cost-effective 
pathways towards elimination. 
There are still some additional considerations that have not been considered as components in 
HAT economic evaluations. Although T. b. gambiense HAT contributes to 95% of the HAT 
disease (World Health Organization (WHO) 2013a), separate strategies for T. b. rhodesiense 
could also be considered.  Cultural beliefs and attitudes towards HAT will also play a role in 
the effectiveness of interventions (Leygues & Gouteux 1989), and although education and 
community sensitization programs for HAT have been evaluated in terms of their societal 
benefit and impact on changing knowledge and behaviour (Kovacic et al. 2013; Palmer et al. 
2014; Waiswa & Kabasa 2010), no studies have shown their benefit in terms of cost-
effectiveness. Methods of delivery and integration of health systems should also be further 
explored in terms of accessibility and availability, as resource constraints and lack of access in 
remote areas may delay elimination timelines if not considered beforehand (Laveissiere et al. 
1998; Simarro et al. 2014). 
 Potential Use of Cost-Effective Modelling for HAT Control and 
Elimination 
It was quite evident from the literature review that modelling will play a role in the economic 
evaluation of HAT. Most of the previous economic evaluations conducted were based on 
models, and modelling is known to assist with forecasting future economic consequences 
(Drummond et al. 2005).  Decision makers would benefit from the use of whole disease 
modelling of alternative elimination scenarios because it would allow them to consider the 
implications and incremental benefits of each potential strategy. Previous economic evaluation 
studies reliant on modelling have addressed how individual interventions reduced 
transmission but not how these interventions, or combinations of them, could lead to eventual 
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elimination or interruption of disease transmission. Current modelling techniques for 
economic evaluation, including those used to evaluate the impact of uncertainty related to 
model  parameters, would also be useful for decision makers in communicating the 
consequences of choosing non-cost-effective strategies (Claxton 1999). Additionally, 
modelling the feasibility of interventions through health service delivery is also necessary. For 
example, the results from an economic evaluation regarding diagnostic algorithms (Lutumba, 
Meheus, et al. 2007) showed that sometimes even the most cost-effective tools may not be 
affordable or feasible in some of the locations where HAT occurs (Lutumba, Meheus, et al. 
2007).  
 Potential Use of Economic Evaluation Methodology in HAT Control and 
Elimination 
A few considerations of cost-effective interventions could be gleaned from the few economic 
evaluations found. This was highlighted in the scenario described by Lutumba et al. (Lutumba, 
Makieya, et al. 2007b) in which case-detection with treatment was more cost-effective than 
treatment alone, and an economic evaluation of diagnostic algorithms showed that the 
addition of tests to CATT could increase cost-effectiveness (Lutumba, Meheus, et al. 2007). 
Treatment regimens including melarsoprol and eflornithine were considered cost-effective 
(Politi et al. 1995; Robays et al. 2008) for patients with HAT T. b. gambiense, and Politi’s analysis 
in 1995 also demonstrated a good understanding of economic outcomes because dominance 
was assessed and the importance of the efficiency frontier was illustrated (Politi et al. 1995). 
Dominance refers to the economic concept that an intervention that costs less and has better 
outcomes relative to its comparator is considered dominant (Drummond et al. 2005). In 
regards to budgeting, sensitivity analyses (Shaw 1989; Shaw & Cattand 2001; Lutumba, 
Robays, Miaka, et al. 2005b) demonstrated that prevalence is related to costs. This will be 
important to consider because the cost per patient will increase towards the end goal of HAT 
elimination, but the overall cost per benefit still needs to be ascertained.   
 The economic evaluations reviewed presented some methodological inconsistencies.  For 
example, there was a lack of clarity in reporting costs and consequences incrementally to a 
base-case scenario or relative to the next-best intervention. Historically calculations may have 
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been done this way because of the “generalized cost-effectiveness” method (Hutubessy et al. 
2003), but if incremental and net benefits are always compared to “do nothing” instead of to 
the next-best option available, then the consequences of this methodology could lead to error 
(Weinstein 1990). Furthermore, when multiple strategies are being considered, dominance 
needs to be examined. Although four out of seven studies had more than two competing 
strategies, dominance was only addressed once. Evaluations that ignore dominance could lead 
to decision errors in which the health utility is not maximised at a societal level (Drummond 
et al. 2005; Torrance et al. 1972). Cost-effectiveness was also referred to by the authors without 
making reference to a cost-effectiveness threshold. WHO-CHOICE (WHO n.d.) has defined 
thresholds previously; however,  it is not clear if these thresholds values are acceptable for all 
global stakeholders because the authors did not always refer to a threshold value to determine 
cost-effectiveness. 
 The methodology of CEA with different interventions permits one to compare varying 
strategies across a disease, but the outcomes need to be unified so that decision makers can 
assess these comparators with ease and clarity. It is evident from this review that although 
CEA research may be conducted, the results are hard to interpret without standardization or 
reporting in a common metric (e.g., cost per DALY). Following existing guidelines for 
economic evaluation such as the SIGN Guidelines (Scottish Intercollegiate Guidelines 
Network (SIGN) n.d.) and the more recent Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement (Husereau et al. 2013) or developing guidelines that 
stakeholders feel acceptable for an elimination strategy would allow for consistency of 
analyses for HAT and other neglected tropical diseases.  Formal economic evaluation 
guidelines and even a standard reference case have been developed by various public health 
funders (Stevens & Longson 2013; Canadian Agency for Drugs and Technologies in Health 
(CADTH) 2006; National Institute for Health and Clinical Excellence (NICE) International 
2014), and researchers should consider these standards to further the future of CEA within 
tropical disease and disease elimination decision-making. In addition, traditional CEA 
measures two outcomes (cost and effects), but programs for elimination also need to consider 
time. Health economists will need to consider how to make recommendations to stakeholders 
for strategy prioritization considering all three elements for elimination.  
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3.6 Conclusions 
This review has demonstrated that previous research highlights the main components that 
play a role in elimination. Furthermore, cost-effective modelling and economic evaluation 
have been used and could address future economic concerns regarding elimination. 
Researchers interested in evaluating economic concerns regarding HAT elimination should 
think about modelling elimination strategies to assess cost-effectiveness using standardized 
methodology in order to assist stakeholder and key funders. These analyses would be of use 
since HAT is currently being prioritized as a NTD to reach elimination by 2020. 
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4.1 Abstract 
The control and eventual elimination of human African trypanosomiasis (HAT) requires the 
expansion of current control and surveillance activities. A systematic review of the published 
literature on the costs of HAT prevention, treatment, and control, in addition to the economic 
burden, was conducted. All studies that contained primary or secondary data on costs of 
prevention, treatment and control were considered, resulting in the inclusion of 42 papers. The 
geographically focal nature of the disease and a lack of standardization in the cost data limit 
the usefulness of the available information for making generalizations across diverse settings. 
More recent information on the costs of treatment and control interventions for HAT is needed 
to provide accurate information for analyses and planning. The cost information contained 
herein can be used to inform rational decision making in control and elimination programs, 
and to assess potential synergies with existing vector-borne disease control programs, but 
programs would benefit significantly from new cost data collection. 
4.2 Introduction 
Human African trypanosomiasis (HAT), which is also known as sleeping sickness, is caused 
by an infection with either of two parasites: Trypanosoma brucei rhodesiense or Trypanosoma 
brucei gambiense. Both types are transmitted by different tsetse fly species. They are 
microscopically indistinguishable, but occur in separate areas of Sub-Saharan Africa (SSA). A 
total of 37 countries between 14◦N and 20◦S latitude and covering 1.55 million km2 have 
reported cases (P P Simarro et al. 2012; Pere P Simarro et al. 2012).  T.b. gambiense occurs in 
west and central Africa, while T.b. rhodesiense is endemic in eastern and southern Africa. There 
is no overlap between the endemic areas with Uganda being the only country endemic for 
both forms, albeit in different areas of the country (Burri 2008). An estimated 70million people 
(P P Simarro et al. 2012; Pere P Simarro et al. 2012) and about 50 million head of cattle are at 
risk of trypanosomiasis infection (Fevre, Wissmann, et al. 2008; Kristjanson et al. 1999). The 
main reservoir host for T.b. gambiense is humans, while cattle or wild bovids serve as the main 
reservoir host for T.b. rhodesiense. Animal to human, animal to animal, and human to human 
transmission all occur with T.b. rhodesiense. Transmission varies as a function of vector density 
and biting behaviour. A total of 7216 HAT cases for both T.b gambiense and T.b rhodesiense were 
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reported in 2012 (World Health Organization (WHO) 2013c) and the World Health 
Organization (WHO) estimates the number of actual infections to be around 20,000 (World 
Health Organization (WHO) 2013c). In 2014, WHO approved a declaration to target gambiense 
HAT elimination (Holmes 2014) and one to target rhodesiense HAT (WHO n.d.).A previous 
review of the available economic evaluations for HAT (Sutherland et al. 2015) demonstrates 
that although cost-effectiveness has been assessed previously for control of the disease little is 
known about the cost-effectiveness of strategies targeting elimination. Funding and support 
for HAT declined from the1970s through the 1990s, contributing to the resurgence of the 
disease in the late 1990s (Smith et al. 1998); however, since the WHO’s roadmap to NTD control 
and elimination was published in 2012 (WHO 2012), there is a renewed commitment from 
global stakeholders to achieve HAT elimination by 2020 (Zhang et al. 2010; London 
Declaration 2013; WHO 2012; Bill & Melinda Gates Foundation n.d.). This requires that the 
total cost of potential strategies for elimination along with current and emerging technologies 
(Steinmann et al. 2015) are accurately estimated to ensure that funding is sustained throughout 
the elimination process. The purpose of this paper is to summarize the available information 
on costs for HAT prevention, treatment, and control to serve as a reference for future economic 
evaluations and national budgeting endeavours. The paper begins with a brief description of 
the treatment, prevention and control strategies for the disease to provide relevant contextual 
information and some potential interventions for elimination. It then presents a systematic 
review of the published literature that included primary and secondary data on costs, indirect 
costs and economic burden related to HAT programs. The paper concludes with a discussion 
on priority areas of economic data collection for elimination strategy development. 
 Prevention, treatment, control of HAT 
 In general, the prevention of HAT includes reducing bites from tsetse flies, early diagnosis 
and treatment of cases. While individual protection against bites may be useful in some 
instances, the fly can penetrate light weight clothing and repellants are not common in many 
endemic areas. Thus community level vector control and screen and treat programs, which 
involve the detection of human cases for subsequent treatment, are typically employed 
together. Several techniques are recommended for the control of tsetse fly populations: 
sequential aerial insecticide spraying to tar-get adult flies during the first spray and tsetse flies 
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as they emerge from pupal stages in the ground during subsequent sprays; ground spraying 
to target pupae and resting flies; the use of odor-baited or visual-baited (e.g. black or blue 
cloth) insecticide treated traps and targets; sterile insect release; and insecticide treatment of 
cattle(ICT) (Welburn et al. 2009). A total of 13 Sleeping Sickness National Control Programs 
are developing vector control activities (out of 24 countries reporting HAT cases) (J R Franco 
et al. 2014), although in some countries institutions other than national control programs are 
also engaged in vector control activities. Few drugs are available for the treatment of 
trypanosome infections. Pentamidine and suramin are the main treatments for 1st stage T.b. 
gambiense and T.b. rhodesiense, respectively (World Health Organization (WHO) 2013c).The 
2nd stage of T.b. rhodesiense is treated with the organo- arsenical compound melarsoprol 
(World Health Organization (WHO) 2013c), which is associated with severe adverse reactions, 
mainly arsenical encephalopathy, occur-ring in 10% of the patients and frequently fatal (10–
70% mortality)(Pépin & Milord 1994; Burri 2008). Nifurtomix–eflornithine combination 
therapy (NECT) is currently the treatment of choice for stage 2 T.b. gambiense and is listed on 
the WHOs Model List of Essential Medicines 
(http://apps.who.int/iris/bitstream/10665/93142/1/EML 18 eng.pdf?ua=1). It involves an in-
hospital treatment combining intravenous infusions of eflornithine with oral treatments of 
nifurtimox (World Health Organization (WHO) 2013c). An alternative treatment for T.b 
gambiense is eflornithine monotherapy which must be given in a high dose for an extended 
duration and is recommended when NECT is unavailable, but is not as well tolerated as NECT 
(World Health Organization (WHO) 2013c). Melarsoprol is used when patients treated with 
NECT relapse (World Health Organization (WHO) 2013c). New treatments are currently being 
developed: fexinidazole is a 10-day oral medication (Tarral 2014) that could potentially be used 
even if health systems lack the infrastructure or resources to administer NECT. Another 
potential treatment option is a single-dose oxaborole compound (Tarral 2014), allowing 
patients to be potentially treated locally and thus avoiding travel to specialized treatment 
centres that are often far from home. Active and passive case finding are crucial to identify 
and treat cases to curb transmission. 
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4.3 Methods 
A systematic electronic search of literature published in the English and French language was 
conducted using PubMed (MED-LINE), EMBASE, and JSTOR databases in 2013. The 
following search terms were used: trypanosomiasis, African sleeping sickness, and (econ, 
economics, cost, cost-effectiveness, cost-benefit, economic, internal rate of return, eradication, 
elimination, health systems, vertical, integration). All results were initially reviewed for 
relevance based on a review of the title and abstract; the selected publications were then 
further reviewed for relevance using the full text. The bibliographies of identified references 
were also searched, as well as the grey literature using Google and Open Content search 
engines. All papers with primary or secondary data on economic burden, costs of 
interventions, or health system implications of control and elimination programs were selected 
for more detailed review. All papers with primary data on costs of any topic related to 
treatment, prevention, control, indirect costs and economic burden were included. Figure 9 
illustrates the incremental results of the search. A total of 960 papers were identified as 
potentially relevant; a total of 42 papers met the criteria. All cost data were adjusted to USD in 
the year of the initial study (if the researchers had not already done so) if this information was 
available using historical exchange rate data from the Oanda currency converter 
(http://www.oanda.com/currency/converter/). If information on the year of the study was not 
available, the year of the publication was used as a basis for adjustment. The availability of 
historical exchange rates varies across countries; as such, studies identified with foreign cost 
data prior to historical exchange rate availability were first converted to USD using the first 
year exchange rate data were available. All costs were then adjusted to 2012 USD using the 
U.S. Gross Domestic Product Deflator series from the U.S. Bureau of Economic 
Analysis(http://www.bea.gov). 
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Figure 9. Incremental search results and final studies included 
 
4.4 Results 
 Prevention: vector control costs 
Sequential aerosol techniques 
Sequential aerosol techniques (SAT) refer to the spraying of targeted areas with a non-residual 
insecticide from a fixed wing of an airplane at set intervals. The first spray is designed to kill 
adults, with subsequent sprays targeted at killing young adult tsetse as they emerge from 
puparia buried in the ground but before they deposit larvae. Few cost estimates of SAT were 
identified. Shaw and others used data collected from SAT activities in Botswana to develop a 
cost model and hypothetical budget for Uganda; SAT in both settings were estimated to cost 
USD 410.56 per km2, with the bulk of costs incurred due to flying time of the aircraft and type 
of insecticide used (Shaw et al. 2007; Shaw et al. 2013).While relatively few peer reviewed 
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published studies of SAT were identified through electronic searches, several secondary 
sources of historical cost data from African locations were noted in Allsopp and Hursey 
(Allsopp & Hursey 2004). Botswana and Zambia (1973, 1980) reported USD 231.95 per km2 of 
Endosulfan and pyrethroids; Nigeria (1977) reported USD 890.62 per km2of Endosulfan (Lee 
1983); Cote d’Ivoire (1979) reported USD 617.00 per application of Endosulfan (Lee 1983); and 
Zambia (1968–1978) reported a range of USD 827.38–1,103.19 per km2, although the insecticide 
used was not mentioned (Allsopp & Hursey 2004; Evinson & Kathuria 1984). One study in 
West Africa also reported the cost of non-SAT from a helicopter to be between USD 1.55–
2.75per hectare, assuming 2000–3,500 hectares covered per application, respectively (F. E. 
Brandl 1988). The historical literature also suggests that the cost per area covered is inversely 
proportional to the total area sprayed, because fixed and capital costs for SAT do not increase 
proportionally with the total area covered. Additionally it is noted that elimination of tsetse 
from targeted areas requires high dosages of insecticide sprayed five times at narrow spray 
band widths, while SAT or other aerial insecticide application targeted only at control of tsetse 
could relax all these parameters and perhaps reduce cost per km2 by 30–50% (Allsopp & 
Hursey 2004). Across several ecologically distinct settings, SAT in general is thought to cost 
between USD 285.81 628.79 per km2 (Cattand et al. 2001). 
Sterile insect techniques 
Sterile insect technique (SIT) refers to mass release of sterile male tsetse flies, which then 
compete with non-sterile males to mate with females, resulting in adult female flies unable to 
produce offspring. This method of vector control is generally used in areas where the number 
of flies is relatively low; as such, it is typically employed following SAT or other vector control 
strategies that first reduce vector density. Using a 10% discount rate, SIT was estimated to cost 
USD 840.76 per km2 over a ten year period (Shaw et al. 2007). In West Africa, the estimated the 
cost of adding SIT to an existing intervention was USD 970.00/km2, although in areas where 
substantially fewer sterile males would be required, the cost of SIT could fall to USD 303.12-
363.75/km2  (Feldman 2004) depending on how many sterile males are released per kilometre 
and the cost of the flight plan employed (Vale & Torr 2005). 
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Ground spraying 
Ground based spraying of insecticides can be conducted using either pressurized spray pumps 
or thermal fogging equipment and may be targeted to wide swaths or to specific areas or 
habitat believed to be tsetse resting areas. Relatively little literature on the costs of ground 
spraying was identified, including three studies cited which could not be obtained in hard 
copy for review, but whose results are summarized from secondary sources. A study during 
the late 1950’s in Kenya reported ground spraying costs at USD 367.26 per km2. In Nigeria, 
from 1955 to 1969, costs were reported to range between USD 29.74–592.84 per km2; and, in 
Zimbabwe during the early 1980’s cost ranged between USD260.68–274.05 per km2 (Allsopp & 
Hursey 2004). One study reported cost between USD 315.00–1,574.98 per km2 in 1989, although 
no additional information was provided (Shaw 1989). 
Traps and targets 
Traps and targets refer to direct suppression methods that function by trapping flies or by 
using visual attractants such as large dark coloured cloth (targets), which can be treated with 
insecticide. These tools can be baited with odour based attractants to attract flies from a 
distance, or modified in various manners and produced in alternate sizes and shapes. Such 
vector control tools have been deployed for direct tsetse suppression and as a barrier method 
to prevent invasion/re-invasion of tsetse into specific geographic areas. Costs first estimated 
in 1997 have recently been updated, suggesting that targets cost between USD 266.75 and USD 
466.81 per km2 (Shaw 2004; Barrett 1997). The cost of using targets to produce a linear barrier 
has been estimated to be USD 2425.00 per km to establish and USD 1940 per km per year to 
maintain (Shaw 2004). The cost of using monopyramidal traps are estimated at USD 31.52 per 
km2, assuming 17 cattle per km2 (Shaw 2004). The cost of targets has also been estimated at 
USD 305.76 per km2 in Botswana (McCord et al. 2013; Mullins et al. 1999), and USD 128.03when 
used for control (Allsopp & Hursey 2004; McCord et al. 2012). Traps used for reclamation 
purposes have been estimated to cost between USD 1.05 and USD 2.05 per hectare per year 
over a period of 5–20 years, when fully discounted (F E Brandl 1988). The cost perkm2when 
traps and targets are deployed for elimination purposes ranges from USD 343.14 and USD 
880.27 per km2, depending on the discount rate and the number of traps deployed per km2 
(Shaw et al. 2007). Other factors influencing trap or target cost include the size and type of trap 
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used, insecticide or odour based attractant used and dosage, as well as the deployment method 
and density and lifetime of the trap in the field (Shaw et al. 2007; Esterhuizen et al. 2011). 
Insecticide treated cattle (ITC) 
In West Africa ITC is mainly limited to control of animal trypanosomiasis (nagana), but in East 
Africa it has also been shown to help control HAT because cattle serve as an important 
reservoir for T.b. rhodesiense. The costs for ITC vary depending on the scope of application (i.e., 
whole cattle pour-on vs. leg and belly application only), the density of cattle in the area, and 
the insecticide chosen. The cost of ITC has been estimated to be USD 164.54 per km2 for the full 
pour-on treatment when there are 15 cattle per km2 (Barrett, 1997; Budd, 1999; Shaw, 2004). 
Updated cost estimates from Uganda suggest that the least expensive application is treatment 
of cattle legs and belly with α-cypermethrin spray (USD14.55 per km2 assuming 8 cattle per 
km2) followed by full body α -cypermethrin spray (USD 67.90 per km2) and pour on 
treatment(USD 218.25 per km2) (Shaw et al. 2007).  Models restricting the application of 
insecticide to only the legs and bellies of cattle, where most tsetse bites occur, produced similar 
cost estimates (Torr et al. 2007; Vale & Torr 2005). Table 8 presents additional vector control 
cost information. 
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Table 8. Other vector control costs 
Authors Year Description of cost Cost 
Sequential Aerial Techniques (SAT) 
Shaw 2007 Administration, supervision, and other indirect "non-field" costs USD 36.37/km2 (14% of non-field costs) 
Entomological surveys, monitoring, feasibility studies USD 223.10/km2 
Aerial spraying-  five cycles USD 3,734.99/km2  
Cost for creating a tsetse-free zone for isolated tsetse populations  USD 720.22/km2 & USD 608.67/km2 
Sterile Insect Technique (SIT) 
Vale & 
Torr 
2005 Cost of rearing and sterilizing a male USD 0.11 
Cost of release including accompaniment USD 1.01/km2/week 
Eradication Estimate USD 42,033.91/insect population 
Shaw 2007 Administration, supervision, and other indirect "non-field" costs  USD 56.99 km2 (19% of non-field costs) 
Entomological surveys, monitoring, feasibility studies USD 235.22/km2 
Capital items, fly rearing, fly release USD 801.46/km2 
Creating a tsetse-free zone for isolated tsetse populations: + SIT alone USD 919.07/km2 
Creating a tsetse-free zone for isolated tsetse populations: SIT + 90 day ITC USD 1,228.26/km2 
Creating a tsetse-free zone for isolated tsetse populations: SIT + 80% SAT USD 1,228.26/km2 
Traps and Targets 
Shaw 1989 Total cost per trap (per person protected in 1st year) USD 24.50-27.76/ trap (USD 0.82/person) 
Total cost per screen (per person protected in 1st year) USD 6.53-13.07 per screen (USD 3-6.53/person) 
Gouteux 1987 Cost per kit USD 14.70 
Brightwell 1991 Trap/odor bait system per  unit 
 
USD 12.96 
Okoth 1991  Monoscreen - local  USD 1.86 
 Monoscreen -  imported materials  USD 1.92 
 Biconical - local  USD 7.23 
 Biconical - imported  USD 7.47 
 Pyramidal Traps - local  USD 3.68 
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 Pyramidal Traps - imported  USD 3.87 
Abila 2007 Pyramidal Traps cost per m USD 4.50 
Modified pyramidal cost per m USD 3.86 
Biconical & modified cost per m USD 4.50 
Monoscreen  cost per m USD 2.89 
Shaw 2007 Administration, supervision, and other indirect "non-field" costs USD 36.37/km2  (14% of non-field costs) 
4 Traps/km2 (10 teams) USD 213.40 
4 Traps/km2 (15 teams) USD 277.66 
4 low cost Traps/km2 (10 teams) USD 191.57 
4 low cost traps/km2 (15 teams) USD 244.92 
8 Traps/km2 (20 teams) USD 426.80 
8 Traps/km2 (30 teams) USD 444.32 
10 Traps/km2 (25 teams) USD 534.71 
10 Traps/km2 (38 teams) USD 693.55 
20 Traps/km2 (50 teams) USD 1,068.21 
20 Traps/km2 (75 teams) USD 1,388.31 
Creating a tsetse-free zone for isolated tsetse populations: G. fuscipes  USD 1,115.50/km2 
Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse USD 602.61/km2 
Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse  USD 491.06/km2 
Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse species + 
local labor 
USD 563.81/km2 
Shaw  2013 Average field cost per km2 USD 561.25 
Average cost of field studies per km2 USD 188.56 
Average cost of field deployment teams based on 10 teams USD 15.53 
Cost of trap maintenance per annum per km2 USD 61.67 
Insecticide Treated Cattle (ITC) 
Vale & 
Torr 
2005 Insecticide containing 20% α-cypermethrin purchased and shipped USD 30.46 per liter 
Cost per animal USD 0.002/animal/day 
Torr et al 
2007 
2007 Savings in insecticide: only treating the belly & legs of cattle 80 % 
Cost per animal whole-body regime USD 2.22/animal/year  
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Estimated cost per animal for restricted regime USD 0.22/animal/year 
Shaw 2007 Administration, supervision, and other indirect "non-field" costs USD 36.67/km2  (14% of non-field costs) 
Entomological surveys, monitoring, feasibility studies USD 223.10/km2 
α-cypermethrin spray USD 8.49 per animal per year 
α-cypermethrin spray, restricted application USD 1.82 per animal per year 
Traditional pour-on (spot-on) USD 27.28 per animal per year 
Creating a tsetse-free zone for isolated tsetse populations: pour (4/km2) USD 368.60/km2 
Creating a tsetse-free zone for isolated tsetse populations: spray (4/km2) USD 293.42/km2 
Creating a tsetse-free zone for isolated tsetse populations: pour-on (8/km2) USD 477.72/km2 
Creating a tsetse-free zone for isolated tsetse populations: spray (8/km2) USD 327.37/km2 
Creating a tsetse-free zone for isolated tsetse populations: restricted (8/km2 and fewer 
studies) 
USD 162.47/km2 
Creating a tsetse-free zone for isolated tsetse populations: spray USD 215.82/km2 
Page 108 of 321 
 
 Costs of treatment and hospitalization for HAT 
Treatment costs 
For treatment of first stage T.b. gambiense infection, pentamidine is the WHO recommended 
drug (WHO n.d.). In Africa, approximately 1% of patients die due to pentamidine, though 
why pentamidine mortality occurs is not well explored (Burri 2008). No costing studies on the 
treatment of first stage HAT due to T.b. gambiense with pentamidine were identified in the 
literature search. Costs of pentamidine treatment were estimated by Lutumba et al.(Lutumba, 
Meheus, et al. 2007) and Shaw and Cattand (Shaw & Cattand 2001) to be USD 2.05 per vial and 
USD 25.61 total drug costs, respectively. Suramin, although effective as a treatment for first 
stage illness is largely avoided for T.b.gambiense infection because of the potential for allergic 
reactions associated with onchocerciasis co-infection (Burri 2008). The recommended 
treatment for first stage T.b. rhodesiense infection is suramin administered parenterally over a 
period lasting up to 30 days (Burri 2008).  Record reviews of hospital data combined with past 
literature were used to estimate the cost of treatment for early and late stage T.b. rhodesiense in 
Urambo district Tanzania; although this study failed to differentiate costs of late stage versus 
early stage patients, they reported an estimated cost of USD 130.95 per patient, including 
admission, hospitalization, diagnostic and patient costs. Of this, the patient paid USD 30.31 
out-of-pocket, while the net cost to the health system was estimated to be USD 100.64 
(Matemba et al. 2010).The first line second-stage treatment of T.b gambiense is NECT and has 
been estimated to cost USD 1550.74 for a kit containing 4treatments resulting in the cost of 
USD 387.68 for one treatment.(Pere P Simarro et al. 2012) Alternative treatments such as 
melarsoprol or eflornithine may be used as well (World Health Organization (WHO) 2013c). 
Using clinical data from T.b. gambiense patients in Caitxo, Angola, a decision tree model was 
developed to estimate the total cost per patient treated, including costs of supportive care in 
addition to adverse events such as arsenical encephalopathy; treatment with melarsoprol was 
USD 708.03, while treatment per patient with elflornithine was approximately USD 997.14 
(Robays et al. 2008). Eflornithine was more efficacious in terms of mortality prevention; this 
translated into improved cost-effectiveness for eflornithine vs. melarsoprol despite the higher 
cost. Melarsoprol is currently the only drug available for treatment of stage II T.b rhodesiense 
infection. No studies on the costs of treatment for stage II T.b. rhodesiense infection were 
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identified; however, as the treatment regimen is expected to be similar to that used for stage II 
T.b. gambiense infection, the costs from the two studies discussed above may be relevant 
(Robays et al. 2008; Politi et al. 1995). No specific studies on the costs of encephalopathy as a 
severe adverse event associated with the administration of melarsoprol were identified; 
however, the direct costs of management of these complications were estimated in the context 
of the decision model discussed above to be between USD 23.60–59.00 (Robays et al. 2008).The 
cost of the new treatment options, fexinidazole has been estimated to be less than USD 50 per 
patient (Tarral 2014) while no estimates have been confirmed for oxaborole. Table 9 lists 
additional treatment costs identified. 
Table 9.  Costs for diagnostics and treatment for HAT 
Authors Year Description Cost (USD) 
Diagnostics 
Lutumba  
2006 
Lymph node puncture (LNP) USD 0.28/per test 
FBE USD 0.30/per test 
TBF USD 0.78/per test 
CTC USD 1.10/per test 
mAECT USD 4.08/per test 
Lutumba 2005 Cost per person screened USD 2.23 
WHO 1998 CATT test screen per person (one time) - 
  
USD 0.73  
  CATT test screen per person (one time) - 
  
USD 0.44  
  CATT test screen per person (one time) - 
  
USD 0.26 
Wastling  2010 LAMP  with Quant-IT Pico Green (per 100 
 
USD 371.30  
LAMP with Turbidity (per 100 reactions) USD 0.001 
LAMP with hydroxynapthol blue (per 100 
 
USD 0.001 
LAMP with Calcein and MnCI2 (per 100 
 
USD 0.001 
Treatment 
Lutumba 2003 Pentamidine per vial USD 2.05 
Shaw & Cattand 2001 Pentamidine drug costs per treatment USD 25.61  
Shaw & Cattand 2001 Suramin drug costs per treatment USD 41.79 
Politi 1995 1 treatment of Elfornithine USD 285.06 
Robays 2008 2 treatments of Elfornithine USD 334.31 
Simarro 2012 Average total cost of Elfornithine 
administration 
USD 745.08 
Simarro 2012 NECT 4 treatments USD 1,550.74 
Simarro 2012 NECT 1 treatment USD 387.68 
Lutumba 2003 Melarsoprol per vial USD 7.06 
Lutumba 2007 Melarsoprol treatment USD 144.10 
Politi 1995 Melarsoprol treatment per patient USD 66.99 
Robays 2008 Melarsoprol-Prednisolone treatment per 
 
USD 75.52 
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Hospitalization costs 
Treatment of HAT generally requires close supervision due to the risks associated with 
treatment; treatment of late stage disease invariably requires hospitalization. There is little in 
the literature about specific costs of hospitalization for treatment due to HAT. When including 
both early and late stage infections, the mean length of a hospital stay has been estimated at 
25 days (Matemba et al. 2010). In this study the total costs to the health service were estimated 
to be USD 2.42 per patient per night in the hospital and USD 1.21 per initial diagnosis. A second 
study in Angola estimated the auxiliary staff cost to be USD 7.43 and USD 17.70 per patient 
per day for treatment with melarsoprol and eflornithine, respectively; the cost of expatriate 
staff regardless of which drug was used was estimated to be USD 6.73 (Robays et al. 2008). In 
addition, the cost of nurse time per diem for the administration of melarsoprol and eflornithine 
is USD 5.90–17.70 and USD 5.90 - 23.60, respectively; the cost of an adverse event associated 
with the administration of melarsoprol is estimated to be USD 44.61 (Robays et al. 2008). 
 Control costs for HAT 
Case detection and surveillance costs 
Of the 60 million people estimated to be at risk for HAT, only 3-4 million are under any form 
of surveillance (Cattand et al. 2001). A 2001 paper by Shaw and Cattand builds on a series of 
previous WHO reports and analytical work on control and surveillance of trypanosomiasis to 
outline five potential surveillance methods and to estimate their costs and cost-effectiveness 
using as spreadsheet model (Shaw & Cattand 2001). These include active case detection, which 
is divided into (1) monovalent surveillance teams looking only for sleeping sickness, (2) 
polyvalent teams looking for other diseases in addition to HAT, and (3) sampling of 
community workers to collect blood on filter paper. Passive case detection, which is divided 
into (4) fixed-post surveillance or traditional surveillance in which patients who cannot be 
diagnosed with another disease are eventually referred to a HAT treatment center for further 
testing, or (5) sampling of patients at rural health centres to collect blood on filter paper 
regardless of the reason for the patients original presentation. Road blocks near health centers 
have also been used as a form of active case detection. Table 10 summarizes costs associated 
with case detection and surveillance. 
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Table 10. Cost for case detection/surveillance strategies for T.b. gambiense HAT 
Authors Year Description of cost Cost (USD) 
Shaw 1989 Surveillance at health center USD 2.20 per person tested (USD 0.62 per 
population) 
Road blocks near health centers USD 1.34 per person tested (USD 0.13 per 
population) 
Multipurpose mobile team USD 1.25 per person tested (USD 0.16 per 
population) 
Single-purpose mobile team USD 1.71 per person tested (USD 0.85per 
population) 
Cost per serological test USD 1.58 
Cost per parasitological exam USD 2.53 
Shaw & 
Cattand 
2001 Rural health centers and mobile teams 
(0.05%) 
USD 2,696.15 per patient found 
Rural health centers and mobile teams 
(1%) 
USD 161.77-188.73per patient found 
Rural health centers and mobile teams 
(1%-5%) 
Approximately USD 40.44 per patient found 
Rural health centers and mobile teams 
(20%) 
Approximately USD 13.48 
Rural health centers and mobile teams 
(50%) 
Approximately USD 6.74 
Community health workers (0.05%) Just under USD 2,700 per patient found 
Community health workers (1%) Less than USD 134.81 per patient found 
Community health workers (1% -5%) USD 29.66 per patient found 
Community health workers (20%) Approximately USD 13.48 per patient found 
Community health workers (50%) Approximately USD 6.74 per patient found 
Passive or fixed detection posts (0.05%) USD 67.40 per patient found 
Passive or fixed detection posts (1%) USD 26.96 per patient found 
Passive or fixed detection posts (1%-5%) USD 18.87 per patient found 
Passive or fixed detection posts (20%) Approx. USD 13.48 per patient found 
Passive or fixed detection posts (50%) Approx. USD 13.48 per patient found 
Initial screening and parasitological 
exams 
USD 3.37-4.72 per person 
Lutumba 
et al 
2007 Annual costs for operations of mobile 
teams 
 
     Vehicles USD 7,212.62 
     Medical and lab supply (includes 
CATT reagents) 
USD 3,884.26 
     Training USD 945.25 
     Personnel USD 16,212.57 
     Medical and lab supply USD 20,826.57 
     Essential drugs (not for HAT) USD 2,955.42 
     Vehicle operation & maintenance USD 7,318.18 
 
Diagnostic costs 
The most frequently used method for diagnosis of T.b. gambiense is the card agglutination test 
for trypanosomiasis (CATT); lumbar puncture is also necessary for determination of 
cerebrospinal fluid involvement. Controlled lumbar punctures are recommended for late stage 
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West African trypanosomiasis every 6 months for up to 3years after diagnosis and therapy. In 
East African trypanosomiasis they should be carried out more frequently (i.e. every 3 months 
during the first year). The cost of CATT is estimated at USD 2.51 per test (Molyneux et al. 2010). 
Costs associated with diagnostic tests, in addition to new loop-mediated isothermal 
amplification (LAMP) methodologies are presented in Table 9. Some of the treatment and 
surveillance studies noted above also include the costs of diagnosis of the disease in their total 
cost estimates (Shaw & Cattand 2001). 
 Economic burden 
Human and animal trypanosomiasis has been estimated to cause a large economic burden to 
families and livestock producers in endemic areas. The diseases are thought to be important 
contributors to rural underdevelopment (Kristjanson et al. 1999; Budd 1990; Swallow 2000). 
While this review focuses on the human health and economic effects of HAT, T.b. rhodiesiense, 
which infects both humans and animals, may also be responsible for a significant economic 
impact through limitations on land use and livestock rearing due to increased mortality and 
limited weight gain among infected livestock (Jemal et al. 1995; Jemal & Hugh-Jones 1995; 
Agyemang et al. 2010; Agyemang et al. 1991; Wilson et al. 1986; M Kamuanga et al. 
2001).Although the economic impact of trypanosomiasis has been addressed in recent years, 
much of this research has been focused on animal trypanosomiasis (nagana or other variants). 
While HAT is related and overlapping geographically with transmission of animal 
trypanosomiasis, interactions between the two diseases and the associated economic impacts 
are fairly complex. For instance in areas where similar vectors transmit both human and 
animal trypanosomes, vector control interventions against tsetse are likely to reduce the 
burden of both human and animal disease. Similarly in East Africa where the parasite affects 
both humans and animals, many preventative and treatment interventions could bring 
benefits through reduced transmission to both humans and animals. However, in West Africa 
where T.b. gambiense infects only humans, trypanosome targeted interventions, such as case 
detection and treatment, are likely to bring benefits only to humans; interventions targeting 
the trypanosomiasis burden in livestock may provide benefits to humans only through 
improved agricultural productivity, and are unrelated to the burden of HAT, except where 
these interventions might have an effect on vectors that transmit the human parasite. More 
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complicated to estimate or measure are the indirect costs which could be the result of long-
term changes in production systems or land use due to the presence or risk of trypanosomiasis 
in both animal and human populations (Shaw, 2004). Several studies were identified that 
attempted to quantify the economic burden of African trypanosomiasis, or estimate returns to 
investment in the control of animal or human trypanosomiasis (Wilson et al. 1986; Woudyalew 
Mulatu, Swallow, B.M. et al. 1997; Rowlands et al. 1999; BLANC et al. n.d.; Shaw & 
Munstermann 1994; F. Brandl 1988; Putt et al. 1980).  It is also estimated that across sub-
Saharan Africa farmers spends upwards of USD 30 to 40 million a year on trypanocides to 
protect their livestock (Holmes & Geerts 2004). Approximately 45-50 Million cattle are thought 
to live in zones of trypanosomiasis risk (Kristjanson et al. 1999; Budd 1990)  ; significant 
increases in numbers of adult cattle and in cattle ownership were observed after the rollout of 
tsetse control measures in Burkina Faso (M Kamuanga et al. 2001).  In the late 1990s it was 
estimated that improved trypanosomiasis control could return benefits of USD 700 million per 
year in Africa in terms of meat and milk productivity alone, and USD 1.3 billion if producer 
and consumer surpluses were considered (Kristjanson et al. 1999); other studies estimated 
considerably higher increases in annual agricultural out-put of approximately USD 4.5 billion 
(Budd 1990; Swallow 2000).Using interviews, one study estimated the direct and indirect costs 
to patients and their families to be a net loss of approximately 25% of the families’ annual 
income per case (Gouteux et al. 1987). Additional results from a study in the DRC reported 
that the median loss per HAT patient household on average was USD249.94, which is 
approximately 43% of annual household revenue based on agricultural (Lutumba, Makieya, 
et al. 2007b), while in Tanzania USD 30.54–61.08 was the estimated total household loss (Reid 
et al. 2012). Out-of-pocket expenses for patients and their families also contribute to economic 
burden for HAT. Matemba and colleagues (Matemba et al. 2010) found that on average USD 
0.59 per night was required for relatives accompanying the patient to the hospital for 
treatment. Matemba and colleagues (Matemba et al. 2010) also found a return trip for 
treatment had a mean cost of USD 7.91, while meals were USD 17.70 per patient treated. Family 
members that had to pay for accommodation, on average spent USD 29.50 over the course of 
treatment. Out-of-pocket payments were also required for direct medical expenses including 
a screening treatment card (USD 0.46 - 0.57) (Robays et al. 2008) or lab tests (USD 0.59) 
(Matemba et al. 2010). Lastly, non-medical costs for hospital patients have been estimated to 
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be USD 80.72 in rural Tanzania, including the costs associated with an accompanying person 
to the hospital/clinic (Matemba et al. 2010). 
4.5 Discussion 
This paper reviews the literature on the costs associated with the prevention, treatment and 
control of HAT. This information is important, as donors and control programs increase 
funding and attention to strategies for eventual elimination. Importantly, this review lends 
insight into the scarcity of literature on costs that if updated, could improve the efficiency of 
prevention and control activities. In addition, this information is useful for collating cost 
information in a common valuation system is also important for stakeholders interested in 
developing economic evaluations to aid the decision making process. There were few studies 
focused specifically on the costs related to health systems research principles to the prevention, 
control, or treatment of HAT. This is likely due to the limited focal nature of the disease, which 
complicates our general understanding of how HAT control and treatment interaction 
complement one another. Though large swaths of the African continent are theoretically at 
risk, in reality there are relatively few cases, which tend to be concentrated in known foci. For 
this reason, potential health system interactions likely have limited application at a national or 
regional scale. It is likely that HAT deaths are greatly underreported (Odiit et al. 2004). 
Underreporting suggests that there is a gap in terms of how HAT control and treatment impact 
health information systems. Improving disease surveillance and case detection is seen as one 
of the great challenges to reducing morbidity and mortality due to HAT. While polyvalent 
screening teams might be more efficient than the use of single purpose HAT active case 
detection (Shaw & Cattand 2001), the disease remains highly focal and thus investment in the 
use of integrated surveillance is unlikely to impact health information system quality or 
coverage outside of the foci of HAT transmission. In addition, since HAT is invariably fatal if 
left untreated, all medicines required for HAT care must be considered essential for HAT 
endemic countries, and are listed as essential drugs by the WHO. As a neglected tropical 
disease, relatively little funding for new drug development is available globally, and the drugs 
for treatment of the disease are not marketed. These drugs (elfornithine, pentamidine and 
melarsoprol manufactured by Sanofi-Aventis, and suramin and nitrofurimox manufactured 
Page 115 of 321 
 
by BayerSchering Pharma) are made available freely to the WHO by the manufacturers. We 
were unable to identify any studies examining the impacts of HAT programs on the 
availability and quality of human resources. Much of the control of HAT is based on vector 
control programs, which are typically vertically organized and run either in parallel or entirely 
outside of existing health system infrastructure. They thus pose a risk for diversion of human 
resources outside of the public health sector in some cases. Alternatively, surveillance 
strategies could be built on existing health management information systems (HMIS) or 
community based surveillance platforms potentially improving both, albeit in the limited 
areas of HAT foci. Another gap relates to a paucity of cost information on how HAT control 
and treatment impacts service delivery. While the global impact of HAT treatment on service 
delivery is likely limited, the need for invasive and painful diagnostic measures (i.e. lumbar 
puncture) and dangerous treatments that require expensive monitoring over long periods of 
time suggests the potential for a serious burden on the health systems delivery of other 
services in areas with significant case-loads. Furthermore, there is documented evidence of 
increases in HAT transmission and risk in areas of conflict, both increasing the burden of 
disease in areas with major challenges for service delivery but also disproportionately 
increasing the need for improved service delivery (Berrang-Ford et al. 2011). Lastly, many of 
the studies identified lack standardization in terms of cost estimates, methods for presenting 
results, criteria for which costs are presented, and an overall accounting of all inputs as part of 
a treatment or control program. In addition, many of the vector control costs are quite old. 
This complicates the differentiation between financial and economic costs, which in turn 
creates challenges when making comparisons. In the context of increased attention to 
neglected topical diseases in general, and HAT specifically, recent and standardized 
information on the costs for prevention, treatment and control interventions is needed. 
4.6 Conclusion 
The disease and disability resulting from HAT infection is enormous, which could negatively 
affect overall productivity of an individual and household. The results of this review show 
that recent and standardized information on the costs for prevention, treatment and control 
interventions is very scarce. While the literature available on costs provides useful 
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information, most of the literature is outdated, focused on specific ecological contexts within 
countries, and is limited in terms of usefulness for developing estimates of the economic 
burden across Africa. The information presented herein should be updated to improve cost 
estimation. The collection of relevant and current cost data could play a meaningful role in 
funding and advocacy for resource mobilization for the control and elimination of HAT. 
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5.1 Summary 
Background 
Trypanosoma brucei (T b) gambiense is targeted to reach elimination as a public health problem 
by 2020 and full elimination by 2030. To achieve these goals, stakeholders need to consider 
strategies to accelerate elimination. Hence, we aimed to model several options related to 
current and emerging methods for case detection, treatment, and vector control across settings 
to assess cost-eﬀectiveness and the probability of elimination. 
Methods 
Five intervention strategies were modelled over 30 years for low, moderate, and high 
transmission settings. Model parameters related to costs, eﬃcacy, and transmission were 
based on available evidence and parameter estimation. Outcomes included disability-adjusted 
life-years (DALYs), costs, and long-term prevalence. Sensitivity analyses were done to 
calculate the uncertainty of the results. 
Findings 
To reach elimination targets for 2020 across all settings, approaches combining case detection, 
treatment, and vector control would be most eﬀective. Elimination in high and moderate 
transmission areas was probable and cost- eﬀective when strategies included vector control 
and novel methods, with incremental cost-eﬀectiveness ratios (ICERs) ranging from US$400 
to $1500 per DALY averted. In low transmission areas, approaches including the newest 
interventions alone or in combination with tiny targets (vector control) were cost-eﬀective, 
with ICERs of $200 or $1800 per DALY averted, respectively, but only strategies including 
vector control were likely to lead to elimination. Results of sensitivity analyses showed that 
allowing for biennial surveillance, reducing vector control maintenance costs, or variations of 
active surveillance coverage could also be cost-eﬀective options for elimination, depending on 
the setting. 
Interpretation 
Although various strategies might lead to elimination of T b gambiense, cost-eﬀective 
approaches will include adoption of emerging technologies and, in some settings, increased 
surveillance or implementation of vector control. 
Funding  
Bill and Melinda Gates Foundation.  
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5.2 Introduction 
Human African trypanosomiasis, or sleeping sickness, is caused  by  Trypanosoma  brucei  (T  b)  
gambiense  and T b rhodesiense. Approximately 70 million people live in  at-risk  areas  in  sub-
Saharan  Africa.(Jose R Franco et al. 2014)   According  to Global Burden of Disease (GBD) data 
from the Institute for   Health   Metrics   and   Evaluation   (IHME),   human African   
trypanosomiasis   contributes   an   estimated 560 262 disability-adjusted life-years (DALYs) to 
the global burden of disease  and ranks sixth in reference to the number of deaths among 
neglected tropical diseases.(GBD 2013 Mortality and Causes of Death Collaborators 2014) T b 
gambiense is primarily maintained in a human–tsetse cycle, whereas T b rhodesiense 
transmission entails a large spectrum  of  reservoir  animals,  mainly  game.  Thus, elimination 
eﬀorts have primarily targeted T b gambiense. In 2011, WHO published a roadmap towards 
overcoming the impact of ten neglected tropical diseases (NTDs),(WHO 2012)  and this 
commitment was renewed in January, 2012, as the London   Declaration   on   Neglected   
Tropical   Diseases, supported by the collaboration Uniting to Combat NTDs, became a new 
benchmark for elimination goals. It was then that the goal of control, described as reduction 
of disease to acceptable levels, was shifted to elimination, which pursues zero incidence in a 
deﬁned geographical area.(Dowdle 1998)     Human    African    trypanosomiasis    caused    by 
T b gambiense was one of the diseases targeted for elimination as a public health problem by 
2020, which is deﬁned as less than one case per 10 000 people per year,(WHO 2012; World 
Health Organization (WHO) 2013a) and complete elimination by 2030. As the year 2020 
approaches, stakeholders committed to T b gambiense elimination have recognised that current 
interventions are resource-intensive, costly, and infeasible in remote or sociopolitically 
unstable areas, hindering foreseen elimination goals.(World Health Organization (WHO) 
2013a; Holmes 2014; Yamey et al. n.d.) Moreover, with several emerging novel technologies 
and approaches for surveillance, diagnosis, treatment, and prevention (vector control) of T b 
gambiense, now is the time to investigate whether new technologies can accelerate elimination 
and, if so, how to allocate current resources to the right combination of interventions.(Tediosi 
et al. 2013) 
We aimed to analyse the cost-eﬀectiveness of strategies for control and elimination of human 
African trypanosomiasis caused by T b gambiense and to forecast the eﬀect of these approaches 
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on disease transmission. The outcomes presented here aim to assist decision makers in 
determining which strategies are most likely to lead to elimination and will show good value 
for money. 
5.3 Methods 
 Potential strategies for control and elimination 
Various scenarios of current interventions and emerging methods  have  been  proposed  for  
control  and  elimination   of   human   African   trypanosomiasis   caused   by T  b  
gambiense.(Steinmann et al. 2015)     We  developed  a  series  of  strategies using these scenarios 
over time to ascertain which combination of interventions would be most likely to sustain 
control or accelerate towards elimination. After preliminary modelling (appendix C.7), we 
identiﬁed ﬁve strategies as relevant options for control or elimination of human African 
trypanosomiasis caused by T b gambiense, which are depicted in Figure 10. Strategy A, 
“control”, is one of two strategies recommended  by  WHO(World Health Organization 
(WHO) 2013a)    and  aims  to  bring  the  number  of annual  cases  to  an  acceptable  level.  It  
focuses  on screening and treating patients and reﬂects the current approach practised by most 
national sleeping sickness control programmes across sub-Saharan Africa. In strategy 
A, patients self-report to local health centres (referred to as passive surveillance) and active 
case- ﬁnding is done by teams of health workers who seek out patients living in aﬀected areas 
(active surveillance). Diagnosis is done in public during in-village screening campaigns and 
requires blood testing for serological conﬁrmation of antigens in response to the parasite. 
Blood tests are conﬁrmed using the card-agglutination trypanosomiasis test (CATT).  Patients 
who have a positive CATT undergo parasitological conﬁrmation of the disease. If conﬁrmation 
is received they are referred for lumbar puncture to check the cerebrospinal ﬂuid, to 
diﬀerentiate if the disease is in the early stages of development (stage 1 disease) or if the 
parasite has entered the CNS (stage 2 disease). In October, 2016, the approved treatment for 
human African trypanosomiasis on WHO’s essential drug list for stage 1 disease was 
pentamidine, whereas nifurtimox-eﬂornithine combination therapy was the ﬁrst-line, 
parenteral treatment for patients who have progressed to stage 2. 
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Strategy B, “control plus tiny targets”, is the second strategy recommended by WHO and 
incorporates vector control to supplement the screen-conﬁrm-stage-treat approach. Tiny 
targets are small insecticide-impregnated screens measuring 0·5 × 0·25 m that are more cost- 
eﬀective and easier to deploy than are their larger predecessors (1 × 1 m² target; Box 1).(Shaw 
et al. 2015; Solano et al. 2013) 
The remaining three strategies incorporate innovative approaches in relation to surveillance, 
diagnosis, and treatment for control of T b gambiense, which are expected to arrive between 
2016 and 2019. Strategy C, “new technologies 2016”, maintains strategy A until 2016, after 
which time case-detection will be switched to more ﬂexible teams on motorbikes and diagnosis 
of disease will be done using a ﬁrst-generation rapid diagnostic test algorithm (panel). 
Conﬁrmation and staging will be done using the loop-mediated isothermal ampliﬁcation 
(LAMP) technique, and treatment for the second stage of disease will switch to ten oral doses 
of fexinidazole. This process is continued until 2019, when fexinidazole will be considered for 
treatment of both stage 1 and 2 disease and a second-generation rapid diagnostic test will be 
available (panel). Strategy D, “new technologies 2016 and 2019”, mirrors strategy C until 2019, 
when a new oxaborole compound, SCYX-7158, will be available for treatment of  both  stages  
of  disease  with  one  oral  dose  (Box 1). 
Figure 10. Summary of potential strategies for control and elimination of human African trypanosomiasis 
caused by T b gambiense 
  
Feasible scenarios are shown that could lead to elimination of human African trypanosomiasis caused by Trypanosoma brucei (T b) gambiense, based on current 
interventions and those in the pipeline.(Steinmann et al. 2015) Every scenario contains a component of surveillance, diagnostics, and treatment interventions to 
interrupt transmission of T b gambiense for a population at risk. Passive surveillance is combined with annual active surveillance in high-risk areas and with biennial 
surveillance in moderate-risk areas. In low-risk settings, active surveillance is not done and reliance is solely on passive surveillance. These approaches are based on 
recommendations for T b gambiense control outlined by WHO.(World Health Organization (WHO) 2013a) For all scenarios when the model reaches elimination, it 
switches to passive surveillance only (the model assumes no reinvasion of cases or ﬂies after elimination is reached). CATT=card-agglutination trypanosomiasis test. 
NECT=nifurtimox-eﬂornithine combination therapy. RDT=rapid diagnostic test. 
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 Box 1. Highlights of new treatments and emerging technologies used in the current modelling for control 
and elimination of human African trypanosomiasis caused by Trypanosoma brucei gambiense 
 
 
2013: tiny targets  
Traditional targets for vector control in the field are quite large and costly with respect 
to maintenance and deployment. New targets (Vestergaard-Frandsen, Lausanne , 
Switzerland) are significantly smaller in size and cost less than their large 
predecessors.(Shaw et al. 2015; Tirados et al. 2015)  Tiny targets are made of a blue 
fabric that attracts flies, which are then killed by the insecticide-impregnated 
screens.(Liverpool School of Tropical Medicine n.d.) 
 
2016: Motorbike surveillance teams  
Surveillance teams comprised of one or two people on a motorbike are feasible with the 
newer diagnostic technologies that are easy to carry in a backpack and do not require 
cold-chain storage.  Motorbikes also increase coverage because they can reach areas 
large trucks cannot access due to roads in poor condition. (Steinmann et al. 2015) 
 
2016: fexinidazole 
Fexinidazole is a well-tolerated oral treatment to be given for 10 consecutive 
days(Tarral et al. 2011) currently undergoing Phase III trials(Drugs for Neglected 
Diseases initiative (DNDi) 2014a) for human African trypanosomiasis stage 2 and also y 
stage 1 patients.  
 
2016: rapid diagnostic test algorithm,  1st generation 
1st generation rapid diagnostic test (RDT) have been made available.(Büscher et al. 2014; 
Sternberg et al. 2014) This algorithm considers the potential of such tests in combination 
with loop-mediated isothermal amplification (LAMP), for which staging is done using 
blood instead of cerebrospinal fluid obtained through lumbar puncture. (Steinmann et 
al. 2015) 
 
2019: rapid diagnostic test algorithm,  2nd generation 
A 2nd generation RDT with recombinant antigens that requires no additional blood 
sample or lumbar puncture for parasitological staging and confirmation.(Steinmann et 
al. 2015) 
 
2019: SCYX-7158 
SCYX-7158 is an oxaborole compound currently being tested in a phase I clinical 
trial,(Maser et al. 2012)  Itis a single dose oral tablet that aims to cure both disease 
stages. (Steinmann et al. 2015) 
  
 
Finally, strategy E, “new technologies 2016 and 2019 plus tiny targets”, assesses the eﬀect of 
combining strategy D with tiny targets. In strategies C, D, and E, we assumed that, by 2019, 
oral treatment will be appropriate for either stage of disease and, hence, parasitological 
conﬁrmation for staging will no longer be necessary. 
Based on recommendations by WHO, (World Health Organization (WHO) 2013a)  we 
assumed that active screening was done annually in settings with high transmission and 
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biennially in areas with moderate transmission, and that no active screening component was 
included in low transmission settings, where detection relies solely on passive surveillance. 
We also assumed that only passive surveillance would be implemented after elimination, until 
2042. We did not model scenarios in which reinvasion of cases (tsetse ﬂy or human) happened 
after elimination. We based our estimated timelines on every producer’s estimate of products 
in the pipeline for human African trypanosomiasis caused by T b gambiense during 2013; hence, 
the timelines we present here are to be taken as examples because, in reality, technologies 
could arrive sooner or later on the market than planned. For example, a ﬁrst-generation rapid 
diagnostic test arrived on the market in 2013 and has been used in endemic countries across 
sub-Saharan Africa since 2016. Moreover, evaluation of a second-generation rapid diagnostic 
test has been completed by the Foundation for Innovative New Diagnostics (FIND) and 
commercialisation is now expected in December, 2016, rather than 2019 as forecasted. 
 Health effect and economic modelling  
To assess the long-term costs, health eﬀects, and likelihood of the given strategies maintaining 
control or leading to elimination, we used an ordinary diﬀerential equation model of human 
African trypanosomiasis caused by T b gambiense (Figure 11; appendix C.4).(Chris M. Stone & 
Chitnis 2015) We divided the human population into several compartments: susceptible (ie, 
uninfected); infected (but not yet infective); asymptomatic (ie, stage 1 disease); removed (ie, 
stage 2 disease); or being treated. The asymptomatic state is not synonymous with the absence 
of symptoms in the clinical sense but is stated as such to diﬀerentiate the primary stage of the 
disease from the second, more severe, stage. We also tracked the number of people who died 
from human African trypanosomiasis over time and assumed that, although human beings 
have stage 2 disease or are being treated, they are generally recumbent and not present in 
tsetse habitat. We divided tsetse ﬂies into susceptible, exposed, and infected compartments. 
We accounted for heterogeneity in exposure to tsetse bites by modelling two human 
populations, one in which individuals lived and worked in a low transmission setting and the 
other in which people travelled between a low transmission area and one with greater 
exposure to tsetse bites. A possible animal reservoir was assumed to not contribute 
signiﬁcantly to transmission of human African trypanosomiasis caused by T b gambiense.(Jose 
R Franco et al. 2014) The model structure, transmission parameters for areas with high, 
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moderate, and low transmission, and investigations of the use of current technologies to reach 
elimination have been described in detail elsewhere.(Chris M. Stone & Chitnis 2015) We ﬁtted 
the model using a Bayesian importance resampling procedure to three stable prevalence levels 
that coincide with slightly above low (0·02%), moderate (0·112%), and high (1·61%) 
transmission areas, deﬁned previously by WHO. Parameters that varied between the 
strategies related to speciﬁc interventions are provided in appendix C.2. 
For every model run, we allowed populations to reach a stable level of transmission over a 
300-year period, in the absence of interventions. We then introduced interventions as speciﬁed 
by the diﬀerent control and elimination strategies. If elimination was achieved in any run, we 
switched the interventions to post-elimination activities (passive surveillance). We tracked the 
disease burden attributable to human African trypanosomiasis by assigning a DALY value 
whenever an individual entered a relevant compartment (stage 1 disease, stage 2 disease, or 
death from disease). We calculated costs associated with interventions through incorporated 
cost functions. 
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Figure 11. Ordinary differential equation model 
 
(A)Heterogeneity captured by diﬀering exposure levels of two populations living in the same area. Population 
1 lives and works in a low-exposure habitat (eg, village). Population 2 commutes between habitats with low and 
high exposure, each harbouring tsetse and animal populations (eg, cattle) of varying sizes. (B) Transmission for 
populations in each habitat includes susceptible, infected, asymptomatic, and removed compartments (health 
states) for human beings, and susceptible, exposed, and infected compartments for tsetse ﬂies (vectors).  
 Costing inputs, sources, perspective, and outcomes 
Our  analysis  is  from  the  perspective  of  a  funder  of a   national   sleeping   sickness   control   
programme; we modelled the annual prevalence, costs, and health outcomes (deﬁned as 
DALYs)(World Health Organization (WHO) n.d.) over 30 years, starting in 2013 (appendix 
C.1). We discounted costs and DALYs at 3% annually(National Institute for Health and 
Clinical Excellence (NICE) International 2014; World Health Organization (WHO) 2003) and 
assessed cost-eﬀectiveness by calculating the incremental cost-eﬀectiveness ratio (ICER)   of   
each   strategy   relative   to   its   next   best comparator. 
We developed a common unit for every intervention within a speciﬁc category then calculated 
a per diem cost based on cost functions for case detection, diagnostics, drug treatment, and 
vector control interventions. We took data inputs for direct costs from previous work,(Keating 
et al. 2015) country reports,  expert  opinions,  and  manufacturers,  when estimates were not 
published or available publicly. Cost parameters and formulas for cost functions are available 
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in appendix C.2. We converted unit prices from countries other than the USA to US$ using 
purchasing power parity listed in the World Economic Outlook database, (International 
Monetary Fund (IMF) 2014) and changed costs reported in € to US$ with the average exchange 
rate lists published on the European Central Bank Statistical Data Warehouse. We then inﬂated 
these values to 2013 prices with average consumer price indices.(International Monetary Fund 
(IMF) 2014) 
 Uncertainty analysis 
We did a probabilistic sensitivity analysis to establish the eﬀect of parameter uncertainty on 
the cost-eﬀectiveness and probability of elimination. We imputed parameters related to 
surveillance coverage, cost of interventions, cost of drug treatments, case-detection sensitivity, 
and cost and eﬃcacy of vector control probabilistically based on latin hypercube sampling, 
and we ran 500 simulations. A full description of input parameters is provided in the appendix 
C.2. We plotted probabilistic results as cost-eﬀectiveness acceptability curves for low, 
moderate, and high trans- mission areas and reported the probability of elimination over the 
investigated period. We presented results in probabilistic terms and assessed them at two 
thresholds: elimination as a public health problem (less than one case in 10 000 people) by the 
year 2020; and full elimination (zero cases) by 2030. We did a one- way sensitivity analysis of 
discount rates, vector mortality, and coverage levels across all settings. Because  we  modelled  
no  active  surveillance  in low transmission settings (based on WHO recommendations) in the 
base case analysis, we varied surveillance intensity in this setting to ascertain the potential 
eﬀect on elimination and cost-eﬀectiveness. Previously, another molecule in development for 
human African trypanosomiasis failed to reach the market in late phase trials.(Wenzler et al. 
2009; Harrill et al. 2012) Therefore, we modiﬁed and modelled the strategies to assess the 
potential eﬀect of the oxaborole compound SCYX-7158 experiencing market failure. 
Furthermore, clinical trials for fexinidazole are underway (NCT02169557); hence, we decided 
to investigate the potential eﬀect on elimination if fexinidazole arrives on the market earlier 
than expected (to capture putative positive eﬀects of ongoing trials). 
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  Role of the funding source 
The funder had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all data in the study and had 
ﬁnal responsibility for the decision to submit for publication. 
5.4 Results 
Table 12 shows results from the base case analysis. In high transmission settings, strategy E— 
comprising new technologies in 2016 and 2019 plus tiny targets—resulted in an ICER of $386 
per DALY averted. In a moderate transmission setting, strategy E was also cost-eﬀective, at an 
ICER of $1509 per DALY averted. In low transmission areas, strategy D, consisting solely of 
new technologies in 2016 and 2019, resulted in an ICER of $160 per DALY averted; the next 
best approach after this one was strategy E, leading to an ICER of $1812 per DALY averted. 
Strategy A, the current control, was dominated consistently  across  settings, meaning  that 
this approach costs more money and averted fewer DALYs. 
 
Table 11. Cost-effectiveness analysis of different strategies, by risk transmission area 
Strategy 
Total Mean 
Costs (USD) 
per person 
 
Total Mean 
DALYs per 
person 
Incremental Cost-effectiveness 
Ratio (ICER) 
High risk transmission area    
D.   New technologies  in 2016 and 2019 $45  0.22 - 
C.   New technologies in 2016 $47 0.25 Dominated by Strategy D 
E.   New technologies in 2016 and 2019 with tiny targets $61 0.18 $386 per DALY averted* 
B.   Control  with tiny targets $82 0.20 Dominated by Strategy E 
A.   Control $115 0.34 Dominated by Strategy E 
Moderate risk transmission area    
D.   New technologies  in 2016 and 2019 $20 0.03 - 
C.   New technologies in 2016 $20 0.03 - 
E.   New technologies in 2016 and 2019 with tiny targets $38 0.02 $1509 per DALY averted* and ¥ 
B. Control  with tiny targets $48 0.02 Dominated by Strategy E 
A. Control $55 0.04 Dominated by Strategy E 
Low risk transmission area    
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C.   New technologies in 2016 $2 0.04 - 
A. Control $3 0.04 Dominated by Strategy C 
D.   New technologies  in 2016 and 2019 $3 0.03 $160 per DALY averted¥ 
E.   New technologies in 2016 and 2019 with tiny targets $42 0.01 $1’812 per DALY averted* 
B. Control  with tiny targets $45 0.01 Dominated by Strategy E 
DALY = disability adjusted life year.*Relative to strategy D. ¥Relative to strategy C.  
 
Figure 12 shows the variability surrounding mean costs and DALYs of every strategy and cost-
eﬀectiveness acceptability curves. In high transmission areas, at the cost-eﬀectiveness 
threshold of $400 per DALY averted, strategy E had the highest probability of being cost-
eﬀective. In settings of moderate transmission, strategies D and E both had the highest 
probability  of  being  cost-eﬀective,  at  a  threshold  of $1500 per DALY averted. In low 
transmission settings, strategy D had the highest probability of being cost- eﬀective, at a 
threshold of $200 per DALY averted, but at a threshold of $1800 per DALY averted, strategy B 
(in which tiny targets are added to current control eﬀorts) had the highest probability of being 
cost-eﬀective, competing with strategy E. 
The results of the one-way sensitivity analysis are summarised in appendix C.5.2. In high 
transmission areas, strategy E remained cost-eﬀective over a range of parameter variations; 
however, the ICER for this approach decreased relative to base case estimates when mortality 
with tiny targets increased ($244 per DALY averted), when annual costs of vector control 
maintenance were reduced ($309 per DALY averted), when patients received oral treatments 
at home exclusively ($318 per DALY averted), or when active surveillance coverage was less 
than 80% ($49–205 per DALY averted). In areas of moderate transmission, strategy E also 
remained the most cost-eﬀective option, with reductions in ICER from the base case analysis 
ranging from $317 to $1447 per DALY averted using the same parameter variations as for high 
transmission settings. In  low  transmission  settings,  strategy  D typically remained the most 
cost-eﬀective option across a range of parameter variations and was near to or lower than $100 
per DALY averted either when maximum increases to passive surveillance were attributed to 
the arrival of fexinidazole on the market ($33 per  DALY  averted)  or when  biennial  active 
surveillance campaigns were initiated ($123 per DALY averted). 
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Figure 13 shows that, in high transmission areas, achieving the London Declaration targets for 
elimination of T b gambiense by 2020 and full elimination in 2030 is probable (appendix C.8). 
Particularly, strategies with vector control alone or vector control combined with new 
technologies (strategies B and E, respectively) have a more  than  90%  chance   of   reaching   
elimination in 2020 and 2030, whereas strategies including new technologies alone  (strategies  
C  and  D)  have  an 80% chance. If regimens currently in place are maintained (strategy A), 
reaching elimination by 2020 or 2030 is less likely (roughly 50%). In areas of moderate 
transmission, all strategies have a more than 80% chance of reaching the London targets by 
2020. Full elimination by 2030 would be feasible with strategies that include vector control 
(96%; strategies B and E), whereas adopting new interventions in the absence of tiny targets 
(68%; strategies C and D), or current control activities (roughly 50%; strategy A), are less likely 
to reach full elimination in the next few decades. Similar to moderate transmission settings, in 
areas of low transmission, achieving elimination as a public health problem is almost certain 
with strategies that include tiny targets (97–99%; strategies B and E). Adopting new 
technologies alone without vector control (strategies C and D) are unlikely to reach 2020 
targets (24–45%) but are superior to the current control approach (0·05%; strategy A). Full 
elimination in low transmission areas will require strategies that include vector control (83–
86%; strategies B and E), but will lead to delays in achieving elimination goals. 
In high and moderate transmission areas, where active surveillance is maintained, a decrease 
in the eﬀectiveness of vector control (from 5·49% to 1% mortality) would have no eﬀect on 
elimination targets, however; in low transmission areas, ineﬀective vector control would 
render elimination elusive. Further improving the eﬃcacy of targets (increase from 5·49% to 
10%) would have relatively little eﬀect compared with the base case analysis for high 
transmission areas but would guarantee elimination in moderate and low transmission 
settings with strategies that include vector control. Including active surveillance in addition to 
passive surveillance in low transmission areas, whether biennial or annual, would ensure that 
2020 elimination targets will be achieved, but full elimination by 2030 is still most likely to 
occur with strategies that include vector control (appendix C.8). By contrast, the strategy 
currently in place (strategy A) is least likely to achieve full elimination. Varying the coverage 
of new technologies in low transmission zones had little eﬀect relative to the base case results; 
however, an increase in treatment coverage with the oxaborole compound SCYX-7158 to 
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approximately 45% led to a slight increase in the probability of elimination for strategies that 
included the oxaborole molecule (ie, strategies D and E) in these same areas. As provided in 
appendix C.8, coverage levels were varied in high and moderate transmission areas and 
showed overall that strategies with vector control (strategies B and E) would probably lead to 
elimination even when coverage was as low as 20%. Elimination as a public health problem 
(less than one in 10 000) was also achievable by 2030 when active screening coverage was 
equivalent to 60% and if oral tablet interventions become available (strategies C and D). 
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Figure 12. Probabilistic sensitivity analysis  
 
Cost-and-eﬀect planes (left) and cost-eﬀectiveness acceptability curves (right) for areas of high, moderate, and low 
transmission. Dots in the cost-and-eﬀect planes represents the outcome of costs per person versus disability-adjusted life years 
(DALYs) per person for every simulation. Mean results for every strategy are depicted as squares. The cost-eﬀectiveness 
acceptability curves show the probability that a given strategy is cost-eﬀective based on the net monetary beneﬁt of every 
strategy at varying cost-eﬀectiveness thresholds.  
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Figure 13. Probability of reaching targets 
 
Probability of achieving London declaration targets (left) and full elimination (right) in areas of high, moderate, 
and low transmission. The London Declaration deﬁnes elimination, in concordance with the WHO roadmap, as 
either elimination as a public health problem or less than one case in 10 000 people.(World Health Organization 
(WHO) 2013a) 
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5.5 Discussion 
Overall, our simulations show that continuing to screen and treat individuals for human 
African trypanosomiasis caused by T b gambiense, using currently available drugs and 
diagnostic methods (strategy A), is not cost-eﬀective compared with alternative strategies that 
are becoming available. Although this approach might lead to control over the next four 
decades, it is less likely to reach full elimination across transmission settings by 2030. Adopting 
new interventions as they arrive on the market in combination with use of tiny targets (strategy 
E) is the most cost-eﬀective approach for control and elimination of    human     African     
trypanosomiasis     caused     by T b gambiense, at a threshold appropriate for low-income and 
middle-income countries,(The World Bank 2016)  while leading to elimination  goals  in  high  
transmission  areas.  In  moderate transmission zones, continually adopting new technologies 
as they arrive on the market alone (strategy D) or combined with tiny targets (strategy E) has 
a probability of being cost-eﬀective near thresholds suitable for middle-income nations, (The 
World Bank 2016) with both these strategies likely to achieve London Declaration targets; 
however, only strategy E is likely to reach full elimination. In low transmission areas, a 
conundrum for decision makers between cost-eﬀectiveness and elimination persists. Adopting 
new interventions in the absence of vector control measures (strategy D) has the highest 
probability of being cost-eﬀective at a threshold of $200 per DALY averted(National Institute 
for Health and Clinical Excellence (NICE) International 2014) but is unlikely to achieve short-
term or longterm elimination targets. Adding tiny targets to current control measures (strategy 
B) or in combination with new technologies (strategy E) is more likely to lead to elimination 
but is only likely to be cost-eﬀective at thresholds above $1500 per DALY averted.(The World 
Bank 2016) These results highlight the economic constraints for global investments for 
elimination in areas with moderate and low transmission across  sub-Saharan  Africa.  More 
than 98% of current cases of human African trypanosomiasis caused by T b gambiense are in 
low-income countries with a reported gross national income of roughly $400 per person 
annually, (The World Bank 2016) whereas cost- eﬀectiveness thresholds for global investors 
are closer to $300 per DALY averted.(National Institute for Health and Clinical Excellence 
(NICE) International 2014) 
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It is important to note that these insights are based on a limited number of strategies, for which 
results reﬂect the synergies of the input parameters available: in speciﬁc situations, current 
methods could well be adequate. For instance, elimination of human African trypanosomiasis 
caused by T b gambiense in Equatorial Guinea (Luba, Bioko Island) focused on a screen-and-
treat campaign mechanism.(Simarro et al. 2006) Furthermore, our results show that addition 
of active biennial surveillance in low transmission areas would be a cost-eﬀective option, 
leading to elimination at less than $150 per DALY averted. Findings of ﬁeld studies and 
modelling exercises(Tirados et al. 2015; Courtin et al. 2015; Pandey et al. 2015; Rock et al. 2015; 
de Vries et al. 2016) have conﬁrmed our work, also showing that surveillance and treatment 
in combination with vector control can interrupt transmission in a shorter time span than can 
screen-and-treat campaigns alone. However, our analysis also examines the economic 
outcomes of these strategies, showing that although the cost-eﬀectiveness of adding tiny 
targets will vary by setting, reducing vector control maintenance costs or varying surveillance 
coverage rates in combination with tiny targets could improve cost-eﬀectiveness in high 
transmission areas while still possibly reaching elimination targets. 
Many aspects of T b gambiense epidemiology remain elusive. For example, in recent years, the 
implications of asymptomatic carriers,(Bucheton et al. 2011; Welburn et al. 2016) potential 
animal reservoirs for human African trypanosomiasis caused by T b gambiense,(Bucheton et al. 
2011) case reports of congenital transmission,(Lindner & Priotto 2010) systematic non-
compliance of at-risk subgroups,(Welburn et al. 2016; Bilonda Mpiana et al. 2015)  and the part 
played by vectors(Welburn et al. 2016) have been considered or reconsidered. Changes to 
available evidence could potentially aﬀect optimum elimination strategies, because our model 
assumes that animal reservoirs do not contribute signiﬁcantly to transmission of T b 
gambiense,(Chris M. Stone & Chitnis 2015) that asymptomatic carriers are suﬃciently rare in 
their occurrence,(Checchi et al. 2008) that vectors do transmit T b gambiense, and that sexual 
transmission is infrequent. If additional evidence to the contrary becomes available, new 
modelling studies should be developed to assess the eﬀect that these novel insights into the 
epidemiology of human African trypanosomiasis might have on elimination goals. 
Our assessments of new technologies have been made in the hope that the foreseen molecules 
would reach the market. Fexinidazole is now in phase 3  trials, (Drugs for Neglected Diseases 
initiative (DNDi) 2014a) with new studies for stage 2 human African trypanosomiasis in adults 
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and children. Findings of interim analyses show that fexinidazole is on track to come to the 
market, with a high possibility that it might be available for both stages of the disease in 
2019.(Jones & Avery 2015) Furthermore, results from the one-way sensitivity analysis also 
showed that if oxaborole compounds fail to reach the market, fexinidazole in combination with 
new diagnostic methods would still be a cost-eﬀective alternative likely to lead to elimination. 
Assuming that the oxaborole compound SCYX-7158 becomes available in the near future as a 
safe, single-dose oral compound, elimination becomes highly feasible and could possibly be 
considered as a tool for mass drug administration to prevent resurgence in areas that have 
high exposure rates to infected vectors. There is also uncertainty surrounding the sensitivity 
and speciﬁcity of current and emerging diagnostic tests, because diagnostic accuracy is related 
directly to prevalence and to identiﬁcation by the diagnostic test of antibodies that the hosts 
produce. These diﬃculties within diagnostic methods have also hindered research and 
development of a rapid diagnostic test that can diﬀerentiate stages of disease, meaning that 
lumbar puncture might be necessary for a longer time than once hoped. 
Economic concerns still remain because emerging technologies might also need a change in 
the health-care structure of aﬀected countries. Although our analysis assesses the cost-
eﬀectiveness of strategies, ﬁnancing for a chosen strategy and assessing the budget eﬀect that 
an elimination campaign would have on the current allotted ﬁscal space of decision makers 
are both necessary for global commitments towards elimination to be sustained.(Lee et al. 
2015) The indirect costs to society also need to be assessed because new treatments and 
reduced transmission will decrease potential out-of-pocket expenditures for aﬀected 
families(Matemba et al. 2010) and reduce productivity losses for aﬀected individuals. 
Moreover, reduction of tsetse ﬂies could potentially aﬀord communities access to land 
currently not inhabited, cultivated, or used for alternative economic gains.(Radio New 
Zealand 2015) 
Progress reports for elimination show that cases of human African trypanosomiasis caused by 
T b gambiense are on the decline,(Simarro et al. 2015) which is a tribute to the concerted eﬀorts 
of the global community working towards elimination of this disease. However, there are still 
populations living in at-risk areas not under surveillance. This situation calls for continued  
and  swift  diﬀusion of upcoming interventions in the pipeline across sub-Saharan Africa to 
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further accelerate the decline of human African trypanosomiasis transmission and to ensure 
that 2020 targets and beyond become a reality. 
5.6 Research in context 
 Evidence before this study 
Eﬀorts to estimate the ﬁnancial resources needed for elimination of neglected tropical diseases 
have been done by WHO and collaborations including Uniting to Combat NTDs and The 
Lancet Commission on Investing in Health. Furthermore, in 2015 and 2016, several researchers 
used modelling exercises to investigate the probability of elimination with available 
interventions in west and central Africa. However, a full economic assessment of multiple 
interventions for human African trypanosomiasis caused by Trypanosoma brucei (T b) gambiense 
has not been attempted. Building on our previous work, in which we identified and considered 
new technologies as potential strategies to achieve elimination, we used a modelling approach 
to assess the cost-effectiveness and the probability of elimination of five intervention 
strategies. 
 Added value of this analysis 
Our analysis shows that potential additional gains can be made with emerging technologies, 
particularly short or single-dose oral treatments (fexinidazole and the oxaborole compound 
SCX-7158), rapid diagnostic tests, and tiny targets. We also addressed trade-offs between costs, 
health effects and elimination timelines that need to be considered by decision makers. 
Additionally, our results indicate that strategic planning for elimination campaigns should be 
tailored to suit the transmission situation of a given focus. 
 Implications of all the available evidence 
The results presented in this report harmonise the contributions of current and emerging 
technologies that will be available to eliminate sleeping sickness and show good value for 
money, hence providing national sleeping sickness control programmes and global funders 
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with evidence-based solutions for the elimination of human African trypanosomiasis caused 
by T b gambiense. 
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6.1 Abstract 
Introduction 
Global health expenditures continue to increase albeit the fact that countries are being 
encouraged to achieve universal health coverage and alleviate poverty. It is hoped that 
elimination of HAT Tbg would assist in this goal, but the financial estimates to do this are still 
unknown. The objectives of this analysis are: 1) forecast the financial cost of control and 
elimination programs; and 2) estimate the risk to poverty by assessing financial protection. 
Methods 
In order to estimate the total costs to health services and individuals: 1) potential elimination 
programs were defined; 2) the direct costs of programs was calculated; and 3) the per case out-
of-pocket payments (OOPs) by program and financial risk protection indicators were 
estimated. Unit prices were converted in International Dollars (USD) using purchasing power 
parity (PPP) listed in the World Economic Outlook (WEO) database and discounted at 3%. The 
mean results for both direct program costs and OOPs were calculated from a number of 
simulations and reported along with 95% confidence intervals. Total costs per program were 
reported for the financial program costs. Proportions of catastrophic health expenditures at 
10% and 25% were reported for OOPs related to HAT Tbg. 
Results 
Across sub-Saharan Africa, HAT Tbg maintaining “Control” would lead to a decline in cases 
and cost $630M. In comparison, the cost of “Elimination” programs ranged from $410.9M to 
$1.2 billion. Maintaining “Control” would continue to cause impoverishment and CHEs to 
households; while all Elimination programs would lead to significant reductions.  
Conclusion 
Overall, the total costs of either control or elimination programs would be near 1 billion USD 
in the next decade. However, only elimination programs will reduce the number of cases and 
improve financial risk protection for households who are impacted by HAT Tbg. 
 Page 140 of 321 
 
6.2 Introduction 
Over the last two decades, global health expenditures per capita have more than doubled, and 
continue to increase annually.(World Health Organization n.d.) In several countries a large 
proportion of the health expenditure is funded by patients out-of-pocket with severe 
consequences to the financial protection of the household. Yet policy makers at all levels rarely 
take into account the potential consequences on a household’s economic conditions of health 
policies and interventions. In the last decade, Neglected Tropical Diseases (NTDs) increasingly 
attracted the interested of global health investors and there is currently a global mandate to 
achieve disease elimination of several NTDs.(Uniting to Combat Neglected Tropical Diseases 
2016) In order to comprehensively define the economic implications for NTDs in particular for 
key stakeholders, an “Eradication” or “Elimination Investment Case” (EIC) framework  was 
developed.(Tediosi et al. 2013) At present, this approach has been applied to onchocerciasis 
(“river blindness”) and lymphatic filariasis (LF, “elephantiasis”), highlighting that investments 
in elimination or eradication of such diseases leads to economic, health and ethical 
benefits.(Kastner et al. 2015; Stone et al. 2016; Kastner et al. 2017; Kastner et al. 2016; Kim, 
Remme, et al. 2015; Kim, Sicuri, et al. 2015; Kim et al. 2017; Bailey et al. 2015) Thus far, cost-
effective elimination strategies for human African trypanosomiasis (HAT) Trypanosoma brucei 
gambiense (T.b.g). have been identified,(Sutherland et al. 2017) and the ethical considerations 
of each strategy have been formally assessed (Merritt et al, under review);  however, a summary 
of the direct costs required for national control and elimination programs have yet to be 
ascertained.   
 
HAT T.b.g, also known as “sleeping sickness” is caused by the presence of the T.b.g parasite 
that is transmitted by the bite of a tsetse fly from human reservoirs.(World Health 
Organization (WHO) 2013c) Symptoms of the disease in the early stages include fever, 
headaches, joint pain and itching(Uniting to Combat NTDs n.d.); however, second stage 
symptoms resemble more severe neurological elements as the parasite eventually crosses the 
blood brain barrier. Affected individuals in the second stage may display behaviours similar 
to that of a patient with mental illness leading to societal rejection, disdain and isolation even 
after the disease has been treated and the patient recovers.(Mpanya et al. 2012)  Although 
several Sub-Saharan nations have tsetse inhabited areas with the potential of transmitting T.b. 
gambiense, currently there are 14 endemic countries that still reported having HAT cases in 
 Page 141 of 321 
 
2013(Jose R Franco et al. 2014) with Ghana having one case in 2014 after several years of being 
case free(Jose R Franco et al. 2014). Patients infected with the disease are traditionally required 
to undergo a chemotherapy regimen at treatment centres that are accessible but often far from 
the villages of those most affected(Simarro et al. 2014). This requires that patients be away 
from their families and absent from occupational obligations post-treatment resulting in 
financial consequences.(Mpanya et al. 2012)  
Recent technological developments in treatments, surveillance approaches and diagnostics, 
along with feasible vector control interventions(Steinmann et al. 2015) have shown that there 
are new alternatives to  treat, identify and prevent g-HAT that are cost-effective; decision 
makers now need to calculate the annual and future budget implications to sustain elimination 
strategies, as well as consider the economic implications for the communities involved. This 
manuscript aims to estimate the potential costs associated with these two perspectives. First, 
to forecast the financial impact that elimination programs may need to sustain elimination 
targets; and secondly, to alert decision makers of the implications for financial risk protection 
to households affected by HAT T.b.g. 
6.3 Methods 
In order to estimate the direct costs and societal impacts, the current control and potential 
elimination programs at a national level needed to be defined. Then for each program it is 
necessary to estimate the associated direct costs, households out of pocket payments and 
financial risk protection indicators. Our approach considers both the perspective of the 
national and global funders who are interested in the direct costs associated with HAT T.b.g. 
elimination (including health services and vector control), and a societal perspective (i.e. out-
of-pocket payments).  
 
Unit prices were converted in International Dollars (USD) using purchasing power parity 
(PPP) listed in the World Economic Outlook (WEO) database.(International Monetary Fund 
(IMF) 2014) Prices that were reported in Euros were converted to International Dollars (USD) 
using the average exchange rates lists on the European Central Bank Statistical Data 
Warehouse. Once all costs were converted to USD, they were then inflated to 2013 dollars 
using average consumer price indices (CPI).(European Central Bank (Eurosystem) 2014) The 
mean results for both direct program costs and societal costs are calculated along with 95% CI 
are to express the uncertainty surrounding the mean simulations. Costs are discounted at 3% 
and reported from 2013 and 2020 for a time horizon of 7 years.   
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 Defining control and potential elimination programs 
A priority setting exercise was undertaken in order to define optimal programs according to 
cost-effectiveness and probability of elimination based on a previously published economic 
evaluation for strategies including new technologies in the elimination of T.b. 
gambiense(Sutherland et al. 2017).  The micro-strategies originated from potential approaches 
to elimination foreseen with technologies that became available in 2013 and onwards 
described in Steinmann et al(Steinmann et al. 2015). The strategies ranged from adding new 
tiny targets for vector control in addition to the current ‘screen and treat’ programs readily 
available, to including a new oral tablet (i.e. oxaboroles) treatment that may eliminate the need 
for prolonged in-hospital treatment. These were further combined in Sutherland et al in 
2017(Sutherland et al. 2017) and modelled as five mutually exclusive macro-strategies for 
elimination to determine cost-effective options per foci. These macro-strategies for elimination 
were further categorized into national elimination programs, based on several cost-
effectiveness thresholds. Each program is briefly described hereafter and within Table 12, with 
additional details for the approach provided in appendix D.1.   
 
Table 12. Description of programs for control and elimination 
Program Cost-effectiveness 
threshold  
Scenario description 
Control  Reference In alignment with the EIC methodology (Tediosi et al) we 
use the “control” as the counterfactual scenario which 
equates to recommendations by the WHO during 2013: 
total reliance on passive reporting in low transmission 
areas, biennial screening in moderate areas and annual 
screening in high transmission with the screening and 
treatment of CATT and pentamidine (stage1)/NECT(stage 
2) respectively.  
Elimination I 
 
~$200 per DALY averted  Involves the recommended surveillance levels for HAT by 
“Control”, but switching to new technologies for 
treatment (fexinidazole and oxaboroles) and diagnostics 
(rapid diagnostics with motorbike screening campaigns) 
in all areas but not implementing vector control strategies 
including tiny targets  
Elimination II  
 
 
 
 
~$700 per DALY averted Involves biennial surveillance in low risk transmission 
areas, currently recommended surveillance levels for HAT 
by WHO in moderate and high risk areas, switching to 
new technologies for treatment and diagnostics in all 
areas, and implementing vector control strategies 
including tiny targets but only in high risk transmission 
areas 
Elimination III ~$1500 per DALY averted Involves biennial surveillance in low risk transmission 
areas, currently recommended surveillance levels for HAT 
by WHO in moderate and high risk areas, switching to 
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new technologies for treatment and diagnostics in all 
areas, and implementing vector control strategies 
including tiny targets but only in moderate and high risk 
transmission areas 
*WHO surveillance recommendations: Low risk (no active surveillance, passive surveillance only), Moderate – biennial surveillance, High – 
annual surveillance 
 
Control  
In alignment with the EIC methodology (Tediosi et al) we use “Control” as the counterfactual 
scenario which equates to recommendations by the WHO: total reliance on passive reporting 
in low transmission areas, biennial screening in moderate areas and annual screening in high 
transmission foci. The screening and treatment include the card agglutination trypanosomiasis 
test (CATT) and nifurtomix-eflornithine combination therapy (NECT) respectively.  
 
Elimination I (~$200 per DALY averted) 
Involves currently recommended surveillance levels as defined by the WHO, switching to new 
technologies for treatment (fexinidazole and oxaboroles) and diagnostics (rapid diagnostics 
with motorbike screening campaigns) in all foci.   
 
Elimination II (~$700 per DALY averted) 
Involves scaling up to biennial surveillance in low risk transmission areas, currently 
recommended surveillance levels for HAT by WHO in moderate and high risk areas, 
switching to new technologies for treatment and diagnostics in all area. The deployment of 
tiny targets is included, but only in high risk foci. 
 
Elimination III(~$1500 per DALY averted) 
Involves scaling up to biennial surveillance in low risk transmission areas, maintaining the 
current recommendations of surveillance by WHO in moderate (biennial) and high risk areas 
(annual), switching to new technologies for treatment and diagnostics in all areas, and 
implementing vector control strategies including tiny targets for both moderate and high risk 
transmission areas. 
 
 Forecasting the financial impact of national programs  
A “bottom-up approach” was used to estimate the total sub-Saharan costs. A dynamical 
transmission model developed by Stone & Chitnis(Christopher M. Stone & Chitnis 2015) has 
been used previously to estimate long-term costs and effects for control and elimination 
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programs for HTA T.b.g.(Sutherland et al. 2017). In our analysis, we exported the mean annual 
cost per person per foci (from 500 simulations) for each program related to: surveillance 
(including diagnostics), treatment and vector control. These per person estimates were then 
projected to estimate country related costs based at risk populations areas(World Health 
Organization (WHO) 2013c)  and finally aggregated for a cumulative cost across the 14 
endemic sub-Saharan countries.  
 
The calculated estimations and methods for the programs and interventions are provided in 
appendix D.2.  
 
 Forecasting financial protection (financial protection analysis (FPA)) 
The estimated number of cases in 2013 was 6228 by Franco et al (Franco et al. 2017) and, based 
on the four aforementioned programs for control and elimination, the number of expected 
cases was projected across sub-Saharan Africa, again using the model published by Stone and 
Chitnis (Chris M. Stone & Chitnis 2015). It was assumed that each estimated Tbg case would 
represent a single household. A financial risk protection analysis (FPA) model was built in MS 
Excel 2010, and used Bayesian sampling techniques to estimate the household related data 
required for the FPA including: income, non-medical (NM) expenses (i.e. food) and medical 
expenses (i.e. out-of-pocket payments (OOP)).  The median income of $1360 per annum was 
derived from the average gross national income (GNI) of the 13 endemic nations impacted by 
Tbg, with costs of non-medical expenses (i.e. food) derived from the literature(Depetris 
Chauvin et al. 2012; Lutumba, Makieya, et al. 2007b). The total medical expenses paid by 
households was estimated from HAT studies found in the literature as well.(Matemba et al. 
2010) For the purpose of this analysis, we assumed that 100% of affected households would 
actually incur medical expenses. The catastrophic health expenditures (CHE) was calculated 
using the proportion of medical expenses related to g-HAT from a household’s total income 
less a basic need (i.e. food). The proportions of CHE at 10% and 25% were reported as defined 
by the SDG 3.8.2.(Bank 2017). A normal distribution was applied to case estimates, while 
gamma distributions were applied to all cost inputs. A poverty line (PL) of $1.9 per diem (Bank 
2017) was used to account for the economic status of sub-Saharan Africa. It was assumed that 
the PL would be the same in 2013 and 2020. For each program, 10,000 simulations were run to 
generate the mean reported outcomes and 95% Confidence Intervals. To understand the 
potential impact of poverty with current and future technologies, the program “Control 2013” 
was used as a comparative baseline measure to the alternative options. The outcomes of the 
FPA are reported across Sub-Saharan African and by country income levels. A full summary 
of the input parameters and calculations for the financial protection analysis are provided in 
appendix D.3. 
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6.4 Results 
 Financial impact 
From 2013 until 2020, the cumulative costs of control and elimination programs of the 
strategies modelled are listed in Table 13. The results demonstrate that maintaining the current 
control programs, without taking new technologies into consideration, will incur a total cost 
of $630.6 million (95% CI: $630.3 to $631.0 million) across sub-Saharan Africa. Introducing the 
first option of elimination programs (“Elimination I”) leads to a total financial impact of $410.9 
million (95% CI: $410.7 to $411.1 million); while scaling up to “Elimination II” would yield a 
total of $988.0 million (95% CI: $987.6 to $988.5 million). Implementing “Elimination III” across 
all sub-Saharan nations would lead to a total cost of $1248.1 million (95% CI: $1247.2 to $1249.1 
million). The net impact of each program in comparison to “Control” demonstrates that 
“Elimination I” would actually lead to cost-savings ($-219.8, 95%CI: $-219.6 to $-219.9), while 
net increases of $357.4 million (95% CI: $357.3 to $357.5 million) and $617.5 million (95% CI: 
$616.9 to $618.1 million) for “Elimination II” and “Elimination III” respectively. When 
evaluating the proportion of health expenses further, 80-87% of financial burden for g-HAT 
will allotted to low-income countries.  In particular, the Democratic Republic of the Congo 
(DRC), which has the second lowest income of all the endemic Sub-Saharan countries, but the 
highest number of cases, would be responsible for 65-72% depending on the program selected. 
Furthermore, if affordability was being assessed using GNI levels, CAR, DRC, Guinea and 
Uganda would only be able to afford “Elimination II”.   
 
For each program, as depicted in Figure 14, the majority of costs for control and elimination 
programs are driven by screening and diagnostic costs that come passive, and/or active 
screening campaigns (68-90% of total costs). The ongoing costs for control also begin to plateau 
after several years; while, although the costs of elimination programs are high in the earlier 
years, they decline to 3-5% of the overall costs in later years. The additional cost of vector 
control to “Elimination II” and “Elimination III” programs contribute to 9% and 29% of the 
total program costs respectively.  
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Figure 14. Financial impact: categorical costs across time horizon  
 
NOTE: 2014 includes costs from 2013 and 2014 combined
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Table 13. Financial impact:  T.b. gambiense programs across across sub-Saharan Africa 
    Control  
2020 
(Counterfactual) 
Elimination I  
2020 
~$200 per DALY averted 
Elimination II  
2020 
~$700 per DALY averted 
Elimination III 
2020 
~$1500 per DALY averted 
 GNI  Cases in 
2013¥ 
Population at 
risk* (x103) 
Total 
(USD million) 
95%CI  
(USD million) 
Total 
(USD million) 
95%CI  
(USD million) 
Total 
(USD 
million) 
95%CI  
(USD million) 
Total 
(USD 
million) 
95%CI  
(USD million) 
Total, gross-financial impact*  6228 54958 630.6 630.3- 631.0 410.9 410.7-411.1 988.0 987.6-988.5 1248.1 1247.2-1249.1 
Total, net-financial impact**  NA NA NA NA -219.8 -219.6 to -219.9 357.4 357.3-357.5 617.5 616.9-618.1 
Country, income-level, gross-financial impact 
LIC 1006 or less 6105 45,325 546.97 546.65 to 547.28 353.05 352.77 to 333.14 765.29 764.92 to 765.34 998.19 997.45 to 999.04 
LMIC 1006-3995 33 4369 23.15 23.13 to 23.15 17.82 17.80 to 17.82 116.90 116.84 to 116.96 129.68 129.61 to 129.76 
UMIC¶ 3996-12235 89 5209 60.51 60.47 to 60.55 40.08 40.06 to 40.11 105.85 105.79 to 105.91 120.21 120.12 to 120.28 
Country, gross-financial impact 
CAR 330 59 555 6.94 6.93-6.94 4.5 4.45-4.46 8.66 8.66-8.66 11.00 10.99-11.01 
DRC 380 5647 38032 454.66 454.40-454.93 293.6 293.4-293.7 641.1 640.8-641.4 835.1 834.5-835.8 
Guinea 470 78 1279 4.44 4.44-4.44 3.89 3.88-3.89 36.50 36.48-36.52 39.87 39.85-39.89 
Uganda 680 9 2116 38.13 38.11-38.15 23.81 23.80-23.82 35.42 35.40-35.43 58.39 58.33-58.46 
South Sudan 940 117 2397 34.00 33.98-34.02 21.59 21.58-21.61 33.08 33.06-33.11 41.25 41.21-41.29 
Chad 980 195 946 8.80 8.79-8.80 5.66 5.66-5.66 10.53 10.52-10.53 12.58 12.57-12.59 
Cameroon 1360 6 221 0.67 0.67-0.67 0.7 0.70-0.70 8.83 8.82-8.83 9.33 9.33-9.34 
Cote d'Ivoire 1460 7 1300 5.46 5.46-5.46 4.52 4.51-4.52 37.43 37.41-37.45 41.58 41.55-41.60 
Congo, Rep. 2710 20 2380 17.01 17.00-17.02 11.53 11.52-11.53 40.16 40.14-40.18 48.29 48.26-48.32 
Nigeria 2970 0 468 0.01 0.01-0.01 1.07 1.07-1.07 30.48 30.47-30.50 30.48 30.47-30.50 
Angola 4850 69 4300 59.15 59.11-59.19 38.85 38.83-38.88 93.86 93.81-93.91 107.36 107.28-107.43 
Gabon 9450 17 878 0.61 0.61-0.61 0.76 0.76-0.76 11.30 11.29-11-31 11.68 11.67-11.68 
Equatorial Guinea 12640 3 31 0.75 0.75-0.75 0.47 0.47-0.47 0.69 0.69-0.69 1.17 1.17-1.17 
95% CI = 95% confidence interval 
CAR = Central African Republic; DRC = Democratic Republic of Congo 
*Includes countries with endemic cases from 2000-2014 reported in Franco et al 2017; **net budget impact compared to “Control” ¥Includes 13 endemic countries in 2013, excluding Ghana ¶Includes UMIC and one HIC 
(Equatorial Guinea GNI greater than $12236) 
Blue indicates countries that can afford the Elimination program using GNI as cost-effectiveness threshold 
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 Financial risk protection  
The impacts related to poverty from the Financial Protection Analysis (FPA) are summarized 
in Table 14. Overall, in comparison to the baseline year 2013, maintaining a similar “Control” 
program till 2020 will not have an impact on poverty indices. Although the number of cases 
may decline, the OOP health expenditures related to attending treatment centres for HAT 
treatment will still lead to impoverishment (22%), immiserization (31%) and catastrophic 
health expenditures at both 10% and 25% of HAT Tbg households.  Scaling up to “Elimination” 
programs, that result in medications that can be taken at home or within local villages, will 
reduce the risk of impoverishment in the future by at least 5% for all elimination programs in 
comparison to control and reduce the number of households facing CHEs to less than 1%. In 
addition, “Elimination” programs lead to the fewest number of forecasted cases in the future. 
This dual impact is on households with Tbg is shown in the series of Pen’s Parade diagrams 
illustrated in Figure 15. Unfortunately, the reduction of OOP will not end poverty completely.  
 
Additional FPAs were evaluated by country income levels (Refer to Table 3). The results again 
demonstrate that the LICs would be the most vulnerable to OOPs with 99.4% and 98.8% of the 
households experiencing CHEs at 10% and 25% respectively if “Control” is maintained. 
Pursuing “Elimination” programs would reduce the number of households facing CHEs to 
less than 1%. In addition, although at first glance it appears that there are fewer being 
impoverished, this is only due to the fact that the majority of the households in LICs will risk 
immiserization (approximately 85%) for healthcare payments related to HAT, even with 
“Elimination” programs.  LMICs have smaller populations of households at risk of 
impoverishment (0.49%) and CHEs when “Control” is in place, however; introducing 
“Elimination” programs could also eliminate CHEs and reduce the proportion of those 
impoverished to less than 0.5%. There is not foreseen risk to poverty related to HAT Tbg 
expenditures in UMICs. 
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Table 14. Financial protection: poverty impact of out-of-pocket payments related to T.b. gambiense households in sub-Saharan Africa for control and elimination programs  
 
Control 
 2013 
(95% CI) 
Control  
2020 
(95% CI) 
Elimination I 
2020 
(95% CI) 
Elimination II  
2020 
(95% CI) 
Elimination III 
2020 
(95% CI) 
Total cases (N) 6228* 2319 1768 76 56 
Sub-Saharan Africa       
Impoverishing 22.00% (21.96 to 22.03) 21.99% (21.94 to 22.04) 15.64% (15.59 to 15.70) 15.48% (15.23 to 15.73) 15.41% (15.11 to 15.71) 
Immiserizing 30.95% (30.92 to 30.99) 30.95% (30.90 to 31.01) 30.95% (30.88 to 31.01) 30.94% (30.61 to 31.27) 30.91% (30.53 to 31.30) 
Catastrophic  (CHE) at 10% 62.89% (62.85 to 62.93) 62.93% (62.87 to 62.99) 1.25% (1.23 to 1.27) 1.27% (1.20 to 1.35) 1.23% (1.14 to 1.32) 
Difference in % from Control 2013 NA 0.04% (0.02 to 0.06) -61.64% (-61.61 to -61.66) -61.61% (-61.65 to -61.,57) -61.66% (-61.71 to -61.61) 
Catastrophic  (CHE) at 25% 30.95% 30.96% (30.90 to 31.02) 0.49% (0.48 to 0.50) 0.51% (0.46 to 0.56) 0.48% ( 0.43 to 0.54) 
Difference in % from Control 2013 NA 0.01% (-0.01 to 0.04) -30.46% (-30.44 to -30.49) -30.44% (-30-45 to -30.42) -30.46% (-30.49 to -30.44) 
LIC      
Impoverishing 15.04% (15.02 to 15.07) 15.09% (15.04 to 15.13) 14.98% (14.92 to 15.03) 15.23% (14.98 to 15.48) 15.02% (14.71 to 15.32) 
Immiserizing 84.95% (84.93 to 84.98) 84.91% (84.87 to 84.96) 84.95% (84.89 to 85.00) 84.72% (84.47 to 84.97) 84.89% (84.59 to 85.19) 
Catastrophic  (CHE) at 10% 99.44% (99.43 to 99.45) 99.43% (99.42 to 99.44) 0.86% (0.84 to 0.87) 0.82% (0.76 to 0.88) 0.91% (0.83 to 0.99) 
Difference in % from Control 2013 NA -0.01% (-0.02 to -0.01) -98.58% (-98.59 to -98.57) -98.62% (-98.68 to -98.56) -98.53% (-98.61 to -98.46) 
Catastrophic  (CHE) at 25% 98.80% (98.80 to 98.81) 98.78% (98.77 to 98.80) 0.24% (0.24 to 0.25) 0.25% (0.21 to 0.28) 0.26% (0.22 to 0.30) 
Difference in % from Control 2013 NA -0.02% (-0.03 to -0.01) -98.56% (-98.56 to -98.56) -98.56% (-98.58 to -98.53) -98.54% (-98.58 to -98.51) 
      
LMIC      
Impoverishing 0.49% (0.49 to 0.50)  0.49% (0.48 to 0.50)  0.08% (0.08 zo 0.09) 0.09% (0.07 to 0.11) 0.10% (0.07 to 0.13) 
Immiserizing 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Catastrophic  (CHE) at 10% 29.07% (29.04 to 29.11) 29.07% (29.01 to 29.13) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Difference in % from Control 2013 NA 0.00% (-0.03 to 0.02) -29.07% (-29.04 to -29.11) -29.07% (-29.04 to -29.11) -29.07% (-29.04 to -29.11) 
Catastrophic  (CHE) at 25% 0.03% (0.03 to 0.03) 0.03% (0.03 to 0.03) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Difference in % from Control 2013 NA 0.00% (NA) -0.03% (-0.03% to -0.03%) -0.03% (-0.03% to -0.03%) -0.03% (-0.03% to -0.03%) 
      
UMIC***      
Impoverishing 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Immiserizing 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Catastrophic  (CHE) at 10% 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Difference in % from Control 2013 NA 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Catastrophic  (CHE) at 25% 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
Difference in % from Control 2013 NA 0.00% (NA) 0.00% (NA) 0.00% (NA) 0.00% (NA) 
      
95% CI = Confidence interval; *Estimated cases from WHO (Franco 2017),***Includes UMIC and one HIC (Equatorial Guinea GNI greater than $12236) 
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Figure 15. Pen’s Parade: Estimated out-of-pocket payments impact on poverty related to T.b. gambiense 
households in sub-Saharan Africa for control 2013 vs.  elimination II 
A. Control 2013 
 
B. Elimination II 2020 
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6.5 Discussion 
Across sub-Saharan Africa, HAT T.b.g control and elimination programs will require 
substantial funding and fiscal commitments over the coming years. A “Control” program will 
lead to fewer cases in the coming years, but will still cost millions of dollars to funders and 
have no impact on reducing poverty indices encouraged by the SDGs. Moving to 
“Elimination” is an attractive option, but the “Elimination” programs that are most likely to 
reduce cases and alleviate OOPs related to g-HAT (Elimination II and III), may not be 
affordable for LICs that share the greatest burden of at risk communities. In addition, the 
majority of the funding required will need to be allocated to in-country surveillance and 
diagnostics annually, while traditionally for HAT only the treatments have been donated with 
the majority of the healthcare costs reliant on NGOs and national fragile health systems.  The 
results of this two-part analysis demonstrate that there is a need to prepare substantial funds 
for elimination, not only for treatments and preventative measures (i.e. vector control) but also 
to the health system itself. In addition, it has demonstrated that the strive to elimination 
programs may alleviate the risk of impoverishment and thus contributing to reach the 
millennial SDGs.  
 
The results of the analysis on financial burden highlight that “Elimination” programs are the 
most favourable in achieving global goals. However decision makers will have to assess the 
fiscal space needed especially since availability of new HAT treatments has historically had 
delays in Pan-African uptake in the market. There may be a risk that LICs will opt for the less 
aggressive “Elimination I” program, but this will not lead to a slower decline in cases 
compared to other elimination options. In addition, to offset the costs of surveillance that are 
the main driver of these programs, community health workers or volunteers may be enlisted. 
Again, as in other NTD efforts, this may alleviate direct costs, but increase productivity losses. 
 
In addition, HAT is not the only NTD ear-marked for elimination/eradication, and so it must 
be kept in mind that there is still competition for funds even though the costs of elimination 
are known. For instance, the pan-African costs for HAT elimination programs range from $0.42 
to $1.24 billion, while world-wide onchocerciasis elimination and eradication programs are 
estimated to be $2.7 and $2.9 billion respectively.(Kim, Sicuri, et al. 2015) This may pose a 
challenge for HAT during prioritization of funding for NTDs. For example, the onchocerciasis, 
eradication and elimination programs are cost-saving relative to control and the per person at 
risk cost  for HAT remains a relatively costly disease with programs ranging from $3 to $10 
per person annually compared to ranges of $1.5 to $3.9 per treatment in the onchocerciasis 
programs.(Kim, Sicuri, et al. 2015)  
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HAT T.b. gambiense is already known to be a disease that affects the poor, but the current 
results demonstrate that households who are already near the poverty line, may fall: closer to 
the poverty line, under the poverty line (impoverished), or further into poverty (immiserized). 
However, the results of this analysis are still conservative as, recent evidence shows that there 
are often additional expenses prior to the diagnosis of HAT as households seek alternative 
care and guidance when family members are ill.(Bukachi et al. 2017)  
 
Although the methodology for poverty assessments using household surveys has been 
established(Wagstaff & van Doorslaer 2003; Bank 2017), the approach of modelling 
prospectively to understand its impact on future technologies within an EIC is novel. The 
financial protection analysis presented here is also not based on household surveys and 
instead relies on secondary data and modelling to generate conclusions. However, it 
demonstrates the potential to provide useful information in a decision making context for new 
technologies. In addition, the FPA does not address other societal costs, such as the loss of 
wages (productivity), which has been done within an eradication investment case for other 
neglected diseases.(Stone et al. 2016; Kim, Sicuri, et al. 2015)  These costs have recently been 
estimated along with other NTDs for elimination by Lenk et al.,  and demonstrate that the 
contribution of productivity loss to HAT is substantial.(Lenk et al. 2018) 
 
There are also economic gains from elimination that could also be considered in future EIC 
assessments. For instance, tsetse free areas may increase access to water areas without menace 
and even land use opportunities. The concept of addressing both positive and negative 
impacts to households related to disease expenditures has been recently explored in 
observance of non-communicable diseases in Bangladesh.(Mirelman et al. 2016) Future 
research in prospective FPA could also consider if and how additional income to at risk 
communities (i.e. households) that may result from elimination and assist to offset OOPs 
related to CHEs.  
 
Although this analysis highlights the financial benefits of elimination programs, at the time of 
its inception, it was assumed that novel interventions would arrive on the market as 
scheduled. The efficacy of fexinidazole has been proven(Mesu et al. 2018) however it still 
awaits European Medicines Agency (EMA) approval as of January 2018.(Drugs for Neglected 
Diseases initiative (DNDi) 2018)  In addition, previous modelling (Sutherland et al. 2017) 
estimated the arrival of a novel one time treatment in 2018, while it is currently estimated to 
be submitted to the EMA in 2021.(Drugs for Neglected Diseases initiative (DNDi) 2017) In the 
interim, subsidies for travel, accommodation and food could be considered, with the current 
national sleeping sickness control programs (NSCCPs) to encourage patients to attend without 
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the risk of poverty. Nonetheless, the scale up of elimination activities has begun in at least nine 
endemic nations,(FIND n.d.) and there is a continual decline in cases supporting the model’s 
estimations.  
 
Our results also assume 80% coverage is maintained for surveillance programs.  This coverage 
rate shows promise in leading to elimination but may be hard to achieve. Although 30% of the 
high transmission areas are covered, on average, only 2% of the continent is experiencing some 
level of screening. Furthermore, there are several countries that have not established formal 
NSCCPs (i.e. Gambia, Guinea-Bissau, Liberia), although foci risk areas exist.(Franco et al. 2017) 
Hence, the scale up to elimination will be substantial not only in funds, but for logistics on the 
ground. Scaling up coverage may reveal also that there are more cases than once thought, and 
adjustments to the elimination forecast and budgets will have to be made. Long-term 
commitments to funding post-elimination will be needed as the possibility of asymptomatic 
cases and unknown reservoirs comes to the forefront. An example of this was seen recently in 
Ghana where one case was found in 2013 after 12 years of no cases being reported.  
 
 Conclusion 
Overall, the results demonstrate that an “Elimination II” foci–specific program that deploys: 
targets in high risk areas with annual surveillance, adopts new technologies in all areas and 
implements biannual surveillance in moderate and low transmission zones, remains within 
cost-effectiveness thresholds for some low and lower-middle income countries. It could also 
achieve elimination goals for 2020 in the long-run and leads to financial protection for families 
impacted by HAT T.b.g. Global stakeholders and funders should ensure that low income 
countries whose national sleeping sickness control programs (NSCCPs) are unable to secure 
funds nationally for elimination should be supported as they share a disproportionate load of 
the disease burden. The elimination of HAT T.b.g. does have a high cost, but with continued 
efforts and support from global stakeholders, it is hoped that those already at risk of poverty 
will not be the ones to pay it.  
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6.6 Summary Box 
 
6.7 Keywords 
economics, sleeping sickness, NTDs, elimination, finance, budget, out-of-pocket, catastrophic 
health expenditures, financial protection, Trypanosoma brucei gambiense, priority setting, health 
policy decision making 
Key questions 
• What is already known about this topic? 
o Financing sustainable health systems will increase Universal Health 
Coverage, but there are unknown costs related to elimination of neglected 
tropical diseases; in particular, human African trypanosomiasis (HAT) 
Trypanosoma brucei gambiense (T.b.g). 
o The cost-effectiveness of strategies to eliminate HAT T.b.g. have proven to 
differ by foci, but how this translates into financial burden for funders and 
the communities at risk is still unknown 
• What are the new findings? 
o National programs that combine varying cost-effective strategies and lead 
to elimination of HAT T.b.g. will generate millions of dollars in the coming 
decade, and improve financial protection (alleviate poverty) by reducing 
the occurrence of catastrophic health expenditures (CHE) to households 
impacted by HAT T.b.g. 
o Several countries burdened with sleeping sickness may not be able to 
afford optimal elimination programs based on GNI levels 
• How might this influence practice 
o Decision makers interested in elimination should not only consider the 
costs  associated with the national programs but also the societal 
perspective when prioritizing programs for the elimination of neglected 
tropical diseases (NTDs) 
o Health financing and funding support will need to be addressed if 
elimination goals and sustainable development goals (SDGs)  to eliminate 
   b  hi d 
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7.1 Abstract 
Human African trypanosomiasis (HAT), commonly known as ‘sleeping sickness’, is a 
neglected tropical disease (NTD) targeted for elimination as a public health problem by 2020. 
Knowing the restrictions that the diagnostic and treatment paradigm for HAT incurs, 
researchers for HAT Trypanosoma brucei (T.b.) gambiense encourage the adoption of new 
technologies that will improve chances of health systems integration. Taking on a health 
systems thinking approach, this paper aims to describe the systemic implications of moving 
from a non-integrated to integrated system, and to use health systems modelling to determine 
if future integrated approaches could be of use if analysed prior to implementation. 
In the context of sleeping sickness integration will change the health systems approach that 
active surveillance programs have relied on for the last century. The main changes in the 
system scaling up to elimination will be seen at the local and national level as the burden of 
care will shift to countries. Using modelling to simulate potential impacts could provide useful 
information to decision makers at the national level in order for them to anticipate which 
changes need to be addressed to maximize capacity and ensure that HAT patients do not go 
untreated.  
Integration is an inevitable change that will be needed for sustainable healthcare systems and 
autonomy for nations that have had healthcare services managed by external collaborators for 
decades. Careful planning and consideration using systems thinking and modelling analyses 
can help decision makers to contain the processes as they occur and it is hoped that these 
approaches can be used as an option for decision makers to evaluate anticipated changes more 
critically. 
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7.2 Backgrounds 
Human African trypanosomiasis (HAT) is a neglected tropical disease (NTD) targeted for 
elimination as a public health problem by 2020. Detection of HAT currently relies on vertical 
surveillance programs where patients are identified in their villages or self-report to 
specialized health centres, and endure delays in waiting for confirmation of laboratory tests 
and further results in large out-of-pocket payments (Sutherland 2016, under development). 
Knowing the restrictions that the diagnostic and treatment paradigm for HAT incurs, 
researchers for gambiense HAT encourage the adoption of new technologies that will improve 
chances of health systems integration.(Palmer 2012; Burri 2014; Lejon et al. 2013) Hence as new 
technologies become available, understanding the benefits and/or consequences of integration 
need to be fully evaluated. An EIC investment case for HAT (Tediosi et al. 2013) has used 
dynamical modelling to evaluate the long-term cost-effectiveness of new 
technologies,(Sutherland et al. 2017) forecast elimination, assess financial and socio-economic 
implications;8  and assess ethical impacts; however, the operational feasibility of such 
interventions has not yet been ascertained.  Health system modelling has proven to be useful 
in several examples in literature in evaluating the operational constraints that changes in 
health service delivery may have on the systems components (Pilgrim et al. 2008; Pilgrim & 
Chilcott 2007; Lim et al. 2013). In addition, modellers working on NTDs also recognize the 
need to not only address the transmission components of infectious disease, but how 
campaigns and strategies towards elimination will operate on the field.(Hollingsworth et al. 
2015) It is proposed that the integration of programs into the local health centres could be 
modelled to forecast outcomes related to capacity, service delivery and even perhaps estimate 
the level of diagnostic proficiency that would be necessary from the health care workforce to 
sustain elimination efforts.  
 
Taking on a holistic thinking method commonly practised in health systems thinking, the first 
part of this paper aims to discuss the components of the current system, along with potential 
integration that is predicted to be feasible with new interventions arriving on the market. 
Secondly, using a simple health systems model, scenarios will be simulated at the local setting 
                                                     
8 Chapter 6. Sutherland & Tediosi 
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to determine if future integrated approaches can be tested for benefits or losses prior to 
implementation. 
7.3 Overview of health systems in the context of Gambiense HAT 
 ‘Control’ of Gambiense HAT in relation to the health system 
To understand the current context of HAT within the health system, and overview of the 
present day events were compartmentalized into the six building blocks of the health 
system.(de Savigny & Adam 2009) This evidence was gathered from the most recent global 
stakeholders meeting for Gambiense HAT elimination(Sutherland 2016) and are summarized 
in Figure 24 with further details listed in Appendix H.  
In regards to the delivery of medical services for HAT, the approach is quite vertical and with 
the main governance coming from MSF and the NSSCP with little involvement from the local 
health care system although this is expanding(Sutherland 2016; Simarro et al. 2014). As 
outlined in the supply chain delivery diagram in Figure 25A., the current approach to 
providing treatment relies on the countries requesting medication through the WHO and then 
in turn the treatment supplies being provided to the countries after WHO has procured the 
items from the pharmaceutical companies. Although WHO recommends NECT as the 
appropriate stage two treatments for HAT, the nifurotomix tablets are used off – label and 
hence the countries take the sole responsibility for this. This requires some regulatory 
clearance from the WHO and countries prior to the drug being available. It should be noted 
that melarsoprol is still used in some areas when there are treatment failures. The supplies are 
then delivered to MSF who distributes them to the appropriate programs. Aside from the 
NSCCP that operate under the MoH in affected nations, the operations of HAT control are 
quite peripheral to the system. MSF operates their own sleeping sickness supply chain, 
surveillance and treatment centres – and although they work in collaboration with the national 
programs, they are essentially an independent entity. 
A large number of actors in regards to financing come from the western hemisphere and the 
same trend are true for those involved research and development activities (R&D). However, 
countries with national programs within their Ministry of Health (MoH) receive country 
funding;  and vector control initiatives are also often funding at the country level within 
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agriculture departments.(Sutherland 2016) Those participating in the countries are the people 
and community themselves along with the local health care workforce, national sleeping 
sickness control programs (NSCCP) and treatment centres in the at risk nations. The current 
paradigm does not incorporate community health workers to treat disease as the medical 
expertise to diagnose and treat HAT is quite specialized.  
Figure 16. Health systems building blocks for Gambiense HAT services 
 
MSF= Médecins sans Frontières, NSSCP = National sleeping sickness control program, LHC = local health centre, CHW = 
community health worker, CATT = card agglutination trypanosomiasis test, IoTM =  Institute of Tropical Medicine - University 
of Antwerp , RDT = rapid diagnostic test, WHO = world health organization, NTD = neglected tropical disease, PATTEC = Pan 
African Tsetse Eradication Campaign  , FAO=Food and Agriculture organization of the United Nations , PAAT = Programme 
Against African trypanosomiasis, NGO = non-governmental organization, R&D = research and development, TAG = task 
advisory group 
Orange indicates potential changes in health system due to integration 
 
 Systems thinking for emerging technologies related to Gambiense HAT 
services 
Refer to Figure 16, the script highlighted in orange identifies the potential additions to the 
health system resulting from integration. Governance, finance and information appears to 
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remain the same current funders are still committed to support HAT programs(Sutherland 
2016), but realizing the substantial efforts and financial resources that elimination will bring, 
there may be a need for new funders to come aboard. Also with the integration of new 
personnel and the national systems, the ministries of health of the nations involved will be 
required to play a stronger role in the governance. Changes for service delivery are also 
highlighted in Figure 17B. The diagnostics and medical treatments although simpler to 
disseminate will continue to come from abroad, which may still impose challenges in health 
service delivery that are seen in countries with war zones and in adequate transport routes to 
isolated areas, especially during rainy seasons(USAID 2009). The hope for integration is that 
with rapid diagnostic test and oral tablets, HAT will be a ‘normal disease’(Burri 2014; 
Sutherland 2016) and tasks for diagnosis and treatment can be shifted to community health 
workers and/or the local workforce through training initiatives.(Bukachi et al. 2005; Palmer 
2012) Tiny targets are also easier to deploy that their larger predecessors and several studies 
have shown that community involvement in vector control interventions is feasible.(Kovacic 
et al. 2013; Sutherland 2016). Taking into consideration that new diagnostics, treatments and 
vector prevention tools are hoped to be deployed in a non-vertical manner; the greatest 
changes from the systems perspective for integration will be within countries in relation to 
service delivery and health workforce. 
 Page 162 of 321 
Figure 17. Overview of service delivery for HAT diagnostics and treatment   
A. Current control(specialized, non-integrated) B. Potential elimination (fully integrated) 
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7.4 Potential analytical approach for systems integration  
From systems perspective, adoption of new interventions will impact the health care 
workforce and health service delivery the most of integration is to move forward. Knowing 
this, one can develop a simple system to reflect the current scenario, and then model 
alternative scenarios to evaluate the impact on the system. Models to demonstrate operation 
concerns have been used form health systems to replicate systems dynamics (Windisch et al. 
2011), supply chain management (Assi et al. 2011; Alfonso et al. 2012; Spiliotopoulou et al. 
2013)  and patient interactions with services while in the system. (Pilgrim et al. 2008; Pilgrim 
& Chilcott 2007; Lim et al. 2013) 
 Control versus elimination scenarios 
Potential scenarios of current and new technologies coming available(Steinmann et al. 2015) 
were presented 2014, and were further evaluated for cost-effectiveness,9 financial expenditures 
and OOPs10 driven by a dynamical transmission model(Christopher M. Stone & Chitnis 2015). 
As an example, only three situations were considered as depicted outlined in Table 15 focusing 
control as a non-integrated system and elimination scenarios as integrated treatment options.   
Table 15. Scenarios modelled for integrated and non-integrated health systems 
Scenario Health system 
structure 
Description 
Control 
 
 
Non-integrated Self-reporting patients may go to a local health 
centre first or may decide to go directly to 
specialise HAT treatment centre for diagnosis. 
Regardless of where patient presents with 
symptoms, treatment is done with 
pentamidine for stage 1 or NECT for stage 2 at 
the specialized treatment centre. 
                                                     
9 Chapter 5. Sutherland et al., Seeing beyond 2020: An economic evaluation of contemporary and 
emerging strategies for Trypanosoma brucei gambiense elimination (under review LGH) 
10 Chapter 6. Sutherland et al., Counting the costs:  Financial costs and out-of-pocket expenditures 
related to control and elimination plans for Trypanosoma brucei gambiense across sub-Saharan Africa 
(under development) 
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Elimination 2016 
 
 
Fully integrated  Patient self-reports to any centre and rapid 
diagnostics are used at local centres local health 
centres to determine if patient has HAT and 
treatment with pentamidine for stage 1 while 
fexinidazole (Winthrop ®) is being used for 
stage 2 treatment. 
Elimination 2019 
 
 
 
Fully integrated Patient self-reports to any centre and can 
receive diagnosis and treatment immediately 
regardless of stage with oxaborole.  
 
 Modelling the health system 
In order to envision the potential implications of health system integration for HAT, a discrete-
event simulation (DES) health systems model has been developed using SIMUL8®. 
(Sutherland et al. 2014) The model inter-arrival time was parameterized to simulate 100,000 
patients (refer to  appendix E.2) over a one year time horizon (passive reporting only) with a 
prevalence of 1.61%, 0.112%, 0.020%  to represent foci of high, moderate and low transmission 
according to the thresholds indicated by the World Health Organization(World Health 
Organization (WHO) 2013c). The hypothetical village had access to three health centres 
containing different resources and capacity as presented in Figure 18. This structure was based 
on evidence from mapping efforts in the DRC that show that there are often several local 
centres closer to villages prior to reaching a specialized HAT treatment centre (refer to 
appendix E.3). Data inputs for the model were estimated based on the literature, grey 
literature, national program reports and clinical trial site characteristics11 with the majority of 
evidence originating from the Democratic Republic of the Congo (DRC). Two types of health 
systems were modelled: A “Non-Integrated HS” where patients could report to local centres 
but would be referred to HAT Centres for treatment versus an “Integrated HS” where patients 
could be screened and treated at any centre. The model considers components related to time 
(e.g. treatment time, etc.) and probability of events occurring (e.g. patient’s reporting to a 
health centre, etc.). Details regarding the input parameters are available in Table 16.  
                                                     
11 Information regarding staff resources at clinical trial sites in DRC were provided by MedRes, 
SwissTPH 
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Figure 18. Discrete event simulation (DES) model in Simul8® for health systems servicing Gambiense HAT   
 
 
It was assumed in the model that patients that report to health centres with HAT and were not 
diagnosed (false negatives) went untreated. The main outcome evaluated was the number of 
patients treated and time that the patients spent in the ‘health systems’. This model only looks 
at self-reporting to the health system and not those who may have been detected by an active 
surveillance campaign and are now arriving at a centre for treatment. It assumes that patients 
will receive treatment soon after diagnosis. Model assumes that patients will be able to access 
a health facility once they have made the decision to ‘self-report’ travel. Hence road delays or 
turning back from war torn zones is not taken into account in the current version of the model. 
Model structure permits one to evaluate patient’s accessibility (includes desire to seek 
treatment, geographic nearness of health facility and way to reach health facility (time, method 
of transportation, etc.) and the availability of being able to get the health services that they 
seek once they have accessed the health centre.(Levesque et al. 2013) In this case outcomes of 
number of patients treated, time spent in the system and wait times were measured. A 
sensitivity analysis (SA) was conducted by examining low and high values for the mean 
distribution of the probability of self-reporting, the diagnostic accuracy of the healthcare centre 
1 (HC 1) and healthcentre 2 (HC 2), and prevalence to examine the impact on the number of 
patients treated. 
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Table 16. Key input parameters 
Parameter Name Mean Estimate  Data Source 
Health service resources   
HAT centre   
Nurse, MD, Lab technician, Health worker 1, 1, 1, 2 Treatment centres, DRC 
   
HC 1   
MD, Health worker (CHW) 1, 1 Assumption 
   
HC 2   
MD, Health worker (CHW) 1, 1 Assumption 
   
Epidemiological characteristics   
HAT prevalence (high, moderate, low) 1.61%, 0.112%, 0.020%   Sutherland, under review 
Stage 1 prevalence 32.5% PNTHLA report 
Probability patient self-reports to HC 0.6 – 0.65*  
Treatment time (pentamidine (stage 1), NECT (stage 2))  12 days, 14 days  
Treatment time  fexinidazole (both stages) 10 days  
Treatment time  oxaborole (both stages) 1 day  
   
Health centre characteristics   
Distance HC 1 1 hour (Simarro et al. 2014) 
Distance HC 2 3 hours (Simarro et al. 2014) 
Distance HAT HC 5 hours (Simarro et al. 2014) 
Probability HC 1 correct diagnosis 0.5   
Probability HC 2 correct diagnosis 0.5  
Probability HAT HC correct diagnosis 1.0  
HC = Health Centre, HAT = human African trypanosomiasis, HS = Health System, NECT = Nifurtimox-Eflornithine Combination 
Therapy, SA = Sensitivity Analysis, *Patient reporting probability varies from HC to HAT treatment centre 
 
 Potential impacts 
In low and moderate risk settings the impact on the number of patients treated was similar. 
However, in areas with transmission over 1%, integration increases by 87% (fexinidazole); and 
improves a further 90% when oxaborole is introduced in 2019.(Refer to Figure 19) 
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Figure 19. Number of patients treated in the system by risk transmission area 
 
Seeing that the variation of patients treated was highest when transmission risk is high, a 
sensitivity analysis was done for this focus specifically. The results listed in Table 17 
demonstrate that in a non-integrated system, the prevalence rates have little impact as it 
appears that the current system is likely acting at capacity in a high transmission area. 
Improving diagnostic accuracy and encouraging patients in combination with integrated 
treatments reaches more patients. Although decreases in prevalence will open up space in the 
health system, foci with high transmission or areas experiencing outbreaks would be better 
handled with an integrated system.  
Table 17. Sensitivity analysis results (high risk foci only) 
 Number patients treated 
Parameter Non-integrated Fully integrated Fully integrated 
Treatment pentamidine, NECT pentamidine, fexinidazole oxaborole 
Base case value 164 306 580 
HC diagnostic accuracy (0.3, 1.0) 163,164 296,320 384,763 
Probability patient self-reports to  
HC1 (0.3, 0.9) or HC2 (0.35, 0.95) 
163,162 302,311 552,623 
Prevalence (0.5%, 5%) 46,165 47, 321 55, 1646 
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7.5 Discussion 
Health systems thinking is important process to conceptualize the impacts that moving from 
control to elimination will have on the health system. In the context of sleeping sickness, this 
is especially true as new interventions providing room for integration will change the health 
systems approach that active surveillance programs have relied on for the last 
century.(Steverding 2008) The main changes in the system scaling up to elimination will be 
seen at the local and national level as the burden of care will shift to countries. Using modelling 
to simulate potential impacts could provide useful information to decision makers at the 
national level in order for them to anticipate which changes need to be addressed to maximize 
capacity and ensure that HAT patients do not go untreated. For instance the current modelling 
results show that in high risk foci, adopting new technologies in an integrated system while 
improving patient self-reporting and health care workers to correctly identify patients leads 
to highest number of patients treated. Although this approach has provided a framework for 
thinking about health system changes in moving towards elimination there are still several 
issues to be addressed.    
 Are we ready to lose ‘control’?  
The goal of integration seems desirable however; there are still concerns, that the current 
infrastructure of the nations burdened with HAT, may not be ready. Examples from the past 
including supply chain integration efforts in Mozambique (USAID DELIVER PROJECT 2012) 
show that the transfer of responsibilities can lead to inefficiency if not addressed prior to 
implementation. Also, risk associated with shifting the responsibility of distribution of 
treatments to national medical stores needs to also ensure that the donated interventions reach 
the patients and are not lost to corrupt processes. As fexinadzole in tablet form is already 
available in online as Winthrop®, countries will need to maintain regulatory processes so that 
sub-standard or counterfeit tablets lacking the active ingredient do not proliferate the market. 
The consequences of ignoring this will only lead to delays in elimination and increase financial 
and societal costs associated with the disease burden. Delivery approaches to tools also needs 
to be taken into consideration with a bit of creativity at hand. It has already been proposed 
that motorbike carriers are sufficient to deliver rapid diagnostic tests and oral 
tablets(Sutherland 2016), but considering alternative transportation mechanism such as 
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helicopters (Burri, personal communication) or drones (Awoonor-Williams, personal 
communication) to isolated areas could prove to be useful in remotes areas across sub-Saharan 
Africa.  There is also a need to think over maintaining a consistent supply of tools in areas 
experiencing civil conflict or war where routine deliveries may not be feasible. Looking for 
local storage with the new technologies, as is done with long lasting insectide net (LLINs) for 
malaria,(Roll Back Malaria n.d.; Roll Back Malaria n.d.) could be adopted for integration as 
there will be no need for a cold chain.  
As demonstrated in this overview, the people involved in HAT treatment and the at risk 
populations themselves will play a larger role if integration is to come to pass. This may prove 
to be difficult since as cases dwindle motivation and opportunities to train and treat staff are 
difficult.(Sutherland 2016) People with experience in HAT near to larger hospitals may be able 
to transfer expertise in chemotherapy over to oncology if possible, or move into areas of animal 
trypanosomiasis where understanding of the parasite is transferable. This paper has focused 
on gambiense HAT integration in the health system, however gambiense HAT is small 
component of the health system in sub-Saharan Africa that are burdened also with malaria, 
HIV, NCDs and other NTDs to name a few. NTD programs often operate in specialized silos, 
but with the context of moving towards MDGs of sustainability in health systems, a systems 
thinking approach would be valuable in also assessing combined NTD programs and the 
ability of the health care workforce to appropriate differentiate between the plethoras of 
symptoms that patients present themselves with. Integrating HAT programs with other NTD 
programs may encourage interest, and training with the new diagnostics as well as disease 
differentiation could help motivate interest and will improve accuracy of syndromic 
algorithms.(Palmer 2012) Community health workers (CHW) will be encouraged to take on a 
larger role, but as various vertical NTD programs are happening simultaneously, this may be 
too much pressure or workload on communities. Integrating NTD programs without losing 
the quality and community relationships that successful programs have instilled needs to be 
addressed.  Communication between the NSSCP and communities will also be crucial. 
Encouraging patient self-reporting at health care facility may happen inadvertently when 
communities become aware that the new interventions are less invasive to diagnose and have 
simpler routes for treatment.  Passive health care approaches should be sensitive to 
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community preferences(Palmer 2012; Mpanya et al. 2015; Mpanya et al. 2012) and ethical 
consideration will be further evaluated elsewhere. 
In regards to information for the health care system, thus far the WHO has the most 
information as it collects data from all the NSSCPs and has also combined efforts with FAO to 
identify at risk transmission areas and locations of health facilities using spatial information 
(Pere P Simarro et al. 2012; Simarro et al. 2014) However, this information is not always 
publically available and is limited as not all areas are under surveillance, hence the global 
stakeholders should consider who to harmonise data in order to accurately track elimination 
progress as integration rolls-out.  
There are several institutions and financiers involved in HAT, but as integration will bring on 
new entities for service delivery and the health care workforce, there do not seem to be new 
donors or funding avenues on the horizon. As elimination for HAT ensues and steps towards 
integration are made additional funds will be required. For instance, in addition to elimination 
costs that are already estimated to be millions annually for HAT(Seddoh et al. 2013)12 
increasing the community health workforce will also come at a cost (McCord et al. 2013; Singh 
& Sachs 2013). In order to avoid ‘donor fatigue’,  again combining HAT with other NTD 
programs or beginning to seeking alternative funding mechanisms will also be inevitable. 
Although from economic and business level perspective program integration and alternative 
funding sources this seems logical, the changes that may be thrust upon the current governing 
bodies if not done appropriately may hinder elimination efforts on the ground. This is yet 
another caveat to consider when thinking of integrative efforts for elimination.  
 Being one step ahead of integration concerns 
Despite the anticipated concerns regarding moving to an integrated system in order to scale 
up control to elimination, modelling health systems provides an opportunity for decision 
makers to assess initiatives.  This simple analysis focuses on three of the nine scenarios 
developed by Steinmann et al(Steinmann et al. 2015), but there are also still alternative 
scenarios that could be run through the model. An example of this would be to vary 
parameters to evaluate how preventing access to one of the centres in the system (i.e. due to 
                                                     
12 Chapter 6. Sutherland & Tediosi 
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war or route unavailable in the rainy season) would impact treatment and to plan buffer stocks 
for such circumstances. As previously stated, building a model that evaluates ‘combined’ NTD 
programs or various diseases would also be of use. Planning for integration could also be done 
by varying the number of health centres available to treat HAT in the system to determine the 
minimum number of centres needed in an area to alleviate travel burden. Future health 
systems modelling efforts could also include cost parameters so that the relative costs and even 
cost-effectiveness of programs for integration can be determined. 
While the results thus far have focused primarily on accessibility with time and location being 
the main adaptation of moving from a non-integrated to integrated system, issues associated 
with availability related to supply chain constraints and health care worker availability could 
be further manipulated in the model. Adding in medical supplies to the model could allow 
national programs to estimate supplies and minimum stock levels required; and varying the 
number of health professionals available to treat could also be varied in the model to estimate 
the number of trained workers needed.   
There are also technical aspects to consider within discrete-event simulation (DES) models. 
For instance, with limited data available, further research will be needed to validate the 
outcomes using real-world evidence. There are also several assumptions made during this first 
iteration of model development that may impact outcomes if the model is to be used further. 
For instance, the model assumes that people treated immediately while in real life people may 
have to go home and wait for parasitological confirmation, and it does not track misdiagnosed 
individuals (i.e. false negatives, false positives) or repeated screeners. The model could be 
adapted to include this. There is also no consideration of uncertainty or consideration of how 
patients diagnosed with active surveillance interact with the system. The benefits of using the 
Simul8® software allow decision makers to evaluate resource constraints related to staff and 
medical supplies but it remains difficult to incorporate disease transmission hence a dynamical 
model is still needed for this component of assessing elimination. Further modelling efforts 
could work towards combining these components so that health resources and transmission 
can be analysed in unison.  
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7.6 Concluding remarks‘ - Getting a grip’  
Integration is an inevitable change that will be needed for sustainable healthcare systems and 
autonomy for nations that have had healthcare services managed by external collaborators for 
decades. These changes may lead to a feeling of uncertainty, or ‘losing control’. Careful 
planning and consideration using systems thinking and modelling analyses can help decision 
makers to contain the processes as they occur. In the context of an elimination investment case, 
it is important to see the operational challenges to be assessed not as an additional analysis to 
the EIC but maybe the most crucial. The funding will come, the drugs and diagnostics made – 
but if system is not properly prepared to treat patients, what good is it? The investments for 
elimination for neglected tropical diseases will require millions of dollars annually(Seddoh et 
al. 2013)and billions over the next few decades(Kim, Sicuri, et al. 2015)13 and often fail to 
formally address the implementation process, it is hoped that this approach can be used as an 
option for decision makers to evaluate anticipated changes more critically. 
 
 
                                                     
13 Chapter 6. Sutherland & Tediosi 
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8.1 Summary 
We sought to assess formally the extent to which different control and elimination strategies 
for human African trypanosomiasis Trypanosoma brucei gambiense (Gambiense HAT) would 
exacerbate or alleviate experiences of societal disadvantage that traditional economic 
evaluation doesn’t take into account. Justice-Enhanced Cost-Effectiveness Analysis (JE-CEA) 
is a normative approach under development to address social justice considerations in public 
health decision making alongside other types of analyses. It aims to assess how public health 
interventions under analysis in comparative evaluation would be expected to influence the 
clustering of disadvantage across 3 core dimensions of well-being: agency, association and 
respect. As a case study to test the approach, we applied it to 5 strategies for Gambiense HAT 
control and elimination, in combination with 2 different other evaluations: a cost-effectiveness 
analysis, and a probability of elimination analysis. We have demonstrated how JE-CEA 
highlights the ethical importance of adverse social justice impacts of otherwise attractive 
options and how it indicates specific modifications to policy options to mitigate such impacts. 
JE-CEA holds promise as an approach to help decision makers and other stakeholders consider 
social justice more fully, explicitly, and systematically in evaluating public health programs.  
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8.2 Introduction 
In 2010, the World Health Organization (WHO) published a Roadmap to Elimination 
for several neglected tropical diseases ((Cochi & Dowdle 2011; Thompson, K. M., Rabinovich 
& Contch 2011; Walker & Rabinovich 2011; Walker & Lupp n.d.)NTDs)(WHO 2012). It was 
endorsed by global donors who signed the London Declaration targets for 2020 NTDs 
elimination (London Declaration 2013). Since then, committed decision makers have struggled 
to assess formally the feasibility, costs, and consequences of eliminating or eradicating a target 
disease.  In 2012, an investment case was proposed for 3 NTDs – onchocerciasis, lymphatic 
filariasis, and human African trypanosomiasis – to serve as a comprehensive analysis of 
clinically efficacious, feasible pathways to disease elimination or eradication, including 
required resources and operational investments (Tediosi et al. 2013). This initiative deployed 
the eradication investment case (EIC) framework, developed expressly to support the use of 
traditional techniques of health and economic assessment in deliberations about whether to 
undertake elimination or eradication of candidate infectious diseases (Cochi & Dowdle 2011; 
Thompson, K. M., Rabinovich & Contch 2011; Walker & Rabinovich 2011; Walker & Lupp 
n.d.). EIC components related to probability of elimination and cost-effectiveness have been 
assessed for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis, but 
methods have been lacking to guide comparative assessment of broader social impacts across 
candidate elimination and eradication scenarios as called for by the EIC designers (Thompson, 
K. M., Rabinovich & Contch 2011; Walker & Rabinovich 2011; Tediosi et al. 2013; Sutherland 
et al. 2017).  
The EIC designers’ conception of broader social impacts encompasses not only effects 
on intergenerational justice and global health equity (Emerson 2011; Tediosi et al. 2013), but 
also forms of psychological, psychosocial, and social impact that primarily affect people as 
subjects of personal life experience (Muela & Hausmann-Muela 2013; Tediosi et al. 2013). We 
focus here on the need for a method to assess the latter, experiential forms of impact in the 
EICs for NTDs. In an effort to fill this gap in the context of EICs for lymphatic filariasis and 
onchocerciasis, Bailey and colleagues (Bailey et al. 2015) first presented a method of ethical 
analysis informed by theories of social justice. As a pilot case, however, their discussion 
considered mainly the impacts attributable to the diseases, not to interventions, and did not 
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attempt a finer-grained comparison among different pathways toward the goal of disease 
elimination or eradication. 
 Zwerling and colleagues (Zwerling et al. 2017) have built upon Bailey and colleagues’ 
approach in developing an innovative methodology called justice-enhanced cost-effectiveness 
analysis (JE-CEA). They have presented an initial proof-of-concept illustration, using a 
hypothetical example (and moving outside of the NTD EICs discussion) specifically to suggest 
how JE-CEA might be used to compare novel vs. standard treatment regimens for multi-drug 
resistant tuberculosis (Zwerling et al. 2017). The justice enhancement (JE) component of JE-
CEA is intended to assess, alongside the results of cost-effectiveness analysis (CEA), the 
compared options’ expected impacts upon patients’ experiences of societal disadvantage, such 
as “stigma, shame, social isolation, loss of agency and family strain” (Zwerling et al. 2017). In 
the present article, operating for the first time with a completed CEA and probability of 
elimination analysis (Sutherland et al. 2017), we explore the adaptation of Zwerling and 
colleagues’ JE-CEA methodology for use in the economic assessment of pathways to the 
elimination or eradication of NTDs, taking human African trypanosomiasis Trypanosoma brucei 
gambiense as a salient NTD example.  
 Human African trypanosomiasis T.b. gambiense 
 Human African trypanosomiasis Trypanosoma brucei gambiense, or ‘Gambiense HAT’ 
for short, is one of 10 NTDs targeted for elimination by 2030 (WHO 2012; Uniting to Combat 
NTDs n.d.; World Health Organization (WHO) 2013a). Gambiense HAT, often called ‘sleeping 
sickness’, is an insect-borne parasitic infectious disease with at-risk areas spanning 24 African 
countries. Cases are currently being reported from 13 countries (Jose R Franco et al. 2014). 
Gambiense HAT is most prevalent in low-income countries with the areas at risk 
encompassing mainly the poor rural population (Pere P Simarro et al. 2012). It has 2 clinical 
manifestations as it progresses from a less acute to more severe stage. Stage 1 is a febrile illness; 
Stage 2 brings more severe symptoms, including disruption of the sleep-wake cycle, seizures, 
paralysis, weakness, confusion, psychosis, and eventual progression to coma and death if 
untreated (World Health Organization (WHO) 2013a). Historically, disease control measures 
have focused on treatment of human cases to reduce the parasite reservoir, and, in some areas, 
vector control programs to reduce transmission (Bennett et al. 2016). 
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A recent modelling study has compared the most promising Gambiense HAT 
elimination strategies in terms of cost-effectiveness and probability of reaching elimination 
(Sutherland et al. 2017). Although the disability-adjusted life-year (DALY) measure used in 
the cost-effectiveness analysis captures some disease-associated disability and mortality, the 
potential impacts of elimination strategies on the distribution of intervention-induced 
disadvantages like stigma and social exclusion have yet to be assessed (Sutherland et al. 2017). 
8.3 Normative approach 
 Cost-effectiveness analysis (the CEA component of JE-CEA) is a prominent form of 
economic evaluation, a set of methods for comparative analysis often used to help prioritize 
budget-constrained resource allocation for public health program options (Drummond et al. 
2005; Walker et al. 2011). Norms of distributive justice are pervasively implicated in health-
related uses of economic evaluation, starting with the concern to consider opportunity costs 
in allocating limited public resources (Brock et al. 2017). To deliberate on what would 
constitute an optimal use of resources in public health decision contexts, however, it’s 
necessary also to consider (inter alia) other applicable norms of distributive justice.  
One of these other norms is social justice. The concept of social justice invokes a “moral 
imperative to avoid and remediate unfair distributions of societal disadvantage” (Dukhanin 
et al. 2018; Faden & Shebaya 2016; Powers & Faden 2006; Wolff et al. 2007). Social justice as a 
moral consideration is of major importance to public health and, in the economic evaluation 
of public health program options, it can either converge with or present trade-offs with 
comparably important moral considerations like the maximization of aggregate health benefit 
(Kass 2001; Childress et al. 2002; Faden & Shebaya 2016; Brock et al. 2017). Different 
conceptions of social justice vary in their accounts of what societal disadvantage is and what 
makes for inequitable distributions of it. JE-CEA is an analytic technique designed for use by 
economic evaluators who seek to apply to the decision context at hand a certain conception of 
social justice, which is centered on protecting and relieving people from severe societal disadvantage 
in multiple dimensions of well-being. Like other normative approaches to justice in public health, 
this conception of social justice can be explicated in terms of its position along each of two 
normative axes featuring, respectively, objects of distribution and distributive principles 
(Persad 2018; Dukhanin et al. 2018).   
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 Objects of Distribution: Multidimensional Metrics of Well-Being 
Whereas the object of distribution for traditional CEA is aggregate health benefit, 
typically assessed by summary measures like DALYs averted, alternative techniques enable 
users to consider other objects as well. JE-CEA is meant to help users apply to health-related 
economic evaluation the normative proposition that health is one among other core dimensions of 
well-being holding fundamental ethical importance as “basic determinants of the character and 
quality of human life” (Bailey et al. 2015). This proposition is common to a family of theories 
of justice grounded in multidimensional metrics of well-being, whose defining members are 
capabilities theories and well-being theories.  Each theory in its own way focuses the 
requirements of justice on societal obligations to enable people to exercise core capabilities or 
to function in core dimensions of well-being(Nussbaum 2011; Wolff et al. 2007; Powers & 
Faden 2006). 
We don’t aim here to add new substantive argumentation to the cumulative case that 
proponents of these theories have already made for regarding other dimensions of well-being 
as comparable to health in fundamental ethical importance. Because of the importance of social 
justice as a moral consideration in public health, it is ethically preferable for the 
methodological repertoire of health-related economic evaluation to encompass the full range 
of leading conceptions of social justice, and so, with respect to objects of distribution, to include 
techniques for assessing the impacts of compared options on people’s experiences of 
disadvantage in multiple dimensions of well-being (Dukhanin et al. 2018). Expanding the 
methodological repertoire in this way still leaves it up to users and their stakeholders to 
determine whether, under what conditions, and for what reasons the use of such techniques 
is warranted. 
 Distributive Principles: Prioritization Norm 
JE-CEA belongs to a family of techniques designed for use by people who seek to 
temper the maximizing distributive principle familiar to users of traditional CEA (Cookson et 
al. 2017; Johri & Norheim 2012; Norheim et al. 2014). The purpose of the JE component is to 
enable users to apply a prioritization norm that is broadly consistent with prioritarian, 
egalitarian, and sufficientarian distributive principles, and which we articulate here as ‘to 
protect and relieve people from severe societal disadvantage’. This norm is of comparable concern to 
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prioritarians aiming to uplift the worst off in society (Wolff et al. 2007), egalitarians aiming to 
avoid and redress undue inequalities, and sufficientarians aiming to avoid and remediate each 
person’s experience of shortfalls from sufficient levels of, for instance, capability (Nussbaum 
2011) or functioning (Powers & Faden 2006). Again, we don’t aim here to make additional 
arguments in support of these non-maximizing distributive principles. Rather, our point is 
that so far as it’s ethically preferable for the methodological repertoire of economic evaluation 
to be able to accommodate the full range of leading conceptions of social justice, it should 
include techniques for applying this prioritization norm to relevant forms of program impact.  
JE-CEA is meant to help users apply this prioritization norm in the first instance to 
certain dimensions of well-being besides health. The JE component is designed to assess the 
impacts of compared public health program options in multiple non-health dimensions of well-
being, and to do so alongside the CEA component, which retains its traditional maximizing 
distributive principle with respect to its traditional target object, aggregate health benefit. One 
might ask, why not also modify the CEA component internally? That is, if health is comparable 
to other dimensions of well-being in ethical importance, and is thus one among other sites of 
societal disadvantage potentially subject to the prioritization norm, why continue to assess 
program options’ health impacts only in terms of traditional CEA? While we acknowledge 
that this question must be addressed in due course, we have chosen to bracket it at the present 
early stage in JE-CEA’s development. Our starting point is the fact that traditional CEA is in 
wide use, and indeed has been used in preparing the EIC for Gambiense HAT, presenting a 
timely real-world occasion to explore the use of JE-CEA. Too, whereas there is already a robust 
scholarly literature on internal modifications to CEA, a recent systematic review finds 
relatively little work on how to complement economic evaluation with assessment of the 
comparably important moral concern about the impacts of health interventions on people’s 
experience in multiple non-health dimensions of well-being (Dukhanin et al. 2018). What we 
explore here is a decidedly incremental approach, attempting to make methodological 
progress one step at a time, holding CEA’s traditional normative bearings constant and 
supplementing it with JE. 
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8.4 Structure of JE-CEA 
 Even holding CEA internally constant, there might be many ways to design an 
analytic technique that would fill the identified methodological gap. By demonstrating the use 
of JE-CEA as overlaid onto a completed CEA in a specific decision context, we hope also to 
advance the discussion of kindred techniques for which JE-CEA might serve initially as a foil. 
The longer-term goal is to strengthen methodological capacity in the field of health-related 
economic evaluation to represent the relevant conception of social justice. As we outline the 
structure of JE-CEA, then, we describe key methodological choices in the awareness that other 
designers might reasonably choose differently.  Zwerling and colleagues construct the JE 
component of JE-CEA as a more formal expression of the method of ethical analysis that Bailey 
and colleagues first developed to extend the EIC framework. The structure of that precursor 
method responds to a set of desiderata, derived from the EIC literature, on meeting the need 
for a method to assess psychological, psychosocial, and social impacts in the NTD EICs (Bailey 
et al., 2015: 630-631):  
“Ideally, this method should strengthen EIC-supported deliberations by (1) delineating 
ethically important categories of benefits and burdens not otherwise captured in the 
EIC framework, (2) assessing aspects of distributive equity and fairness not otherwise 
captured, (3) recognizing widely varying life circumstances among people affected by 
the diseases and interventions, and (4) ethically interpreting the evidence base 
concerning disease-specific psychological, psychosocial, and social impacts.”  
Desideratum (3) provides the rationale for Bailey and colleagues’ choice to draw on 
theories of justice derived from multidimensional metrics of well-being (Powers & 
Faden 2006; Wolff et al. 2007; Venkatapuram 2011; Sen 2009; Alkire 2002; Crocker 2008; 
Ruger 2009; Nussbaum 2011). In attributing fundamental ethical value to each of the 
basic dimensions of well-being that affect the quality of human lives across widely 
varied conceptions of the good life, this approach…has fair claim to support a 
maximally broad consensus among people with different national, cultural, and 
personal backgrounds. Breadth of consensus is a matter of great importance in the EICs 
and for related global policy choices about eradicable infectious diseases considering 
the wide range of individuals and groups who stand to be involved or affected.” 
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While some of these theories in themselves identify as many as ten or fourteen core 
dimensions, Bailey and colleagues focus on four points of convergence or overlap identified 
in virtue of their robust endorsement across multiple theories: three core dimensions of well-
being that ought to be protected and promoted by socially just health policies; and one core 
prioritization norm.  
The supposition behind the choice to focus on points of convergence or overlap across 
the theories is not the implausible expectation that each theory, taken in its entirety, would 
deliver the same result in the EIC decision context, but rather that the few elements on which 
the theories converge or overlap, in virtue of their plural theoretical grounding, have “more 
robust stability and salience for ethical assessments” than would the other, “relatively more 
controversial elements…that lack plural grounding in multiple theories”(Bailey et al. 2015; Sen 
2009). These four elements form a core framework of social justice, embodying a distinct 
specification of the more generic conception of social justice (protecting and relieving people from 
severe societal disadvantage in multiple dimensions of well-being) discussed farther above.  
 Specification of Normative Proposition about Objects of Distribution 
In response to EIC desideratum (1), agency, association, and respect are the core 
categories of benefits and burdens (besides life and health, which are otherwise captured in 
the EIC framework by traditional assessment techniques like CEA) that Bailey and colleagues 
identify as points of convergence or overlap among the contributing theories of justice. They 
characterize agency as “the ability to lead one’s own life and engage in activities one finds 
meaningful”; association as “the ability to engage in a full range of intimate, familial, friendly, 
community, economic, and civic relationships with other people”; and respect as “the 
recognition, by others and oneself, of one’s equal moral value, worth, and dignity as a person” 
(Bailey et al., 2015: 631-632; see 631-632 for detailed derivations from contributing theories).  
We explicate here a corresponding specification of the more generic normative 
proposition – that health is one among other core dimensions of well-being holding fundamental ethical 
importance – entertained farther above about objects of distribution: namely, that, whatever non-
health dimensions of well-being hold fundamental ethical importance, agency, association, and 
respect are the least controversial candidates for representation among potential objects of distribution 
that users of health-related economic evaluation ought to have the methodological capacity to assess. 
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This specification does not deny that other dimensions of well-being might also be worthy 
candidates; rather, it selects agency, association, and respect as dimensions that it makes the 
most sense to start with in building the methodological capacity to assess non-health 
dimensions. Bailey and colleagues (2015: 631-632) justify the selection of agency, association, 
and respect by appeal to distinctively robust inter-theoretical agreement on their ‘core’ status. 
This selection might be challenged by disputing the choices to include or exclude certain 
theories of justice in the set of contributing theories, and by reexamining the contributing 
theories to confirm or disconfirm the identified loci of convergence/overlap. Either or both 
forms of challenge could generate variant sets of ‘least controversial candidate’ dimensions of 
well-being, with corresponding variations in the structure of JE-CEA. Even so, the overall 
approach of identifying such focal points remains viable as a means of seeking the least 
controversial normative grounding for JE-CEA. For the sake of simplicity in the initial stages 
of JE-CEA’s methodological development, Zwerling and colleagues follow Bailey and 
colleagues’ selection by focusing the JE component of JE-CEA on agency, association, and 
respect. We do the same in our exploration of JE-CEA in the Gambiense HAT EIC decision 
context.  
 Specification of Prioritization Norm 
In response to EIC desideratum (2), Bailey and colleagues (2015: 631, italics added) find 
that theories of justice using multidimensional metrics of well-being converge on the following 
core prioritization norm, which picks out aspects of distributive equity and fairness not 
otherwise captured in the EIC framework: that “it is a priority and duty of justice to avert and 
alleviate clusters of disadvantage in multiple dimensions of well-being.” For purposes of the present 
discussion, we read this as a specification of the more generic prioritization norm discussed 
farther above (to protect and relieve people from severe societal disadvantage). The key normative 
commitment defended in the contributing theories’ explicit supporting arguments for the 
specified prioritization norm is to protect and relieve already-disadvantaged people from 
vicious cycles whereby personal setbacks caused by adverse impacts in some dimensions of 
well-being expose them to adverse impacts in other dimensions, making them even worse off 
(Wolff et al. 2007; Powers & Faden 2006; Venkatapuram 2011). This commitment has 
heightened salience for public health programs addressing health problems to which people 
are disproportionately exposed through pre-existing disadvantages such as severe poverty 
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and social marginalization (Faden & Shebaya 2016). The intent of JE-CEA is to focus on just 
such decision contexts, NTDs being a prime example (Azoh Barry 2014).  
In response to EIC desideratum, Bailey and colleagues (Bailey et al. 2015) propose to 
interpret the evidence base on disease-specific psychological, psychosocial, and social impacts 
by first examining the empirically known impacts on each of the three selected core 
dimensions of well-being, then asking “how those impacts might create or exacerbate” cross-
dimensional clustering of disadvantage, and finally comparing the scenarios under analysis in 
terms of the revealed patterns of impacts on disadvantage by the lights of the prioritization 
norm. They use this method chiefly to analyze the evidence about disease-attributable impacts 
of lymphatic filariasis (LF) and onchocerciasis (oncho), with the aim of informing the ethical 
rationale for investing global health resources in programs to control, eliminate, or eradicate 
LF and oncho. For each of these NTDs, neither of which is fatal in short order if untreated, the 
evidence indicates many distinctly disadvantageous impacts of the disease itself upon agency, 
association, and respect, impacts that stand in need of distinct assessment by means over and 
above the traditional measures that can already assess impacts on life (survival) and health. 
By contrast, because of Gambiense HAT’s catastrophic morbidity and rapid 
progression to fatality if untreated, the disease’s adverse impacts on life and health as assessed 
by traditional measures are largely coextensive with its disadvantageous impacts on agency, 
association, and respect. For this reason, our background assumption is that effective 
interventions used in the Gambiense HAT disease control and elimination strategies will 
themselves avert and alleviate disease-attributable adverse impacts on pre-existing clustered 
disadvantage as experienced by individual members of the at-risk population. The distinct 
purpose of JE-CEA, as we are exploring its use in the Gambiense HAT EIC decision context, is 
to compare the candidate disease control and elimination strategies with respect to how far 
they might worsen (or not) any pre-existing clustered disadvantage through adverse impacts 
attributable to people’s undergoing the public health interventions that the strategies deploy. 
That is, relative to a population baseline of pre-existing clustered disadvantage, some 
interventions in themselves may have the effect of worsening that clustered disadvantage 
whereas others under comparison do not -- for example, diagnostic testing for Gambiense 
HAT by means of lumbar puncture conducted in public vs. a rapid diagnostic test that can be 
done in private.  
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The scope of application for the prioritization norm in JE-CEA is given by the prior 
scope of the policy question addressed by the CEA component (Zwerling et al. 2017). In the 
context of deciding on optimal strategies for control and elimination of Gambiense HAT, the 
scope of the relevant CEA component is restricted to populations whose members are, largely 
because of the pre-existing clustered disadvantage that they are likely to have in common, at 
risk of Gambiense HAT in endemic areas. With reference to the population inside the scope of 
the policy comparison, the ideal social justice outcome is for no one to experience worsened 
clustering of disadvantage through their experience of undergoing the interventions; short of 
the ideal, it is better for as few people as possible to experience worsened clustering of 
disadvantage, and for those who do to experience as little of it as possible. For this reason, the 
principal attribute on which the JE component of JE-CEA is meant to help users to evaluate 
the options under comparison is the extent to which each option might worsen pre-existing 
clustered disadvantage by imposing adverse intervention-attributable impacts. 
This emphasis is in keeping with the analytic orientation of traditional CEA, which is 
designed to compare options partly in terms of incremental differences in units of effectiveness 
(such as DALYs); similarly, JE-CEA is designed to present alongside CEA an additional 
comparison of the same options, in terms of incremental differences in their impacts on 
people’s experiences of disadvantage. JE-CEA takes empirical findings as input “to track the 
occurrence, magnitude, and breadth of cross-cutting impacts on the three core dimensions of 
well-being” where,  “[u]sing three impact levels, the social justice assessment for a given 
scenario under analysis could be either ‘expected not to worsen. . .’, ‘may worsen. . .’, or 
‘expected to worsen...’,” the pre-existing clustering of disadvantage (Zwerling et al. 2017). 
These assessments can then be examined alongside the results of CEA, and any other 
applicable forms of evaluation of interest to decision makers, as performed for the same set of 
options. 
The contributing theories of justice that converge on JE-CEA’s specified prioritization 
norm use the idea of clustered disadvantage for various purposes. One of these theories, that 
of Wolff and de-Shalit (2007) uses it to solve “the indexing problem” of identifying who is 
among the least advantaged in society at large: with the answer being “groups of people who 
appear towards the bottom in several important categories of disadvantage, whose 
functionings in these categories are at a low level or very insecure”. Within JE-CEA’s scope of 
application in the types of decision contexts for which it is designed, we take the indexing 
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problem to have been pre-solved by the restriction of programmatic scope to a disease, like 
Gambiense HAT, to which people are typically exposed by conditions likely to impose 
multidimensional disadvantage (e.g., being both impoverished to the point of curtailed agency 
and marginalized to the point of curtailed association). The guiding ethical concern for users 
of JE-CEA, given that the compared program options’ intended beneficiaries are likely already 
among the worst off in those terms, is to give some priority to not exacerbating the prior 
clustering of disadvantage in non-health dimensions of well-being as an unintended 
consequence of health-promoting interventions. An intervention-attributable adverse impact 
in any one of JE-CEA’s core dimensions – agency, association, or respect – might exacerbate 
prior clustering of disadvantage even by compounding a person’s prior disadvantage only in 
that one dimension, so far as they were already disadvantaged in one or two of the other core 
dimensions too, making the post-intervention cross-dimensional pattern even more 
disadvantageous than the pre-intervention pattern. Intervention-attributable impacts that 
cross two or three core dimensions add further clustering in themselves. Nonetheless, variants 
on JE-CEA, or kindred techniques, might specify differently the generic prioritization norm, 
for instance by somehow weighting impacts on the selected core non-health dimensions, 
without using the idea of clustering either to describe the prior baseline of disadvantage or to 
make the social justice assessment in evaluating the compared program options. Again, for the 
sake of simplicity in the initial stages of JE-CEA’s methodological development, Zwerling and 
colleagues retain Bailey and colleagues’ specified version of the generic prioritization norm, 
and we do the same here. 
Whereas Zwerling and colleagues illustrate the use of JE-CEA in conjunction with a 
decision tree technique for CEA comparisons (Zwerling et al. 2017), our adaptation will 
instead illustrate it in conjunction with a dynamical transmission modelling approach for CEA 
comparisons, as is more appropriate for the Gambiense HAT decision context (Steinmann et 
al. 2015; Sutherland et al. 2017). In addition, whereas Zwerling and colleagues confine their 
discussion of justice enhancement to its conjunction with the main CEA analysis in their 
example of novel vs. standard multi-drug resistant tuberculosis regimens, we consider in the 
Gambiense HAT decision context the conjunction of justice enhancement not only with CEA 
but also with a probability of elimination analysis.  
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8.5 Justice-enhance cost-effectiveness analysis for Gambiense HAT 
control and elimination strategies 
 Overview of Methods 
In our proposed adaptation for the Gambiense HAT disease control and elimination 
decision context, JE-CEA proceeds in 3 phases (Box 1). Phase 0 is to identify the options to be 
evaluated. Phase 1 is to construct social justice assessments, drawing on the best available 
evidence, corresponding to people’s experiences of disadvantage under each option. Phase 2 
is to represent these assessments along with the CEA to demonstrate JE-CEA. We will also 
extend the justice enhancement technique of social justice assessment to the probability of 
elimination predictions for Gambiense HAT. 
Box 1. Overview of methods for Justice-Enhanced Cost-effectiveness Analysis (JE-CEA) as 
applied to Gambiense HAT test case 
 
 
 Phase 0: Identify options of interest 
  CEA compares health interventions in terms of their incremental cost-effectiveness 
ratio (ICER). The ICER is defined as the incremental cost of implementing a given intervention 
relative to the next best intervention (the difference in cost between the two) divided by the 
incremental effectiveness of implementing it relative to the next best intervention (the 
difference in effectiveness between the two). Traditionally, effectiveness has been measured in 
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terms of health, using health measures such as DALYs averted. The ICER can be expressed as 
the incremental cost per DALY averted. An intervention is ‘dominated’ when another 
intervention costs less and has better outcomes relative to it. 
 Our application of JE-CEA builds on a prior CEA study that modelled cost- 
effectiveness and probability of reaching elimination of Gambiense HAT for several strategies 
featuring different combinations of standard approaches and emerging technologies for HAT 
diagnosis and treatment over 30 years (2013-2042), using a dynamical transmission model 
(Sutherland et al. 2017). These strategies are composed of varying scenarios previously 
described, where each scenario is characterized by its availability between 2013 and 2042, its 
approaches to case identification, diagnosis, and treatment, and whether vector control is 
included as an additional method to prevent transmission (Steinmann et al. 2015).  A major 
aim of the prior modelling study was to assess the value of investing in novel Gambiense HAT 
technologies vis-à-vis the goal of reaching elimination.   
The objects of analysis in the prior CEA study by Sutherland and colleagues (2017), 
and correspondingly in our illustration of JE-CEA, are the strategies considered as each would 
be implemented over the full 30-year time horizon. It is important to distinguish between the 
cost of investing in a strategy over that full 30-year time horizon and the annual cost per case 
found, which may fluctuate from year to year, and which for elimination strategies will 
increase over time as disease prevalence declines. Whereas the CEA highlights the value for 
money of investing in each strategy relative to its comparators over the 30-year time horizon, 
the annual cost per case relates instead to the annual budget for carrying out the selected 
program (which would be assessed differently in the decision-making dossier).   
 For purposes of illustrating JE-CEA, we focus on the 5 strategies most important to 
consider for areas where transmission risk is low (Figure  20) (Sutherland et al. 2017). The first 
strategy continues the current paradigm. The other 4 strategies, which deploy varying 
combinations of novel technologies, were shown to dominate all other alternatives to the 
current paradigm on grounds of either probability of elimination or cost-effectiveness, or both 
(Sutherland et al. 2017).  
 The Control strategy (Strategy A in Sutherland et al., (2017)) depicts the current 
Gambiense HAT treatment paradigm. The term Control in this analysis refers to a form of 
disease control program in the sense of a public health intervention strategy intended to ‘control’ 
the disease, that is, to reduce its "incidence, prevalence, morbidity or mortality to a locally 
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acceptable level as a result of deliberate efforts” with the understanding that “continued 
intervention measures are required to maintain the reduction” (Dowdle 1998). (This is by 
contrast with ‘control’ in the experimental sense of a neutral, non-intervention, no-impact 
baseline, and by contrast too with ‘control’ in what is perhaps a colloquial sense of merely 
observing the status quo while taking no deliberate action to influence future disease 
parameters.) Thus, the Gambiense HAT Control strategy, like all the other strategies under 
comparison in our analysis, is an active public health intervention that must be assessed for its 
potential adverse impacts on pre-existing clustered disadvantage. During Control, in low-
transmission settings, WHO advises that patients seek out treatment (passive surveillance) 
(World Health Organization (WHO) 2013a). Suspected cases undergo blood serum tests (card 
agglutination test for trypanosomiasis, or CATT) to find antigens in response to parasite 
presence. To determine the stage of the disease, lumbar puncture at a health facility is required 
to draw cerebrospinal fluid for parasitological confirmation. Confirmed cases are referred to 
specialized treatment centres. People in stage 1 of the disease require 12-day intravenous 
treatment in hospital with pentamidine. People in stage 2 require 14 days of nifurtomix-
eflornithine (chemotherapy) in hospital.   
 Control with tiny targets (Strategy B in Sutherland et al., 2017), a potential strategy for 
elimination, combines the current treatment paradigm (Control) with novel vector control 
interventions called ‘tiny targets’: small flag-like traps colored to attract tsetse flies and 
covered with insecticide to kill them (Steinmann et al. 2015). 
 Accelerated technologies (Strategy D in Sutherland et al., 2017) maintains Control until 
2016, when new diagnostics become available. Local health centers could then use a rapid 
diagnostic test (HAT Sero K) instead of CATT, and use loop-mediated isothermal 
amplification of DNA (LAMP) for parasitological confirmation. Lumbar puncture would still 
be required at a health facility for staging.  Stage 1 treatment remains the same but patients in 
stage 2 can take a 10-day oral regimen of fexinidazole.  Then in 2019, a novel one-day oral 
tablet, oxaborole SCYX-7158, is expected to become available to treat both stages of the disease, 
rendering differential diagnosis unnecessary, so that a rapid diagnostic test alone would 
suffice with no lumber puncture for staging. The all-oral treatment for both stages could also 
mean that patients no longer need to leave their village for treatment.  
 Accelerated technologies with biannual surveillance is the same as Accelerated technologies 
except that screening is conducted every two years (‘Strategy D+ in Sutherland et al., 2017). 
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Because surveillance teams conduct open screening campaigns in villages, the diagnostic 
procedures, including lumbar puncture for staging, would all be done publicly, until the oral 
Oxaborole treatment arrives for both stages in 2019. 
 Accelerated technologies with tiny targets (Strategy E in Sutherland et al., 2017) is the 
same as Accelerated technologies except that it simultaneously deploys vector control with tiny 
targets.  
Figure  20. Strategies for control and elimination in low risk transmission areas* 
 
 
 Phase 1: Construct social justice assessments 
Phase 1 is to construct social justice assessments corresponding to people’s experiences of 
disadvantage for each option under evaluation (Bailey et al., 2015: 632; cf. Zwerling et al., 2017: 
S71-S72). Step 1 is to assess people’s experience in core dimensions of well-being under each 
option. Step 2 is to assess the impact of each option on the clustering of disadvantage across 
core dimensions of well-being. 
Step 1. Assessment of people’s experience in core dimensions of well-being 
 Because all untreated cases of HAT are debilitating and fatal, any safe and effective 
preventive or therapeutic intervention that people willingly accept is clearly better than none 
in terms of agency, respect, and association. But the standard and novel interventions 
deployed under different Gambiense HAT control and elimination strategies may themselves 
vary in the nature, intensity, and distribution of their impacts on core dimensions of well-
being. The point of constructing social justice assessments is to estimate the ‘price’ in mal-
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distributed disadvantage imposed by the current paradigm (i.e., Control as an ongoing public 
health intervention strategy) as compared with alternative strategies.  
 Step 1 is to ask whether and, if so, how, people experience adverse impacts on agency, 
respect, or association because of their exposure to the specific health interventions deployed 
under each strategy. To find out, primary qualitative data collection would be ideal (Zwerling 
et al., 2017: S72). Future qualitative studies are required for the development and refinement 
of JE-CEA methodology for use in any specific decision context, including the Gambiense HAT 
context. For purposes of the present  analysis, however, we drew on a systematic review of 
empirical literature about people’s experiences of standard HAT diagnosis and treatment 
interventions (Muela and Hausmann-Muela, 2013).(Muela & Hausmann-Muela 2013) Table 1 
relates the most striking findings from this literature to the strategies under analysis.  
 Our application of JE-CEA in this paper deals only with low-transmission areas, 
where case identification is limited to passive surveillance undertaken in more private clinic 
settings under 4 of the 5 strategies considered: Control, Control with tiny targets, Accelerated 
technologies, and Accelerated technologies and tiny targets; thus, for each of those 4 strategies, the 
literature indicates that social justice impacts would occur mainly through treatment 
experiences.  Under 1 of the 5 strategies considered, namely Accelerated technologies with 
biannual surveillance, the literature indicates that standard approaches to active surveillance for 
HAT, because they occur in public, bring embarrassment and shame (especially for those who 
need lumbar puncture to determine their stage of a stigmatized disease), and thereby infringe 
significantly on respect (Mpanya et al., 2012). In the Discussion section, we will return to this 
point and consider the need for more private and dignified approaches to active screening. 
 Regarding treatment technologies, the most marked impacts on disadvantage under 
both strategies deploying standard treatment (Control and Control with tiny targets) are 
experienced by patients at disease Stage 2, and they arise from the 6+ months’ post-treatment 
prohibitions on patients’ activities. For example, qualitative studies conducted in the 
Democratic Republic of Congo report that communities commonly uphold prohibitions on 
heavy labor and sexual intercourse during the 6+ month post-treatment period (Robays et al. 
2007; Mpanya et al. 2012; Mpanya et al. 2015). The prohibition on heavy labor amounts to 
“forced inactivity” (Robays et al. 2007) that severely restricts the patient’s agency. The 
prohibition on sexual intercourse stirs up “marital problems and conflicts” ,(Robays et al. 2007) 
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a critical setback in association. Moreover, “a strong element of social control” and victim-
blaming in the event of “[t]reatment failure and other complications” arise from the widely 
held perception that patients’ adherence to post-treatment prohibitions – which also preclude 
smoking, drinking alcohol, eating hot food, and walking in the sun – is key to recovery 
(Mpanya et al., 2012: 7). As one focus group participant said, “A person must be near at all 
times to keep an eye on him, to make sure he avoids all these things” (Mpanya et al., 2012: 7, 
Table 3). Such intense social monitoring and potential victim-blaming are setbacks in the 
domain of respect. JE-CEA is precisely intended to represent these sorts of adverse impacts on 
agency, association, and respect, over and above the costs already measurable by existing 
evaluation techniques. 
 We hypothesize that the substitution of novel diagnostic and treatment technologies 
would remove the specific adverse impacts of standard approaches without introducing 
comparable new ones. By contrast, the addition of ‘tiny targets’ as a vector control intervention 
would not in itself change the quality of people’s diagnostic and treatment experiences, but 
would rather serve to reduce HAT incidence over time so that fewer people are exposed to 
HAT diagnosis and treatment. 
 Wherever novel diagnostic and treatment technologies are implemented in the future, 
their successful implementation will require ongoing community consultation, and empirical 
research would be needed to test our substitution hypothesis. As noted by Mpanya and 
colleagues, the intensive post-treatment prohibitions that presently take the form of taboos 
originated in communities’ uptake of past communications with healthcare providers trying 
to manage HAT treatment with a relatively toxic drug (melarsoprol) (Mpanya et al. 2015; 
Kovacic et al. 2016). Even where the use of less toxic drugs makes such prohibitions no longer 
medically necessary, they might still be believed necessary by the community. Under those 
circumstances, on one hand, the possibility arises for public health interventions to facilitate 
the evolution of community norms through respectful dialogue and education in collaboration 
with community opinion leaders; on the other hand, if community norms do not evolve for 
whatever reason, the social justice impacts resulting from enforcement of the prior norms 
might carry over to new treatment modalities.  
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Step 2.  Assessment of impact on clustering of disadvantage across core dimensions of well-
being  
 The next step is to assess the impact of each strategy on the clustering of disadvantage. 
At least 3 assessment levels are possible. For ease of visualization when considering social 
justice impacts alongside results from other forms of evaluation, Zwerling and colleagues 
proposed a color-coding scheme representing 3 levels of expected impact (Zwerling et al. 
2017).  We propose a similar color-coding scheme (adjusted for readers with color-blindness) 
as follows: 
- Orange: “Expected to worsen the clustering of disadvantage”,  
- Yellow: “May worsen the clustering of disadvantage” and  
- Turquoise: “Expected not to worsen the clustering of disadvantage.”  
While finer, intermediate gradations are possible in principle, their definition requires further 
development of JE-CEA methodology. Meanwhile, JE-CEA can still reveal striking contrasts 
among the social justice impacts of different strategies under analysis (Figure 2)14.  
 Because standard treatment for Stage 2 of HAT tends to impose post-treatment 
burdens in all 3 core dimensions of well-being (Figure 21), the Control and Control with tiny 
target strategies warrant an assessment of “Expected to worsen the clustering of 
disadvantage”, relative to the pre-existing clustered disadvantage shared by the population at 
risk of Gambiense HAT. By contrast, the Accelerated technologies and Accelerated technologies with 
tiny target strategies, under their component scenarios that roll out post-2016, promise to avoid 
imposing comparable post-treatment burdens(Sutherland et al. 2017), and so they warrant an 
assessment of “Expected not to worsen the clustering of disadvantage”.  Accelerated technologies 
with biannual surveillance continues to impinge on respect through the screening campaigns 
that will require public lumbar puncture for staging until a treatment for both stages arrives 
in 2019. Because social justice impacts are attributable to this strategy in only 1 core dimension 
of well-being, it is assigned an assessment of ‘May worsen the clustering of disadvantage” 
                                                     
14 Our analysis departs here from the originally proposed JE-CEA approach (Zwerling et al., 2017) in that we don’t 
use length of colored bars to highlight the number of people impacted, because our extension of the Phase 2 social 
justice assessment to the probability of elimination analysis will indirectly highlight the number of people 
potentially impacted over time. 
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(depending on the extent to which this impact might compound pre-existing disadvantages in 
the experiences of people affected).  
Figure 21.  Summary of 'clustering of disadvantage' across well-being by colour 
 
 Phase 2: Consider social justice impacts with CEA 
Figure 22A shows the results of the prior CEA study for the 5 strategies we considered here. 
The Control strategy would cost $3 ($2.52) and incur 0.04 DALYs per person at risk in a low-
transmission area and is dominated by Accelerated technologies, which costs approximately the 
same ($2.97) but incurs 0.01 DALYs less than the control (ICER = $160/DALY averted).  Scaling 
up surveillance in low transmission areas to once every two years (Accelerated technologies with 
biannual surveillance) would cost a total $20 per person at risk, but would incur only 0.004 
DALYs resulting in an ICER of $654 per DALY averted. Control with tiny targets and Accelerated 
technologies and tiny targets are both dominated.  
  Accelerated technologies with biannual surveillance and Accelerated technologies would be 
considered cost-effective. However, some influential global health funders consider $300 per 
DALY averted as a threshold of cost-effectiveness for investments in low income countries 
(National Institute for Health and Clinical Excellence (NICE) International 2014). With that 
constraint, Accelerated technologies would be the only option.  
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 When we overlay our social justice assessments onto the prior CEA results (Figure 
22B), the social justice assessments and CEA results are concordant. Accelerated technologies is 
cost-effective, and in the long run is not expected to worsen clustering of disadvantage. 
Figure 22. Economic evaluation in low risk transmission areas of Gambiense HAT 
A. 
 
B. 
 
An applied extension of Phase 2: Social justice impacts alone considered alongside probability 
of disease elimination (separate from CEA) 
In a previous analysis of elimination targets, the probability of elimination (Figure 23A) 
appeared to be highest under Accelerated technologies with biannual surveillance, Accelerated 
technologies with tiny targets, and Control with tiny targets (Sutherland et al. 2017). Therefore, in 
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the absence of social justice assessment, we would conclude that these 3 options would be the 
best for elimination in a low-transmission area. But when we overlay our social justice 
assessments onto these same outcomes (Figure 23B), Control with tiny targets, in addition to 
performing worse than the other 2 strategies with respect to probability of elimination, has the 
major drawback of being expected throughout its course to worsen the clustering of 
disadvantage for people exposed to stage 2 treatment. As for Accelerated technologies with 
biannual surveillance, although it has the highest probability of leading to elimination at the 
quickest rate, it also has an interim time when it may worsen the clustering of disadvantage 
for people exposed to active surveillance. Thus, Accelerated technologies and Accelerated 
technologies with tiny targets, under which the Gambiense HAT interventions that people would 
experience are not expected to worsen clustering of disadvantage for them, are preferable in 
terms of social justice impacts attributable to interventions. 
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Figure 23. Probability of elimination in low risk transmission areas of Gambiense HAT 
A. B. 
  
 Page 197 of 321 
8.6 Discussion 
Although Accelerated technologies is cost-effective and not expected to worsen the 
clustering of disadvantage, it is unlikely to lead to elimination. The low probability of 
elimination under Accelerated technologies thus presents a trade-off within social justice so far as 
ongoing residual disease incidence would impose future social justice impacts attributable to 
the disease (Bailey et al. 2015) – impacts that could be averted with eventual elimination under 
Accelerated technologies with biannual surveillance, but at the risk of exposing people to other 
social justice impacts attributable to active screening, at least until 2019 when the oral 
Oxaborole treatment suitable for both disease stages would remove the need for public lumbar 
puncture to determine disease stage. Under Accelerated technologies, with the permanent 
prospect of residual disease incidence, all three core dimensions of well-being could remain 
precarious for anyone at risk of Gambiense HAT (because all untreated cases are debilitating 
and fatal), except so far as they could count on timely diagnosis and treatment. From this 
standpoint, however, the saving grace of Accelerated technologies is the roll-out of increasingly 
simplified diagnosis and treatment that would be expected to avert disease-attributable social 
justice impacts while refraining from imposing intervention-attributable social justice impacts. 
This prospect suggests that Accelerated technologies might be favored on social justice grounds 
over Accelerated technologies with biannual surveillance, even taking into account the residual 
disease incidence under Accelerated technologies. The social justice assessments and CEA results 
(setting aside for a moment the probability of elimination analysis) converge on 
recommending Accelerated technologies, given the prevailing cost-effectiveness threshold 
among global heath funders. If that threshold were to increase, however, to the point of 
admitting Accelerated technologies with biannual surveillance, it could present a trade-off between 
cost-effectiveness of Accelerated technologies with biannual surveillance and the superior 
protections against treatment-attributable social justice impacts afforded under Accelerated 
technologies. This may truly be an option, as low middle-income countries may consider cost-
effectiveness thresholds near $1000 per DALY based on their GDP (Santatiwongchai et al. 
2015). Indeed, the global health commitment to Gambiense HAT elimination may require a 
cost-effectiveness threshold of around $700 per DALY averted, to accommodate increased 
active surveillance in low transmission areas (Sutherland et al. 2017).  Another reason why 
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increased active surveillance may be necessary to reach elimination is that the current 
prevalence of HAT is truly unknown. Less than 10% of the at-risk population has been 
screened.  
 Putting all these considerations together, the value that JE-CEA ultimately adds to 
deliberation in the Gambiense HAT decision context is to underscore the ethical importance 
of flagging adverse social justice impacts of otherwise attractive options, so that opportunities 
to mitigate those impacts can then be explored. In this case, JE-CEA renders highly salient the 
need to devise approaches to active screening that protect people’s privacy, confidentiality, 
and dignity better than the current standard procedure. Of course, the ethical importance of 
such protections is a reason, independent of the public health decision context surrounding 
Gambiense HAT elimination, to develop a more respectful active screening approach. So far 
as the global health commitment to NTD elimination is motivated by considerations of social 
justice, consistency and coherence require stakeholders to pursue pathways toward the goal 
that best avert or alleviate adverse social justice impacts for members of at-risk communities 
along the way. If the most attractive option in terms of probability of elimination and cost-
effectiveness turns out to be Accelerated technologies with biannual surveillance, JE-CEA reveals 
that it’s ethically preferable to avoid active screening procedures that require public diagnostic 
procedures. A more progressive solution to the trade-off identified above, between bringing 
future disease incidence to zero and protecting people actively screened along the way, could 
be to develop a modified strategy incorporating more private and dignified active screening, 
Accelerated technologies with biannual surveillance*. On the other hand, the time it would take to 
develop, pilot, and scale up this improved screening procedure might run through 2019, at 
which point the projected availability of oral Oxaborole treatment would permit active 
screening to be done without the need for public diagnostic procedures. This raises the 
possibility of a differently modified strategy, Accelerated technologies with biannual surveillance** 
that would involve delaying the start of biannual surveillance pending the availability of oral 
Oxaborole. Both modified strategies would need to be re-assessed under the other forms of 
evaluation (probability of disease elimination and CEA). 
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8.7 Limitations and directions for future work 
There are still many refinements to be considered as JE-CEA develops. Primarily, JE-CEA is 
not meant to be a decision algorithm. It does not itself resolve ethical tensions or trade-offs but 
rather articulates them explicitly:  Is it better to delay elimination until more equitable tools 
are available? Or should we pursue elimination and try to improve the mitigation of social 
justice impacts along the way? Can we increase our cost-effectiveness threshold for this 
decision? While we have indicated in the Discussion section the beginning of a possible 
deliberative pathway informed by JE-CEA, it is truly up to the stakeholders involved to work 
through these ethical trade-offs. The main normative contribution of JE-CEA is to identify and 
make salient the social justice impacts of options under analysis. The experiential nature of the 
impacts highlighted by JE-CEA suggests that the involvement of patient and community 
representatives and local NTD activists is of utmost importance. For instance, NTD activists 
belonging to at-risk communities could decide to lead a de-stigmatization campaign 
alleviating the current social justice impacts of Accelerated technologies with biannual surveillance, 
so that it could be implemented as is. To facilitate the emergence of community-led solutions, 
JE-CEA could help to organize systematic stakeholder deliberation using multiple criteria 
decision analysis (MCDA) frameworks (Thokala & Duenas 2012) or Delphi panel approaches 
(Assasi et al. 2014).  
Concerns remain regarding our hypothesis that the substitution of novel Gambiense 
HAT diagnostic and treatment technologies would remove the specific adverse impacts of 
standard approaches without introducing comparable new ones. Local perceptions of novel 
technologies are currently unknown and will need to be assessed by medical anthropologists 
and other social scientists. Outdated post-treatment taboos might evolve in synch with the 
appearance of safer treatments on the market (Mpanya et al. 2015). There is evidence that rapid 
diagnostic tests (RDTs) for a disease with a symptomatic profile like that of Gambiense HAT 
(Bisser et al. 2016) are considered acceptable if the communities feel confident in the healthcare 
workers providing the services (Mukanga et al. 2010; Mushi et al. 2016), the supply of RDTs is 
maintained (Diggle et al. 2014) and the cost to the community is minimal (Cohen et al. 2015). 
 The initial version of the JE-CEA framework proposed by Zwerling and colleagues 
(2017) focuses on capturing the “worsening of disadvantage” for interventions under 
assessment. The thought here is that it’s of paramount moral importance to expose and avoid 
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unintended consequences whereby health interventions might worsen further the position of 
people “who were already relatively badly off before enactment of the policy, and who may 
have come into the line of fire of adverse policy impacts through the very pre-existing 
circumstances by which they were already disadvantaged” (Zwerling et al. 2017). There is also 
a potential, however, to consider the positive impacts of new technologies so far as they might 
protect and relieve intended beneficiaries from severe societal disadvantage by promoting 
“‘fertile functionings’ (i.e. those functionings the securing of which is likely to secure further 
functionings)” (Wolff et al. 2007).  For instance, there is emerging evidence that including 
women in vector control campaigns (tiny targets) and elimination programs for Gambiense 
HAT may lead to female empowerment and increase community engagement (Kovacic et al. 
2013; Kovacic 2015). Further research toward the more complete development of JE-CEA and 
kindred techniques should explicitly account for how positive and negative components 
interact when assessing the clustering of disadvantage in Phase 1 of the social justice 
assessment.  
There is also the need to evaluate these results in the context of uncertainty. For 
instance, even in well-funded screening campaigns, systematic bias and social exclusion 
preference may occur, as local campaigns may prioritize urban areas that are more feasible to 
reach, leading to unintentional geographical isolation of rural communities in hard-to-reach 
areas. To take into consideration such situations or other scenarios that deviate from the 
assumptions in the main analysis, the JE-CEA assessment could be conducted for each area 
separately so that decision makers can infer how distributions of social justice impacts vary by 
region. This form of sensitivity or scenario analysis is common practice in CEA modelling, and 
hence the uncertainty analyses for JE-CEA are highly recommended in further applications. 
The approach to conjoining justice-enhancement with traditional techniques of 
economic evaluation may also require refinement. In this study we used the DALY as the main 
outcome, but other health-related quality-of-life (HRQoL) values use indices that ask patients 
about their ability to conduct everyday activities. Hence impacts on agency may already partly 
be captured by such measures. Further applications of JE-CEA may need to ensure that 
‘double-counting’ for components of well-being is ruled out.  
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8.8 Conclusion 
 Zwerling and colleagues (2017) have presented JE-CEA as a novel methodology 
based on the method of ethical analysis that Bailey and colleagues (2015) had earlier proposed 
as suitable to inform public health decision making in EIC decision contexts for NTDs. In this 
paper, we have tested the use of JE-CEA in the context of the Gambiense HAT EIC, 
demonstrating how JE-CEA can help global health decision makers and stakeholders to 
evaluate not only the economic consequences but also the social justice impacts of different 
pathways towards disease control and elimination. 
  In the Gambiense HAT decision context, the structure of JE-CEA as an ‘alongside’ 
method allows its justice enhancement (JE) component to be applied not only to CEA but also 
to probability elimination analysis. In principle, given its structural flexibility, JE-CEA is 
transferable to similar decision contexts for other kinds of public health programs, where 
decision makers commonly evaluate clinical effectiveness, safety, value for money (i.e. cost-
effectiveness), budget impact, and ethical considerations. JE-CEA could help to articulate as 
part of the overall evaluation the sorts of ethical considerations that might otherwise end up 
in a dossier paragraph summarizing available literature on social disparities. Motivated by 
social justice as a moral imperative to avoid and remediate inequitable distributions of societal 
disadvantage, and resting on a normative basis derived from the family of capabilities and 
well-being theories of justice, JE-CEA can be further developed to assess explicitly the 
expected social justice impacts of the options compared. In addition to broadening the 
evidence base available to stakeholders and decision makers, JE-CEA also offers a promising 
approach to including the voices and experiences of people whom public health programs are 
intended to benefit. 
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9. Discussion 
An EIC has been shown to be a labour intensive analysis, but bears the fruit of useful and 
applicable results for decision makers considering investments in NTD elimination.  Although 
thus far various components of the EIC have been discussed as individual elements in 
chapters, they are now summarized in Table 18.  At a national program level, it was 
consistently throughout all the analyses that the current control program is inferior to other 
elimination alternatives. Surveillance programs operating at 80% coverage in moderate and 
risk transmissions areas may reduce the cases, but reaching elimination in low risk 
transmission areas by relying on patients to self-report and bear the burden of out-of-pocket 
(OOP) expenditures to seek treatment will not lead to full elimination across sub-Saharan 
Africa. This in turn renders that current approach to HAT control programs to be dominated 
in all cost-effectiveness analyses and incur the highest societal burden over time, and impinge 
of patient’s core dimensions of well-being. An elimination program that focused on adopting 
new technologies for surveillance delivery, diagnostics and treatment (Elimination I) will save 
costs in the long run while reducing more cases than the current control program, and can be 
fully integrated into the system eventually. It will also reduce CHE related to OOP and 
improve social justice across all domains of respect, association, and agency, however, it may 
not lead to complete elimination in low foci areas.  Scaling-up surveillance in low risk foci all 
the while adopting new innovations and deploying tiny targets in high foci (Elimination II and 
III) seemed to be the optimal approach. Although they require a higher cost-effectiveness 
threshold than $300 per DALY averted used by the BMGF (National Institute for Health and 
Clinical Excellence (NICE) International 2014) they both lead to elimination and have the 
possibility to be fully integrated into the health system. The main concern with these programs 
is that the interim intensive surveillance campaigns low transmission areas may worsen 
disadvantage, and this will need to be addressed. In addition, Elimination III deploys tiny 
targets in moderate risk foci which in turn increases the overall costs and cost-effectiveness, 
but ensures the probability of elimination this area.  
 
These results hence provide a series of information for stakeholders to decide which option is 
the most attractive for their concerns. For instance, global non-governmental (NGOs) 
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organizations may be most concerned with global elimination and prefer elimination 
programs (II and III) that excel in reaching elimination goals. On the other hand, national 
decision makers and investors may be more concerned with cost-effectiveness and may choose 
a more affordable program (Elimination I) forgoing elimination goals within this generation, 
but ensuring case declines in high and moderate risk foci.  There are also other combinations 
of programs for elimination that could be further explored.  
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Table 18. Summary of outcomes for EIC of HAT T.b. gambiense 
For comparison across Control Elimination I Elimination II Elimination III 
Strategies (by foci)     
Low 
Strategy A 
Strategy D Strategy D+ Strategy D+ 
Moderate Strategy D Strategy D Strategy E 
High Strategy D Strategy E Strategy E 
Elimination  
Number of cases expected in 2020 
less than 3000 cases less than 2000 cases less than 100 cases less than 100 cases 
Probability full elimination  (% chance)     
Low No chance in low No chance in low 70% 70% 
Moderate 
60% 70 - 80% 90% 
98%  
High 90% 
Cost-effectiveness Dominated Approx. $300 per DALY averted Approx. $700 per DALY averted Approx. $1500 per DALY averted 
Financial (until 2020) $0.63 billion $0.42 billion $0.98 billion $1.25 billion 
Out-of-pocket  (OOP) in 2020 
CHE 10% 
CHE 25% 
62.93% 
30.96% 
1.25% 
0.49% 
1.27% 
0.51% 
1.23% 
0.48% 
Health systems (passive surveillance) 
treatment integration potential 
Pentamidine-NECT 
No integration 
Full integration 
FEXI 2016   
Full integration OXA 2019 
Full integration 
FEXI 2016  
Full integration OXA 2019 
Full integration 
FEXI 2016   
Full integration OXA 2019 
Ethical considerations* 
                 
*SJA based on low r isk  trans miss i on areas  on ly  where  orange  =  expe cted to  worse n,  ye l low = may wors en disadvantage ,  tur quo ise  =  not  e xpecte d to  worsen;  FEXI =  fe xinidazole ,  OXA = Oxaboro le  
SCYX-7158;  TBD = to  be  de termined,  NOTE;  (Lo ndon dec lara tion ta rgets  le ss  than 2000 cases  in 2020)
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9.1 EIC results for investment decisions (direct applications) 
 EIC for the BMGF 
As the Eradication Investment Case (EIC) project came to a close in 2014, the three reports 
were delivered to the Bill and Melinda Gates Foundation (BMGF) in the summer of 2015 in 
order to make decisions for control, elimination and eradication campaigns relative to the 
diseases over the next coming years. At the initiation of the project the design of the EICs for 
lymphatic filariasis (LF) and onchocherciasis (oncho) were more similar and hence it was 
thought that human African trypanosomiasis Trypanosoma brucei gambiense (hereunto referred 
to as ‘HAT’) could not be compared; but in the end, there are core components of the EIC that 
resonate throughout the three dossiers.  Components related to economic and elimination 
outcomes for the three are summarized in Table 19. Across the three diseases, the results 
demonstrate unanimously that the current strategies are insufficient to reach global goals of 
eradication or elimination. The overall incremental cost-effectiveness rations (ICERS) for 
elimination and or eradication demonstrate that HAT has higher cost-effectiveness ratios than 
the other two. This is due to the fact that extensive financial resources (i.e. surveillance, vector 
control prevention) are necessary investments to detect and treat HAT cases. In regards to 
societal costs, LF and oncho both calculated economic loss as volunteers are used to administer 
mass drug administration (MDA) campaigns for disease eradication. Since there is no safe and 
preventative oral treatment available as yet for HAT, MDA campaigns are not feasible and 
hence the burden of direct costs related to seeking treatment rely on households of HAT 
patients. For this reason OOP expenditures were a more appropriate societal related cost for 
HAT. Overall, the results show that disease specific costs and benefits of eradication and 
elimination, and also demonstrate that EIC can be compared across diseases for possible 
discussions of investment prioritisation. Recent feedback from the BMGF also (personal 
communication, BMGF) reinforced that the dossiers were helpful in NTD funding prioritisation. 
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Table 19. Summary of several components of EICs for onchocerciasis (oncho), lympahtic filariasis (LF) and 
human African Trypanosomiasis (HAT) Trypanosoma brucei  (T.b.) gambiense 
 oncho 
‘river blindness’ 
LF 
‘elephantiasis’ 
HAT 
‘sleeping sickness’ 
Current strategy Control Elimination Control 
Alternative strategies 
Elimination 
Eradication 
Eradication I 
Eradication II 
Eradication III 
Elimination program I 
Elimination program II 
Elimination program III  
Elimination/Eradication 
outcomes 
Current (Control) unlikely 
to reach eradication in next 
3 decades, while scaling up 
to Eradication probable of 
reaching global goals in 
2040(Beer et al. 2015) 
Current (Elimination) likely to 
reach eradication in next 4 
decades, while scaling up to 
Eradication programs 
probable of reaching global 
goals near 2030(Wellcome 
Trust 2015) 
Current (Control) unlikely to 
reach elimination targets in 
next 3 decades, while scaling 
up to Elimination programs 
with new technologies, 
vector control and 
surveillance likely to reach 
global goals 
Cost-effectiveness 
Eradication 
dominant(Sutherland 2016) 
$73 to $220 per DALY 
averted*(Barton et al. 2008) 
Less than $200 to greater 
than $1500 per DALY 
averted 
Financial costs 
Costs ranging from $640 
million(Control)  to  $650 
(Elimination, 
Eradication)18 
Costs ranging from $930 
million (Elimination) to $1.3 
billion (Eradication I)19 
Costs ranging from $410 
million (Elimination I) to 
$1.2 billion (Control 
Elimination II, III)) till 2020 
Societal costs** 
Current (Control) program 
costs $3.7 billion but 
Elimination & Eradication 
reduce costs to $2 billion18 
Current (Elimination) 
program costs $5 billion while 
Eradication programs increase 
costs near $8 billion19 
Current program (Control) 
leads in incurrence of CHEs, 
while Elimination programs 
would reduce CHE to less 
than 2% 
NA = not available 
*CE compared to Elimination, although results suggest that if examined for dominance, Eradication III would be the dominant strategy 
** economic costs for onchocerciasis and LF calculated as donated volunteer time from CHWs, HAT used OOP 
CHE=catastrophic health expenditure 
 Drug discovery funding case for Novartis Institute for Tropical Disease 
(NITD), Singapore  
Another direct application of how these results could be used for funding decisions, was in 
regards to an application for development of a new target product profile (TPP) drug for HAT 
in case oxaborole experiences market failure. The model was used to forecast several strategies 
for treatment in a low transmission area in the absence of vector control to evaluate the 
potential impact that a new TPP would have if fexinidazole arrived in 2016 to treat both disease 
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stages with or without oxaborole arriving on the market a couple years later.(M Kawonga et 
al. 2015; Mary Kawonga et al. 2015)  The results presented in Figure 24 demonstrated that the 
approval of a new TPP in 2022 that could improve coverage due to its ease of use (‘fexinidazole, 
oxaborole and TPP approved’) would further reduce transmission, even in the absence of active 
surveillance. Furthermore, if oxaborole failed to reach market in 2019, but a new TPP was 
available in 2022, reduction of cases could still be attained (‘fexinidazole and oxaborole approved’).  
These outcomes were presented to the Wellcome Trust and resulted in an 8 million GBF grant 
for the development of a new TPP awarded to NITD in collaboration with several academic 
laboratories.(Hoaglin et al. 2011; Jansen et al. 2011) According to the VOI analysis, this also 
seems a reasonable investment given the uncertainty of elimination over the next 30 years for 
an at risk population of nearly 60 million people.  
Figure 24. Control and elimination strategies of new oral treatments 
 
9.2 Lessons learned from the EIC  
As mentioned within the introduction of this thesis, at the onset of the project no formal 
methodology or protocol had been described for the EIC besides the itemized questions 
proposed by the Ernst Strüngmann and hence already established approaches were completed 
along with a few innovative approaches. In the end, the core analytical methodologies were 
completed and this process is outlined in Figure 25.  
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The evidence base collected relied largely on the available literature and hence several reviews 
were undertaken. Accessing national reports, case data available from the WHO repository 
and also speaking to experts in the field were key to understanding this neglected disease as 
often information goes unpublished due to lack of funding or interest from journals. Gathering 
a broad evidence base also highlighted the use of vector control use mainly for prevention in 
animal African trypanosomiasis (AAT), which in turn resulted in a more holistic approach to 
elimination thinking for HAT. This also highlighted that aggregate secondary evidence is quite 
informative in decision making and also time efficient, and makes use of work done by 
previous researchers.  The irony is that, resource rich countries are beginning to spend less on 
primary research and use secondary evidence for investments in health care decision making 
(HTA) while health research in resource poor countries rely more on evidence from high cost 
epidemiological studies to lobby for funding.  Unfortunately this is not a sustainable approach. 
There is also a tendency to ‘over-innovate’ and seek out funding for new research before 
clearly evaluating the existing evidence and seeing if we can use already well-established 
methodologies or liase with a group that may be more advanced than we are. This can be a 
humbling exercise for academics, but is essential for those working in situations with limited 
resources as was the case for HAT. Conceptualising current and alternative strategies was also 
a key process needed at the beginning of the EIC that in the end drove all the subsequent 
analyses.  In the case of HAT, this was also a progressive process as potential scenarios 
involved into foci related strategies which in turn became potential control and elimination 
programs. Although further scenarios, strategies and programs could be hypothesized, this 
processed generated a series of relative options for the various investment profiles of the 
decision makers that will use this information. However, further work on HAT scenarios could 
involve strategies with more variation of the diagnostics tests as these parameters are not 
thought to be a bit more variant that once perceived (M Kawonga et al. 2015; Mary Kawonga 
et al. 2015) and also to explore the possibility of targeted campaigns to high risk  sub-
populations that may be contributing to the overall community disease transmission.   
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Figure 25. EIC project processes 
 
Modelling proved to be one of the key components of the project as it forecasted elimination 
probability for strategies, percentage reduction used to estimate the number of cases, health 
impacts calculated in the modelling using DALYs and cost projections. Subsequently as 
models are data driven, such analyses required a large number of input parameters. The model 
also contains stochastic inputs that led to the calculation of uncertainty in economic evaluation. 
One issue that came to light during the economic evaluation was when the time for choosing 
optimal strategies came. To evaluate the optimal strategy related to the foci specific areas, a 
cost-effectiveness acceptability frontier (CEAF) was generated. The results shown in (Figure 
26) confirm that Strategy D or E are the most CE strategies in high and moderate areas based 
on different CE thresholds; however, in low transmission areas, strategy B no longer serves as 
an option as it was dominated in the base case analysis. From recommended techniques 
(Sutherland 2016) strategy B should not be included as it was dominated in the base case 
analysis, but even when other strategies are removed, it does not compete as an artefact but as 
a cost-effective option with some probability for low risk foci.  This is something that decision 
makers need to consider under uncertainty and hence was why it was still considered a 
possible option in HAT elimination program development.  
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Figure 26. CEAC versus CEAF in low transmission foci 
A. CEAC B.CEAF 
  
 
Through the process of the EIC, it also became evident that it is a work that re of analyses and 
expertise required and experts from various fields (i.e. Modeller, economist, information 
specialist (literature reviewer), ethical philosopher, epidemiologist, principal investigator 
(project manager)) committed over an extended amount of time. This in turn means that future 
EICs, will not come at a small price; however, it has already been shown that these investments 
are worthwhile.  
9.3 Further and continued research within the EIC 
 Governance and funding 
In Chapter 7, health systems thinking was used to amalgamate key actors in the Gambiense 
HAT elimination, and also highlighted that integration would influence most actors at the 
National level with few changes in governance, finance and information.  However, there is 
still a need to evaluate the current power structure of governance for HAT to ensure that 
integration goes smoothly and also to ensure that the key players collaborate towards global 
elimination. Network analyses using social network analysis (Barrett 2013) or Bayesian 
network analysis commonly used in indirect-treatment comparison(Policy Cures 2008),  could 
be a potential avenue to further evaluate the implications that relationships in governance 
have in relation to what is achieved on the ground in the affected nations.  Without any formal 
analysis, the known connections of the actors in the health building blocks (Chapter 7) already 
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reveal (refer to Figure 27) that the BMGF are a high frequency donor with several connections 
to financial ties to MSF, R&D, and WHO. MSF and the NSSCP have the greatest links to the 
patients, families and communities. There are quite a few peripheral institutions whose 
complete roles would require future research. This could be done to discern each players’ 
involvement as the role of new individuals as integration occurs.  Network analysis can also 
be done to show the strengths of the relationships that have the most impact on making 
changes (Sutherland 2016).   
Figure 27. Network of actors included in Gambiense HAT elimination 
 
Legend: grey = internal connection (same institution); green = funding, blue = delivery of services/flow of communications; perforated lines 
indicate new players included in integration of health system 
Health systems building blocks: H = Healthworkforce, S = Service and delivery, G = governance, I = Information, F = Finance;  
MSF=Médecins sans Frontières, NSSCP=National sleeping sickness control programs, CHW=community health worker, Med profess=Medical 
professional, HC=health centre, ITM = Insitute of Tropical Medicine, SDI=Standard Diagnostics Inc., R & D=Research and development, FAO 
= Food and Agriculture organization of the United Nations, PAAT = Programme Against African trypanosomiasis, WHO = WHO 
headquarters (HQ) and WHO (African Regional Office (AFRO), IAEA= International atomic energy agency, AU=African Union, PATTEC= 
Pan African Tsetse Eradication Campaign, ADB = African Development Bank,  NORAD = Norwegian Agency for Development Cooperation 
Governmental, BMF = Bundesministerium für finanzen, SDC= Swiss Development Corporation,  BDC=Business Development Bank of 
Canada,  GE = General Electric,  DFID= Department for international development United Kingdom , AB = Arab Bank,  GTZ = Gesellschaft 
für Technische Zusammenarbeit, AECID= Agency of International Cooperation for Development, MAEE= Ministry of Foreign and European 
Affairs, BMBF= Bundesministerium für Bildung und Forschung,Note: R& D includes academic and research and development partners 
including: WHO collaborating centres, DNDi, FIND, ICIPE, IRD, INRB, ITM, IHMT, Makere University, Swiss TPH (University of Basel) , 
University of Glasgow, University of Liverpool (LSTM), University of Oxford,. University of Warwick, Yale University, Oregon University, 
IDM = Institute for disease modelling 
 
In order to be fully incorporated into the EIC, examining governance changes by program 
would also be necessary. Although maybe integration seems optimal, there could be 
synergistic impacts or relational repercussions from well-established programs that could 
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inadvertently hinder progress even though well intended. This is an application that could be 
further developed in future EIC methodological research. 
There are 24 countries at risk, with 13 endemic, but only 18 representatives listed with NSSCP 
as of 2016.(Winkler et al. 2013) Although some countries may be near declaring status for 
elimination, there is still a concern that there may be foci that are still endemic and six nations 
with no NSSCP, it will be difficult to achieve global elimination. Additionally, with the large 
investments required for elimination discussed previously, some nations make opt for cost-
effective programs at a lower threshold in turn leading to elimination delays. Applications of 
cooperation stemming from ‘game theory’ (Goeree & Levin 2006) could be of potential use in 
understanding impact of collaboration versus no collaboration globally or also how bordering 
countries and weak control over migrating populations could impact elimination efforts.  
Funding is also closely connected to governance issues. As depicted in Figure 27, financing is 
key part of the health system and it is important to know who the key funders are and also 
which components of elimination are being covered. This is often disease and treatment 
specific for global health donations. As is with the case of HAT, the pharmaceutical companies 
donate their treatments, the vector control programs can provide targets at reduced costs, but 
the coverage of the surveillance and health care system then falls on the ministry of health or 
local NGOs. In order to achieve elimination it will be necessary to make sure that funds for all 
components of elimination programs are covered.   A funding gap analysis is also part of the 
EIC that has gone unanswered. To date there is still a need to ascertain is how much money is 
specifically be invested for HAT to understand the additional funds required.  G-FINDER 
(Dixit & Pindyck 1994) estimates that in 2014 alone nearly 50 million was spent on R & D alone 
for sleeping sickness. As there seem to be enough tools necessary for elimination, perhaps 
R&D investments can be diverted to elimination campaigns. This is not to say that R&D is to 
be stopped, but as funders are already overwhelmed by demands, should not prioritisation of 
funds go towards on the ground research that can contribute to elimination? R & D efforts can 
make more direct links to work on the field so that R&D contributes to elimination.  For 
instance, drug trials recruit from the population at risk, contributing to reducing global 
number of cases and field studies with RDTs and tiny targets also simultaneously train health 
workers and with communities respectively. Modelling geographical at risk areas may be 
needed, but maybe this can be done in collaboration with collecting field surveillance 
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databases that can simultaneously improve information systems, surveillance coverage and 
be used for future epidemiological modelling forecasts. These sort of R&D endeavours should 
be encouraged.  Overall HAT is a costly disease, so countries and programs may need to be 
innovative in securing funds. Exploring options for fundraising (E.g. March of Dimes Franklin 
D Roosevelt) can generate global awareness and impresses funders.  For example, a campaign 
called ‘trips for tryps’  could be initiated where airline companies and have passengers donate 
spare change, or even have a ‘pop-up’ advertisement when purchasing  travels online that asks 
for  a small donation.  This is simply an idea, but if the campaign then approached a donor 
and asked them to match dollar for dollar, twice as many funds could be generated.  Other 
funding options could also include collaborating elimination projects that use tiny targets with 
AAT programs that often receive national funding from agricultural and/or economic 
departments.  
 Additional EIC questions unanswered 
There are still issues related to risk and contingency planning for failure to reach targets due 
to unforeseen circumstances (i.e. war, natural disaster) but also to consider formal post-
elimination planning.  For instance, once cases have been reduced to zero, surveillance still 
needs to remain intact in the event of resurgence in a given foci. Integration with the healthcare 
system and improving information systems with ‘triggers’ would be useful so the medical 
professionals are able to catch ‘alerts’ when an outbreak begins. The operational planning and 
implementation still needs to be discussed. The EIC for HAT has provided several programs 
that could be used for elimination, but how countries will implement the scaling up of these 
programs on a daily basis still relies on the NSCCP. Motivation and incentives have also not 
yet been discussed but could be useful if addressed in an EIC. As has been shown with the 
forecasting, the timeline to elimination is long and in the final years uneventful. Already it has 
been seen that health workers in the field for HAT are demotivated and losing 
interest.(Thokala & Duenas 2012; Diaby et al. 2015; Diaby & Goeree 2013) Creative discussion 
may be needed to prevent fatigue during elimination and increase intrinsic motivation and 
interest. For example, countries looking to eliminate HAT could consider giving a national 
holiday once disease elimination is achieved.  Now that the HAT EIC is complete, there will 
probably be a tendency to disregard the results after programs for elimination have been 
chosen. However, global planners should continue to monitor the forecasted outcomes, to 
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ensure that elimination is on track and to update the modelling to readjust the forecast as 
additional information becomes available. This then becomes an iterative process as is seen 
other health decision making processes in health impact assessment (HIA) (Uniting to Combat 
NTDs n.d.) or the PRUFE15 framework within the ministry of health in Ontario, 
Canada.(Goeree & Levin 2006) 
 Methodology and use 
As this was one of the first projects to formally develop an EIC, the methodology still needs to 
be formalized; but given the lessons that have been learned from this project, there is a 
possibility now to develop formal guidelines or protocols for EIC development that are non-
disease specific and also transferable. Instruction should also be given for appropriate 
timelines for the stages involved and perhaps even split the project into phases with interim 
deadlines. Referring again to Figure 33, the first phase could involve the evidence collection, 
synthesis and model development within the first 6-18 months, with the analyses and 
outcomes generated in the next 6-18 months.  Outcomes should be harmonized so that decision 
makers are able to prioritize across diseases as was illustrated in Table 23. Still, there remain 
additional analyses that could have been undertaken for the EIC. For instance, it has been 
mentioned that pursue further research would be worthwhile (Chapter 5, Value of information), 
but the expected value of parameter perfect information (EVPPI) could also be to tell decision 
makers which parameters should be the focus on further research. Additionally, the EIC has a 
close connection to time and delays in investments for decision in elimination have not yet 
properly been discussed. Exploring the techniques available on calculating the pros and cons 
of delayed decisions for investors as discussed by economists (SCORE n.d.) could be of interest 
for further research in EICs. Financial and societal costs outcomes for the HAT EIC were 
limited to a financial protection analysis and cost forecasting but productivity losses could also 
be considered as a formal component of the methodology.  In addition, no formal budget 
impact analysis was done, but perhaps this is a method better left to national decision makers. 
As previously stated, if further research on EIC methodology is to continue, developing the 
health systems thinking and modelling component would be of use, but also broader 
                                                     
15 Program for Assessment of Technology in Health (PATH) reduction of Uncertainty through Field 
Evaluation (PRUFE) 
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implications of local settings could be considered. For instance, depending on the tropical 
disease, water and sanitation (WaSH) programs can have quite an impact. Ethical 
considerations also have been shown to highlight discordance between components of cost-
effectiveness and elimination targets, but these discrepancies still need to be resolved. 
The EIC also has various components that allow for the possibility of a multi-criteria decision 
analysis (MCDA) framework. (Molyneux et al. 2010; Zhang et al. 2010) Using this approach, 
decision makers could decide on which components of that full analysis have greater weight 
(i.e. cost-effectiveness, social justice, etc.) and then after completing each assessment would 
receive a score for each disease based on the a priori weighting scheme.  
 EICs for other NTDs investment decisions 
Elimination and eradication campaigns are still underway for several other diseases,(World 
Health Organization (WHO) n.d.) and investors committed to other disease areas are 
beginning to see a need to develop elimination programs that demonstrate good value for 
money. The Novartis Foundation has already initiated an EIC for Buruli ulcer (Leprosy 
(Hansen disease))(Hackett et al. 2014) and now Schistosomiasis Consortium for Operational 
Research and Evaluation (SCORE) also plans to formally assess elimination with an EIC 
dossier.(Chris M. Stone & Chitnis 2015) Yet there are still many other neglected diseases that 
will benefit from EIC reporting (e.g. American trypanosomiasis (Chagas), Trachoma, Soil-
transmitted Helminthiasis),  and new epidemics continually on the rise in tropical 
environments (i.e. Ebola, Zika Virus) and these areas should be explored.    
9.4 Conclusion 
The EIC has proven to be a useful approach that is both technically feasible and informative.  
However a continued development of methodology may be needed if it is to be applied to 
other NTDs to assist global DMs in eradicating diseases that affect the poor and improving 
sustainable development goals (SDGs). The EIC for HAT has provided various options for 
stakeholders to move towards elimination, but funding gaps may abound so countries may 
need to be innovative in securing additional funds for HAT specifically as donors may favour 
alternative diseases that appear more cost-effective according to their willingness-to-pay 
thresholds. Integration is inevitable and necessary for the advent of sustainable health systems 
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in the developing world, but more strategic planning in this area is needed. Health systems 
modelling and operational research methods show promise but may need to be explored 
further to see their use within an EIC.  
Now is the time to move forward. Although impact of delayed investment not formally 
assessed, delays in actions inevitably lead to delays in reaching elimination timelines. Declines 
in cases will be seen, but additional, continuous and sustained pressure will be required for 
elimination. This is not the time for lethargy or complacency in moving ahead, and global 
investors should not relax as cases decline. To full stop transmission getting less than one case 
will be the most difficult as the tail end of elimination is logarithmic and tends to plateau at 
low numbers.  There are still unanswered concerns about elimination, but decision makers 
should be cautious to not ‘over-analyse’ when things just need to get done. The truth is we 
know what to do and we have the tools to do it,(National Institute for Health and Clinical 
Excellence (NICE) International 2014), hence the current need is to put research into practise 
and prioritize moving forward instead of contemplating additional research questions.   
Researchers and medical professionals also need to make an effort to translate knowledge to 
next generation as if the hope of elimination is achieved; this will be the last generation to 
observe various cases, parasite and treatment, to allow for a combination of trained 
professionals but also younger health workers who will be around for the next half century to 
offer expertise.  
9.5 Recommendations towards HAT elimination 
 Immediate goals 
• National Sleeping Sickness Control Programs (NSSCP) should select appropriate 
programs towards elimination with the given tools so that they can begin to secure 
appropriate funding and establish networks for smooth delivery of products. The 
WHO stakeholders for Gambiense HAT elimination could be used as an opportunity 
to commit to or make a declaration of chosen elimination strategies 
• Secure long-term funding commitments and consider additional funding innovations 
• Surveillance needs to be improved and will probably require a combination of active 
and passive surveillance until the passive healthcare system is prepared to integrate 
 Page 218 of 321 
the newer technologies. Increases in surveillance coverage need to be initiated while 
simultaneously collecting surveillance from the field into an accurate case reporting 
information systems. Starts identifying local health centres and local NTD initiatives 
to partner with to be ready to integrate fexinidazole in 2018.  
• Maximise efforts work with clinical trial people to refer cases for clinical trials and 
researchers work directly with new technologies in field studies so that progress in 
R&D contributes to overall elimination goals.  
• Local initiatives Scale up health workforce to have working knowledge of ‘sleeping 
sickness’ as well as differentiation between it and other febrile illness also common in 
other tropical diseases. Deploy targets and teaching communities to maintain traps for 
sustainability.  
 Long-term goals 
• Monitoring EIC projections on annual basis 
• Integration with other elimination/eradication campaigns for NTDs  
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Appendix A: Chapter 1 
 
 Guiding Questions (from Guide to Preparing EIC version 07.11.11)  
Overarching question research 
question(s) 
Methodology Result (Outcome measure) 
Section I: The proposed investment    
I.1 The disease and its global health significance What options are available? • Literature review of 
available and emerging  
interventions 
Scenarios, strategies, programs 
options 
I.2 The current state of control efforts 
 
•  •   
I.3 How eradication can be achieved 
 
•  •   
I.4 Post-eradication scenarios •  •   
Section II: Rationale for investing •  •   
II.1 Biological and technical feasibility •  •   
II.2  Health and economic burden of disease •  •   
II.3 Assessment of total costs 
What is the total cost of the post-eradication plan? 
•  •   
II.4 Cost-effectiveness and cost-benefit analyses •  •   
II.5 Public goods obtainable through eradication  •  •   
II.6 Strengthening health systems • What options demonstrate 
good value for money? 
• What options can we afford? 
• What options are logistically 
and operationally feasible? 
• Dynamical disease 
transmission 
modelling 
• Economic evaluation 
• Health system 
modelling 
Probability Elimination 
ICERs 
Capacity 
Section III: Challenges, risks and constraints  •   
III.1 Stakeholder involvement   • Survey of stakeholder 
commitments  
? 
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• Who will do it?(Whose 
involved?) 
 
 
III.2 Challenges, risks and constraints  Ethical, 
Social, and Political 
 
• What is the ethical option? • Justice-enhanced CEA Impact on well-being and 
population affected 
III.3 Epidemiologic Technical and Geopolitical 
Market Dynamics 
•  •   
III.4 Critical risks and risk management plan • What is our contingency plan? 
(E.g. if new technologies don’t 
make it…then what? Should 
consider increases in 
surveillance and vector control 
more seriously – what about 
wars? Strategies for 
containment?) 
? ? 
Section IV: Management and governance     
IV.1 Partnerships and governance    
IV.2 Critical milestones and monitoring 
confirm that appropriate standards are being met? 
   
IV.3 Operational Research Plan •    
IV.4 Evaluating impacts on health systems  • Who will do it? 
• How will it get done? 
? ? 
 Page 262 of 321 
Appendix B: Chapter 3 
 Search strategy 
Type Keywords for MEDLINE 
 
Keywords for EMBASE  
 
Population – 
Human African 
trypanosomiasis 
1. Trypanosomiasis, African/ 1. Trypanosomiasis, African/ 
2. exp Trypanosoma brucei gambiense/ or 
      
     
     
 
2. exp Trypanosoma brucei 
      
    
     
   
 
3. Trypanosom$.mp. 3. Trypanosom$.mp. 
4. Tsetse fl$.mp. 4. Tsetse fl$.mp. 
5. HAT.mp. 5. HAT.mp. 
6. sleeping sickness.mp. 6. sleeping sickness.mp. 
 7. human african trypanosomiasis.mp. 7. human african 
 
 8. Glossin$.mp. 8. Glossin$.mp. 
 9. Tb gambiense.mp. 9. Tb gambiense.mp. 
 10. Tb rhodesiense.mp. 10. Tb rhodesiense.mp. 
 11. T brucei gambiense.mp. [mp=title, 
      
     
    
    
   
11. T brucei gambiense.mp. 
    
     
    
   
   
   
 
 12. T brucei rhodesiense.mp. 12. T brucei rhodesiense.mp. 
 13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 
10 or 11 or 12 
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
or 9 or 10 or 11 or 12 
SIGN Filter – 
Economic 
Models and 
Evaluations  
1. Economics/ 1. Socioeconomics/ 
2. "costs and cost analysis"/ 2. Cost benefit analysis/ 
3. Cost allocation/ 3. Cost effectiveness analysis/ 
4. Cost-benefit analysis/ 4. Cost of illness/ 
5. Cost control/ 5. Cost control/ 
6. Cost savings/ 6. Economic aspect/ 
7. Cost of illness/ 7. Financial management/ 
8. Cost sharing/ 8. Health care cost/ 
9. "deductibles and coinsurance"/ 9. Health care financing/ 
10. Medical savings accounts/ 10. Health economics/ 
11. Health care costs/ 11. Hospital cost/ 
12. Direct service costs/ 12. (fiscal or financial or finance or 
 
13. Drug costs/ 13. Cost minimization analysis/ 
14. Employer health costs/ 14. (cost adj estimate$).mp. 
15. Hospital costs/ 15. (cost adj variable$).mp. 
16. Health expenditures/ 16. (unit adj cost$).mp. 
17. Capital expenditures/ 17. or/1-16 
18. Value of life/  
19. exp economics, hospital/  
20. exp economics, medical/  
21. Economics, nursing/  
22. Economics, pharmaceutical/  
23. exp "fees and charges"/  
24. exp budgets/  
25. (low adj cost).mp.  
26. (high adj cost).mp.  
27. (health?care adj cost$).mp.  
28. (fiscal or funding or financial or 
 
 
29. (cost adj estimate$).mp.  
30. (cost adj variable).mp.  
31. (unit adj cost$).mp.  
32. (economic$ or pharmacoeconomic$ or 
   
 
33. or/1-32  
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 Information, inclusion-exclusion criteria legend  
PICOS Criteria Include Exclude 
Population (P) • African trypanosomiasis in 
humans 
• Children, adults, men, women 
 
• Chagas 
• American Trypanosomiasis 
• Other neglected diseases 
• Cattle and/or livestock 
populations 
• Tsetse fly populations 
 
Intervention(I) & 
Comparators (C) 
 
Interventions that contribute to 
reduction in transmission of disease in 
humans: 
• Passive + Active Surveillance 
Programs  
• Detection and Diagnosis 
• Treatment 
• Vector Control 
• Other (E.g. Health systems, 
community sensitization, etc.) 
• Interventions that DO NOT  
contribute to reduction in 
transmission of disease in 
humans 
 
 
Outcomes (O) • Costs  
• Consequences (E.g. $/DALYs, 
$/LYG, $/LYS, etc.)  
• Costs only 
• Consequences only 
Study (S) • Economic evaluations as defined 
by Drummond et al. 
• CEA, CBA, CUA 
• Health Technology Assessment 
(HTA) reports with economic 
evaluations 
• Modelling studies with economic 
outcomes 
• EEACTs 
• Editorials 
• Mathematical modeling studies 
with no economic outcomes 
• HRQoL studies 
• Cost analyses 
• BIA 
• BOI studies 
• Costing papers/studies 
CEA=Cost-effective Analysis; CUA= Cost-Utility Analysis; CBA = Cost-Benefit Analysis; DALYs =Disability adjusted Life Years,  LYG =Life years 
gained,  LYS =Life years saved , HRQoL =Health Related Quality of Life,  BIA=Budget Impact Analysis, BOI=Burden of illness; EEACTs= Economic 
evaluations alongside clinical trials  
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Appendix C: Chapter 5 
 Methods (additional information) 
C.1.1 Description of potential ‘strategies’ for control or elimination 
Potential Strategy Description 
Strategy A 
Control 
Involves the current recommendations for control requiring 
screening and diagnosis. This begins by patients reporting 
themselves to local health centres (passive surveillance) or being 
detected through an active screening surveillance* in his/her 
community. Blood serology tests using the card-agglutination 
trypanosomiasis test (CATT) identify suspected cases. Lumbar 
puncture is then performed to determine the disease stage. 
Patients confirmed with stage one are treated with 
pentamidine and stage 2 patients with nifurtomix-eflornithine 
combination therapy (NECT).  
Strategy B 
Control with tiny targets 
The same as ‘Strategy A - Control’ in combination with 
insecticide treated screens deployed across foci areas to 
interrupt transmission. 
Strategy C 
New technologies in 2016 
The same as ‘Strategy A - Control’ until 2016. At this time some 
cases to be treated with fexinidazole for second stage HAT as 
most facilities would still be implementing pentamidine for 
Stage 1 treatment. Diagnosis is hoped to be done with a rapid 
diagnostic test (RDT) and using loop-mediated isothermal 
amplification (LAMP) for parasitological confirmation.  
Strategy D 
New technologies in 2016 
and 2019 
The same as ‘Strategy C – New technologies in 2016’ until 2019, 
where it is hoped that at this time a novel oral tablet (oxaborole) 
that can treat both stages of diseases will be available and 
diagnosis done with a simple RDT.  
Strategy E 
New technologies in 2016 
and 2019 with tiny targets 
The same as ‘Strategy D – New technologies in 2016 and 2019’ in 
combination with insecticide treated screens deployed across 
foci areas to interrupt transmission. 
*This includes passive surveillance combined with annual active surveillance in high risk areas and 
passive surveillance combined with biennial surveillance in moderate risk areas. In low risk settings, 
active surveillance not done and reliance solely on passive surveillance. These are based on the 
recommendations for T.b. gambiense control outlined by WHO(World Health Organization 
(WHO) 2013c) 
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C.1.2 Choice of health outcomes and measurement of effectiveness 
The DALY was chosen as the outcome measure and cost USD per DALY averted was 
the item used to measure CE. Cost-effectiveness was assessed by evaluating the 
incremental cost-effectiveness ratio (ICER). Strategies were first aligned from lowest 
to highest cost, with the incremental costs and DALYs averted calculated for each 
strategy relative to its next best option and assessed for dominance. The annual 
prevalence, costs, time to elimination and DALYs over 30 years were calculated for 
each strategy by transmission area. 
C.1.3 Disability adjusted life years (DALY) 
Disability adjusted life years were calculated per diem based on traditional 
methods(World Health Organization (WHO) n.d.) and included the years life lost in 
combination with the years lost to disability (YLD). YLD for stage one and two of the 
disease were considered to be different and estimated values were taken from a recent 
publication by Hackett et al..(Hackett et al. 2014)  In order to derive a value for YLLs, 
life expectancy was assumed to be 66years and the average patient age upon infection 
was assumed to be 25 years of age. The formula for DALY calculations is shown below.  
DALYs per diem = ((mu_s*Rh) + mu_t*Th))*(41.3-((1/s+1/mu_s)/365)) + q*Ih*yldI + 
s*Ah*yldII)  
+ (((mu_s*RhB + mu_t*ThB))*(41.3-((1/s+1/mu_s)/365)) + q*IhB*yldI + s*AhB*yldII) 
Where,  
mu_h = normal human mortality, mu_s = death related to HAT disease, mu_t = death rate, s= 
rate of progression to stage 2 and q= the duration of incubation 
And where compartments described are, 
Sh = susceptible humans, Ih incubating humans , Ah= infective humans  (stage I of disease), 
Rh= removed humans (due to stage II of disease) and Th = treated humans 
And yldI and yldII = refer to years lost to disability for stage 1 and stage 2 respectively 
when, 
 yldI = dw1*(1/((r1+s+mu_h)*365)) 
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yldII = dw2*(1/((r2+mu_s+mu_h)*365)) 
The disability weights for Stage 1 (dw1) and Stage 2 (dw2) of the disease were 0.191 and 
0.81, respectively.  
 
C.1.4 Coverage rate assumptions related to surveillance 
The baseline values for coverage in the passive healthcare system and active screening 
campaigns were taken from the PNTHLA report(Programme National de Lutte Contre La 
Trypanosomiase Humaine Africane (PNLTHA) 2013)  Active surveillance of 80.25% refers to the 
participation rate of a given foci. Hence, this should be interpreted as an active 
screening campaign covering 80% of the population in a given foci, not as a the 
coverage rate of foci across sub-Saharan Africa. In addition, the screening rate of for 
the passive health care system of 2.46% was also taken from the PNTHLA 
report.(Programme National de Lutte Contre La Trypanosomiase Humaine Africane (PNLTHA) 2013) An 
assumption was made that new technologies would improve passive coverage due to 
their ease of use by factors of 3, 6.5 and 10 resulting in coverage improvements of 
approximately  7.4%, 16% and 25% as listed in the table below. 
Improvements of 5% coverage were assumed for active surveillance campaigns using 
motorbikes when new oral tablets (fexinidazole or Oxaborole) and rapid diagnostics 
become available in 2016 and/or 2019. This assumption was based on intuition from 
experts (DNDi, personal communication) that foresaw the ease of distribution and 
feasibility that came with the new technologies. Recent evidence from the field also  
suggests that this may be even higher since the motorbike campaigns may increase 
coverage to nearly 100%.(Sutherland 2016)   
Parameter Description  Distribution Point Estimate alpha* beta* Source 
      
Passive surveillance      
Coverage rate for passive healthcare system Beta 2.46% 2.46 97.54 PNLTHA(Prog
ramme 
National de 
Lutte Contre La 
Trypanosomias
e Humaine 
Africane 
(PNLTHA) 
2013) 
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Coverage rate for new technology for passive 
screening  
     
NECT with CATT algorithm (2013) Fixed 1*2.46%    
Pentamidine, Fexinidazole with RDT 1 algorithm 
(2016) 
Fixed 3*2.46%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
Fexinidazole (both stages) with RDT 1 algorithm 
(2019) 
Fixed 6.5*2.46%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
Oxaboroles with RDT algorithm 2 (2019) Fixed 10*2.46%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
Coverage rate for active screening program  Beta 80.25% 80.25 19.75 PNLTHA(Prog
ramme 
National de 
Lutte Contre La 
Trypanosomias
e Humaine 
Africane 
(PNLTHA) 
2013) 
      
NECT with CATT algorithm 2013  (Mobile trucks) Fixed 0    
Pentamidine, Fexinidazole with RDT 1 algorithm 
(2016) 
Fixed 80.25%+5%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
Fexinidazole (both stages) with RDT 1 algorithm 
(2019) 
Fixed 80.25%+5%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
Oxaboroles with RDT algorithm 2 (2019) Fixed 80.25%+5%   DNDi 2014 
Annual 
Report(Drugs 
for Neglected 
Diseases 
initiative 
(DNDi) 2014a) 
*alpha and beta are the parameter properties required for a beta distribution 
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C.1.5 Discounting 
 
Costs and DALYs were discounted at an annual rate of 3% based on the Bill and 
Melinda Gates (BMGF) Foundation Methods for Economic Evaluation Project (MEEP) 
guidelines(National Institute for Health and Clinical Excellence (NICE) International 
2014) and the WHO-CHOICE guidelines.(World Health Organization (WHO) 2003) 
Discounting was translated to a per diem instantaneous discount rate based on the 
formula:  
𝑇𝑇2013−2042 = � 𝑇𝑇𝑡𝑡(1 + 𝑟𝑟)(𝑡𝑡−2012/365)2042
𝑡𝑡=2013
 
 
Where r = discount rate, t = time, T = total costs or total DALYs accumulated per diem 
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 Input parameters 
Parameter Description Distribution Point 
Estimate 
SD alpha₸ beta₸ Source 
Case detection (surveillance and 
diagnostic) 
      
Population        
Total at risk  population (pop_ar)  100000    Assumption 
Percentage of patients in stage 1 Normal 32.50% 0.0325   PNLTHA(Progra
mme National de 
Lutte Contre La 
Trypanosomiase 
Humaine 
Africane 
(PNLTHA) 2013) 
Percentage of patients in stage 2 Normal 66.94% 0.0669   PNLTHA(Progra
mme National de 
Lutte Contre La 
Trypanosomiase 
Humaine 
Africane 
(PNLTHA) 2013) 
       
Passive surveillance       
Coverage rate for passive healthcare 
system 
      
NECT with CATT algorithm (2013) Beta 2.46%  2.46 97.54 PNLTHA(Progra
mme National de 
Lutte Contre La 
Trypanosomiase 
Humaine 
Africane 
(PNLTHA) 2013) 
Pentamidine, Fexinidazole with RDT 1 
algorithm (2016) 
Fixed, Beta** 7.38%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
Fexinidazole (both stages) with RDT 1 
algorithm (2019) 
Fixed, Beta** 15.99%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
Oxaboroles with RDT algorithm 2 (2019) Fixed, Beta** 24.60%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
Cost annual surveillance passive Normal $1.35 0.1350    
       
Active surveillance        
Truck teams Cost annual surveillance 
start up active pp  
Normal $0.42 0.0420  
 
Lutumba 
2007(Lutumba, 
Makieya, et al. 
2007a) 
Truck teams Cost annual surveillance 
maintenance active pp  
Normal $1.55 0.1549  
 
Lutumba 
2007(Lutumba, 
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Makieya, et al. 
2007a) 
Motorbike teams Cost annual 
surveillance start up active pp  
Normal $0.21 0.0205   WHO(World 
Health 
Organization 
(WHO) n.d.) 
Motorbike teams Cost annual 
surveillance maintenance active pp 
Normal $0.89 0.0886   WHO(World 
Health 
Organization 
(WHO) n.d.) 
       
Coverage rate for active screening 
programs 
      
NECT with CATT algorithm (2013) Beta 80.25%  80.25 19.75 PNLTHA(Progra
mme National de 
Lutte Contre La 
Trypanosomiase 
Humaine 
Africane 
(PNLTHA) 2013) 
Pentamidine, Fexinidazole with RDT 1 
algorithm (2016) 
Fixed, Beta** 85.25%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
Fexinidazole (both stages) with RDT 1 
algorithm (2019) 
Fixed, Beta** 85.25%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
Oxaboroles with RDT algorithm 2 (2019) Fixed, Beta** 85.25%    DNDi 2014 
Annual 
Report(Drugs for 
Neglected 
Diseases 
initiative (DNDi) 
2014a) 
       
Diagnostics       
CATT algorithm sensitivity Beta 84 NA 84 16 Mitashi, 
2012(Patrick 
Mitashi et al. 
2012)  
RDT 1 algorithm sensitivity Beta 96.13 NA 96.13 3.87 Buscher 
2014,(Büscher et 
al. 2014)  
Buscher 
2013(Büscher et 
al. 2013) 
Jamonneau 
2015(Jamonneau 
et al. 2015) 
RDT 2 algorithm sensitivity Beta 96.13 NA 96.13 3.87 
       
CATT algorithm cost Normal 6.17    Lutumba 
2005(Lutumba, 
Robays, Miaka, et 
al. 2005b)  
WHO Technical 
report 
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1998,(World 
Health 
Organization 
(WHO) 1998)  
Lutumba 
2006(Lutumba et 
al. 2006) 
RDT 1 algorithm cost Normal 3.86    Lutumba 
2006,(Lutumba et 
al. 2006)  
Ndung’u 
2015(Ndung’u 
2015) 
FIND(FIND n.d.) 
RDT 2 algorithm cost Normal 0.5 0.05   FIND(FIND n.d.) 
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reatment       
Cost treatment - pentamidine (stage 1), 
per diem 
Gamma 4.50  1 4.50 Shaw & 
Cattand 
2001,(Shaw 
& Cattand 
2001) 
Politi 
1995(Politi et 
al. 1995) 
Cost treatment - NECT(stage 2), per diem Gamma 30.89  1 30.89 Simarro 2011 
and 2012(P P 
Simarro et 
al. 2012; 
Simarro et 
al. 2011) 
Cost treatment - fexinidazole ) per diem Gamma 5.00  1 5 DNDi 
(Drugs for 
Neglected 
Diseases 
initiative 
(DNDi) 
2014b) 
Cost treatment - oxaborole per diem Gamma 2.00  1 2 DNDi 
(DNDi 2013, 
oral 
communicatio
n, 01 October 
2013) 
       
Days Treatment       
Days treatment  - pentamidine Normal 12 0.12   Shaw & 
Cattand 
2001, (Shaw 
& Cattand 
2001) Politi, 
1995(Politi et 
al. 1995) 
Days treatment – NECT Normal 14 0.1   Priotto, 
2009(Priotto 
et al. 2009)  
Days treatment – fexinidazole Normal 10 0.100   Tarral, 
2014(Tarral 
et al. 2011) 
Days treatment – oxaborole Normal 1.00 0.100   DNDi(Drug
s for 
Neglected 
Diseases 
initiative 
(DNDi) 
2014b) 
       
Death rates (Stage 2 only)       
Death rate – NECT Beta 0.0019 0.9982   Priotto 
2009(Priotto 
et al. 2009) 
Death rate – fexinidazole Fixed 0.00    Tarral, 
2014(Tarral 
et al. 2011) 
Death rate – oxaborole Fixed 0.00    DNDi 2014 
Annual 
Report(Drug
s for 
Neglected 
Diseases 
initiative 
(DNDi) 
2014a)*** 
       
Recovery rates (Stage 2 only)       
Recovery rate – NECT Beta 0.03836  0.0384 0.9616 Priotto 
2009(Priotto 
et al. 2009)  
Recovery rate – fexinidazole Beta 0.02740  0.0274 0.9726 Tarral, 
2014(Tarral 
et al. 2011) 
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Recovery rate – oxaborole Beta 0.002740  0.0027 0.9973 DNDi(Drug
s for 
Neglected 
Diseases 
initiative 
(DNDi) 
2014b) 
       
Hospitalisation       
Cost hospitalisation treatment  Gamma $ 24.89  1 24.89 WHO(Worl
d Health 
Organizatio
n (WHO) 
n.d.) 
       
Adverse Events        
Days AE treatment stage 1, stage 2 Normal 1.50 0.150   Assumption  
       
AE st1 (%) Beta 0.0001 0.0000 0.01 99.99 WHO(Worl
d Health 
Organizatio
n (WHO) 
n.d.) 
AE st 2 (%) Beta 0.14 0.0140 14 86.00 WHO(Worl
d Health 
Organizatio
n (WHO) 
n.d.) 
       
Vector control input parameters       
Km2  pop_ar/29.3     
       
Tiny Targets       
VC unit  per km2- Tiny Targets  6.2 0.62   Shaw 
2015(Shaw 
et al. 2015) 
VC annual startup per unit per  km2 – 
Tiny Targets 
Gamma $13.8 NA 1 13.8 Shaw 
2015(Shaw 
et al. 2015) 
VC annual maintenance cost per unit per 
km2– Tiny Targets 
Gamma $13.8 NA 1 13.8 Shaw 
2015(Shaw 
et al. 2015) 
Vector mortality related to VC- All 
Targets 
Beta 5.49 NA 5.49 94.51 Stone & 
Chitnis, 
2015(Chris 
M. Stone & 
Chitnis 2015) 
       
Disability weights       
Stage 1 Fixed 0.191    Hackett, 
2014(Hacket
t et al. 2014) 
Stage 2 Fixed 0.81    Hackett, 
2014(Hacket
t et al. 2014) 
*detailed descriptions of costs and costing functions available in Appendix 
**Increases in coverage for new technologies based on baseline coverage (beta distribution)multiplied by a ‘fixed’ number 
assumed to improve coverage based on assumption that oral treatments combined with new RDTs will be able to reach patients 
at the village level – refer to Appendix for further description 
***Target product profile expected to be safe and non-toxic for SCYX-7158 
****Includes nurse time and hospital bed, hospitalization costs estimated from Shaw & Cattand 2001, Politi 1995, Simarro 
2012, and Robays 2008 
₸alpha  and beta are the parameter properties required for a beta distribution 
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C.2.1 Cost Functions and Parameterization  
Cost Functions  
Costs were pooled when more than one data point was found and a distribution was 
assigned to take the cost variability into account. When only one point estimate was 
found for a cost, 10% of the point estimate was assumed to be the standard deviation. 
In regards to equipment and vehicles, capital costs were taken from published 
estimates and therefore no annuititization was performed as it was assumed that this 
was taken into consideration by the authors who published the estimates. It is also 
important to note that each strategy involves different technologies during different 
times in the time horizon and the input parameters that were associated with each 
intervention were programmed in the model to switch accordingly. 
 
Case Detection (Surveillance and Diagnostics) 
Cost functions were developed to calculate case detection per diem based on the surveillance 
strategy and diagnostic algorithm for each time horizon. Active surveillance in high 
transmission areas was calculated at a per diem rate annually in High transmission areas, 
whereas it was calculated bi-annually in moderate transmission areas. In low transmission 
areas, the costs of active surveillance were excluded.  
The calculations for surveillance were built on assumptions of coverage, where the coverage 
rates for passive and active surveillance for stages 1 and 2 are defined below: 
total_cov_p1=tech_cov_p*(per_p1*cov_p)*sens 
total_cov_p2=tech_cov_p*(per_p2*cov_p)*sens 
total_cov_a=(1+tech_cov_a)*(cov_a)*sens 
 
rate1_p1 =  -log (1-(total_cov_p1))/365 
rate2_p1 = -log (1-(total_cov_p2))/365 
rate_a1 = -log (1-(total_cov_a))/365 
 
Data referring to active and passive surveillance programs were calculated into per person per 
year, and per person for ½ year for bi-annual programs and then developed into various cost 
functions and inputted into the model. Passive costs included the total cost of creating a health 
Centre including: building construction, medical and lab supply, and CATT reagents, training, 
and other equipment.(Lutumba, Makieya, et al. 2007a) 
Start-up costs were calculated at the beginning of the model on a per person basis, and then a 
maintenance cost function was calculated annual (high risk transmission_, bi-annually 
(moderate risk transmission) or not at all (low risk transmission) depending on the risk 
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transmission area being modelled. Case detection and surveillance costs estimated include 
(Building overhead costs, Personnel, Medical and lab supply (includes CATT reagents), 
Essential Drugs, Stationary, Vehicle, operation and maintenance and other operating input) It 
was assumed that active surveillance campaigns have some component of community 
sensitization included and that passive infrastructure already exists to some extent, so no initial 
start-up cost for building passive health care infrastructure was included. 
Annual surveillance start-up = surv_cost_startup*pop_ar 
Annual active surveillance maintenance = (surv_cost_pp_mob*pop_ar*rate_a1) + 
(cost_dtest*pop_ar*rate_a1) + 
 
Annual passive surveillance maintenance = (surv_cost_passive*pop_ar*(rate1_p1 + 
rate2_p1)) 
 
There have been several studies conducted regarding the diagnostic accuracy of HAT 
diagnostic tests. For this model, only the sensitivity estimates are included, and the results are 
also listed in Table 1. . The CATT algorithm accuracy includes the CATT, dilution, parasitology, 
mini Anion Exchange Centrifugation Technique (mAECT)  and LNP(Patrick Mitashi et al. 2012) 
while the RDT algorithms 1 was based on recent estimates from HAT Sero-K Set test(Büscher 
et al. 2013; Büscher et al. 2014; Jamonneau et al. 2015) and parasitology confirmation for RDT 1 
using LAMP. The sensitivity of the RDT algorithms was based on the HAT Sero-K Set test 
alone.(Büscher et al. 2013; Büscher et al. 2014; Jamonneau et al. 2015) 
Parameter Description Short name Distribution  Point 
Estimate 
SD alpha  beta  
Population        
Total at risk  population pop_ar*  100000    
Percentage of patients detected in stage 1 per_p1 Normal 32.50% 0.0325   
Percentage of patients detected in stage 2 per_p2 Normal 66.94% 0.0669   
       
Passive surveillance       
Coverage rate for passive healthcare 
system 
cov_p Beta 2.46%  2.46 97.54  
Coverage rate for new technology for 
passive screening  
 Fixed     
NECT with CATT algorithm tech_cov_p Fixed 1*2.46%    
Pentamidine, Fexinidazole with RDT 1 
algorithm 
tech_cov_p Fixed 3*2.46%    
Fexinidazole (both stages) with RDT 1 
algorithm 
tech_cov_p Fixed 6.5*2.46%    
Oxaboroles with RDT algorithm 2 tech_cov_p Fixed 10*2.46%    
Cost annual surveillance passive surv_cost_passive Normal  $1.35  0.1350     
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There are three main diagnostic algorithms that are used in the model and listed in the 
manuscript. The cost of the CATT algorithm included the average cost of CATT testing 
including fees for reagents ($0.60),(Lutumba, Robays, Miaka, et al. 2005a; World 
Health Organization (WHO) 1998) cost of fresh blood examination (FBE) 
($0.36),(Lutumba et al. 2006) mAECT ($4.87),(Lutumba et al. 2006) and lumbar 
puncture ($0.33).(Lutumba et al. 2006) Costs associated with the current rapid 
diagnostic test was based on the reported cost of RDT SD Bioline HAT($0.50),(FIND 
n.d.)  with the additional cost of FBE and parasitological screening and staging 
confirmation with LAMP ($3.00).(Ndung’u 2015) It was assumed that the future RDT 
would be able to diagnose and stage HAT all in one test, so the only expected expense 
would be the cost of the diagnostic test (0.50) similar to something like RDT SD Bioline 
Active surveillance       
Truck teams Cost annual surveillance 
start up active pp  
surv_cost_startup Normal  $0.42  0.0420    
Truck teams Cost annual surveillance 
maintenance active pp  
surv_cost_pp_mob Normal  $1.55  0.1549    
Motorbike teams Cost annual 
surveillance start up active pp  
surv_cost_startup Normal  $0.21  0.0205   
Motorbike teams Cost annual 
surveillance maintenance active pp 
surv_cost_pp_mob Normal  $0.89  0.0886   
          
Coverage rate for active screening 
program with Mobile teams 
cov_a Beta 80.25% 13.9000 80.25 19.75  
Coverage rate for new technology for 
active screening (%) (0, 5) 
      
NECT with CATT algorithm  tech_cov_a Fixed 0    
Pentamidine, Fexinidazole with RDT 1 
algorithm; Fexinidazole (both stages) 
with RDT 1 algorithm; Oxaboroles with 
RDT algorithm 2 
tech_cov_a Fixed 80.25%+5%    
       
Diagnostics       
CATT algorithm sensitivity sens Beta 84 NA 84 16 
RDT 1 algorithm sensitivity sens Beta 96.13 NA 96.13 3.87 
RDT 2 algorithm sensitivity sens Beta 96.13 NA 96.13 3.87 
       
CATT algorithm cost cost_dtest Normal 6.17    
RDT 1 algorithm cost cost_dtest Normal 3.86    
RDT 2 algorithm cost cost_dtest Normal 0.5 0.05   
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HAT.(FIND n.d.) In regards to the diagnostic test accuracy, sensitivity estimates for 
diagnostic tests for the CATT algorithm were taken from the published literature.(P 
Mitashi et al. 2012) In addition, estimates regarding the diagnostic accuracy of the 
rapid diagnostic were taken from a recent publication by Buscher et al,(Büscher et al. 
2014) It was assumed that the current RDT algorithm and future RDT algorithm would 
be equally accurate. 
*The at risk population (ar_pop) in the model was approximately 100,000. This was based on the fact that 82,500 people 
were in the larger population with a smaller group of people migrating in from the high risk area yielding a total 
population of 100,000 on average. 
 
Treatment 
Treatment cost functions included the cost of treatment and transportation costs (when 
available), also the health resource utilization (E.g. nurse time, hospital bed, etc.) by 
treatment regimen. All related inputs are provided in Table 2. . Costs were calculated 
into per patient per diem costs.  
 
Total treatment costs = (r1*Ahb*s1c) +( r2*Rhb*s2c) +( r1*Ah*s1c) +( r2*Rh*s2c)  
 
Where, 
 
s1c =(s1_days*s1_tx_cost)+( s1_days*s1_hosp_cost) + 
(s1_probAE*s1_days_AE*s1_hosp_cost) 
s2c =(s2_days*s2_tx_cost) +(s2_days*s2_hosp_cost )+ 
(s2_probAE*s2_days_AE*s2_hosp_cost)   
Note: refer to ‘Model’ section for further details regarding Ahb, Rhb, Ah, and Rh. When 
active surveillance is on in the model active, it is assumed to include passive coverage 
and r1 and r2 = rate_a1; while when passive detection is on only in the model, r1 
=rate1_p and r2= rate2_p. Refer to the ‘Case Detection and surveillance’ section for 
further details regarding rate_a1.  
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Treatment Short Name Distribution Point 
Estimate 
SD Alpha Beta 
Cost treatment - pentamidine (stage 1) s1_tx_cost Gamma 4.50  1 4.50 
Cost treatment – NECT (stage 2) s2_tx_cost Gamma 30.89  1 30.89 
Cost treatment - fexinidazole (stage 1 
and/or 2) 
s1_tx_cost,s2_tx_cost Gamma 5.00  1 5 
Cost treatment - oxaborole (stage 1 
and/or 2) 
s1_tx_cost, s2_tx_cost Gamma 2.00  1 2 
       
Days Treatment       
Days treatment  - pentamidine s1_days Normal 12 0.12   
Days treatment – NECT s2_days Normal 14 0.1   
Days treatment – fexinidazole s1_days,  s2_days Normal 10 0.100   
Days treatment – Oxaborole s1_days,  s2_days Normal 1.00 0.100   
       
Death rates (Stage 2 only)       
Death rate – NECT mu_t  Beta 0.0019 0.9982   
Death rate – fexinidazole mu_t  Fixed 0.00    
Death rate – Oxaborole mu_t Fixed 0.00    
       
Recovery rates (Stage 2 only)       
Recovery rate – NECT r3 Beta 0.03836  0.03836 0.96164 
Recovery rate – fexinidazole r3 Beta 0.02740  0.02740 0.97260 
Recovery rate – Oxaborole r3 Beta 0.002740  0.00274 0.99726 
       
Hospitalisation         
Cost hospitalisation treatment  s1_hosp_cost,  s2_hosp_cost, Gamma $ 24.89    1 24.89 
         
Adverse Events         
Days AE treatment stage 1, stage 2 s1_days_AE,s2_days_AE Normal 1.50 0.150     
       
AE st1 (%) s1_probAE Beta 0.0001 0.0000 0.01 99.99  
AE st 2 (%) s2_probAE Beta 0.14 0.0140 14 86.00  
 
Vector Control 
Start-up costs for vector control were calculated upfront while maintenance costs were 
calculated on a per diem basis in the model and totaled in the end. It was assumed that vector 
control maintenance occurred annually. 
The sources for costs related to vector control were taken primarily from 2 recent publications 
by Shaw and colleagues.(Shaw et al. 2015; Shaw et al. 2013) Annual Start-up costs per km2’ for 
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vector control were calculated upfront as capital investments, while maintenance costs were 
calculated on a per diem basis in the model and totaled in the end.  
The annual unit costs for both large and tiny targets are provided in Table 3. The cost function 
for vector control in the model was calculated as follows: 
Vector Control Total Startup cost = (km2* vc_startup_cost *vc_units) 
Vector Control Maintenance = (km2*vc_maint_cost *vc_units) 
 
The total start-up cost for the large targets was based on the assumption that targets were used 
per km2 at a cost of $10.00 each and additional services related to starting a large target program 
would be $118.88 for a total of $128.88 per unit per km2 per target. Assuming that on average 
10 large targets are deployed per km2, this would be a total of $1288.80 in USD 2013. 
Maintenance fees for large targets were also based on estimates from Shaw et al,(Shaw et al. 
2013) where annual cost for 4 and 10 traps per km were reported as $222 and $556 respectively, 
resulting in an annual maintenance cost of approximately $55.60 per km2 per unit. In regards 
to tiny targets, start-up fees including expenditures related to preliminary surveys, 
sensitization, trap monitoring, target maintenance and office support resulting in a cost of 
$85.40 per km2 (including cost of targets, 1.1 USD each), or $13.8 per km2 per tiny target where 
there are approximately 6.2 targets per km2 (1551/250km2).(Shaw et al. 2015) Costs for annual 
maintenance of the vector control program for tiny targets were assumed to remain the same 
as setting up the program as indicated by experts in the field.(Shaw et al. 2015) (personal 
communication, Dr. Alexandra Shaw) It should be noted that that different target densities and 
deployment rates will be used in real-world settings,(Courtin et al. 2015) resulting in variations 
in targets used per km2 and prices per target as negotiated by national programs. However, the 
current field work suggests that $85.4 is likely to remain a representative average cost per km2 
across sub-Saharan Africa. (personal communication, Dr. Alexandra Shaw)  In the model the 
annual costs are divided by 365 to yield a per diem cost. 
Vector control (VC) Short Name Distribution Point 
Estimate 
SD Alpha Beta 
Km2 Km2  pop_ar/29.3    
Large targets       
VC unit - Large Targets vc_units Normal 10.000  1.0000     
VC start-up per km2 - Large Targets vc_startup_cost  Gamma $128.88 NA  1 128.88  
VC maintenance cost - Large Targets vc_maint_cost Gamma $55.6 NA  1 55.60 
       
Tiny Targets       
VC unit  per km2- Tiny Targets vc_units  6.2 0.62   
VC startup per unit per  km2 – Tiny Targets vc_startup_cost  Gamma  $13.8 NA 1 13.8  
VC maintenance cost per unit per km2– Tiny 
Targets 
vc_maint_cost Gamma  $13.8 NA 1 13.8  
Vector mortality related to VC- All Targets mu_vec Beta 5.49  NA 5.49  94.51 
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C.3 Rationale for one-way sensitivity analysis 
Two additional situations were modelled to observe the long-term outcomes if 
fexinidazole were to reach the market for treatment of both stages of HAT in 2016, and 
also what the implications would be if oxaborole failed to reach the market in 2019.  
These additional analyses were run for all three transmission areas. Two specific 
situations were run through the model to specifically evaluate implications in low risk 
transmission settings. For instance, currently WHO does make consideration for 
surveillance in low transmission areas(World Health Organization (WHO) 2013c) yet 
the authors wanted to consider the impact that adding active surveillance in such 
settings would have on elimination targets and cost-effectiveness. Additionally, the 
base case analysis included improvements in the coverage of the passive healthcare 
systems that were based on the assumption that the ease of deployment would 
increase the availability and self-seeking patterns of symptomatic individuals 
suffering from Gambiense HAT.   
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 Modelling 
C.4.1 Description 
 
The model used is based on the version without an animal reservoir as described in Stone & 
Chitnis 2015. Briefly, the equations describing the changes of numbers in human compartments 
(see main text) are given by: 
 𝑑𝑑𝑆𝑆ℎ1
𝑑𝑑𝑡𝑡
 =βh1 + r3Th1– μhSh1 – 𝑏𝑏 𝑓𝑓 𝜃𝜃ℎ1,1 𝐼𝐼𝑣𝑣1(𝑡𝑡)
𝑁𝑁ℎ1
 Sh1(t),  
 𝑑𝑑𝐼𝐼ℎ1
𝑑𝑑𝑡𝑡
 =𝑏𝑏 𝑓𝑓 𝜃𝜃ℎ1,1 𝐼𝐼𝑣𝑣1(𝑡𝑡)
𝑁𝑁ℎ1
 Sh1(t) – (μh + η) Ih1,  
 𝑑𝑑𝐴𝐴ℎ1
𝑑𝑑𝑡𝑡
= η Ih1 – (μh+s1+r)Ah1,  
 𝑑𝑑𝑅𝑅ℎ1
𝑑𝑑𝑡𝑡
 = s1Ah1– (μh+μs1+r)Rh1,  
 𝑑𝑑𝑇𝑇ℎ1
𝑑𝑑𝑡𝑡
 = rAh1 + rRh1- (μh+ μt+r3) Th1,   
 
 𝑑𝑑𝑆𝑆ℎ2
𝑑𝑑𝑡𝑡
 = βh2 + r3Th2– μhSh1 –b f ( 𝜃𝜃ℎ2,1𝐼𝐼𝑣𝑣1(𝑡𝑡)
𝑁𝑁ℎ2
+ 𝜃𝜃ℎ,2 𝐼𝐼𝑣𝑣2(𝑡𝑡)
𝑁𝑁ℎ2
) Sh2(t),   
 𝑑𝑑𝐼𝐼ℎ2
𝑑𝑑𝑡𝑡
 = b f ( 𝜃𝜃ℎ2,1𝐼𝐼𝑣𝑣1(𝑡𝑡)
𝑁𝑁ℎ2
+ 𝜃𝜃ℎ,2 𝐼𝐼𝑣𝑣2(𝑡𝑡)
𝑁𝑁ℎ2
)Sh2(t)  – (μh + η) Ih2,  
 𝑑𝑑𝐴𝐴ℎ2
𝑑𝑑𝑡𝑡
= η Ih2 – (μh+s1+r)Ah2,  
 𝑑𝑑𝑅𝑅ℎ2
𝑑𝑑𝑡𝑡
 = s1Ah2– (μh+μs1+r)Rh2,  
 𝑑𝑑𝑇𝑇ℎ2
𝑑𝑑𝑡𝑡
 = rAh2 + rRh2- (μh+ μt+r3) Th2.   
 
The probability of biting a human for Nv1 is: 
𝜃𝜃ℎ,1 = 𝜎𝜎ℎ(𝑁𝑁ℎ1 + (1 − 𝜉𝜉)𝑁𝑁ℎ2)𝜎𝜎ℎ(𝑁𝑁ℎ1 + (1 − 𝜉𝜉)𝑁𝑁ℎ2) + 𝜎𝜎𝑎𝑎1𝑁𝑁𝑎𝑎1 
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where σi represents the relative preference for human and non-human host types. The 
probability of biting a human for Nv2 is:  
𝜃𝜃ℎ,2 = 𝜎𝜎ℎ𝜉𝜉𝑁𝑁ℎ2𝜎𝜎ℎ𝜉𝜉𝑁𝑁ℎ2 + 𝜎𝜎𝑎𝑎2𝑁𝑁𝑎𝑎2 
The forces of infection on vectors are: 
 
Λv1 = 𝑐𝑐𝑐𝑐𝜃𝜃ℎ1,1 𝐴𝐴ℎ1𝑁𝑁ℎ1 𝑆𝑆𝑣𝑣1 +  𝑐𝑐𝑐𝑐𝜃𝜃ℎ2,1 𝐴𝐴ℎ2𝑁𝑁ℎ2 𝑆𝑆𝑣𝑣1 + 𝑐𝑐𝑎𝑎1𝑐𝑐𝜃𝜃𝑎𝑎,1 𝐴𝐴𝑎𝑎1𝑁𝑁𝑎𝑎1 𝑆𝑆𝑣𝑣1= f 𝑐𝑐𝑎𝑎1𝜎𝜎𝑎𝑎1𝐴𝐴𝑎𝑎1+𝑐𝑐 𝜎𝜎ℎ(𝐴𝐴ℎ1+(1−𝜉𝜉)𝐴𝐴ℎ2)𝑁𝑁𝑎𝑎1𝜎𝜎𝑎𝑎1+𝜎𝜎ℎ(𝑁𝑁ℎ1+(1−𝜉𝜉)𝑁𝑁ℎ2) 𝑆𝑆𝑣𝑣1 
Λv2 = 𝑐𝑐𝑐𝑐𝜃𝜃ℎ,2 𝐴𝐴ℎ2𝑁𝑁ℎ2 𝑆𝑆𝑣𝑣2 + 𝑐𝑐𝑎𝑎2𝑐𝑐𝜃𝜃𝑎𝑎,2 𝐴𝐴𝑎𝑎2𝑁𝑁𝑎𝑎2 𝑆𝑆𝑣𝑣2= f 𝑐𝑐𝑎𝑎2𝜎𝜎𝑎𝑎2𝐴𝐴𝑎𝑎2+𝑐𝑐 𝜎𝜎ℎ𝜉𝜉 𝐴𝐴ℎ2𝑁𝑁𝑎𝑎2𝜎𝜎𝑎𝑎2+𝜎𝜎ℎ𝜉𝜉 𝑁𝑁ℎ2 𝑆𝑆𝑣𝑣2. 
 
The ordinary differential equations describing changes in the vector compartments 
(with i indicating population 1 or 2) are: 
𝑑𝑑𝑆𝑆𝑣𝑣𝑣𝑣
𝑑𝑑𝑡𝑡
 = 𝛽𝛽𝑣𝑣𝑣𝑣(𝑡𝑡)- μvSvi(t) - Λvi(𝑡𝑡) 
𝑑𝑑𝑑𝑑𝑣𝑣𝑣𝑣
𝑑𝑑𝑡𝑡
 = Λvi(𝑡𝑡) − (𝜇𝜇𝑣𝑣 + 𝑣𝑣𝑒𝑒)𝐸𝐸𝑣𝑣𝑣𝑣  
𝑑𝑑𝐼𝐼𝑣𝑣𝑣𝑣
𝑑𝑑𝑡𝑡
 = 𝑣𝑣𝑒𝑒𝐸𝐸𝑣𝑣𝑣𝑣 − 𝜇𝜇𝑣𝑣𝐼𝐼𝑣𝑣𝑣𝑣 
See Stone & Chitnis 2015(Christopher M. Stone & Chitnis 2015) for a complete 
description of the model, how the model was fit to low, moderate, and high 
transmission foci, and a table of transmission parameter values and ranges used in the 
model. 
C.4.2 Predictive accuracy 
We also have compared our model with the annual case numbers reported since 2012. 
The estimated sample is based on a combination of low, moderate and high 
transmission risk settings where it was assumed that 63% of cases were stage 1 and 
37% of cases were stage 2. It was assumed that the percentage of cases reported from 
high, moderate and low foci were 9%, 25% and 66% respectively. This distribution is 
equivalent to the at risk transmission areas.(Jose R Franco et al. 2014) The mean results 
of ‘Strategy A. Control’ forecast real-world data with a R2 = 0.85 when fitted to a linear 
function, and  R2 = 0.98 when fitted to a polynomial function as seen in Figure 1 below.  
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Figure 1.  Correlation of actual reported cases to case forecasted by Stone & Chitnis model 
Estimated T.b. gambiense cases reported by the WHO in 2012, 2013, 2014 and 2015. Mean number of cases 
from ‘Strategy A - Control’ 
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 Results (Strategies A thru E) 
C.5.1 Cost-effectiveness results, base case 
A. Mean incremental CE plane and 
efficiency frontier B. Incremental CE planes (PSA) 
High risk transmission area High risk transmission area 
 
 
Moderate risk transmission area Moderate risk transmission area 
 
 
Low risk transmission area Low risk transmission area 
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C.5.2 One-way Sensitivity Analysis (OWSA) 
C.5.2.1. Sensitivity Analysis Results 
Parameter variation from Base case analysis 
 
Summary of changes relative to base case analysis  
(ICERs at cost /DALY averted*) 
One-way sensitivity analysis    
Lower range , Upper range  
Low Moderate High 
Lower range Upper range Lower range Upper range Lower range Upper range 
1. Discount rate 
(0%, 5%) 
Strategy D - $150 
Strategy E - $1,550 
Strategy D - $167 
Strategy R - $1991 
Strategy E - $1,764 Strategy E - $2044 Strategy E - $390 Strategy E - $385 
2. Vector control mortality rate 
 (1%, 10%) 
Strategy D -   $160 
Strategy E - $6,477 
Strategy D - $160 
Strategy E - $1290 
Strategy E - $7,310 Strategy E - $1447 Strategy E - $1,971 Strategy E - $244 
3. Vector control costs (annual maintenance) per unit/ km2 
($11.30 , $16.13) 
Strategy E - $1,509 Strategy E - $2,117 Strategy E - $1,248 Strategy E - $1,791 Strategy E - $309 Strategy E - $469 
4. Low transmission – coverage rates of new technologies in 
passive surveillance  
      
a. Pentamidine (stage 1), fexinidazole (stage 2) 
(~3%, 30%) 
Strategy D -   $158 
Strategy E - $1,630 
Strategy C - $148 
Strategy E - $1,508 
NA NA NA NA 
b. Fexinidazole (both stages) 
(~3%, 30%) 
Strategy D -   $144 
Strategy E - $1,812 
Strategy C - $33 
Strategy D - $33 
Strategy E - $1,735 
NA NA NA NA 
c. Oxaborole (both stages)  
(~3%, 45%) 
Strategy B - $976 
Strategy C -  $216 
Strategy D - $1,544 
NA NA NA NA 
5. Low transmission – active surveillance (biennial  80%, annual 
80%)  
Strategy D - $123 
Strategy E - $15,930 
Strategy E - $9,899 NA NA NA NA 
Variation of strategies analysis    
6. Oral treatments  taken at home in 2019 Strategy D - $165  
Strategy E - $1,365 
Strategy E - $1,348 Strategy E -  $318 
7. Oxaborole not available in 2019** Strategy B - $1,689 Strategy B - $2,739 Strategy B - $683 
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8. Accelerating timeline for fexinidazole arriving on the market 
for both stages in 2016 
Strategy D - $163  
Strategy E - $1878 
Strategy E - $1,949 Strategy E - $400 
9. Active surveillance coverage – moderate and high    
i. 20% NA Strategy E - $317 Strategy E - $49 
ii. 40% NA Strategy E - $617 Strategy E - $108 
iii. 60% NA Strategy E - $1080 Strategy E - $205 
iv. 95% NA Strategy E - $2354 Strategy E - $98 
*Only incremental cost-effectiveness ratios (ICERs) of cost-effective strategies listed, dominated strategies not shown but are available in the Appendix, NA = not applicable, **Means that only strategies A, B and C are 
available 
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C.5.3 Sensitivity analysis - Probability full elimination reached in low risk transmission areas with additional surveillance 
Full elimination threshold set at less than 1 in a million. 
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C.5.4 Sensitivity analysis - Probability ‘London Declaration’* targets reached in 
high and moderate transmission areas with varying coverage levels for 
active surveillance 
 
*The London Declaration targets elimination, defined in concordance with the WHO Roadmap, as ‘elimination as a public health 
problem’ or less than 1 case in 10,000 population 
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C.5.5 Detailed Sensitivity analysis results 
1. Discount rate variation 
Strategy 
Total 
Mean 
Costs 
(USD) per 
person 
Total 
Mean 
DALYs 
per 
person 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
DISCOUNTING 0% DISCOUNTING 5% 
High risk transmission area  High risk transmission area  
Strategy D  $50  0.23 - Strategy D  $43  0.219   
Strategy C  $53  0.27  Dominated by D Strategy C  $44  0.238   Dominated by D  
Strategy E  $68 0.19  $390  Strategy E  $58  0.181   $385 
Strategy B  $97  0.20  Dominated by E Strategy B  $75  0.192   Dominated by E  
Strategy A  $155  0.40  Dominated by E Strategy A  $97  0.316   Dominated by E  
Moderate risk transmission area  Moderate risk transmission area  
Strategy D  $23  0.03 - Strategy D  $19  0.03 - 
Strategy C  $23  0.03 - Strategy C  $19  0.03  Dominated by D 
Strategy E  $41  0.02  $1,764 Strategy E  $36  0.02  $2,044  
Strategy A  $75  0.05  Dominated by E  Strategy B  $44 0.02  Dominated by E 
Strategy B  $144 0.02  Dominated by E  Strategy A  $46  0.04  Dominated by E 
Low risk transmission area  Low risk transmission area  
Strategy C  $3  0.05  Strategy C  $2  0.03  
Strategy A  $4  0.07  Dominated by C Strategy A  $2  0.04  Dominated by C 
Strategy D  $4  0.04  $150  Strategy D  $2  0.03  $167  
Strategy E  $54 0.01  $1,550 Strategy E  $37  0.01  $1'991 
Strategy B  $59 0.01  Dominated by E  Strategy B  $39 0.01  Dominated by E 
 
2. Vector control mortality  
Strategy 
Total 
Mean 
Costs 
(USD) per 
 
Total 
Mean 
DALYs 
per 
 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
Vector control mortality 1% Vector control mortality 10% 
High risk transmission area  High risk transmission area  
Strategy D $45 0.22  Strategy D $45 0.22  
Strategy C $47 0.25 Dominated by D Strategy C $47 0.25 Dominated by D 
Strategy E $73 0.21 $1'971 Strategy E $57 0.18 $244 
Strategy B $127 0.27 Dominated by E Strategy B $73 0.18 Dominated by E 
Strategy A $115 0.34 Dominated by E Strategy A $115 0.34 Dominated by E 
Moderate risk transmission area  Moderate risk transmission area 
Strategy D  $20  0.03 - Strategy D  $20  0.03 - 
Strategy C  $20  0.03  Dominated by D Strategy C  $20  0.03 - 
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Strategy E  $49  0.02  $7,310  Strategy E  $35 0.02  $1477  
Strategy A  $55  0.04  Dominated by E Strategy B  $42  0.02  Dominated by E 
Strategy B  $78  0.03  Dominated by E Strategy A  $55  0.04  Dominated by E 
Low risk transmission area  Low risk transmission area  
Strategy C  $2  0.035 - Strategy C  $2  0.04  
Strategy A  $3  0.045  Dominated by D Strategy A  $3  0.04  Dominated by C  
Strategy D  $3  0.031  $160  Strategy D  $3  0.03  $160  
Strategy E  $60  0.022  $6447 Strategy E  $33  0.01  $1290 
Strategy B  $60  0.030  Dominated by E  Strategy B  $36 0.01  Dominated by E  
 
3. Vector control costs 
Strategy 
Total 
Mean 
Costs 
(USD) per 
 
Total 
Mean 
DALYs 
per 
 
Incremental Cost-
effectiveness Ratio 
(ICER) 
Strategy 
Total 
Mean 
Costs 
(USD) 
 
 
Total Mean 
DALYs per 
person 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
Vector control maintenance costs $11.30 per unit/km2 ( ~$70 per km2) Vector control maintenance costs $16.13 per unit/km2 ( 
~$100 per km2) 
High risk transmission area  High risk transmission area  
Strategy D  $45  0.22 - Strategy D  $45  0.22 - 
Strategy C  $47  0.25  Dominated by D  Strategy C  $47  0.25  Dominated by 
D 
Strategy E  $58  0.18  $309  Strategy E  $65  0.18  $469  
Strategy B  $79  0.20  Dominated by E  Strategy B  $86  0.20  Dominated by E 
Strategy A  $115  0.34  Dominated by E  Strategy A  $115  0.34  Dominated by E 
Moderate risk transmission area  Moderate risk transmission area 
Strategy D  $20  0.03 - Strategy D  $20  0.03 - 
Strategy C  $20  0.03  Dominated by Strategy 
D  
Strategy C  $20  0.03  Dominated by 
Strategy D 
Strategy E  $35  0.02  $1'248  Strategy E  $41  0.02  $1'791  
Strategy B  $45  0.02  Dominated by Strategy 
E 
Strategy B  $52  0.02  Dominated by 
Strategy E 
Strategy A  $55  0.04  Dominated by Strategy 
E  
Strategy A  $55  0.04  Dominated by 
Strategy E 
Low risk transmission area  Low risk transmission area  
Strategy C  $2   $0.0353  - Strategy C  $2   $0.0353  - 
Strategy A  $3   $0.0445  Dominated by Strategy C Strategy A  $3   $0.0445  Dominated by 
Strategy C 
Strategy D  $3   $0.0309   $160  Strategy D  $3   $0.0309   $160  
Strategy E  $36   $0.0091   $1'509  Strategy E  $49   $0.0091   $2'117  
Strategy B  $38   $0.0100   Dominated by Strategy 
E 
Strategy B  $53   $0.0100   Dominated by 
Strategy E 
4. Coverage rate improvement related to new technologies in low transmission 
areas 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental Cost-
effectiveness Ratio 
(ICER) 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total 
Mean 
DALYs 
per 
 
Increme
ntal 
Cost-
effective
 
 
 
pentamidine-fexinidazole with RDT 1 in 2016, 1x pentamidine-fexinidazole with RDT 1 in 2016, 10x 
Strategy C  $2  0.04  Strategy A  $3  0.04  
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Strategy D  $2  0.03  $158  Strategy C  $4  0.03  $148  
Strategy A  $3  0.04  Dominated by D Strategy D  $5  0.03 Dominat
   Strategy E  $39 0.01  $1630 Strategy E  $41 0.01  $1508 
Strategy B  $45  0.01  Dominated by E Strategy B  $45  0.01  
   
fexinidazole-fexinidazole with RDT 2 in 2019, 1x fexinidazole-fexinidazole with RDT 2 in 2019, 10x 
Strategy C  $1  0.04 - Strategy A  $3  0.04 - 
Strategy A  $3  0.04  Dominated by C Strategy D  $3  0.03  $33  
Strategy D  $3  0.03  $144  Strategy C  $3  0.03  $33  
Strategy E  $42  0.01  $1'812 Strategy E  $42 0.01  $1735 
Strategy B  $45 0.01  Dominated by E  Strategy B  $45 0.01  
   
oxaborole with RDT 2 in 2019, 1x oxaborole with RDT 2 in 2019, 15x 
Strategy D  $1  0.04 - Strategy C  $2  0.04 - 
Strategy C  $2  0.04  Dominated by D  Strategy A  $3  0.04  
   
Strategy A  $3  0.04  Dominated by D Strategy D  $4  0.03  $216  
Strategy B  $34  0.01 $976 Strategy E  $32  0.01  $1'544 
Strategy E  $45 0.01 Dominated by B Strategy B  $45  0.01  
Dominat
   5. Surveillance in low transmission  
Strategy 
Total 
Mean 
Costs 
(USD) per 
 
Total Mean 
DALYs per 
person 
Incremental Cost-
effectiveness Ratio 
(ICER) 
Strategy 
Total 
Mean 
Costs 
(USD) per 
 
Total 
Mean 
DALYs 
per 
 
Increm
ental 
Cost-
effecti
 
 
 
Biannual Annual 
Strategy C  $20  0.005 - Strategy C  $34  0.002 - 
Strategy D  $20  0.004  $123  Strategy D  $34  0.002  - 
Strategy E  $38 0.003  $15930 Strategy E  $37  0.002 $9899 
Strategy B  $49  0.003  Dominated by E  Strategy B  $49  0.002  
  
  
Strategy A  $59  0.006  Dominated by E Strategy A  $71  0.003  
  
 
 
6. Oral treatments taken at home in 2019 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental Cost-
effectiveness Ratio (ICER) 
High risk transmission areas 
Strategy D  $45   $0.224  - 
Strategy C  $46   $0.247   Dominated by D  
Strategy E  $58   $0.184   $318  
Strategy B  $82   $0.196   Dominated by E 
Strategy A  $115   $0.343   Dominated by E 
Moderate risk transmission areas 
Strategy D  $20  0.03  
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Strategy C  $20  0.03  Dominated by Strategy D 
Strategy E  $36  0.02  $1'348  
Strategy B  $48  0.02  Dominated by Strategy E 
Strategy A  $55  0.04  Dominated by Strategy E 
Low risk transmission areas 
Strategy C  $2  0.0353 - 
Strategy A  $3  0.0445 Dominated by C 
Strategy D  $3  0.0309  $165  
Strategy E  $33  0.0091  $1'365  
Strategy B  $45  0.0100  Dominated by Strategy 12  
 
7. Oxaborole fails to reach market (strategies D and E removed) 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental Cost-
effectiveness Ratio 
(ICER) 
High risk transmission areas 
Strategy C  $47  0.25  
Strategy B  $82 0.20 $683 
Strategy A  $115  0.34  
Moderate risk transmission areas 
Strategy C  $20  0.03 - 
Strategy B  $48  0.02 $2739  
Strategy A  $55  0.04 Dominated by B 
Low risk transmission areas 
Strategy C  $2  0.04 - 
Strategy A  $3  0.04  Dominated by C 
Strategy B  $45 0.01 $1689 
 
8. Accelerating timeline for fexinidazole arriving on the market for both stages 
in 2016  
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Incremental Cost-
effectiveness Ratio 
(ICER) 
High risk transmission areas 
Strategy D  $30  0.22 - 
Strategy C  $31  0.25  Dominated by D 
Strategy E  $46  0.18  $400 
Strategy B  $82 0.20  Dominated by E 
Strategy A  $115  0.34  Dominated by E 
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Moderate risk transmission areas 
Strategy D  $12  0.03  
Strategy C  $13  0.03  Dominated by D 
Strategy E  $30 0.02  $1949 
Strategy B  $48  0.02  Dominated by E  
Strategy A  $55  0.04  Dominated by E  
Low risk transmission areas 
Strategy C  $1.7  $0.034   
Strategy D  $2 .4  $0.030 163 
Strategy A  $3   $0.04  Dominated by D 
Strategy E  $42   $0.01   $1878 
Strategy B  $45   $0.01   Dominated by E  
9. Active surveillance coverage 
Moderate risk transmission areas High risk transmission areas 
Strategy 
Total 
Mean 
Costs 
(USD) per 
 
Total Mean 
DALYs per 
person 
Incremental 
Cost-
effectiveness 
Ratio (ICER) 
Strategy 
Total Mean 
Costs (USD) 
per person 
Total Mean 
DALYs per 
person 
Increme
ntal 
Cost-
effective
 
 
 
20%  
Strategy D  $4  0.15  Strategy D  $11  1.37  
Strategy C  $4  0.16  Dominated by D  Strategy C  $14  1.59  
   
Strategy A  $12  0.18  Dominated by D  Strategy A  $34  1.92  
    
Strategy E  $37  0.04  $317  Strategy E  $50  0.57  $49  
Strategy B  $41  0.04  Dominated by E Strategy B  $62  0.61  
   
40%  
Strategy D  $8  0.08  Strategy D  $21  0.65  
Strategy C  $8  0.09  Dominated by D  Strategy C  $24  0.80  
    
Strategy A  $26  0.10  Dominated by D  Strategy E  $50  0.38  $108  
Strategy E  $36  0.03  $617  Strategy B  $64  1.05  
    
Strategy B  $43  0.04  Dominated by E Strategy A  $70  0.41  
   
60%  
Strategy D  $13  0.05  Strategy D  $32  0.37  
Strategy C  $13  0.05  Dominated by D Strategy C  $34  0.45  
   
Strategy E  $36  0.03  $1'080  Strategy E  $53  0.27  $205  
Strategy A  $42  0.07  Dominated by E Strategy B  $76  0.29  
   
Strategy B  $45  0.03  Dominated by E  Strategy A  $91  0.62  
    
95%  
Strategy D  $31  0.02  Strategy D  $65  0.16  
Strategy C  $31  0.02  Dominated by D  Strategy C  $66  0.16  
    
Strategy E  $40  0.02  $2'354  Strategy E  $66  0.14  $98  
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Strategy B  $50  0.02  Dominated by E  Strategy B  $87  0.15  
   
Strategy A  $65  0.03  Dominated by E  Strategy A  $122  0.22  
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 Elimination results (Full results refer to Appendix C.6) 
C.6.1 Coverage results 
20% London 
Declaration 
     Full 
Elimination 
     
  Moderate 
 
  High 
 
  Moderate 
 
  High 
 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy A 0 0.01 0.08 0.00 0.00 0.01 0 0 0 0 0 0 
Strategy B 0.89 0.96 0.96 0.15 0.85 0.89 0 0.84 0.95 0 0.58 0.8 
Strategy C 0 0.01 0.09 0 0 0.10 0 0 0 0 0 0 
Strategy D 0 0.01 0.09 0 0 0.10 0 0 0 0 0 0 
Strategy E 0.90 0.96 0.96 0.25 0.86 0.88 0 0.85 0.95 0 0.64 0.84 
 
40% London 
Declaration 
     Full 
Elimination 
     
  Moderate 
 
  High 
 
  Moderate 
 
  High 
 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy A 0.01 0.43 0.62 0.00 0.20 0.38 0 0 0.01 0 0 0.08 
Strategy B 0.95 0.96 0.98 0.66 0.89 0.90 0 0.92 0.95 0 0.81 0.89 
Strategy C 0.01 0.58 0.83 0 0.38 0.41 0 0 0.04 0 0 0.26 
Strategy D 0.01 0.59 0.91 0 0.39 0.40 0 0 0.04 0 0 0.29 
Strategy E 0.95 0.97 1.00 0.76 0.88 0.89 0 0.92 0.95 0 0.84 0.88 
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60% London 
Declaration 
     Full 
Elimination 
     
  Moderate 
 
  High 
 
  Moderate 
 
  High 
 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy A 0.07 0.89 0.89 0.01 0.49 0.53 0 0.01 0.48 0 0.15 0.38 
Strategy B 0.46 0.91 0.91 0.87 0.91 0.91 0.09 0.94 0.96 0.02 0.89 0.91 
Strategy C 0.46 0.91 0.91 0.16 0.73 0.69 0 0.06 0.55 0 0.39 0.47 
Strategy D 0.49 0.97 0.97 0.16 0.80 0.72 0 0.06 0.56 0 0.40 0.49 
Strategy E 0.95 1.00 1.00 0.88 0.89 0.89 0.21 0.94 0.95 0.18 0.89 0.89 
 
 
80% London 
Declaration 
     Full 
Elimination 
     
  Moderate 
 
  High 
 
  Moderate 
 
  High 
 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy A 0.84 0.90 0.90 0.51 0.72 0.73 0 0.46 0.63 0 0.49 0.61 
Strategy B 0.98 1.00 1.00 0.91 0.92 0.92 0.52 0.95 0.96 0.67 0.91 0.92 
Strategy C 0.93 0.94 0.94 0.77 0.82 0.82 0 0.67 0.70 0.13 0.77 0.80 
Strategy D 0.98 0.99 0.99 0.82 0.82 0.81 0 0.68 0.71 0.14 0.79 0.80 
Strategy E 1.00 1.00 1.00 0.91 0.91 0.91 0.84 0.96 0.97 0.86 0.90 0.91 
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95% London 
Declaration 
     Full 
Elimination 
     
  Moderate 
 
  High 
 
  Moderate 
 
  High 
 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy A 0.91 0.91 0.91 0.74 0.80 0.81 0 0.65 0.69 0.17 0.72 0.77 
Strategy B 1.00 1.00 1.00 0.93 0.93 0.93 0.85 0.96 0.97 0.88 0.93 0.93 
Strategy C 0.99 1.00 1.00 0.90 0.88 0.88 0.61 0.83 0.86 0.80 0.84 0.84 
Strategy D 1.00 1.00 1.00 0.97 0.97 0.97 0.60 0.83 0.83 0.91 0.92 0.93 
Strategy E 1.00 1.00 1.00 0.97 0.97 0.97 0.96 0.98 0.98 0.91 0.92 0.93 
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 Preliminary results for 12 strategies for control and elimination of 
Gambiense HAT 
C.7.1 Description of all 12 strategies for control and elimination  
We have previously developed and reported on (Steinmann et al. 2015) 12 strategies for 
elimination  by combining existing and emerging technologies for Gambiense HAT (refer to 
Figure 1). The current approach for HAT case detection (Control - Strategy 1) relies on patients to 
self-report to local health centers (referred to as passive surveillance) and on active case finding 
done by teams that actively seek out patients living in remote areas (active surveillance). 
Diagnosis is done in public during in-village screening campaigns, and requires blood testing as 
well as a lumbar puncture to confirm the stage of disease. The current approved treatment for 
HAT on the WHO essential drug list for stage 1 of the disease is pentamidine while nifurtomix-
eflornithine combination therapy (NECT) is the first-line, parenteral treatment for patients who 
have progressed to stage 2.(World Health Organization (WHO) 2013c) Strategies 2 and 3 are 
essentially identical to control (Strategy 1) with regard to case detection and treatment; however, 
vector control is added with large targets (Strategy 2) or small targets (Strategy 3). Strategy 4 
begins with control (Strategy 1) until 2016 when case detection is switched to more flexible teams 
on motorbikes and detection of the disease is done using a rapid diagnostic test (RDT) algorithm 
with confirmation and staging done using the loop-mediated isothermal amplification (LAMP) 
technique(Steinmann et al. 2015) and the treatment for the second stage of disease switches to 10 
oral doses of fexinidazole (Refer to Box 1). The impact of adding on vector control is evaluated 
by the addition of large targets then switching to small targets (Strategy 5) or using small targets 
for the entire time period (Strategy 6). Strategy 7 initially is the exact same strategy as Strategy 4, 
up until 2019 when fexinidazole is considered for treatment of both stage 1 and 2 of the disease. 
Likewise, Strategy 8 is the same as Strategy 4 up until 2019, when a new compound, oxaborole, 
will be available for the single oral dose treatment of both stages. Strategies 9 through 12 replicate 
either strategy 7 or 8 by adding on vector control with large targets or switching to small targets. 
Based on recommendations from the WHO,(World Health Organization (WHO) 2013c) it was 
assumed that active screening was done annually in high transmission settings, bi-annually in 
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moderate transmission settings and no active screening component was included in the low risk 
transmission settings, where detection therefore relied solely on passive surveillance. 
Considerations were made for post-elimination activities in that it was assumed that after 
elimination, only passive surveillance would be implemented until 2042. Reinvasion of cases was 
not permitted after elimination was achieved in the model. 
C.7.2 Rationale for five main strategies in final manuscript 
The results from the CEA of the 12 strategies, listed in Table 4 below, demonstrated that all 
strategies including large targets were dominated (Strategies 2, 5, 9 and 10). In addition, strategies 
that on only included new technologies in 2016 (Strategy 4, 5 and 6) were always dominated by 
strategies that continually switched to a oral tablet for both stages. Furthermore, tiny targets with 
a one-time oral dose in 2019 (Strategy 12) always dominated or was equivalent to fexinidazole in 
combination with tiny targets. (Strategy 11) This highlighted that Strategies  7, 8 and 12 were the 
main comparators for strategies relating to cost-effectiveness. Results for the probability of 
elimination analysis also showed that they each exhibited characteristics highlight gains for or 
against elimination that were representative of the original 12. For this reason these four strategies 
were highlighted as the main options for the modelling in the manuscript, and strategy 1 and 3 
were included to represent the current status quo of what is used in the field for national sleeping 
sickness control programs. Strategies 1, 3, 7, 8 and 12 are referred to as ‘Strategy A’, ‘Strategy B’, 
‘Strategy C’, ‘Strategy D’ and ‘Strategy E’ respectively in the manuscript.  
 
Total mean costs, DALYs and incremental cost-effectiveness ratios (ICERs) 
Strategy in 
manuscript Strategy in preliminary analysis 
Incremental Cost-effectiveness Ratio 
(ICER) 
 High risk transmission area  
D 8.   New Tech 2016 & 2019 (oxa) - 
C 7.   New Tech 2016 & 2019 (fexi) Dominated by Strategy 8 (D)  
E 12. VC (tiny) + New Tech 2016 & 2019 (oxa) $386 per DALY averted* 
B 3.   VC (tiny) Dominated by Strategy 12 (E) 
A 1.   Control Dominated by Strategy 12 (E) 
 11. VC (tiny) + New Tech 2016 & 2019 (fexi) Extendedly dominated by Strategy 12 (E) 
 6.   VC (tiny) + New Tech 2016 Dominated by Strategy 12 (E) 
 4.   New Tech 2016 Dominated by Strategy 12 (E) 
 9.   VC (large) + New Tech 2016 & 2019 
 
Dominated by Strategy 12 (E) 
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 10. VC (large) + New Tech 2016 & 2019 
 
Dominated by Strategy 12 (E) 
 5.   VC (large) + New Tech 2016 Dominated by Strategy 12 (E) 
 2.   VC (large) Dominated by Strategy 12 (E) 
 Moderate risk transmission area  
D 8. New Tech 2016 & 2019 (oxa) - 
C 7. New Tech 2016 & 2019 (fexi) - 
E 12. VC (tiny) + New Tech 2016 & 2019 (oxa) $1509 per DALY averted* and ** 
   
B 3. VC (tiny) Dominated by Strategy 12 (E) 
A 1. Control Dominated by Strategy 12 (E) 
 11. VC (tiny) + New Tech 2016 & 2019 (fexi) $1509 per DALY averted* and ** 
 6. VC (tiny) + New Tech 2016 Dominated by Strategy 12 (E) 
 4. New Tech 2016 Dominated by Strategy 12 (E) 
 9. VC (large) + New Tech 2016 & 2019 (fexi) Dominated by Strategy 12 (E) 
 10. VC (large) + New Tech 2016 & 2019 
 
Dominated by Strategy 12 (E) 
 5. VC (large) + New Tech 2016 Dominated by Strategy 12 (E) 
 2. VC (large) Dominated by Strategy 12 (E) 
 Low risk transmission area  
C 7. New Tech 2016 & 2019 (fexi) - 
A 1. Control Dominated by Strategy 7 (C) 
D 8. New Tech 2016 & 2019 (oxa) $160 per DALY averted** 
E 12. VC (tiny) + New Tech 2016 & 2019 (oxa) $1’812 per DALY averted* 
B 3. VC (tiny) Dominated by Strategy 12 (E) 
 4. New Tech 2016 Dominated by Strategy 8 (D) 
 11. VC (tiny) + New Tech 2016 & 2019 (fexi) Dominated by Strategy 12 (E) 
 6. VC (tiny) + New Tech 2016 Dominated by Strategy 12 (E) 
 10. VC (large) + New Tech 2016 & 2019 
 
Dominated by Strategy 12 (E) 
 9. VC (large) + New Tech 2016 & 2019 (fexi) Dominated by Strategy 12 (E) 
 5. VC (large) + New Tech 2016 Dominated by Strategy 12 (E) 
 2. VC (large) Dominated by Strategy 12 (E) 
*relative to Strategy 7 (C), **relative to Strategy 8 (D)  
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 Probability of Elimination results (detailed) 
C.8.1 Base case analysis results 
London Declaration Targets (less than 1 in 10,000)   
 Low 
 
Moderate 
 
High 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy 1 (A) 0.05 0.05 0.05 0.84 0.90 0.90 0.51 0.72 0.73 
Strategy 2 0.97 0.98 0.99 0.98 1.00 1.00 0.91 0.93 0.93 
Strategy 3 (B) 0.97 0.98 0.99 0.98 1.00 1.00 0.91 0.92 0.92 
Strategy 4 0.05 0.10 0.16 0.94 0.95 0.95 0.76 0.81 0.81 
Strategy 5 0.98 0.99 0.99 1.00 1.00 1.00 0.92 0.92 0.92 
Strategy 6 0.98 0.99 0.99 1.00 1.00 1.00 0.92 0.92 0.92 
Strategy 7(C) 0.05 0.24 0.41 0.93 0.94 0.94 0.77 0.82 0.82 
Strategy 8 (D) 0.08 0.45 0.69 0.98 0.99 0.99 0.82 0.82 0.81 
Strategy 9 0.98 0.99 1.00 1.00 1.00 1.00 0.92 0.93 0.93 
Strategy 10 0.99 1.00 1.00 1.00 1.00 1.00 0.91 0.91 0.91 
Strategy 11 0.98 0.99 1.00 1.00 1.00 1.00 0.92 0.93 0.93 
Strategy 12 (E) 0.99 1.00 1.00 1.00 1.00 1.00 0.91 0.91 0.91 
 
Full elimination (less than 1 in 1,000,000)   
 Low 
 
Moderate 
 
High 
 
Intervention 2020 2030 2042 2020 2030 2042 2020 2030 2042 
Strategy 1 (A) 0.00 0.00 0.00 0.00 0.46 0.63 0.00 0.49 0.61 
Strategy 2 0.03 0.49 0.83 0.52 0.96 0.97 0.66 0.91 0.92 
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Strategy 3 (B) 0.03 0.49 0.83 0.52 0.95 0.96 0.67 0.91 0.92 
Strategy 4 0.00 0.00 0.00 0.00 0.66 0.70 0.13 0.75 0.79 
Strategy 5 0.03 0.54 0.84 0.84 0.97 0.97 0.87 0.92 0.92 
Strategy 6 0.03 0.54 0.84 0.84 0.97 0.97 0.87 0.92 0.92 
Strategy 7(C) 0.00 0.00 0.00 0.00 0.67 0.70 0.13 0.77 0.80 
Strategy 8 (D) 0.00 0.00 0.02 0.00 0.68 0.71 0.14 0.79 0.80 
Strategy 9 0.03 0.61 0.85 0.85 0.97 0.97 0.87 0.92 0.92 
Strategy 10 0.03 0.65 0.86 0.84 0.96 0.97 0.86 0.91 0.91 
Strategy 11 0.03 0.61 0.85 0.85 0.97 0.97 0.87 0.92 0.92 
Strategy 12 (E) 0.03 0.65 0.86 0.84 0.96 0.97 0.86 0.90 0.91 
 
C.8.2 One-way Sensitivity Analysis Results 
For the SA results, 2020 based on London declaration targets, full elimination considered for long-term goals at 2030 and 2042. 
Vector control  
Vector control mortality 1%   
 Low 
 
Moderate 
 
High 
 
Intervention 2020* 2030 2042 2020* 2030 2042 2020* 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.84 0.46 0.63 0.51 0.49 0.61 
Strategy 2 0.29 0.02 0.09 0.92 0.74 0.79 0.70 0.71 0.78 
Strategy 3 (B) 0.29 0.02 0.09 0.91 0.74 0.79 0.70 0.71 0.78 
Strategy 4 0.05 0.00 0.00 0.94 0.66 0.70 0.76 0.75 0.79 
Strategy 5 0.32 0.03 0.11 0.97 0.81 0.83 0.84 0.82 0.83 
Strategy 6 0.32 0.03 0.11 0.97 0.82 0.83 0.84 0.82 0.83 
Strategy 7(C) 0.05 0.00 0.00 0.93 0.67 0.70 0.77 0.77 0.80 
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Strategy 8 (D) 0.08 0.00 0.02 0.98 0.68 0.71 0.82 0.79 0.80 
Strategy 9 0.35 0.03 0.12 0.97 0.81 0.84 0.84 0.83 0.84 
Strategy 10 0.40 0.04 0.15 1.00 0.82 0.83 0.86 0.82 0.83 
Strategy 11 0.35 0.03 0.12 0.97 0.82 0.84 0.84 0.83 0.84 
Strategy 12 (E) 0.40 0.04 0.15 1.00 0.82 0.83 0.86 0.82 0.83 
Vector control mortality 10%   
 Low 
 
Moderate 
 
High 
 
Intervention 2020* 2030 2042 2020* 2030 2042 2020* 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.84 0.46 0.63 0.51 0.49 0.61 
Strategy 2 1.00 0.95 1.00 1.00 1.00 1.00 0.95 0.95 0.95 
Strategy 3 (B) 1.00 0.95 1.00 1.00 1.00 1.00 0.94 0.94 0.95 
Strategy 4 0.05 0.00 0.00 0.94 0.66 0.70 0.76 0.75 0.79 
Strategy 5 1.00 0.96 1.00 1.00 1.00 1.00 0.96 0.95 0.95 
Strategy 6 1.00 0.96 1.00 1.00 1.00 1.00 0.96 0.95 0.95 
Strategy 7(C) 0.05 0.00 0.00 0.93 0.67 0.70 0.77 0.77 0.80 
Strategy 8 (D) 0.08 0.00 0.02 0.98 0.68 0.71 0.82 0.79 0.80 
Strategy 9 1.00 0.98 1.00 1.00 1.00 1.00 0.96 0.96 0.96 
Strategy 10 1.00 0.99 1.00 1.00 1.00 1.00 0.95 0.94 0.95 
Strategy 11 1.00 0.98 1.00 1.00 1.00 1.00 0.96 0.96 0.96 
Strategy 12 (E) 1.00 0.99 1.00 1.00 1.00 1.00 0.95 0.95 0.95 
*In 2020, threshold is London Declaration target which I defined as less than 1 in 10,000 
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Surveillance in low transmission  
  
 Biannual surveillance Annual surveillance 
 
Intervention 2020* 2030 2042 2020* 2030 2042 
Strategy 1 (A) 0.95 0.26 0.43 1.00 0.72 0.72 
Strategy 2 1.00 0.92 0.92 1.00 0.95 0.96 
Strategy 3 (B) 1.00 0.91 0.92 1.00 0.95 0.96 
Strategy 4 1.00 0.58 0.69 1.00 0.76 0.77 
Strategy 5 1.00 0.94 0.94 1.00 0.99 1.00 
Strategy 6 1.00 0.94 0.94 1.00 0.99 1.00 
Strategy 7(C) 1.00 0.59 0.70 1.00 0.77 0.77 
Strategy 8 (D) 1.00 0.57 0.69 1.00 0.73 0.73 
Strategy 9 1.00 0.92 0.93 1.00 0.99 0.99 
Strategy 10 1.00 0.92 0.92 1.00 0.99 0.99 
Strategy 11 1.00 0.93 0.93 1.00 0.99 0.99 
Strategy 12 (E) 1.00 0.92 0.92 1.00 0.99 0.99 
*In 2020, threshold is London Declaration target which I defined as less than 1 in 10,000 
 
Coverage rate improvement related to new technologies in low transmission areas 
Pentamidine-fexinidazole with RDT 1 in 2016 
 
 Low 1x High 10x 
Intervention 2020 2030 2042 2020 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 2 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 3 (B) 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 4 0.05 0.00 0.00 0.14 0.00 0.02 
Strategy 5 0.97 0.49 0.83 0.99 0.66 0.86 
Strategy 6 0.97 0.49 0.83 0.99 0.66 0.86 
Strategy 7(C) 0.05 0.00 0.00 0.11 0.00 0.00 
Strategy 8 (D) 0.06 0.00 0.01 0.16 0.00 0.02 
Strategy 9 0.98 0.60 0.86 0.99 0.62 0.86 
Strategy 10 0.99 0.65 0.86 0.99 0.66 0.85 
Strategy 11 0.98 0.60 0.86 0.99 0.62 0.86 
Strategy 12 (E) 0.99 0.65 0.86 0.99 0.66 0.85 
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Fexinidazole-fexinidazole with RDT 2 in 2019 
 
 Low 1x High 10x 
Intervention 2020 2030 2042 2020 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 2 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 3 (B) 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 4 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 5 0.98 0.54 0.84 0.98 0.54 0.84 
Strategy 6 0.98 0.54 0.84 0.98 0.54 0.84 
Strategy 7(C) 0.05 0.00 0.00 0.07 0.00 0.02 
Strategy 8 (D) 0.08 0.00 0.02 0.08 0.00 0.02 
Strategy 9 0.98 0.50 0.83 0.99 0.65 0.87 
Strategy 10 0.99 0.65 0.86 0.99 0.65 0.86 
Strategy 11 0.98 0.50 0.83 0.99 0.65 0.87 
Strategy 12 (E) 0.99 0.65 0.86 0.99 0.65 0.86 
 
Oxaborole with RDT 2 in 2019 
 
 Low 1x High 15x 
Intervention 2020 2030 2042 2020 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 2 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 3 (B) 0.97 0.49 0.83 0.97 0.49 0.83 
Strategy 4 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 5 0.98 0.54 0.84 0.98 0.54 0.84 
Strategy 6 0.98 0.54 0.84 0.98 0.54 0.84 
Strategy 7(C) 0.05 0.00 0.00 0.05 0.00 0.00 
Strategy 8 (D) 0.05 0.00 0.00 0.12 0.01 0.03 
Strategy 9 0.98 0.61 0.85 0.98 0.61 0.85 
Strategy 10 0.98 0.50 0.83 0.99 0.72 0.88 
Strategy 11 0.98 0.61 0.85 0.98 0.61 0.85 
Strategy 12 (E) 0.98 0.50 0.83 0.99 0.72 0.88 
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Accelerating timeline for fexinidazole arriving on the market for both stages in 2016 
 Low 
 
Moderate 
 
High 
 
Intervention 2020* 2030 2042 2020* 2030 2042 2020* 2030 2042 
Strategy 1 (A) 0.05 0.00 0.00 0.84 0.46 0.63 0.51 0.49 0.61 
Strategy 2 0.97 0.49 0.83 0.98 0.96 0.97 0.91 0.91 0.92 
Strategy 3 (B) 0.97 0.49 0.83 0.98 0.95 0.96 0.91 0.91 0.92 
Strategy 4 0.09 0.00 0.00 0.93 0.67 0.70 0.76 0.75 0.79 
Strategy 5 NA NA NA NA NA NA NA NA NA 
Strategy 6 NA NA NA NA NA NA NA NA NA 
Strategy 7(C) NA NA NA NA NA NA NA NA NA 
Strategy 8 (D) 0.12 0.00 0.02 0.98 0.68 0.71 0.82 0.79 0.80 
Strategy 9 0.99 0.62 0.86 1.00 0.97 0.97 0.92 0.92 0.92 
Strategy 10 0.99 0.65 0.85 0.91 0.90 0.91 0.91 0.91 0.91 
Strategy 11 0.99 0.62 0.86 1.00 0.97 0.97 0.92 0.92 0.92 
Strategy 12 (E) 0.99 0.65 0.85 1.00 0.97 0.97 0.91 0.90 0.91 
*In 2020, threshold is London Declaration target which I defined as less than 1 in 10,000 
NOTE: in the published manuscript, Strategy 1 = Strategy 1; Strategy 3 = Strategy B; Strategy 7 = Strategy C; Strategy 8 = Strategy D and Strategy 
12 = Strategy E. 
 
. 
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Pictorial description of 12 strategies for control and elimination 
Time 2013                                                                                                                                                  2016                                                                                                                                                                                  2019 Post Elimination (Passive Surveillance) 
Strategy 1 
(A. Control  
  
Strategy 2 
  
Strategy 3 
(B. Control with tiny 
    
Strategy 4 
   
Strategy 5 
    
Strategy 6 
     
Strategy 7 
C. New technologies 
      
Strategy 8 
D. New technologies 
        
Strategy 9 
     
. 
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 Strategy 10 
     
Strategy 11 
      
Strategy 12 
E. New technologies 
in 2016 and 2019 
with tiny targets 
      
. 
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Appendix D: Chapter 6 
 Priority setting exercise 
Strategies selected using a rationale choice approach. The ICERs included represent strategies 
that were cost-effective as per Sutherland et al 2017.  
Strategies (High risk transmission) Cost DALYs  ICER ($ per  
DALY averted) 
Strategy D, new technologies 2016 and 2019 $45 0.22  
Strategy C, new technologies 2016 $47 0.25 Dominated by Strategy 
D 
Strategy  E,  new technologies 2016 and 2019 plus tiny targets $61 0.18 $386 
Strategy B,  control with tiny targets  $82 0.20 Dominated by Strategy 
E 
Strategy A, control $115 0.34 Dominated by Strategy 
E 
Strategies (Moderate risk transmission) Cost DALYs  ICER 
Strategy D, new technologies 2016 and 2019 $20 0.03 - 
Strategy C, new technologies 2016 $20 0.03 Dominated by Strategy 
D 
Strategy  E, new technologies 2016 and 2019 plus tiny targets $38 0.02 $1509 
Strategy B,  control with tiny targets  $48 0.02 Dominated by Strategy 
E 
Strategy A, control $55 0.04 Dominated by Strategy 
E 
Strategies (Low risk transmission)  Cost DALYs  ICER 
Strategy C, new technologies 2016 $3 0.04  
Strategy A, control $3 0.04 Dominated by Strategy 
C  
Strategy D, new technologies 2016 and 2019 $3 0.03 $160 
 
Strategy  E,  new technologies 2016 and 2019 plus tiny targets $42 0.01 1812 
Strategy B,  control with tiny targets  $45 0.01 Dominated by Strategy 
E 
 
However, SA demonstrated that increased surveillance could be CE, and when compared to 
the current interventions it dominated Strategy E and B. Hence, strategy D plus bi-annual 
surveillance could be considered a CE strategy in areas where the cost-effectiveness threshold 
is near $650 per DALY averted or greater.  
Strategies (Low risk transmission)  Cost DALYs  ICER 
Strategy C, new technologies 2016 $3 0.04  
Strategy A, control $3 0.04 Dominated by Strategy C  
Strategy D, new technologies 2016 and 2019 $3 0.03 $160 
 
Strategy D, new technologies 2016 and 2019 +bi-
annual surveillance 
$20  0.004 $654  
Strategy  E,  new technologies 2016 and 2019 plus 
tiny targets 
$42 0.01 Dominated by Strategy D+ 
Strategy B,  control with tiny targets  $45 0.01 Dominated by Strategy D+ 
 
. 
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Therefore it was decided that 3 options could potentially be available in low transmission areas 
depending on cost-effectiveness thresholds and feasibility of running additional surveillance 
programs. In cases where there was no ICER since the strategy was the comparator, the 
strategy with the lowest cost was considered.  
Range of GNIs from impacted nations ranged from $300 to $13,000 with median near 1410. CE 
thresholds were selected using the GNIs of impact countries as a proxy.  
Program plan Cost-effectiveness threshold Low (ICER) Moderate High 
Control  Reference A  A A 
Elimination I  ~$300 per DALY averted  D  ($160) D (lowest cost) D (lowest cost) 
Elimination II ~$700 per DALY averted D+ ($654) D (lowest cost) E ($386) 
Elimination III  ~$1500 per DALY averted D+ ($654) E ($1509) E ($386) 
 Financial forecast 
The modelling simulates three foci areas reflecting the WHO definition of low, moderate and 
high risk transmission. It also maintains the WHO recommendations for surveillance in such 
areas meaning that no active surveillance is occurring in low transmission areas, whilst 
moderate and high transmission areas experience active screening campaigns with an average 
coverage rate of 80% of the 57 million people reported to be at risk(Franco et al. 2017). Again, 
according to recommendations from the WHO, surveillance in moderate risk areas was 
simulated bi-annually and high transmission areas done annually. 
 
As the model represents three hypothetical risk transmission areas based on low, moderate 
and high prevalence, the annual percentage reduction of cases per year was extracted from the 
model respective to the three risks areas under evaluation. The estimated number of cases was 
then forecasted into the future using the 6228 T.b. gambiense cases reported in 2013 across 13 
endemic nations as a baseline. Estimations from the model and WHO reported cases up to 
2014 were compared for validation of the model’s predictive capacity. Forecasting estimates 
and current estimates for reported cases is depicted in the figure displayed in section D.3.1 of 
this appendix. When the mean of control strategies (with and without vector control) from 
2012 to 2014 was compared to the data currently available, the model predicted cases well (R2= 
0.8301), however the available data is limited and the model’s predictive ability will need to 
be assessed continually. Although control will reduce the number of cases over time, these 
reductions are expected to plateau over the next decade leading to delays in meeting 
elimination targets. However, if elimination strategies that include increased surveillance in 
low transmission areas, innovative technologies to improve coverage or targets to interrupt 
vector transmission (Elimination programs I, II and III) are implemented; the outcome would 
result in achieving near 2000 cases or less across Africa by 2020. Optimal declines were 
. 
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observed in Elimination II and III, where less than 500 cases could be feasible by 2020, and also 
contain strategies that have the highest probability of elimination (Sutherland et al, 2017). 
 
Stone & Chitnis (Chris M. Stone & Chitnis 2015)  and used to calculate cost-effectiveness over 
time (Sutherland et al. 2017) was again used to estimate annual cases, as well as costs for 
treatment, vector control and surveillance. 
D.2.1 Health care expenditures  
National ‘screen & treat’ programs and vector control program costs  
Cost functions related to the expenses incurred for surveillance, treatment, diagnostics and 
vector control programs of T.b. gambiense were developed and incorporated into the model to 
generate an annual cost per person in an at risk transmission area (Sutherland et al. 2017). 
These per person estimates were taken directly from the model outputs annually and then 
multiplied to the at foci defined by WHO(World Health Organization (WHO) 2013c) and  
calculated for current  at risk populations of the 14 endemic countries. The formula to represent 
these calculations can be described as follows: 
�𝐶𝐶𝑓𝑓 = ( 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 + 𝑐𝑐𝑡𝑡𝑡𝑡+ 𝑐𝑐𝑣𝑣𝑐𝑐)𝑓𝑓 × 𝑛𝑛𝑓𝑓30
𝑡𝑡=1
 
Where t represents the years and 𝐶𝐶 are the mean costs over the 30 year time horizon. The costs 
for surveillance =Csur, treatment = Ctx and vector control = Cvc. All are represented as units per 
person in an at risk focus, hence  n = number of people at risk in a focus. A specific focus is 
represented by f   for which there are three: low, moderate and high. And hence the total cost 
of a program is the sum of the three foci areas can be described as: 
𝑇𝑇𝐶𝐶 =  𝐶𝐶𝑙𝑙𝑙𝑙𝑙𝑙 +   𝐶𝐶𝑚𝑚𝑙𝑙𝑑𝑑𝑒𝑒𝑠𝑠𝑎𝑎𝑡𝑡𝑒𝑒  +   𝐶𝐶ℎ𝑣𝑣𝑖𝑖ℎ  
 
  Mean estimate 
Cost $US, (SD) 
Sources 
Financial costs    
Surveillance   Cost per person in at risk 
transmission area 
 
Annual surveillance  0.42 Lutumba 2007 
Mobile team start-up   1.55 Lutumba 2007 
Mobile teams annual maintenance  0.21 Lutumba 2007 
Motorbike team start-up  0.89 Lutumba 2007 
Motorbike team annual maintenance  0.42 Lutumba 2007 
Passive surveillance  1.35 Lutumba 2007 
    
Diagnostics    
CATT algorithm  8.19 Lutumba 2005,WHO Technical 
report 1998, Lutumba 2006 
RDT 1 algorithm   6.17 Lutumba 2006,Ndung’u 2015,FIND 
RDT 2 algorithm  3.86 FIND 
. 
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Treatment*  Cost per person in at risk 
transmission area 
 
Pentamidine  367.56 Shaw 2001, Politi 1995 
NECT  816.46 Simarro 2011 and 2012 
fexinidazole  55.23 DNDi 
oxaborole  2.00 DNDi  
    
Vector control program  Cost per km in at risk 
transmission area 
 
Tiny targets start-up  13.8 Shaw 2015 
Tiny target maintenance   13.8 Shaw 2015 
    
SD  = standard deviation 
*(per diem,  Including hospitalization) 
 Financial protection analysis 
D.3.1 Number of cases (household) estimations 
 
 
Year Control  2020 
(based on 500 
simulations) 
Mean SD SE 95% CI 
low 
95% CI 
high 
Min Max 
2013 6228 0 0   6228 6228 
2014 3951 261 12 3950 4297 3343 5252 
2015 3109 365 16 3108 3381 2593 5086 
2016 2725 404 18 2724 2964 2245 5030 
2017 2532 420 19 2530 2753 2079 5002 
. 
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2018 2425 428 19 2423 2637 1983 4987 
2019 2361 432 19 2359 2568 1916 4978 
2020 2319 435 19 2318 2523 1863 4973 
 
 
       
 
 
 
Year Elimination I          
(based on 
500 
simulations) 
Mean SD SE 95% CI 
low 
95% CI 
high 
Min Max 
2013 6228 0 0   6228 6228 
2014 3889 193 9 3888 4230 3343 4526 
2015 3000 202 9 2999 3263 2593 4228 
2016 2421 144 6 2420 2633 1997 3709 
2017 2201 137 6 2200 2394 1745 3633 
2018 2092 148 7 2092 2276 1582 3602 
2019 1902 224 10 1901 2068 979 3495 
2020 1768 283 13 1766 1922 701 3465 
 
 
 
Year Elimination II          
(based on 
500 
simulations) 
Mean SD SE 95% CI 
low 
95% CI 
high 
Min Max 
2013 6228 0 0   6228 6228 
2014 2217 633 28 2215 2412 943 3395 
2015 1133 421 19 1131 1232 326 2114 
2016 523 239 11 522 569 108 1333 
2017 281 156 7 280 306 42 1158 
2018 167 114 5 166 182 17 1066 
2019 108 89 4 108 117 6 961 
2020 76 74 3 76 82 2 892 
 
 
Year Elimination III          
(based on 
500 
simulations) 
Mean SD SE 95% CI 
low 
95% CI 
high 
Min Max 
2013 6228 0 0   6228 6228 
2014 2023 639 29 2020 2200 724 3177 
2015 917 420 19 915 997 133 1834 
2016 383 229 10 383 417 20 1015 
2017 197 142 6 197 215 3 881 
2018 117 99 4 117 128 1 817 
2019 77 75 3 77 84 0 743 
2020 56 61 3 55 61 0 695 
. 
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D.3.2 Out-of-pocket (OOP) Household health expenditures related to T.b. gambiense 
A cost function for per household OOP expenditure was then developed taking into 
consideration that a family member or friend would attend the treatment clinic with the 
diagnosed individual, and was calculated as follows: 
�𝑂𝑂𝑂𝑂𝑂𝑂𝑠𝑠𝑖𝑖 = 𝑝𝑝𝑣𝑣  × [𝑐𝑐𝑓𝑓𝑒𝑒𝑒𝑒 + ( 𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝑙𝑙𝑚𝑚𝑙𝑙𝑑𝑑𝑎𝑎𝑡𝑡𝑣𝑣𝑙𝑙𝑎𝑎  30
𝑡𝑡=1
× (𝑡𝑡𝑥𝑥𝑑𝑑𝑎𝑎𝑑𝑑𝑠𝑠𝑠𝑠𝑖𝑖 + 𝑟𝑟𝑑𝑑𝑎𝑎𝑑𝑑𝑠𝑠𝑠𝑠𝑖𝑖))  + 2(𝑐𝑐𝑡𝑡𝑠𝑠𝑎𝑎𝑎𝑎𝑠𝑠𝑡𝑡𝑙𝑙𝑠𝑠𝑡𝑡𝑎𝑎𝑡𝑡𝑣𝑣𝑙𝑙𝑎𝑎) + 2(𝑐𝑐𝑚𝑚𝑒𝑒𝑎𝑎𝑙𝑙𝑠𝑠 ×  (𝑡𝑡𝑥𝑥𝑑𝑑𝑎𝑎𝑑𝑑𝑠𝑠𝑠𝑠𝑖𝑖 + 𝑟𝑟𝑑𝑑𝑎𝑎𝑑𝑑𝑠𝑠𝑠𝑠𝑖𝑖))] 
Where pi are the number of cases per stage, and c costs refer to meals (cmeals,), a return trip for 
transportation to the treatment facility (ctransportation) and the per diem accommodation rates 
(caccomodation).  The per diem treatment days defined as 𝑡𝑡𝑥𝑥𝑑𝑑𝑎𝑎𝑑𝑑𝑠𝑠𝑠𝑠𝑖𝑖  are relative the treatment in the 
foreseen program (i.e. Control 2020, Elimination 2020, etc.) The average cost of treatment for 
stage 1 and 2 is used as a the final mean OOP costs per program (refer to the Table in D.3.3). 
 
 
HAT T.b. gambiense affects rural populations across Sub-Saharan Africa, hence mean 
consumption (C) was based on the gross national income (GNI) of the endemic nations. Non-
medical expenses (NM) were estimated using food expenditures as a proxy and it was 
assumed on average that 66.3% of a rural household income (~ $320 annual) was spent on food 
expenditures (Depetris Chauvin et al. 2012). In order to estimate the relative CHE related to 
OOP (shown as ‘M’), the recommended methodology was used(Bank 2017) where:  
Short name OOP Description  Cost   Source 
One time OOP    cfee Hospital entry fees (one time) $2.52 Matemba, 2010     C transportation Transportation (roundtrip) $9.65 Matemba, 2010 
       
Per diem OOP 
 
    Caccomodation Accommodation per diem $1.90  Matemba, 2010 cmeals Meals per diem $2.28  Matemba, 2010     tx days Days of treatment    Pentamidine  12 Steinmann et al  NECT 14 Steinmann et al  fexinidazole 10 Steinmann et al  oxaborole 1 Steinmann et al rdays Days of recovery (related to treatment)    pentamidine 7 Assumption  NECT 7 Assumption  fexinidazole 4 Assumption 
 oxaborole 2 Assumption 
. 
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M(C − NM) 
 
To visualize the impact that OOP had on a household relative to the poverty line, a Pen 
Parades’ diagram, was generated. This image is often used to assist policy makers in reviewing 
the impact that OOP may have on subjecting households to poverty (impoverishing) or 
pushing families with an income below the poverty line, further into poverty (‘immiserizing’).  
. 
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D.3.3 Summary of inputs for the Financial Protection Analysis (FPA) 
Description                 95% Confidence (CI) Source 
Households (cases) Mean Distribution alpha  beta  SD SE MIN MAX low high   
Control 2013 6228             Franco et al, 2017 
Control 2020 2333 Normal     435 19 1863 4973 2318 2523 Stone & Chitnis, France 
et al 2017 
Elimination I 2020 1774 Normal     283 13 701 3465 1766 1922 HAT model (Stone & 
Chitnis), projections  
Elimination II 2020 77 Normal     74 3 2 892 76 82 HAT model (Stone & 
Chitnis), projections  
Elimination III 2020 57 Normal     61 3 0 695 55 61 HAT model (Stone & 
Chitnis), projections  
             
Income (C), annual  Median           
Income - GNI   $1,360  Gamma 2 835 3843 1066 330 12640 2438 3596 World Bank 2013 
Income - lower income GNI   $575  Gamma 25 23 283 115 330 980 538 722 World Bank 2013 
Income - lower-middle income GNI   $2,085  Gamma 25 83 833 417 1360 2970 1717 2533 World Bank 2013 
Income -  middle-upper income GNI   $9,450  Gamma 17 541 3916 2261 4850 12640 6421 11539 World Bank 2013 
            
Non-medical expenses  (NM), annual                       
Non-medical expenses (i.e food) $320 Gamma 319.566 1             Lutumba 2007, Chauvin 
2012 
                        
OOPs, Medical expenses related to HAT Tbg (M) 
 Mean           
Control 2013 $151 Gamma 151.02 1  9.136           Matemba 2010 
Control 2020 $151 Gamma 151.02 1  9.136           Matemba 2010 
Elimination I 2020 $3 Gamma 2.52 1             Matemba 2010 
Elimination II 2020 $3 Gamma 2.52 1             Matemba 2010, 
Elimination III 2020 $3 Gamma 2.52 1             Matemba 2010 
                        
Other inputs                       
CHE threshold 10% and  25%                World Bank 2017  
Poverty line   1.9                 World Bank 2017  
Discount rate  3%                 WHO-CHOICE 
C=consumption, income; GNI=gross national income, NM=non-medical expense, M=medical expense, OOP=out-of-pocket payments, CHE = catastrophic health expenditure 
. 
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Appendix E: Chapter 7 
 Summary of health systems actors and responsibilities 
Health system 
component 
Current Future Responsibility  Source/link 
Finance     
 African Development Bank (ADB)  Funding, donations  
 Arab Bank    
 BMGF  Funding (modelling, R&D, NSSCPs)  
 Department for International Development 
(DFID) of the United Kingdom 
   
 Deutsche Gesellschaft für Technische 
Zusammenarbeit (GTZ) on behalf of the 
Government of the Federal Republic of 
Germany 
   
 National budget  Funding  
 Spanish Agency of International 
Cooperation for Development (AECID). 
   
 The Ministry of Foreign and European 
Affairs (MAEE) of France 
   
 Wellcome Trust  Financing R & D  
Governance     
 WHO Gambiense HAT stakeholders for 
elimination 
 Support  
 PATTEC (vector control)  Coordination and support  
 WHO TAG NTD    
 WHO (country offices)  Procurement  
 NSSCP or NTD programs(MoH) (E.g. 
National HAT Control Programme of the 
DRC (PNLTHA, Democratic Republic of the 
Congo) 
 In country coordination  
  Community   
Service 
Delivery 
    
. 
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 Médecins sans Frontières (MSF) /Doctors 
without Borders 
 Logistics (Bordeaux)   
 MSF treatment centres  In country  
 NSSCP (MoH)  In country  
 NSSCP treatment centres  In country  
  National medical stores   
  CHW   
Medicine and 
technology 
(research) 
    
Treatment pentamidine, melarsoprol and eflornithine 
(DMFO), Sanofi 
fexinidazole (Winthrop ®   
 Nifurtomix (Bayer HealthCare)    
Diagnostics Anitgens for CATT  (ITM, Belgium) 
 
   
     
  HATSeroK-SeT Coris 
BioConcept, Belgium 
 
 
 http://www.dndi.org/wp
-
content/uploads/2015/09/
Bscher_DNDi_ECTMIH_
2015.pdf 
  SD Bioline HAT - Standard 
Diagnostics, Inc. (Republic of 
Korea). 
 
 http://www.finddiagnost
ics.org/resource-
centre/press/121206.html 
 
  Antigens for RDTs MicroCoat 
Biotechnologie GmbH 
(Germany) 
 (https://www.google.com
/patents/WO2001032896
A1?cl=en) 
    (http://www.itg.be/itg/U
ploads/TTP/CATT%20ga
mbiense%20engels%20P
DT_BR_0001_E_6.1.pdf) 
 
 UNK LAMP and parasitological 
confirmation laboratory testing 
  
. 
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Vector control  Tiny targets Vestergaard 
 
 http://www.vestergaard.
com/zerofly-screen 
 
Surveillance Mobile truck, MSF motorbike teams   
 Mobile truck , NSSCP motorbike teams   
 UNK PDA and solar panels for 
motorbike teams 
  
Human 
Resources 
    
 MSF      
 Doctors    
 Nurses    
 Lab technicians (Parasitology)    
 VC maintenance & deployment teams    
 Active surveillance teams, drivers, 
diagnosticians 
   
 NSSCP employees (Management and 
Support) 
   
  CHW   
People     
  Patients  Self-report, seek treatment  
 Families  Support and attend ill family member seeking 
treatment 
 
 Communities  Support community member seeking treatment  
Information     
 FAO (PAAT) Mapping   
 WHO    
 SSNCP     
     
     
     
Research & 
Development 
The International Livestock Research 
Institute (Kenya) 
   
 the Institute of Tropical Neurology (France), 
the 
   
 the Centrafrican Institute of Agronomical 
Research (Central African Republic), 
   
. 
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 FIND  Diagnostics  
 Antwerp(Belgium)  Diagnostics  
 Institute of Tropical Medicine 
(ITM)(Belgium) 
 Diagnostics  
 Glasgow  Diagnostics  
 Liverpool  Vector control  
 Warwick & Yale  Disease modelling  
 FAO  Mapping  
 IDM  Disease prevalence modelling and mapping  
 Swiss TPH  Clinical trials, public policy briefs (economics 
and modelling) 
 
 DNDi  Drug discovery and development  
 NITD  Drug discovery and development  
 Liverpool, Centre of African Studies at the 
University of Edinburgh, LSHTM, Institute 
of Tropical Medicine (ITM)(Belgium) 
 Medical anthropology  
. 
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 Inter-arrival time estimations 
Time Cases 
0.5  
1 124800 
1.24 100644 
1.248 100000 
3.1 40258 
6.24 20000 
12 10400 
12.3 10146 
12.35 10105 
12.4 10064 
12.45 10024 
12.457 10018 
12.458 10017 
12.47 10008 
12.478 10004 
12.48 10000 
12.5 9984 
13 9600 
18 6933 
50 2496 
151 800 
420 297 
1000 124 
  
 
 Bandundu Province, Health Zones, Djuma, Vanga, Bulungu 
 
Map of DRC health facilities: https://dl.dropboxusercontent.com/u/16026677/DRC_Map_v1_9.html 
Note: Shows 3 health zones in Bandundu Province service by 2 HAT treatment hospitals, surrounded by 13 local facilities with 
the capacity to diagnose, but not treat. The example of 1 HAT treatment hospital with 2 alternative local centres was based on this 
representation. 
 
